asset purchase agreement by and between baxano …

SL1 1342200v6 109188.00001

ASSET PURCHASE AGREEMENT

BY AND BETWEEN

BAXANO SURGICAL, INC.,

as Seller,

AND

EXWORKS CAPITAL FUND I, L.P.

as Purchaser

Case 14-12545-CSS Doc 191 Filed 12/31/14 of 221

1 SL1 1342200v6 109188.00001


THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of this 31st day of December, 2014, by and between Baxano Surgical, Inc., a Delaware corporation, formerly known as Trans1 Inc. and successor to Baxano, Inc. (the “Seller”), and ExWorks Capital Fund I, L.P. (the “Purchaser”). The Seller and the Purchaser are sometimes individually referred to herein as a “Party” and collectively as the “Parties.”

WHEREAS, the Seller is engaged in utilizing the Acquired Assets (hereinafter defined) in the business of designing, developing, marketing, and selling (i) flexible surgical instruments under its iO-Flex® product line that allow surgeons to treat lumbar spinal stenosis during spinal decompression procedures (the ““iO-Flex® Products”); (ii) disposable facetectomy instruments under its iO-Tome® product line that allow surgeons to perform rapid facetectomies while working above exiting nerves (the “iO-Tome® Products”); and (iii) tools, equipment, and inventory in the field of bone graft harvesting including, without limitation, the trochar introducer the trephine saw assembly, tissue dilator shaft assembly, tissue dilator sheath subassembly, and iliac crest bone graft harvesting products (the “Bone Graft Harvesting Products”) (suchbusiness as conducted by the Seller as of the date hereof, the “Acquired Business”); and

WHEREAS, Seller is engaged in other aspects of the medical device and instruments business (“Non-Acquired Business” and, together with the Acquired Business, the “Business”)that is not included in the Acquired Assets.

WHEREAS, the Seller is the owner of the Acquired Assets; and

WHEREAS, on November 12, 2014 (the “Petition Date”), a voluntary petition for relief was filed by the Seller under Chapter 11 of Title 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), under Case Number 14-12545 (CSS) (the “Bankruptcy Case”); and

WHEREAS, the Seller desires to sell and the Purchaser desires to purchase the Acquired Assets all in accordance with, and subject to, the terms and conditions contained in this Agreement; and

WHEREAS, the Acquired Assets shall be sold to the Purchaser free and clear of all Liens and Encumbrances pursuant to Section 363 of the Bankruptcy Code, and subject to the Sale Order.

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

ARTICLE I DEFINITIONS

For purposes of this Agreement (including any Exhibits or Schedules attached hereto), the following terms shall have the meanings indicated below, unless the context clearly requires otherwise:


2 SL1 1342200v6 109188.00001

“510(k) Clearances” shall mean, collectively, the FDA cleared 510(k) Filings relating to any Product identified on Schedule A-4 to Exhibit A.

“510(k) Filings” shall mean, collectively, the pre-market notifications submitted by or on behalf of the Seller to the FDA relating to any Product identified on Schedule A-4 to Exhibit A.

“510(k) Supporting Materials” means, collectively, all technical files, drawings and documents supporting the submissions for FDA clearances, device registrations, design files, marketing and manufacturing files, and filings and correspondence with the FDA, in each case that relate to the 510(k) Filings.

“Acquired Assets” shall mean all of the assets and properties of the Seller identified on Exhibit A except for the Excluded Assets.

“Acquired Business” is defined in the Recitals to this Agreement.

“Affiliate” shall mean, with respect to a specified Person, any other Person which directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the specified Person; provided that such Person shall be deemed an Affiliate for only so long as such control exists. For purposes of this definition and the definition of Related Person, the term “control” includes, without limitation, the possession, directly or indirectly, of the power to direct the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

“Amendia” shall mean Amendia, Inc., a Georgia corporation.

“Ancillary Documents” shall mean all other agreements, documents and instruments to be executed and delivered by the Purchaser and/or the Seller pursuant to this Agreement.

“Assigned Contracts” shall mean, collectively, those Contracts included in the Acquired Assets, which shall consist solely of the Contracts identified on Schedule A-3 to Exhibit A.

“Assignment and Assumption Agreement” shall mean the Assignment, Delegation and Assumption Agreement to be executed at the Closing between the Seller and the Purchaser in the form attached hereto as Exhibit B, pursuant to which, among other things, the Seller will assign and transfer to the Purchaser all of its right, title and interest under the Assigned Contracts, if any, on the terms and conditions set forth therein.

“Assumed Liabilities” shall mean, collectively, (i) all liabilities arising after the Closing with respect to the Assigned Contracts, (ii) all liabilities arising with respect to the Acquired Business arising on or after the Closing Date, (iii) the Cure Amounts, to the extent provided in Section 2.3 hereof, (iv) one-half (1/2) of any and all Transfer Taxes, (v) all PTO for Retained Employees, and (vi) all obligations of the Purchaser under this Agreement.

“Assumption/Cure Notice” means the Notice of Possible Assumption and Assignment of Executory Contracts and of Cure Amounts delivered to counterparties to Contracts with the Seller pursuant to the Sale Procedures Order.


3 SL1 1342200v6 109188.00001

“Bankruptcy Case” shall have the meaning given to it in the Recitals to this Agreement.

“Bankruptcy Code” shall have the meaning given to it in the Recitals to this Agreement.

“Bankruptcy Court” shall have the meaning given to it in the Recitals to this Agreement.

“Bid Procedures” shall mean the bid procedures governing the process by which the sale of the Acquired Assets shall occur, which are attached to the Sale Procedures Order as Exhibit I.

“Bill of Sale” shall mean the bill of sale to be delivered at Closing by the Seller to the Purchaser in the form attached hereto as Exhibit C. The Bill of Sale shall be assignable by Purchaser to Amendia with no other approval of the Seller or Bankruptcy Court required.

“Bone Graft Harvesting Products” shall mean all tools, equipment, and inventory owned by Seller in the field of bone graft harvesting including, without limitation, the trochar introducer the trephine saw assembly, tissue dilator shaft assembly, tissue dilator sheath subassembly, and iliac crest bone graft harvesting products.

“Book Value” means book value as of the Closing Date based on the Seller’s standard valuations in its books and records.

“Book Value of Closing Inventory” means the Book Value of Inventory on the Closing Date.

“Books and Records” means, collectively, all books, records, documents, lists and files relating or pertaining to the Business, the Acquired Assets, including price lists, lists of accounts, customers, prospects, suppliers, and personnel, all Products, business and marketing plans, historical sales data, credit records, and all books, ledgers, files and business records (including all FDA and other regulatory records, submissions, forms and other files, maintenance records, financial records and books of account), in any of the foregoing cases, whether in electronic form or other media, excluding, however, the Corporate Documents.

“Business Day(s)” shall mean calendar days other than Saturdays, Sundays and days on which banking institutions in Wilmington, Delaware are authorized by Law to close.

“CE Marks” means the “Conformité Européenne” (European Conformity) mark examination certificates for any of the Products identified on Schedule A-4 to Exhibit A.

“CE Mark Supporting Materials” means all regulatory filings relating to the CE Marks (including all technical files, drawings and documents supporting submissions and approvals, device registrations, pre- and post- approval design files, marketing and manufacturing files and filings, and correspondence with any applicable Governmental Body).

“Code” means the Internal Revenue Code of 1986, as amended.

“Claim” means a “claim” as defined in Section 101(5) of the Bankruptcy Code.

“Closing” is defined in Section 8.1.


4 SL1 1342200v6 109188.00001

“Closing Date” is defined in Section 8.1.

“Contracts” shall mean any agreement or contract, whether written or oral.

“Cure Amount” shall mean, with respect to any Assigned Contract, the amount due and owing to each non-debtor counterparty to such Assigned Contract to cure any defaults required to be cured as a condition of assumption of such Assigned Contract pursuant to Section 365(b)(1) of the Bankruptcy Code.

“Deposit” is defined in Section 3.1(a).

“Employee Benefit Plan” means any material “employee benefit plan” (as such term is defined in ERISA Section 3(3)) that is covered by Title I of ERISA and is maintained or sponsored by the Seller or any of its ERISA Affiliates or to which the Seller or any of its ERISA Affiliates has any obligation to contribute.

“Encumbrance” shall mean with respect to any asset and to the extent not a Lien, any charge, claim, equitable interest, lien, option, pledge, security interest, or right of first refusal, trust, restriction, covenant, easement, license, lease, mortgage, conditional or installment sale contract, title retention contract, transferability restriction, obligation, or title defect.

“Environment” has the meaning set forth in the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (“CERCLA”), 42 U.S.C. § 9601 et seq.

“Environmental Condition” means the presence or introduction into the Environment of any Hazardous Materials (and any resulting air, soil, groundwater or surface water contamination without regard to the location to which such resulting contamination has migrated or spread) as a result of which the Seller has or may become materially liable to any Person in connection with the Business or by reason of which the Acquired Assets may materially suffer.

“Environmental Laws” means all Laws that (i) regulate or relate to the protection or clean-up of the Environment; the use, treatment, generation, storage, transportation, handling, disposal or release of Hazardous Materials; or the preservation or protection of waterways, groundwater, drinking water, air, wildlife, plants or other natural resources; or (ii) imposes liability with respect to any of the foregoing, including the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. Section 9601 et seq.; the Resource Conservation and Recovery Act, 42 U.S.C. Section 6901 et seq.; the Federal Water Pollution Control Act, as amended, 33 U.S.C. Section 1251 et seq.; the Toxic Substances Control Act, 15 U.S.C. Section 2601 et seq.; the Clean Air Act, 42 U.S.C. Section 7401 et seq.; the Safe Drinking Water Act, 42 U.S.C. Section 300f et seq.; or the Oil Pollution Act of 1990, 33 U.S.C. Section 2701 et seq.

“Equipment” means any “equipment,” as that term is defined in the UCC.

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended.

“ERISA Affiliate” means each entity that is treated as a single employer with the Seller for purposes of Section 414 of the Code.


5 SL1 1342200v6 109188.00001

“Escrow Agent” shall mean Stevens & Lee, P.C.

“Escrow Agreement” shall mean the agreement substantially in the form attached hereto as Exhibit D .

“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

“Excluded Assets” shall mean the following property, assets, rights and interests of the Seller:

(a) Cash. All cash, checks, cash equivalents, cash in transit, and cash on hand or on deposit in any operating account or other account or reserve;

(b) Accounts Receivable. All accounts receivable of the Seller, including all accounts receivable of the Seller as of the Petition Date;

(c) Contracts. All Contracts, including any Employee Benefit Plan, other than the Assigned Contracts;

(d) Transaction Documents. All rights of and benefits to the Seller under this Agreement and the Ancillary Documents;

(e) Refunds and Credits. All rights to refunds of or credits for Taxes of the Seller paid prior to the Closing Date, and any records relating to the Seller’s Taxes;

(f) Insurance Proceeds. All insurance premiums, policies, contracts and coverage obtained by the Seller and all rights to insurance proceeds and recoveries from or under any Contracts of insurance, indemnity or similar agreement;

(g) Causes of Action. All avoidance claims and causes of action arising under Chapter 5 of the Bankruptcy Code and all other claims and causes of action under the Bankruptcy Code or non-bankruptcy Laws, and the proceeds from any of the foregoing other than claims for refund of Transfer Taxes paid by the Purchaser pursuant to Section 10.15;

(h) Deposits. All deposits made by the Seller prior to the Closing Date and all claims and rights to the refund of all or any portion thereof; provided, however, that Deposits shall be deposits of money only and any deposit of Equipment that is part of the Acquired Assets shall not be deemed a Deposit hereunder;

(i) Corporate Documents & Records. All employee records and corporate seals, minute books, charter documents, stock transfer records, record books, Tax returns and all other files, books and records relating to the organization, existence or capitalization of the Seller (the “Corporate Documents”);

(j) Retainers. All professional retainers paid by the Seller to its advisors or Representatives in connection with the Bankruptcy Case and the transactions contemplated herein;


6 SL1 1342200v6 109188.00001

(k) Non-Transferrable Assets. All property of the Seller that is not lawfully transferrable or is required by law to be retained by the Seller; and

(l) Other Assets. The Baxano tradename and all other rights, benefits or property of the Seller which is not an Acquired Asset.

“Excluded Liabilities” shall mean, collectively, any and all liabilities of the Seller of any kind or description other than the Assumed Liabilities.

“FDA” shall mean the United States Food and Drug Administration and any successor thereto.

“Final Order” shall mean an order, judgment or other decree as to which (a) the operation or effect has not been reversed, stayed, modified or amended, (b) no appeals or motions for reconsideration are pending, and (c) any and all appeal periods have expired.

“GAAP” shall mean generally accepted accounting principles in the United States, consistently applied.

“Goods” means any “goods,” as that term is defined in the UCC.

“Governmental Authorization” means any consent, license, permit, certificate of authority, registration, franchise, right, Order or notice, qualification or similar right (including any 510(k) Clearances and CE Marks) issued, granted, given, or required by or under the authority of any Governmental Body or pursuant to any Laws

“Governmental Body” means any federal, state, local, municipal, foreign or other governmental or quasi-governmental entity or authority of any nature, including the FDA and its equivalent authority or body in any foreign jurisdiction.

“Hazardous Materials” shall mean all “hazardous substances” or “toxic substances” as those terms are defined by the CERCLA.

“Intellectual Property” shall mean, collectively, any and all (i) patents, patent applications and patent disclosures, together with all reissuances, continuations, continuations in part, revisions, extensions and reexaminations thereof (“Patents”), (ii) trademarks, service marks, trade dress, logos, trade names, assumed names and corporate names, together with all translations, adaptations, derivations and combinations thereof and including all goodwill associated therewith, and all applications, registrations and renewals in connection therewith (“Trademarks”), (iii) copyrightable works, all copyrights and all applications, registrations and renewals in connection therewith, mask works and all applications, registrations and renewals in connection therewith (“Copyrights”), (v) trade secrets and confidential business information (including ideas, research and development, know-how, technology, inventions, formulas, compositions, processes and techniques, technical data, designs, drawings, specifications, customer, distributor and supplier lists, pricing and cost information and business and marketing plans and proposals) (“Trade Secrets”), (vi) computer software (including data and related software program documentation in computer-readable and hard-copy forms) (“Software”), and


7 SL1 1342200v6 109188.00001

(vii) web sites, web site domain names and uniform resource locators, in each case, which are owned, licensed, or used by the Seller in connection with the Business.

“Inventory” means any “inventory,” as that term is defined in the UCC, pertaining to the Products and Acquired Business, including raw materials and components, work-in-process, demonstration Products, finished goods, and other materials, spare parts, components, and supplies, as well as all packaging and labeling inventories, supplies, and materials.

“Inventory Adjustment” means an amount equal to one hundred percent (100%) of the difference between (a) $1,400,000.00 and (b) the Book Value of the Closing Inventory on the Closing Date. If the Book Value of Closing Inventory exceeds $1,400,000.00, there will be no Inventory Adjustment.

“iO-Flex® Products” shall mean, collectively, flexible surgical instruments designed, developed, marketed, and sold by the Seller in connection with the Acquired Business under its iO-Flex® product line allowing surgeons to treat lumbar spinal stenosis during spinal decompression procedures.

“iO-Tome® Products” shall mean, collectively, disposable facetectomy instruments designed, developed, marketed, and sold by the Seller in connection with the Acquired Business under its iO-Tome® product line allowing surgeons to perform rapid facetectomies while working above exiting nerves.

“Knowledge of the Seller” and “to the Seller’s Knowledge” shall mean the actual or constructive knowledge of Ken Reali, the Seller’s Chief Executive Officer, or John L. Palmer, the Seller’s Chief Restructuring Officer, after due inquiry.

“Laws” shall mean all federal, state and local laws, ordinances, rules, regulations, standards, and Orders.

“Liabilities” means liabilities, obligations or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured or otherwise, including obligations and liabilities related to any Claim.

“Lien” has the meaning given to such term in the Bankruptcy Code.

“Liquidated Cure Amounts” means all Cure Amounts relating to Assigned Contracts which are stated in a Final Order of the Bankruptcy Court.

“Material Adverse Effect” means any event, circumstance, change, occurrence or effect that, individually or in the aggregate, has a material and adverse effect upon the assets, liabilities, financial condition or operating results of the Acquired Business or the Acquired Assets, taken as a whole; provided, however, that any adverse change, event, development or effect arising from or relating to any of the following shall not be deemed to constitute, and shall not be taken into account in determining whether there has been, a Material Adverse Effect: (i) the United States economy, the global economy, in each case, as a whole, or the industry or markets in which the Seller operates; (ii) the filing of the Bankruptcy Case; (iii) national or international political or social conditions, including the engagement by the United States in hostilities, whether or not


8 SL1 1342200v6 109188.00001

pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack upon the United States, or any of its territories, possessions, or diplomatic or consular offices or upon any military installation, equipment or personnel of the United States; (iv) financial, banking, or securities markets (including any disruption thereof and any decline in the price of any security or any market index); (v) changes in GAAP; (vi) changes in Law or Orders; (vii) the taking of any action contemplated by this Agreement or any of the Ancillary Documents; (viii) any “act of God,” including, but not limited to, weather, natural disasters and earthquakes; (ix) changes resulting from the announcement of the execution of this Agreement or any of the transactions contemplated hereby; (x) the termination of any Contract that is not an Assigned Contract; (xi) any adverse change to the Acquired Business prior to the date hereof; or (xii) any adverse change to the Acquired Business that is cured by the Seller prior to the Closing Date.

“Material Contracts” is defined in Section 4.10.

“Maximum Cure Amount” means the maximum Cure Amount claimed by a counterparty to an Assigned Contracts in a timely objection to the Assumption/Cure Notice applicable to such Assigned Contract.

“Net Proceeds of the Sale” means the gross cash proceeds of the sale minus (i) the amounts payable pursuant to subparagraphs [20] (a) and (b) of the Sale Order.

“Non-Acquired Business” is defined in the Recitals to this Agreement.

“Non-Disclosure Agreement” means any and all confidentiality agreements and/or non-disclosure agreements executed by the Purchaser as a condition to obtaining confidential and/or proprietary information from the Seller.

“Order” shall mean any award, decision, injunction, judgment, order, ruling, subpoena, or verdict entered, issued, made, or rendered by any court, administrative agency, or other Governmental Body.

“Ordinary Course of Business” means the ordinary course of the Seller’s Business consistent with past practice (including with respect to quantity and frequency).

“Outside Closing Date” shall mean February 28, 2015.

“Owned Intellectual Property” is defined in Section [4.12](a).

“PTO” means all liabilities of the Seller for or with respect to any accrued vacation, sick days, personal days and/or other paid time-off payable or otherwise owing to any of the Retained Employees as of the Closing.

“Permitted Liens and Encumbrances” means (i) easements, covenants, conditions and restrictions of public record; (ii) any zoning or other governmentally established restrictions or encumbrances; (iii) Liens and/or Encumbrances arising under any leases to which any leased personal property comprising of a portion of the Acquired Assets or the Leased Real Property is subject; (iv) the Liens and Encumbrances listed on Schedule 1(a) hereto; and (v) any Encumbrances or liabilities created by this Agreement.


9 SL1 1342200v6 109188.00001

“Previously Assumed Assigned Contracts” means all Assigned Contracts which were assumed by the Seller prior to the Closing Date.

“Products” shall mean, collectively, the iO-Flex® Products, the iO-Tome® Products, and all Bone Graft Harvesting Products.

“Person” shall mean any individual, corporation, general or limited partnership, limited liability company, joint venture, estate, trust, association, or other legal organization.

“Proceeding” shall mean any action, demand, complaint, inquiry, suit, injunction, dispute, arbitration, audit, hearing, investigation, litigation, citation, notice of violation (or similar notice), or suit (whether civil or criminal) commenced, brought, conducted, or heard by or before, or otherwise involving, any Governmental Body.

“Purchase Price” is defined in Section 3.1.

“Purchaser Disclosure Letter” is defined in Article V.

“Purchaser Material Adverse Effect” shall mean a material and adverse effect on the Purchaser’s ability to consummate the transactions contemplated by this Agreement and the Ancillary Documents.

“Related Person” (i) with respect to a Person who is an individual, shall mean, (a) any other individual having a relationship with such specified individual (by blood, marriage or adoption) of grandparent, parent, child, grandchild, aunt, uncle, niece, nephew, sister, brother or first cousin (collectively, “Relatives”), (b) any Person that is controlled by such individual or any one or more members of such individual’s Relatives; and (c) any Person with respect to which such individual or one or more members of such individual’s Relatives serves as a director, officer, partner, or trustee (or in a similar capacity); and (ii) with respect to a specified Person other than an individual, shall mean (a) any Affiliate of such specified Person; and (b) each Person that serves as a director, officer, partner, or trustee (or in a similar capacity) of such specified Person.

“Representative” shall mean, with respect to a particular Person, any director, officer, employee, agent, consultant, advisor, or other representative of such Person, including legal counsel, accountants and financial advisors.

“Required Notification” is defined in Section 6.6.

“Retained Employees” means all employees of the Seller who are offered employment by the Purchaser and who accept such offer effective on the Closing Date.

“Sale Procedures Motion” shall mean that certain motion filed by the Seller in the Bankruptcy Case on November 19, 2014 (D.I. 43) pursuant to which, among other things, the Seller requested an order (a) approving the Bid Procedures, (b) approving procedures relating to the assumption and assignment of executory contracts, including procedures for establishing cure claims, (c) establishing a date for an auction, and (d) scheduling a sale hearing.


10 SL1 1342200v6 109188.00001

“Sale Procedures Order” shall mean the order of the Bankruptcy Court entered on December 12, 2014 approving the Sale Procedures Motion.

“Sale Order” shall mean an Order of the Bankruptcy Court pursuant to the Bankruptcy Code approving this Agreement and the transactions contemplated hereby substantially in the form attached hereto as Exhibit E and made part hereof.

“Sarbanes Oxley Act” is defined in Section 4.21.

“Securities Act” shall mean the Securities Act of 1933, as amended.

“SEC Reports” is defined in Section 4.21.

“Seller Disclosure Letter” is defined in Article IV.

“Seller’s Facilities” shall mean 110 Horizon Drive, Suite 230, Raleigh, North Carolina.

“Tax” and “Taxes” shall mean individually or collectively, as appropriate, any and all U.S. or non-U.S., federal, state, county, local, municipal or other taxes, charges, imposts, rates, fees, levies or other assessments.

“Termination Notices” shall mean notices, in form and substance satisfactory to the Purchaser in the exercise of reasonable discretion, directing third parties in possession of any Acquired Assets to turn over those assets to the Purchaser.

“Transfer Taxes” is defined in Section 10.15(b).

“UCC” means the Uniform Commercial Code as in effect in the State of Delaware.

ARTICLE II AGREEMENTS TO SELL AND PURCHASE; RELATED MATTERS

2.1. Agreement to Sell and Purchase Acquired Assets. On the Closing Date, subject to the performance by the Parties of the terms and provisions of this Agreement and satisfaction of the terms and conditions set forth in the Sale Order, the Seller shall sell, convey, assign, transfer and deliver to the Purchaser, and the Purchaser shall purchase, acquire and accept from the Seller, the Acquired Assets, free and clear of all Liens and Encumbrances other than Permitted Liens and Encumbrances, to the fullest extent permitted by Section 363 of the Bankruptcy Code.

2.2. Assumed Liabilities/Excluded Liabilities. On the Closing Date, the Purchaser shall assume and become responsible for, and shall pay, perform, fulfill and discharge, all of the Assumed Liabilities. The Purchaser is not assuming and will have no obligation to assume, perform, or discharge any of the Excluded Liabilities, all of which shall remain the sole responsibility and obligation of the Seller.

2.3. Assigned Contracts. The Purchaser is not assuming and will have no obligation to assume, perform, or discharge any Contracts, all of which shall remain the sole


11 SL1 1342200v6 109188.00001

responsibility and obligation of the Seller, except for the Assigned Contracts. As to the Assigned Contracts:

(a) At Closing, Seller shall assign to Purchaser all of the Assigned Contracts and (i) Purchaser shall pay to the applicable counterparty the Liquidated Cure Amount with respect to any Assigned Contract which is not a Previously Assumed Assigned Contract and as to which a Liquidated Cure Amount exists as of the Closing Date, (ii) Seller shall pay to the applicable counterparty the Liquidated Cure Amount with respect to any Assigned Contract which is a Previously Assumed Assigned Contract and as to which a Liquidated Cure Amount exists as of the Closing Date, (iii) Purchaser shall pay to the Escrow Agent, pursuant to the terms of the Escrow Agreement, the Maximum Cure Amount (or such lesser amount as the Court may determine constitutes an adequate reserve) with respect to any Assigned Contract which is not a Previously Assumed Contract and as to which a Liquidated Cure Amount does not exist as of the Closing Date, and (iv) Seller shall pay to the Escrow Agent, pursuant to the terms of the Escrow Agreement, the Maximum Cure Amount (or such lesser amount as the Court may determine constitutes an adequate reserve) with respect to any Assigned Contract which is a Previously Assumed Contract and as to which a Liquidated Cure Amount does not exist as of the Closing Date. As to any Assigned Contract as to which a Liquidated Cure Amount does not exist as of the Closing Date, the Escrow Agent shall pay the Liquidated Cure Amount to the applicable counterparty promptly following the existence of a Liquidated Cure Amount and promptly return to the Purchaser or Seller, as applicable, the amount, if any, by which the Maximum Cure Amount (or such lesser amount as the Court may determine constitutes an adequate reserve) paid by the Purchaser or Seller exceeds the Liquidated Cure Amount.

(b) Purchaser shall provide in a timely fashion any and all information required by the Bankruptcy Code and the Bankruptcy Court to evidence Purchaser’s capability of satisfying the conditions contained in Sections 365(b)(1)(C) and 365(f)(2)(B) of the Bankruptcy Code with respect to the Assigned Contracts.

(c) At Closing, to the extent the performance by the Seller under an Assigned Contract is supported by a letter of credit, the Purchaser shall cause such letter of credit to be terminated or cash collateralized in a manner acceptable to the Seller in the exercise of its reasonable discretion.

2.4. Competing Transactions; Bankruptcy Court Approval. This Agreement is subject to approval by the Bankruptcy Court and the consideration by the Seller of higher or better competing bids pursuant to the Sale Procedures Order and the Bid Procedures approved thereby (each, a “Competing Bid”). Until the transactions contemplated by this Agreement are consummated, the Seller is permitted to cause its Representatives and Affiliates to initiate contact with, solicit or encourage submission of any inquiries, proposals or offers by, any Person in connection with any sale or disposition of the Acquired Assets. In addition, the Seller shall have the responsibility and obligation to respond to any inquiries or offers to purchase all or any part of the Acquired Assets and perform any and all other acts related thereto which are required under the Bankruptcy Code, the Sale Procedures Order or other applicable Law, including, supplying information relating to the Business and the assets of the Seller to prospective purchasers. In soliciting Competing Bids and in conducting any auction resulting from the receipt of a Competing


12 SL1 1342200v6 109188.00001

Bid for the Acquired Assets, the Seller shall comply with the Sale Procedures Motion and Bid Procedures

2.5. Stalking Horse Designation. The Seller hereby designates the Purchaser as the Stalking Horse for the Acquired Assets pursuant to paragraph 12 of the Sale Procedures Order. In the event the Acquired Assets are not sold to the Purchaser, the Purchaser shall be entitled to the Bid Protections described in paragraph 12 of the Sale Procedures Order to the extent the conditions to such entitlement stated in such paragraph are satisfied.

2.6. No Collusive Bidding. The Seller acknowledges that (a) the Purchaser has disclosed that it is purchasing the Acquired Assets with the intent of assigning its rights hereunder to Amendia or re-selling the Acquired Assets to Amendia under a separate agreement between the Purchaser and Amendia, and (b) even though Amendia was a potential bidder to purchase the Acquired Assets directly from the Seller, the Purchaser has disclosed its relationship with Amendia and the Seller is satisfied that the agreement between the Purchaser and Amendia does not constitute collusive bidding or a violation of applicable law that would constitute a basis for avoiding the sale or the recovery of damages under Section 363(n) of the Bankruptcy Code.

ARTICLE III PURCHASE PRICE

3.1. Payment of Purchase Price. The purchase price for the Acquired Assets shall be Four Million and 0/100 Dollars ($4,000,000.00) plus the Assumed Liabilities and minus the Inventory Adjustment, if applicable, (the “Purchase Price”). The Purchase Price shall be payable by Purchaser to Seller as follows:

(a) As security for Purchaser’s faithful performance of its obligations hereunder, concurrent with the execution of this Agreement, Purchaser shall deposit into escrow Four Hundred Thousand and 00/100 Dollars ($400,000.00) (the “Deposit”) pursuant to and in accordance with the Escrow Agreement. The Deposit shall be held by the Escrow Agent in the Escrow Agent’s trust account pursuant to the terms of the Escrow Agreement and will not generate interest payable to either the Seller or the Purchaser. Subject to Section 9.2 and the Escrow Agreement, at the Closing, the Deposit shall be released to the Seller and applied against the Purchase Price.

(b) At the Closing, the Purchaser shall pay to the Seller the balance of the cash portion of the Purchase Price in excess of the Deposit, by wire transfer of immediately available funds to an account or accounts designated in writing by the Seller prior to the Closing.

3.2. Tax Allocation of Purchase Price. The Purchase Price shall be allocated among the Acquired Assets in accordance with the IRS Form 8594, Asset Acquisition Statement Under Section 1060 as agreed by their respective accountants in good faith consistent in all respects with applicable Laws. The Seller and the Purchaser shall file their respective Tax returns in accordance with such allocation and shall not take any position inconsistent with such allocation, unless the Seller or the Purchaser, as the case may be, reasonably determines (and notifies the other Party) that such allocation is contrary to applicable Law.


13 SL1 1342200v6 109188.00001

3.3. Inventory Adjustment. Within seven (7) before the Closing Date, the Purchaser and the Seller will jointly determine the Book Value of the Closing Inventory based on Seller’s electronic records of the Inventory along with Seller's production of confirmation letters from the ten (10) largest distributors of the Products or another methodology mutually acceptable to the Parties.

ARTICLE IV REPRESENTATIONS AND WARRANTIES OF THE SELLER

Except as set forth in the disclosure letter delivered by the Seller to the Purchaser on the date hereof (the “Seller Disclosure Letter”) or as disclosed in any of the SEC Reports, the Seller represents and warrants to the Purchaser as follows:

4.1. Organization. The Seller is a corporation duly formed, validly existing and in good standing under the laws of the State of Delaware and is duly qualified to do business as a foreign corporation and is in good standing in each other jurisdiction where the operation of the Business by the Seller requires such qualification, except where the failure to be so qualified would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

4.2. Power and Authority. Upon entry of the Sale Order by the Bankruptcy Court, Seller shall have all requisite power and authority to enter into this Agreement and the Ancillary Documents and to consummate the transactions contemplated hereby and thereby. This Agreement has been duly executed and delivered by the Seller. Upon entry of the Sale Order by the Bankruptcy Court, this Agreement shall constitute a valid and binding obligation of the Seller, enforceable against the Seller in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar Laws and principles of equity affecting creditors’ rights and remedies generally.

4.3. Non-contravention. Subject to the entry of the Sale Order by the Bankruptcy Court, the execution and delivery of this Agreement or any other Ancillary Document to which the Seller is a party, the performance by the Seller of its obligations hereunder and thereunder, will not (i) violate any provision of the organizational documents of the Seller, (ii) result in a violation or breach of, or constitute (with or without due notice or lapse of time or both) a default or breach (or give rise to any right of termination, amendment, cancellation or acceleration) under any Contract, (iii) violate any Law or Order applicable to the Business or the Acquired Assets, or (iv) result in the imposition of any Lien or Encumbrance on the Acquired Assets (other than Permitted Liens and Encumbrances); other than, in the case of (ii) or (iii) above, any violation, conflict, breach, default, acceleration, termination, modification, cancellation or notice that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.

4.4. Consents. Upon entry of the Sale Order by the Bankruptcy Court, no approval, consent or authorization of, or declaration, filing or registration with or any notification to any Governmental Body or any other third Person is required in connection with the execution, delivery or performance by the Seller of this Agreement or the consummation by the Seller of the transactions contemplated hereby.


14 SL1 1342200v6 109188.00001

4.5. Liabilities. The Seller has no Liabilities with respect to the Acquired Assets for which the Purchaser will be responsible after Closing except Assumed Liabilities.

4.6. Title. The Seller has good and marketable title to, or a valid leasehold interest in, all of its properties and assets which comprise the Acquired Assets, free and clear of all Liens and Encumbrances other than Permitted Liens and Encumbrances and other Liens and Encumbrances which will be divested from the Acquired Assets by the Sale Order. Upon the completion of the transactions contemplated hereby, the Purchaser will be vested with good and marketable title to the Acquired Assets, free and clear of all Liens and Encumbrances other than Permitted Liens and Encumbrances and any Lien and/or Encumbrance imposed upon the Acquired Assets by the Purchaser or any of its creditors or other financing sources.

4.7. Litigation. There are no actions, suits, proceedings, orders, investigations, or claims pending, or to the Seller’s Knowledge, threatened against the Acquired Assets or Acquired Business, at Law or in equity, or before or by any Governmental Body which will interfere with the ownership or use by the Purchaser of the Acquired Assets after the Closing.

4.8. Condition of Tangible Personal Property. The material machinery, Goods, Equipment, furniture, leasehold improvements, fixtures and other tangible personal property (other than Inventory), which comprise a portion of the Acquired Assets are in good operating condition and repair, ordinary wear and tear excepted. That portion of the Acquired Assets which is comprised of finished goods Inventory consists of a non-obsolete, quality and quantity usable and, except for demonstration Inventory, salable in the Ordinary Course of Business.

4.9. Location of Inventory. Schedule 4.9 identifies all third parties that are in possession of any Acquired Assets which is Inventory and sets forth the locations of such Inventory.

4.10. Material Contracts. Schedule 4.10 lists each of the following written Contracts to which the Seller is a party or by which it is bound relating to the Business: (i) any Contract with material vendors (including manufacturing representatives and distributors) or material suppliers providing for the purchase by the Seller of products or other materials, including Contracts with any material original equipment manufacturers or other material suppliers or vendors that provide to the Seller parts, assemblies, components and other products used in the manufacture and production of any Product; (ii) each licensing agreement with respect to any Intellectual Property material to the Business; (iii) each Contract entered into by the Seller for, or regarding, the sale or distribution of Products by any material distributor, broker, agent or other Representative of the Seller; (iv) each of the Leases; and (v) each Contract between the Seller and any material consultant or independent contractor (collectively, the “Material Contracts”). The Seller has provided the Purchaser with true and correct copies of each Material Contract.

4.11. Reserved.

4.12. Intellectual Property.

(a) Schedule 4.12(a) identifies all Patents and Trademarks which are owned by the Seller (together will all other Intellectual Property owned by the Seller, the “Owned


15 SL1 1342200v6 109188.00001

Intellectual Property”). All Owned Intellectual Property that is currently registered with any Governmental Body complies in all material respects with all applicable Laws.

(b) Schedule 4.12(b) lists all licenses, sublicenses and other agreements pursuant to which a third party authorizes the Seller to use, practice any rights under, or grant sublicenses with respect to, any Intellectual Property owned by such third party and material to the Business, other than licenses, sublicenses or other agreements that consist solely of “shrink-wrap”, “click-to-accept” or similar commercially available or otherwise standard end-user licenses.

(c) Schedule 4.12(c) lists all licenses, sublicenses and other agreements pursuant to which the Seller authorizes a third party to use, practice any rights under, or grant sublicenses with respect to, any material Owned Intellectual Property or pursuant to which the Seller grants rights to use or practice any rights under any Intellectual Property owned by a third party and material to the Business.

(d) To the Knowledge of the Seller, (i) no Intellectual Property identified on Schedule 4.12(a) has been infringed or challenged in any way, nor has any Proceeding been threatened with respect thereto, and (ii) except as set forth on Schedule 4.12(d), none of such Intellectual Property has infringed or infringes upon the rights of any Person nor, to the Knowledge of the Seller, has been alleged to infringe upon the rights of any Person.

(e) To the Knowledge of the Seller, (i) none of the Owned Intellectual Property has been or has been alleged to have been, misappropriated from any Person, and (ii) no employee, subcontractor, consultant, independent contractor, or other Person claims any rights to any of the Owned Intellectual Property. Without limiting the generality of the foregoing, any and all Owned Intellectual Property conceived, invented or developed on behalf of the Seller by any employee, subcontractor, consultant, independent contractor, or other Person has been duly and validly assigned and transferred to the Seller pursuant to and in accordance with an assignment of inventions or similar agreements.

4.13. Compliance with Law, Governmental Authorizations, Etc.

(a) Except as set forth on Schedule 4.13(a): (i) since January 1, 2012, the Seller has complied in all material respects with all Laws that are applicable to the Products or the Seller’s conduct or operation of the Business, and (ii) since January 1, 2012, the Seller has not received any written notice from the FDA or any other Governmental Body or other Person regarding any actual, alleged, or potential violation of, or failure to comply with, any Law or any actual, alleged, or potential enforcement action by the FDA or any other Governmental Body.

(b) Schedule 4.13(b) contains a list of all CE Marks, 510(k) Clearances, other international approvals and 510(k) Filings relating and pertaining to the Business. The Seller is in compliance in all material respects with all Laws (including regulations promulgated by the FDA or any other Governmental Body) relating or pertaining to such 510(k) Clearances, 510(k) Filings, CE Marks and the Products covered thereby.

(c) Schedule 4.13(c) contains a complete and accurate list of each Governmental Authorization that is held by the Seller other than the CE Marks and the 510(k)


16 SL1 1342200v6 109188.00001

Clearances which otherwise relate and are material to the Business including the Products. Each Governmental Authorization listed on Section 4.13(c) is valid and in full force and effect, and the Seller is in compliance in all material respects with all such Governmental Authorizations.

(d) The Seller has never, either voluntarily or involuntarily, initiated, conducted or issued, or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, warning notice, investigator notice or other notice or action disclosing an alleged material defect or lack of material safety or efficacy of any Product.

(e) The Products that are within the Acquired Assets are merchantable and fit for purpose for with they were designed.

4.14. Legal Proceedings; Orders. There is no Proceeding pending that challenges, or that is reasonably likely to have the effect of preventing, delaying or rendering illegal any of the transactions contemplated by this Agreement. There is no Order to which the Business or any Product is currently subject.

4.15. Tax Matters.

(a) The Seller has filed (or has had filed on its behalf) all material Tax returns required to have been filed by it in connection with the Business. All such Tax returns were and are true, complete and correct in all material respects. No claim has been made by a Governmental Body in a jurisdiction where the Seller does not file Tax returns to the effect that the Seller is or may be subject to taxation by that jurisdiction. The Seller has not requested any extension of time within which to file any Tax return, which Tax return has not since been timely filed.

(b) The Seller has, within the time and in the manner prescribed by applicable Laws, paid all Taxes that are due and payable by the Seller and attributable to the Business or the Acquired Assets. No deficiency for any such Taxes has been proposed, asserted or assessed against the Seller that has not been resolved and paid in full.

(c) There are no Tax Liens or Encumbrances for Taxes upon the Acquired Assets and as of the end of the day on the Closing Date there will be no such Tax Liens or Encumbrances. There is not and, as of the end of the day on the Closing Date there will not be, any liability for Taxes affecting the Acquired Assets for which the Purchaser will at any time have any liability for payment.

4.16. Environmental Matters. Except for conditions that, either individually or in the aggregate, would not reasonably be expected to result in material liability under Environmental Laws and to the Sellers’ Knowledge, the Seller, in the conduct of the Business: (i) has transported, stored and/or disposed of any Hazardous Materials brought on to the Leased Real Property in compliance in all material respects with all applicable Environmental Laws, (ii) has operated the Business with all material Governmental Authorizations required under any applicable Environmental Law, and (iii) has not received any written notice of any investigation, Proceeding or Order concerning any material Environmental Condition applicable to the conduct of the Business as currently conducted or the ownership and use by the Seller of the material


17 SL1 1342200v6 109188.00001

Acquired Assets. There is no pending or, to the Sellers’ Knowledge, threatened civil or criminal litigation, written notice of violation, written inquiry or information request by any Governmental Body, relating to any material violation of Environmental Law involving the Seller that is applicable to the conduct of the Business or the ownership and use of the material Acquired Assets.

4.17. Employee Matters. Schedule 4.17 sets forth an accurate list of (i) all officers, directors, and employees of the Seller and (ii) the rate of compensation (and the portions thereof attributable to salary, bonus and other compensation, respectively) of each of such officers, directors, and employees as of the last payroll date immediately preceding the date of this Agreement.

4.18. Employee Benefit Plans.

(a) The SEC Reports identify each material Employee Benefit Plan maintained by the Seller. Each such Employee Benefit Plan complies in all material respects with the applicable requirements of ERISA, the Code, and other applicable Laws. All material required reports and descriptions (including Form 5500 Annual Reports, summary annual reports, and summary plan descriptions) have been timely filed and distributed appropriately with respect to each such Employee Benefit Plan.

(b) Each Employee Benefit Plan described in Section 4.15(a) is intended to be qualified under Section 401(a) of the Code is so qualified and has been determined by the IRS to be so qualified.

(c) The Seller has not, and at no time in the past has had, an obligation to contribute to a “defined benefit plan” as defined in Section 3(35) of ERISA, a pension plan subject to the funding standards of Section 302 of ERISA or Section 412 of the Code, a “multiemployer plan” as defined in Section 3(37) of ERISA or Section 414(f) of the Code or a “multiple employer plan” within the meaning of Section 210(a) of ERISA or Section 413(c) of the Code.

(d) All (i) insurance premiums required to be paid with respect to, (ii) benefits, expenses and other amounts due and payable under, and (iii) contributions, transfers or payments required to be made to, any Employee Benefit Plan described in Section 4.15(a) prior to the Closing Date will have been paid or made on or before the Closing Date.

4.19. Labor Matters. The Seller is not a party to nor is bound by, or has an obligation to perform under, any collective bargaining agreement or any other Contract with a labor union or labor organization. The Seller has not received any written notice of any outstanding representation petitions involving the Seller before the National Labor Relations Board or any state labor board, and to the Knowledge of the Seller, no such petition has been threatened.

4.20. Insurance. Schedule 4.20 sets forth a list of each insurance policy maintained by the Seller with respect to the Business and the Acquired Assets as of the date hereof. Each such policy of insurance is in full force and effect.


18 SL1 1342200v6 109188.00001

4.21. Financial Statements and SEC Reports. From January 1, 2012 through June 30, 2014, the Seller had timely filed or furnished all reports, schedules, forms, statements and other documents required to be filed or furnished by it with the Securities and Exchange Commission (collectively, the “SEC Reports”), all of which have complied as of their respective filing dates in all material respects with all applicable requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder (the “Sarbanes-Oxley Act”). The audited and unaudited financial statements (including the related notes thereto) of the Seller included (or incorporated by reference) in the SEC Reports have been prepared in accordance with GAAP applied on a consistent basis throughout the periods involved and fairly present in all material respects the financial position and the results of operations, changes in stockholders’ equity and cash flows of the Seller as of their respective dates (subject, in the case of any unaudited or interim statements therein, to normal year-end audit adjustments and to any other adjustments set forth therein and lack of footnotes).

4.22. Brokers and Finders. Other than Houlihan Lokey Capital, Inc., no broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated hereby based upon arrangements made by or on behalf of the Seller and at Seller’s expense or as an administrative claim in the Bankruptcy Case.

4.23. Representations and Warranties are Exclusive. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE IV, SELLER MAKES NO REPRESENTATION OR WARRANTY, EXPRESS OF IMPLIED, AT LAW OR IN EQUITY, WITH RESPECT TO ANY FACT OR MATTER RELATING OR PERTAINING TO THE ACQUIRED ASSETS OR THE BUSINESS OR ANY OTHER MATTER, INCLUDING WITH RESPECT TO MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OR USE OR NON-INFRINGEMENT, AND ANY SUCH OTHER REPRESENTATIONS AND/OR WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED AND NONE SHALL BE IMPLIED AT LAW OR IN EQUITY. THE PURCHASER HEREBY EXPRESSLY ACKNOWLEDGES AND AGREES THAT, EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS ARTICLE IV, THE PURCHASER IS ACQUIRING THE ACQUIRED ASSETS ON AN “AS-IS, WHERE-IS” BASIS. ALL REPRESENTATIONS AND WARRANTIES OF THE SELLER SHALL EXPIRE ON THE CLOSING DATE AND THEREAFTER BE OF NO FURTHER FORCE OR EFFECT.

4.24. Scheduled Assets and Contracts v. Acquired Assets and Assigned Contracts. Notwithstanding that some disclosure schedules hereto may include assets and contracts which are not Acquired Assets or Assigned Contracts, it is understood and agreed that the Purchaser is purchasing only Acquired Assets and that there are no Assigned Contracts hereunder.

ARTICLE V REPRESENTATIONS AND WARRANTIES OF PURCHASER.

Except as set forth in the disclosure letter delivered by the Purchaser to the Seller on the date hereof (the “Purchaser Disclosure Letter”), the Purchaser represents and warrants to the Seller as follows.


19 SL1 1342200v6 109188.00001

5.1. Organization. The Purchaser is a Limited Partnership duly formed, validly existing and in good standing under the laws of the State of Delaware and has all requisite power and authority to conduct its business and own and operate its properties.

5.2. Power and Authority. The Purchaser has all requisite power and authority to enter into this Agreement and the Ancillary Documents and to consummate the transactions contemplated hereby and thereby. This Agreement has been duly executed and delivered by the Purchaser. This Agreement is a valid and binding obligation of the Purchaser, enforceable against the Purchaser in accordance with its terms.

5.3. Non-contravention. Neither the execution and delivery of this Agreement or any other Ancillary Document to which the Purchaser is a party, will (i) violate any provision of the organizational documents of the Purchaser, or (ii) violate any Law or Order applicable to the Purchaser.

5.4. No Proceedings. There are no actions, suits or proceedings pending, or to the actual knowledge of the Purchaser, threatened, before or by any Governmental Body, against the Purchaser which would affect the Purchaser’s ability to proceed with the transactions contemplated by this Agreement.

5.5. Bankruptcy Matters. Purchaser is capable of satisfying the adequate assurance of future performance conditions contained in Section 365 (f)(2)(B) of the Bankruptcy Code with respect to each Assigned Contract.

5.6. Consents. No consent, waiver, authorization or approval of any person or declaration, filing or registration with any Governmental Body or other Person is required in connection with the execution and delivery by the Purchaser of this Agreement or the performance by the Purchaser of its obligations hereunder or thereunder.

5.7. Financing. The Purchaser has cash on hand, availability under existing lines of credit, or other immediately available financial resources sufficient to pay the Purchase Price at the Closing.

5.8. Certain Relationships. Neither the Purchaser nor any officer, director, manager, member, Representative or Affiliate of the Purchaser is an officer or director of the Seller or a Related Person of any officer, director or key employee of the Seller. Except as set forth in Schedule 5.7, neither the Purchaser nor any officer, director, manager, member, Representative or Affiliate of the Purchaser has entered into any Contract with any officer, director or key employee of the Seller.

5.9. Brokers and Finders. No Person has acted, directly or indirectly, as a broker, finder or financial advisor for the Purchaser in connection with the transactions contemplated hereunder and no Person is entitled to any fee or commission or like payment in respect thereof.

ARTICLE VI COVENANTS OF THE PARTIES


20 SL1 1342200v6 109188.00001

6.1. Access to Information. The Seller shall permit the Purchaser’s Representatives to have, upon prior written notice, reasonable access during normal business hours and under reasonable circumstances, and in a manner so as not to interfere with the normal business operations of the Seller, to the premises, personnel, books, records, and documents of or pertaining to the Acquired Business; provided, that the Seller may restrict the foregoing access to the extent that in the reasonable judgment of the Seller, any Laws applicable to the Seller require it to restrict access to any of its business, properties, information or personnel; and provided, further, that such access shall not unreasonably disrupt the operations of the Seller. The Purchaser shall comply with, and shall cause its Representatives to comply with, all of its obligations under the Non-Disclosure Agreement with respect to the terms and conditions of this Agreement and the transactions contemplated hereby and the information of the Seller and the Acquired Business disclosed or accessed pursuant to this Section 6.1, which agreement shall remain in full force and effect until the Closing Date. Notwithstanding anything to the contrary contained in this Agreement, the Seller shall not be required to provide any information or access that the Seller reasonably believes could violate applicable Law.

6.2. Conduct of the Acquired Business. From the date hereof until the Closing Date, except as otherwise provided in this Agreement or consented to in writing by the Purchaser (which consent shall not be unreasonably withheld, conditioned or delayed), and subject in all respects to the Bankruptcy Code and orders of the Bankruptcy Court (including, without limitation, the Sale Order), the Seller shall: (a) conduct the Acquired Business in the Ordinary Course of Business; and (b) use its commercially reasonable efforts to preserve intact its material business relationships with customers, suppliers, and other Persons having business dealings with it relating to the Acquired Business, and to keep available the services of its officers, members and key employees.

6.3. Reserved.

6.4. Further Actions Regarding 510(k) Clearances and Filings, CE Marks and Intellectual Property Administration. Promptly following the Closing Date, the Seller shall execute and deliver such documents and instruments of transfer or assignment, and take all such other actions, as may be necessary or required under any applicable Laws or reasonably requested by the Purchaser or any applicable Governmental Body from time to time, in order to (a) effectively transfer and assign to the Purchaser all of the Seller’s right, title, and interest in and to any 510(k) Clearances, 510(k) Filings and CE Marks included in the Acquired Assets, and (b) take such other actions (all at the Purchaser’s expense) as the Purchaser shall reasonably request or require in order to transfer ownership thereof and responsibility therefor to the Purchaser.

6.5. Further Actions Regarding Acquired Assets. The Seller shall execute and deliver all documents and instruments and take all actions as may be necessary or required under any applicable Contract or Lease or reasonably requested by the Purchaser (at the Seller’s expense), in order to (a) allow the Acquired Assets to remain in the Seller’s Facilities for at least thirty (30) days (at the Seller’s cost and expense), (b) provide the Purchaser access to the Acquired Assets during such period for the Purchaser to inspect, take possession of and remove the Acquired Assets from the Seller’s Facilities and to extract from the Seller’s Salesforce, Customer Relationship Management (“CRM”) and the Enterprise Resource Planning (“ERP”) systems


21 SL1 1342200v6 109188.00001

information relating to the Products, the Acquired Assets and Acquired Business; and (c) where the Acquired Assets are located outside of the Seller’s Facilities, the Seller shall make commercially reasonable efforts to assist the Purchaser in gaining access to such Acquired Assets provided, however, the foregoing shall not apply to Inventory in the possession of any distributor who is continuing as a distributor for the Purchaser for any period of time after the Closing Date nor to any Acquired Assets located at Venta Medical, Inc. (“Venta”) unless the Purchaser does not utilize the manufacturing services of Venta after the Closing Date. The Seller shall also take all reasonable and customary actions to secure and safeguard the Seller’s Facilities, all at the Seller’s cost and expense. The foregoing notwithstanding, the Purchaser acknowledges that the Seller has advised the Purchaser that, immediately following Closing the Seller intends to terminate the employment of all, or substantially all, of its employees and agrees that that Seller shall not have any obligation to (x) assist the Purchaser in effecting removal of Acquired Assets from the Seller’s Facilities or in the extraction of information from the Seller’s Salesforce, CRM and ERP systems but, rather, shall only be required to provide the Purchaser access to the Seller’s Facilities for thirty (30) days following the Closing Date in order to allow the Purchaser to effect such removal and extract such information, nor (y) effect physical delivery to the Purchaser of any Acquired Assets, whether located at the Seller’s Facilities or elsewhere.

6.6. Notification of Certain Matters. From time to time prior to the Closing Date, the Parties shall promptly notify each other of the occurrence or non-occurrence of any event or circumstance that as applicable, indicates (a) that any of the representations and warranties set forth herein may not be, will not be, or are not, true and correct, or (b) any failure on its part to comply with or satisfy, in any material respect, any covenant, agreement or condition to be complied with or satisfied by it pursuant hereto (any such notification, a “RequiredNotification”); provided, however, that in each case, such disclosure shall not be deemed to (i) amend or supplement any Schedule hereto, or (ii) cure any breach of such representation, warranty, covenant or agreement or satisfy any condition set forth herein.

6.7. Cooperation. Subject in all respects to the Bankruptcy Code, the Parties shall use their respective commercially reasonable efforts not involving litigation to (a) take or cause to be taken all actions, and to do or cause to be done all other things, necessary, proper or advisable to expeditiously satisfy the closing conditions set forth in Article VII and to consummate the transactions contemplated hereby as promptly as practicable, and (b) obtain in a timely manner all necessary waivers, consents and approvals and to effect all necessary registrations and filings in connection with the foregoing. Nothing in this Agreement shall be construed so as to prohibit or restrict the Seller from winding up its operations and, provided it has complied with its obligations under the Agreement that have arisen to the date of such winding up, once it has done so, it shall have no further obligations hereunder.

6.8. Records Retention and Access. For a period of six (6) years following the Closing or such shorter period that records are required to be retained by applicable Laws (but in no event less than three (3) years), the Purchaser shall furnish to the Seller, to the extent in the Purchaser’s possession and following receipt of a reasonable, written request therefor, information that is necessary for the Seller to prepare for, prosecute or defend against any Proceeding related to the Acquired Business, to validate claims filed in the Bankruptcy Case and/or to enable the Seller and its Representatives to prepare, complete and file all required federal, state and local Tax returns in accordance with applicable Laws. Should there be any requests for materials for


22 SL1 1342200v6 109188.00001

discovery or materials requiring electronic discovery beyond four (4) hours effort by an employee of Purchaser, Seller shall bear Purchaser's reasonable cost of compliance with such requests.

6.9. Confidentiality. The Purchaser acknowledges and agrees that the Non-Disclosure Agreement remains in full force and effect and shall remain in full force and effect from the date hereof through and including the Closing Date, and covenants and agrees to keep confidential, in accordance with the provisions of the Non-Disclosure Agreement, any and all information and other materials provided to or accessed by the Purchaser pursuant to this Agreement. After the Closing, Purchaser shall own the information it has purchased and shall be released from the confidentiality obligations with respect to that information.

6.10. Certain Agreements. From the date hereof through the Closing Date, the Parties shall not enter into any Contract other than those which are specifically contemplated by this Agreement or the Ancillary Documents.

6.11. Bankruptcy Matters. The Seller shall use commercially reasonable efforts to seek relief from the fourteen (14) day stay provided by Section 6004(h) of the Bankruptcy Code. At the hearing to consider approval of this Agreement, the Seller will request that the Sale Order be modified to extend the protections afforded to the Purchaser under Section 363 (including, without limitation, section 363(m)) of the Bankruptcy Code to Amendia as assignee or transferee of the Purchaser. If such request is denied by the Bankruptcy Court, the Seller shall have no further obligations related to such request and such denial shall not affect any obligations of the Purchaser hereunder.

ARTICLE VII CONDITIONS TO CLOSING

7.1. Conditions to Obligations of Each Party. The respective obligations of each Party to consummate the transactions contemplated hereby shall be subject to the satisfaction at or prior to the Closing of the following conditions:

(a) Proceedings; Orders. No Governmental Body of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any Law or Order (whether temporary, preliminary or permanent) that (i) is in effect and (ii) has the effect of making the transactions contemplated hereby illegal or otherwise prohibiting consummation of such transactions.

(b) Sale Order. The Bankruptcy Court shall have entered the Sale Order and the fourteen (14) period provided by Section 6004(h) of the Bankruptcy Code shall have expired or been waived by the Bankruptcy Court.

7.2. Additional Conditions to Obligations of the Purchaser. The obligations of the Purchaser to effect the transactions contemplated hereby are subject to satisfaction or waiver of the following additional conditions:

(a) Representations and Warranties. The representations and warranties of the Seller set forth in this Agreement shall be true and correct (without giving effect to any


23 SL1 1342200v6 109188.00001

limitation as to “materiality” or “Material Adverse Effect” or similar qualifications) as of the Closing Date, as if made as of such time (except to the extent that such representations and warranties expressly speak as of another date, in which case such representations and warranties shall be true and correct as of such date), except where the failure of such representations and warranties to be so true and correct would not, individually or in the aggregate, have a Material Adverse Effect.

(b) Agreements and Covenants. The Seller shall have performed and complied with all of its covenants hereunder in all material respects through the Closing.

(c) Documents. All of the documents, instruments and agreements required to be executed and/or delivered by the Seller on or prior to Closing pursuant to Section 8.2 of this Agreement shall have been executed by the parties thereto other than the Purchaser and delivered to the Purchaser.

(d) Closing Date Inventory. The Book Value of the Closing Date Inventory must be at least $ 1,200,000.00.

(e) Consent to Sale. Hercules Technology Growth Capital. Inc. (“Hercules”) shall consented to the sale to Purchaser of the Acquired Assets.

(f) No Litigation. No litigation shall have been filed alleging manufacturing design or other defects in the Products that are within the Acquired Assets between the date of the Agreement and the Closing Date and which could reasonably be expected to interfere with the ability of the Purchaser to conduct the Acquired Business.

7.3. Additional Conditions to Obligations of the Seller. The obligations of the Seller to effect the transactions contemplated hereby are subject to satisfaction or waiver by the Seller of the following additional conditions:

(a) Representations and Warranties. The representations and warranties of the Purchaser set forth in this Agreement shall be true and correct (without giving effect to any limitation as to “materiality” or similar qualifications) as of the Closing Date, as if made as of such time (except to the extent that such representations and warranties expressly speak as of another date, in which case such representations and warranties shall be true and correct as of such date), except where the failure of such representations and warranties to be so true and correct would not, individually or in the aggregate, have a Purchaser Material Adverse Effect.

(b) Agreements and Covenants. The Purchaser shall have performed and complied with all of its covenants hereunder in all material respects through the Closing.

(c) Documents. All of the documents, instruments and agreements required to be executed and/or delivered by the Purchaser on or prior to Closing pursuant to Section 8.3 of this Agreement shall have been executed by the parties thereto other than the Seller and delivered to the Seller.

ARTICLE VIII CLOSING; DELIVERIES AT THE CLOSING


24 SL1 1342200v6 109188.00001

8.1. Closing. The closing of the transactions contemplated hereby (the “Closing”)shall take place at the offices of Stevens & Lee, P.C., 1818 Market St., 29th Floor, Philadelphia, PA., or such other place or remotely by mail, e-mail and/or wire transfer, in each case to the extent acceptable to each of the Parties, as soon as practicable following the satisfaction or waiver of the conditions set forth in Article VII hereof and in any event within three (3) Business Days thereafter (the “Closing Date”). The Closing shall be deemed to have occurred at 12:01 a.m., Eastern Standard Time, on the Closing Date.

8.2. Deliveries by the Seller at the Closing. At the Closing, Seller shall furnish and deliver to the Purchaser the following:

(a) the Bill of Sale, duly executed by the Seller;

(b) the Assignment and Assumption Agreement, duly executed by the Seller for the Assigned Contracts, if any;

(c) all Termination Notices, duly executed by the Seller;

(d) an Assignment of Trademarks executed by the Seller in the form(s) attached hereto as Exhibit F;

(e) an Assignment of Patents executed by the Seller in the form(s) attached hereto as Exhibit G;

(f) a non-foreign certification executed by the Seller in form and substance reasonably satisfactory to the Purchaser and that satisfies the requirements of Treasury Regulation § 1.1445-2(b)(2);

(g) a certificate, dated as of the Closing Date and signed the Seller, certifying that each of the conditions set forth in Sections 7.2(a) and 7.2(b) have been satisfied;

(h) Reserved;

(i) Reserved;

(j) a copy of the Sale Order; and

(k) all other certificates, instruments and documents required to be delivered by the Seller pursuant to this Agreement or any of the Ancillary Documents and such other documents customarily delivered and viewed as necessary or advisable by Purchaser.

8.3. Deliveries by the Purchaser at the Closing. At the Closing, the Purchaser shall furnish and deliver to the Seller the following:

(a) the portion of the Purchase Price in excess of the Deposit (and all interest thereon in accordance with the Escrow Agreement), by wire transfer of immediately available funds to an account designated in writing by the Seller provided, however, the Net Proceeds of


25 SL1 1342200v6 109188.00001

Sale payable to Hercules pursuant to subparagraph [20(d)] of the Sale Order shall be paid directly to an account designated in writing by Hercules;

(b) an authorization, in form and substance satisfactory to the Seller and in accordance with the Escrow Agreement, to the Escrow Agent to release the Deposit (and all interest thereon) to the Seller;

(c) the Assignment and Assumption Agreement, duly executed by the Purchaser for the Assigned Contracts, if any;

(d) a certificate, dated as of the Closing Date and signed the Purchaser, certifying that each of the conditions set forth in Sections 7.3(a) and 7.3(b) have been satisfied;

(e) a list of all Retained Employees; and

(f) all other certificates, instruments and documents required to be delivered by the Purchaser pursuant to this Agreement or any of the Ancillary Documents.

ARTICLE IX TERMINATION

9.1. Termination. This Agreement may be terminated at any time prior to the Closing:

(a) By mutual written consent of the Seller and the Purchaser;

(b) By (i) the Seller if, as of the day after the Outside Closing Date, any condition to the obligation of the Seller to close has not been satisfied, provided, however, that if the Closing has not occurred on or before the Outside Closing Date due to a material breach of any representations, warranties, covenants or agreements contained in this Agreement by Seller, then Seller may not terminate this Agreement pursuant to this Section 9.1(b) and (ii) the Purchaser if, as of the day after the Outside Closing Date, any condition to the obligation of the Purchaser to close has not been satisfied provided, however, that if the Closing has not occurred on or before the after the Outside Closing Date due to a material breach of any representations, warranties, covenants or agreements contained in this Agreement by the Purchaser, then the Purchaser may not terminate this Agreement pursuant to this Section 9.1(b);

(c) Automatically, and without further action by any Party, upon the issuance of a Final Order to restrain, enjoin or otherwise prohibit the closing of the transactions contemplated hereby provided that neither the Seller nor the Purchaser shall not take any action to support entry of such an order;

(d) Automatically, and without further action by any Party, if the Bankruptcy Case is converted into a case under Chapter 7 of the Bankruptcy Code or is dismissed, provided that neither the Seller nor the Purchaser shall not take any action to support such conversion or dismissal;


26 SL1 1342200v6 109188.00001

(e) By the Purchaser, if the Purchaser is not in material breach of its obligations under this Agreement, and if (i) the Seller fails to close on the Closing Date notwithstanding the satisfaction of all conditions to the obligation of the Seller to Close (other than conditions related to deliveries to be made at Closing by the Purchaser provided the Purchaser is ready, willing and able to make such deliveries as of the Closing Date), (ii) any of the representations and warranties of the Seller herein become untrue or inaccurate such that the condition set forth Section 7.2(a) would not be satisfied or (iii) there has been a breach on the part of the Seller of any of its covenants or agreements contained in this Agreement such that the condition set forth in Section 7.2(b) would not be satisfied, and, in the case of clauses (ii) and (iii) hereof, such breach (if curable) has not been cured within ten (10) days after written notice thereof to the Seller; and

(f) By the Seller, if the Seller is not in material breach of its obligations under this Agreement, and if (i) the Purchaser fails to close on the Closing Date notwithstanding the satisfaction of all conditions to the obligation of the Purchaser to close (other than conditions related to deliveries to be made at Closing by the Seller provided the Seller is ready, willing and able to make such deliveries as of the Closing Date), (ii) any of the representations and warranties of the Purchaser herein become untrue or inaccurate such that the condition set forth in Section 7.3(a) would not be satisfied or (iii) there has been a breach on the part of the Purchaser of any of its covenants or agreements contained in this Agreement such that the condition set forth in Section 7.3(b) would not be satisfied, and, in the case of clauses (ii) and (iii) hereof, such breach (if curable) has not been cured within ten (10) days after written notice thereof to the Purchaser.

(g) Automatically, and without further action by any Party, if (i) the Purchaser is not the Successful Bidder or Backup Bidder (each as defined in the Bid Procedures), or (ii) if the Purchaser is the Backup Bidder, upon Closing with the Successful Bidder.

9.2. Effect of Termination. Except as provided in this Section 9.2, in the event of the termination of this Agreement pursuant to Section 9.1, this Agreement (other than this Section 9.2, Section 6.9, and Article X (other than Sections 10.5 and 10.15(b)), which shall survive such termination) will forthwith become void, and there will be no liability on the part of any Party to the other and all rights and obligations of any Party will cease, except that nothing herein shall relieve any Party from liability for any intentional and material breach of this Agreement. Upon termination of this Agreement (x) pursuant to Section 9.1(a), (b), (c), (d), (g) or (h), the Escrow Agent shall promptly disburse the Deposit to the Purchaser pursuant, in the case of a termination pursuant to Section 9.1(g), to the terms of the Bid Procedures, (y) pursuant to Section 9.1(e), the Escrow Agent shall immediately disburse the Deposit to the Purchaser upon the entry of a Final Order by the Bankruptcy Court finding that there has been a breach by the Seller of the type described in Section 9.1(e) which has not been cured within the applicable time period set forth therein (or is not curable), or (z) pursuant to Section 9.1(f), the Escrow Agent shall immediately disburse the Deposit (and all interest thereon) to the Seller upon the entry of a Final Order by the Bankruptcy Court finding that there has been a breach by the Purchaser of the type described in Section 9.1(f) which has not been cured within the applicable time period set forth therein (or is not curable). The requirement for the entry of a Final Order for the disbursement of the Deposit as set forth in clauses (y) and (z) of the preceding sentence shall not be interpreted so as to require the entry of a Final Order before either the Seller of the Purchaser may exercise their respective rights to terminate this Agreement pursuant to Sections 9.1(e) or 9.1(f), as applicable. If


27 SL1 1342200v6 109188.00001

any Party purports to terminate this Agreement based on an alleged breach of this Agreement by the other Party and if such other Party shall dispute whether such breach occurred, the non-prevailing Party shall pay 50% of the prevailing Party’s legal fees and reasonable expenses related to such dispute in addition to whatever other remedies may be available to the prevailing Party, including specific performance.

ARTICLE X MISCELLANEOUS

10.1. Expiration of Representations, Warranties and Agreements. No representations or warranties made by the Seller in this Agreement or in any Ancillary Document delivered pursuant to this Agreement shall survive beyond the Closing Date. However, the foregoing shall not be deemed to exculpate or relieve any party or individual from liability for actionable, intentional fraud.

10.2. Assignment. Neither this Agreement nor any interest herein may be assigned or transferred by either Party to any other Person without the prior written consent of the other Party, which consent may be given or withheld in the sole discretion of such other Party; provided (a) Purchaser may, at any time prior to January 15, 2015, assign its rights (but not its obligations) hereunder to Amendia without the consent of the Seller, and (b) Purchaser may assign or transfer any remaining rights (but not its obligations) to Amendia following Closing without the consent of the Seller..

10.3. Notices. All notices, requests and other communications under this Agreement shall be in writing and shall be either (a) delivered in person, (b) sent by certified mail, return-receipt requested, (c) delivered by a recognized delivery service or (d) sent by facsimile transmission and addressed as follows:

If intended for the Purchaser: Andy Hall ExWorks Capital Fund I, L.P. 333 W. Wacker Drive, Suite 1620 Chicago, IL 60606

With a copy to: Donald F. Baty, Esquire Honigman Miller Schwartz and Cohn LLP 2290 First National Building 660 Woodward Avenue Detroit, MI 48226

And a copy also to: Michael F. Rozmajzl Amendia, Inc. 1755 West Oak Parkway Marietta, Georgia 30062


28 SL1 1342200v6 109188.00001

And a copy to:

If intended for the Seller:

Michael A. Steel Brennan, Manna & Diamond, LLC 75 East Market Street Akron, Ohio 44308

Baxano Surgical, Inc. 110 Horizon Drive Suite 203 Raleigh, North Carolina 27615

With a copy to: Robert Lapowsky, Esquire Stevens & Lee, P.C. 1818 Market St., 29th Floor Philadelphia, PA 19103

or at such other address, and to the attention of such other person, as the parties shall give notice as herein provided. A notice, request and other communication shall be deemed to be duly received if delivered in person or by a recognized delivery service, when delivered to the address of the recipient, if sent by mail, on the date of receipt by the recipient as shown on the return receipt card, or if sent by facsimile, upon receipt by the sender of an acknowledgment or transmission report generated by the machine from which the facsimile was sent indicating that the facsimile was sent in its entirety to the recipient’s facsimile number; provided that if a notice, request or other communication is served by hand or is received by facsimile on a day which is not a Business Day, or after 5:00 P.M. on any Business Day at the addressee’s location, such notice or communication shall be deemed to be duly received by the recipient at 9:00 A.M. on the first Business Day thereafter.

10.4. Further Assurances. Each of the Parties hereto shall execute such documents (including, without limitation, the Ancillary Documents) and take such further actions as may be reasonably required or desirable to carry out the provisions hereof and the transactions contemplated hereby or, at or after the Closing, to evidence the consummation of the transactions consummated pursuant to this Agreement.

10.5. Entire Agreement; Modifications; Waivers. This Agreement (together with the Exhibits and Schedules hereto), the Ancillary Documents, and the Non-Disclosure Agreement constitute the entire agreement between the Parties with respect to the subject matter hereof and thereof and supersedes all prior understandings of the Parties with respect to the subject matter hereof and thereof. No supplement, modification or amendment of this Agreement will be binding unless executed in writing by each Party. No waiver of any of the provisions of this Agreement will be deemed to be or will constitute a continuing waiver. No waiver will be binding unless executed in writing by the Party making the waiver.

10.6. Applicable Law; Jurisdiction and Venue; Jury Trial Waiver. THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE. The Parties agree that jurisdiction and venue for any litigation arising out of


29 SL1 1342200v6 109188.00001

this Agreement shall be in the Bankruptcy Court; provided, however, that if at the time of commencement of any such litigation, there is no longer a pending Bankruptcy Case, jurisdiction and venue for any litigation arising out of this Agreement, provided jurisdiction may be obtained under applicable law, shall be in the U.S. District Court for the District of Delaware, and the Parties each hereby waive any objections they may have with respect thereto (including any objections based upon forum non conveniens). EACH OF THE PARTIES HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT, ANY ANCILLARY DOCUMENT, OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.

10.7. Headings and Captions. The headings and captions in this Agreement are inserted for convenience of reference only and in no way define, describe, or limit the scope or intent or otherwise affect the interpretation of, this Agreement or any of the provisions hereof.

10.8. Binding Effect. This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective successors and permitted assigns.

10.9. Time is of the Essence. With respect to all provisions of this Agreement, time is of the essence. However, if the first date or last date of any period which is set out in any provision of this Agreement falls on a day which is not a Business Day, then, in such event, the time of such period shall be extended to the next day which is a Business Day.

10.10. Remedies Cumulative. Except as herein expressly set forth, no remedy conferred upon a Party by this Agreement is intended to be exclusive of any other remedy herein or by law provided or permitted, but each shall be cumulative and shall be in addition to every other remedy given herein or now or hereafter existing at law, in equity or by statute.

10.11. Interpretation and Construction.

(a) As used herein the words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation”.

(b) As used herein, the words “herein,” “hereof,” “hereunder” and similar terms shall refer to this Agreement unless the context requires otherwise.

(c) For purposes of this Agreement, whenever the context so requires, the neuter gender includes the masculine and/or feminine gender, and the singular number includes the plural and vice versa.

10.12. Estoppel. Each Party confirms and agrees that (a) it has read and understood all of the provisions of this Agreement; (b) it is familiar with major sophisticated transactions such as those contemplated by this Agreement; (c) it has negotiated with the other Party at arm’s length with equal bargaining power; and (d) it has been advised by competent legal counsel of its own choosing.

10.13. Joint Preparation. The Parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation


30 SL1 1342200v6 109188.00001

arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement.

10.14. Expenses; Transfer Taxes.

(a) Except as otherwise expressly provided in this Agreement, each Party will bear its respective expenses incurred in connection with the preparation, negotiation, execution, and performance of this Agreement and the transactions contemplated hereby, including all fees and expenses of agents, representatives, counsel, and accountants.

(b) The Purchaser and Seller shall each pay one-half (1/2) of all sales, use, transfer, real property transfer, documentary, recording and similar Taxes and fees, and any deficiency, interest or penalty asserted with respect thereof arising out of or in connection with the transactions contemplated hereby (“Transfer Taxes”).

10.15. Counterparts. This Agreement may be executed at different times and in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by e-mail shall be as effective as delivery of a manually executed counterpart of this Agreement.

10.16. Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced under any Law or as a matter of public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect.

[Signature page follows]


SL1 1342200v6 109188.00001

EXHIBIT A

ACQUIRED ASSETS

The Acquired Assets to be purchased by the Purchaser and sold on the Closing Date to the Purchaser by the Seller shall include all of the Seller’s right, title and interest in and to all of the following assets, but specifically excluding, however, the Excluded Assets:

1. Product Rights. All of the Seller’s right, title, and interest in and to all of the Products, including all of the Seller’s rights with respect to the design, development, manufacturing, marketing, sale, and distribution of the Products throughout the world, regardless of whether such Products are in development or any other stage of the product life cycle, and including all rights with respect to any modification, improvement, or enhancement thereto.

2. Inventories. All Inventory, including raw materials and components, work-in-process, finished goods, and other materials, spare parts, components, and supplies, as well as all packaging and labeling inventories, supplies, and materials wherever located.

3. Other Tangible Personal Property. All (a) property described on Schedule A-1 to this Exhibit A, and (b) other items not described on Schedule A-1 consisting of Goods, machinery, Equipment, tooling, molds, and other fixed assets, trade fixtures, furnishings, vehicles, furniture, displays, display materials, signs, tools, computer hardware (other than computer hardware related to the CRM, ERP and Salesforce systems), accessories, artwork, office and other equipment, appliances, and other tangible personal property, and any replacement parts for any such tangible assets, in all cases to the extent related to the Products.

4. Intellectual Property. That portion of the Owned Intellectual Property identified on Schedule A-2 to this Exhibit A, and all goodwill associated therewith and all reissuances, continuations, continuations in part, revisions, extensions and reexaminations thereof.

5. Assigned Contracts. All of the Seller’s rights and interests as of the Closing Date under or relating to the Contracts specifically identified on Schedule A-3 to this Exhibit A.

6. Books and Records. All Books and Records related to the Products including without limitation all original data and records related to the Products, including client and customer lists and records, referral sources, research and development reports and records, software programs, customer relationship management records related to the historical Product sales, production reports and records, service and warranty records, equipment logs, operating guides and manuals, financial and accounting records, creative materials, advertising materials, promotional materials, studies, reports, correspondence and other similar documents and records. The foregoing notwithstanding, the Books and Records including in the Acquired Assets shall not include the ERP, CRM and Salesforce systems (as to which access will be provided as described in the Agreement) or any Corporate Documents.

7. Governmental Authorizations. All transferable Governmental Authorizations, identified on Schedule A-4 to this Exhibit A (including the 510(k) Clearances, 510(k) Filings, and CE Marks identified thereon, and the 510(k) Supporting Materials and CE Mark Supporting


SL1 1342200v6 109188.00001

Materials relating thereto. All regulatory filings, certifications, and approvals from the U.S. Food and Drug Administration and its foreign counterparts including all pending applications therefore or renewals thereof incorporated into or necessary for the Seller’s products, including, for example, CE approval, ISO9001, ISO 13485, CMCDA, quality assurance systems and related documentation and software, and any other regulatory certifications including but not limited to the assets listed in Schedule A-4.).

8. Rights; Warranty Claims. All of Seller’s rights, claims, counterclaims, credits, causes of action or rights of set-off against third parties that relate to warranties, indemnities and all similar rights to the extent related to any Acquired Assets.

9. Goodwill. All goodwill associated with the Products.

10. Other Assets. Those other assets of the Seller identified on Schedule A-5 to this Exhibit A.


SL1 1342200v6 109188.00001

Schedule A-1

Other Tangible Personal Property

1. All hard copy training materials for iO-Flex and iO-Tome consisting of; a. Training videos b. Surgical technique guide c. Bone models

2. All hard copy Design History Files for iO-Flex, iO-Tome and Bone Graft Harvester 3. All hard copy SalesForce Data pertaining to iO-Flex, iO-Tome and Bone Graft Harvester 4. All hard copy Clinical Study Files for iO-Flex Specific to the STRIDE and original iO-Flex

Study5. All tooling, inspection and manufacturing located at Venta described in Schedule A-1A 6. All manufacturing equipment and machinery located at various vendors listed in

Schedule A-1B 7. The iO Flex saw bone models at Baxano Surgical – approximately 2 cases 8. Approximately 17 cases of Baxtor demonstration models at Baxano Surgical 9. Ten 13 inch wide by 72 inch long rolling wire racks used to store iO inventory 10. Five 24 inch wide by 72 inch long rolling wire racks used to store iO inventory


Venta�Tran

sfer�Final�Che

cklist�1

2/1/14

��Sche

dule�A1�A�

�

Page

�1�o

f�11�

�

EQ o

r Tag

N

umbe

r A

sset

N

umbe

r Lo

catio

nD

escr

iptio

n M

anuf

actu

rer

Mod

el #

Tr

ansf

er

Dat

e EQ

s - C

ontr

olle

d Eq

uipm

ent

EQ

0001

-09

0039

0 V

ario

us

Cal

iper

, 6"

Mitu

toyo

C

D-6

"CS

X

10/2

2/14

E

Q00

01-1

6 00

463

Var

ious

C

alip

er, 6

" M

ituto

yo

500-

196-

20

10/2

2/14

E

Q00

01-1

7 00

462

Var

ious

C

alip

er, 6

" M

ituto

yo

500-

196-

20

10/2

2/14

E

Q00

01-1

8 10

139

Var

ious

C

alip

er, 6

" M

ituto

yo

500-

196-

20

10/2

2/14

E

Q00

02-0

3 10

140

Var

ious

M

icro

met

er

Mitu

toyo

29

3-34

0 10

/22/

14

EQ

0002

-06

1014

3 V

ario

us

Mic

rom

eter

M

ituto

yo

293-

340

10/2

2/14

E

Q00

05-0

3 00

437

Var

ious

P

in G

ages

- .0

115

- .06

05" (

Min

us)

Mey

er G

age

M0

Z - M

inus

10

/22/

14

EQ

0005

-05

0043

4 V

ario

us

Pin

Gag

es -

.011

- .0

60" (

Min

us)

Mey

er G

age

M0

Z - M

inus

10

/22/

14

EQ

0007

00

450

CE

R

Forc

e G

auge

- 50

lb

Cha

tillo

n E

-DFE

-050

10

/22/

14

EQ

0008

00

464

CE

R

Forc

e G

auge

- 10

0 lb

C

hatil

lon

E-D

FE-1

00

10/2

2/14

E

Q00

08-1

0 00

448

CE

R

Forc

e G

auge

- 10

lb

Cha

tillo

n D

FGS

10

10/2

2/14

E

Q00

10

0044

7 C

ER

P

ouch

Cut

ting

Fixt

ure

Bax

ano

n/a

10/2

2/14

E

Q00

13-0

1 00

018

CE

R

Hot

Air

Sta

tion

Bea

hm D

esig

ns

210-

A 10

/22/

14

EQ

0013

-02

0001

1 C

ER

H

ot A

ir S

tatio

n B

eahm

Des

igns

21

0-A

10/2

2/14

E

Q00

13-0

4 00

069

CE

R

Hot

Air

Sta

tion

Bea

hm D

esig

ns

210-

A 10

/22/

14

EQ

0013

-05

0010

5 C

ER

H

ot A

ir S

tatio

n

Bea

hm D

esig

ns

210-

A 10

/22/

14

EQ

0013

-06

1017

5 C

ER

H

ot A

ir S

tatio

n B

eahm

Des

igns

21

0-A

10/2

2/14

E

Q00

13-0

7 00

479

CE

R

Hot

Air

Sta

tion

Bea

hm D

esig

ns

210-

A 10

/22/

14

EQ

0014

-01

0039

5 O

CE

R

Var

iabl

e S

peed

Grin

der

NS

K N

akni

sh In

c.

Ele

ctor

Em

ax

NE

129

10/2

2/14

EQ

0014

-02

0039

7 O

CE

R

Var

iabl

e S

peed

Grin

der -

No

Han

dpie

ce

NS

K N

akni

sh In

c.

Ele

ctor

Em

ax

NE

129

10/2

2/14

EQ

0014

-03

0040

1 O

CE

R

Var

iabl

e S

peed

Grin

der -

No

Han

dpie

ce

NS

K N

akni

sh In

c.

Ele

ctor

Em

ax

NE

129

10/2

2/14

EQ

0014

-05

0040

4 O

CE

R

Var

iabl

e S

peed

Grin

der

NS

K N

akni

sh In

c.

Ele

ctor

Em

ax

NE

129

10/2

2/14

EQ

0015

-01

0047

7 C

ER

Fl

uid

Dis

pens

er

EFD

87

0 10

/22/

14

EQ

0015

-02

0049

1 C

ER

Fl

uid

Dis

pens

er

EFD

87

0 10

/22/

14

EQ

0015

-04

0048

2 C

ER

Fl

uid

Dis

pens

er

EFD

12

00

10/2

2/14

E

Q00

15-0

5 10

176

CE

R

Flui

d D

ispe

nser

E

FD

1200

10

/22/

14

EQ

0015

-06

0049

5 C

ER

Fl

uid

Dis

pens

er

EFD

12

00

10/2

2/14

E

Q00

16-0

1 00

478

CE

R

UV

Lig

ht S

ourc

e D

ymax

39

370

10/2

2/14

E

Q00

16-0

3 00

492

CE

R

UV

Lig

ht S

ourc

e D

ymax

39

370

10/2

2/14

E

Q00

16-0

4 00

109

CE

R

UV

Lig

ht S

ourc

e D

ymax

B

lue

Wav

e 75

10

/22/

14

EQ

0016

-05

0020

0 C

ER

U

V L

ight

Sou

rce

Dym

ax

Blu

e W

ave

76

10/2

2/14

E

Q00

16-0

6 00

485

CE

R

UV

Lig

ht S

ourc

e D

ymax

B

lue

Wav

e 75

10

/22/

14

EQ

0017

-01

0000

9 C

ER

La

ser W

elde

r La

ser S

tar T

ech.

52

5-22

83

10/2

2/14

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 37

of 2

21

Venta�Tran

sfer�Final�Che

cklist�1

2/1/14

��Sche

dule�A1�A�

�

Page

�2�o

f�11�

�

EQ o

r Tag

N

umbe

r A

sset

N

umbe

r Lo

catio

nD

escr

iptio

n M

anuf

actu

rer

Mod

el #

Tr

ansf

er

Dat

e E

Q00

17-0

2 00

091

CE

R

Lase

r Wel

der

Lase

r Sta

r Tec

h.

512-

191-

080-

4 10

/22/

14

EQ

0018

-01

1015

6 C

ER

R

uler

, Met

al 2

4"

not a

vaila

ble

5R

10/2

2/14

E

Q00

20

0001

5 O

CE

R

TIG

Wel

der

Mille

r M

axst

ar 2

00 L

X

10/2

2/14

E

Q00

21-0

4 00

440

OC

ER

A

bras

ive

Cut

-off

Saw

M

icro

Mar

k M

icro

Lux

10

/22/

14

EQ

0022

00

428

OC

ER

R

ollin

g M

ill A

JS

L80

10/2

2/14

E

Q00

23-0

2 00

398

Var

ious

M

icro

scop

e no

t ava

ilabl

e no

t ava

ilabl

e 10

/22/

14

EQ

0023

-04

0049

8 V

ario

us

Mic

rosc

ope

Am

Sco

pe

not a

vaila

ble

10/2

2/14

E

Q00

23-0

9 10

169

Var

ious

M

icro

scop

e M

eiji

EM

Z-5

10/2

2/14

E

Q00

23-1

0 00

399

Var

ious

M

icro

scop

e - n

o lig

htbo

x M

eiji

EM

Z-5

10/2

2/14

E

Q00

23-1

1 10

171

Var

ious

M

icro

scop

e O

lym

pus

SZ4

045

10/2

2/14

E

Q00

23-1

2 00

471

Var

ious

M

icro

scop

e O

lym

pus

SZ4

045

10/2

2/14

E

Q00

23-1

3 00

497

Var

ious

M

icro

scop

e O

lym

pus

SZ4

045

10/2

2/14

E

Q00

23-1

4 00

387

Var

ious

M

icro

scop

e A

mS

cope

no

t ava

ilabl

e 10

/22/

14

EQ

0023

-16

1017

2 V

ario

us

Mic

rosc

ope

Mei

ji E

MZ-

5 10

/22/

14

EQ

0023

-17

0045

7 V

ario

us

Mic

rosc

ope

Oly

mpu

s S

Z404

5 10

/22/

14

EQ

0023

-18

0039

4 V

ario

us

Mic

rosc

ope

Oly

mpu

s S

Z404

5 10

/22/

14

EQ

0023

-19

0049

3 V

ario

us

Mic

rosc

ope

Oly

mpu

s S

Z404

5 10

/22/

14

EQ

0023

-20

0009

9 V

ario

us

Mic

rosc

ope

Oly

mpu

s S

Z404

5 10

/22/

14

EQ

0023

-21

0010

0 V

ario

us

Mic

rosc

ope

Oly

mpu

s S

Z404

5 10

/22/

14

EQ

0023

-22

0010

1 V

ario

us

Mic

rosc

ope

Oly

mpu

s S

Z404

5 10

/22/

14

EQ

0023

-23

0010

2 V

ario

us

Mic

rosc

ope

Oly

mpu

s S

Z404

5 10

/22/

14

EQ

0023

-24

0020

7 V

ario

us

Mic

rosc

ope

Oly

mpu

s S

Z404

5 10

/22/

14

EQ

0023

-25

0020

6 V

ario

us

Mic

rosc

ope

Oly

mpu

s S

Z404

5 10

/22/

14

EQ

0023

-26

0020

8 V

ario

us

Mic

rosc

ope

Oly

mpu

s S

Z404

5 10

/22/

14

EQ

0023

-28

0047

6 V

ario

us

Mic

rosc

ope

Oly

mpu

s S

Z404

5 10

/22/

14

EQ

0023

-29

1016

7 V

ario

us

Mic

rosc

ope

Oly

mpu

s S

Z404

5 10

/22/

14

EQ

0023

-30

1016

8 V

ario

us

Mic

rosc

ope

Oly

mpu

s S

Z404

5 10

/22/

14

EQ

0035

-01

0045

4 C

ER

A

rbor

Pre

ss

McM

aste

r Car

r n/

a 10

/22/

14

EQ

0035

-02

0045

5 C

ER

A

rbor

Pre

ss

McM

aste

r Car

r n/

a 10

/22/

14

EQ

0035

-03

1017

3 C

ER

A

rbor

Pre

ss

McM

aste

r Car

r n/

a 10

/22/

14

EQ

0035

-04

0044

9 C

ER

A

rbor

Pre

ss

Dak

e 90

1006

10

/22/

14

EQ

0038

-01

0046

1 C

ER

D

igita

l Dis

pay

w/ L

oad

Cel

l (10

0lb)

Tr

ansd

ucer

Tec

h.

DP

M-3

/TH

A-1

00-Q

10

/22/

14

EQ

0048

-09

0047

3 C

ER

R

uler

, Met

al 1

9.5"

(50

cm)

Sta

rrett

C63

6 10

/22/

14

EQ

0048

-10

1017

7 C

ER

R

uler

, Met

al 1

9.5"

(50

cm)

Sta

rrett

C63

6 10

/22/

14

EQ

0059

00

467

Var

ious

Th

erm

omet

er

Fluk

e 51

II

10/2

2/14

E

Q00

60-0

6 00

468

CE

R

Ther

moc

oupl

e - T

ype

K (-

40C

to 4

80C

) C

oppe

r Atk

ins

Type

K -

4913

8-K

10/2

2/14

E

Q00

60-0

8 10

106

CE

R

Ther

moc

oupl

e - T

ype

K (-

40C

to 4

80C

) C

oppe

r Atk

ins

Type

K -

4913

8-K

10/2

2/14

E

Q00

60-0

9 10

105

CE

R

Ther

moc

oupl

e - T

ype

K (-

40C

to 4

80C

) C

oppe

r Atk

ins

Type

K -

4913

8-K

10/2

2/14

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 38

of 2

21

Venta�Tran

sfer�Final�Che

cklist�1

2/1/14

��Sche

dule�A1�A�

�

Page

�3�o

f�11�

�

EQ o

r Tag

N

umbe

r A

sset

N

umbe

r Lo

catio

nD

escr

iptio

n M

anuf

actu

rer

Mod

el #

Tr

ansf

er

Dat

e E

Q00

63-0

3 10

151

Var

ious

S

top

Wat

ch

EA

I S

-970

0 10

/22/

14

EQ

0075

-02

0044

2 C

lean

ing

Ultr

ason

ic C

lean

er, B

rans

on 8

510

Bra

nson

B

8510

-DTH

10

/22/

14

EQ

0085

00

486

CE

R

Rad

iom

eter

Acc

u-C

al 5

0 D

ymax

TM

-053

Acc

u-C

al 5

010

/22/

14

EQ

0085

-02

C

ER

R

adio

met

er A

ccu-

Cal

50

Dym

ax

Acc

u-C

al 5

0 10

/22/

14

EQ

0091

-01

0043

0 O

CE

R

OP

HIR

Nov

a II

Dis

play

O

PH

IR O

ptro

mic

s N

ova

II 10

/22/

14

EQ

0091

-02

0042

9 O

CE

R

OP

HIR

Nov

a II

Dis

play

O

PH

IR O

ptro

mic

s N

ova

II 10

/22/

14

EQ

0104

-01

0049

4 C

ER

Fl

uke

Dig

ital M

ultim

eter

Fl

uke

179

10/2

2/14

E

Q01

04-0

3 00

469

CE

R

Fluk

e D

igita

l Mul

timet

er

Fluk

e 17

9 10

/22/

14

EQ

0104

-05

0042

3 C

ER

Fl

uke

Dig

ital M

ultim

eter

Fl

uke

179

10/2

2/14

E

Q01

04-0

6 00

490

CE

R

Fluk

e D

igita

l Mul

timet

er

Fluk

e 17

9 10

/22/

14

EQ

0110

00

386

OC

ER

V

ulca

n Fu

rnac

e D

ents

ply

Ney

tech

3-

1750

10

/22/

14

EQ

0119

-02

0041

4 O

CE

R

NL

Pro

be S

haft

to L

ug W

eldi

ng F

ixtu

re

Bax

ano

n/a

10/2

2/14

E

Q01

22-0

1 00

451

CE

R

MB

S Y

-Lug

Crim

per

Bax

ano

n/a

10/2

2/14

E

Q01

22-0

2 10

144

CE

R

MB

S Y

-Lug

Crim

per -

Low

er D

ie

Bax

ano

n/a

10/2

2/14

E

Q01

22-0

3 10

145

CE

R

MB

S Y

-Lug

Crim

per -

Upp

er D

ie

Bax

ano

n/a

10/2

2/14

E

Q01

22-0

4 10

146

CE

R

MB

S Y

-Lug

Crim

per -

Mid

dle

Die

B

axan

o n/

a 10

/22/

14

EQ

0125

-02

1014

7 V

ario

us

Tim

er -

Cou

ntdo

wn

Con

trol C

ompa

ny

2360

9-19

6 10

/22/

14

EQ

0125

-04

1010

9 V

ario

us

Tim

er -

Cou

ntdo

wn

McM

aste

r Car

r 89

25-1

35

10/2

2/14

E

Q01

25-0

5 10

137

Var

ious

Ti

mer

- C

ount

dow

n M

cMas

ter C

arr

8925

-136

10

/22/

14

EQ

0125

-06

1014

8 V

ario

us

Tim

er -

Cou

ntdo

wn

McM

aste

r Car

r 89

25-1

36

10/2

2/14

E

Q01

25-0

7 10

149

Var

ious

Ti

mer

- C

ount

dow

n M

cMas

ter C

arr

8925

-136

10

/22/

14

EQ

0125

-08

1015

0 V

ario

us

Tim

er -

Cou

ntdo

wn

McM

aste

r Car

r 89

25-1

36

10/2

2/14

E

Q01

34-0

2 10

110

CE

R

Tip

Pre

ssin

g Fi

xtur

e B

axan

o n/

a 10

/22/

14

EQ

0135

-02

1011

1 C

ER

Ti

p S

taki

ng F

ixtu

re

Bax

ano

n/a

10/2

2/14

E

Q01

37-0

1 00

481

CE

R

Wel

ler S

olde

ring

Sta

tion

Wel

ler

WD

1002

10

/22/

14

EQ

0137

-02

0048

0 C

ER

W

elle

r Sol

derin

g S

tatio

n W

elle

r W

D10

02

10/2

2/14

E

Q01

37-0

3 00

470

CE

R

Wel

ler S

olde

ring

Sta

tion

Wel

ler

WD

1003

10

/22/

14

EQ

0137

-04

0049

6 C

ER

W

elle

r Sol

derin

g S

tatio

n W

elle

r W

D10

02

10/2

2/14

E

Q01

44-0

1 00

408

Var

ious

Lo

ng 1

.25D

Sha

ft Tr

im to

Len

gth

Fixt

ure

Bax

ano

n/a

10/2

2/14

E

Q01

64-0

2 10

112

CE

R

Pro

be H

andl

e P

ress

Fix

ture

B

axan

o n/

a 10

/22/

14

EQ

0165

10

113

CE

R

Pro

be P

lung

er P

ress

Fix

ture

B

axan

o n/

a 10

/22/

14

EQ

0165

-02

1011

3 C

ER

P

robe

Plu

nger

Pre

ss

Bax

ano

n/a

10/2

2/14

E

Q01

68

1021

4 O

CE

R

MB

S H

andl

e Fl

ange

to S

haft

Wel

ding

Fix

ture

B

axan

o n/

a 10

/22/

14

EQ

0169

00

406

OC

ER

M

BS

Sha

ft to

Y-lu

g A

lignm

ent F

ixtu

re

Bax

ano

n/a

10/2

2/14

E

Q01

74

0045

3 C

ER

M

BS

Han

dle

Ass

embl

y Fi

xtur

e B

axan

o n/

a 10

/22/

14

EQ

0174

-02

0045

2 C

ER

M

BS

Han

dle

Ass

embl

y Fi

xtur

e B

axan

o n/

a 10

/22/

14

EQ

0175

00

456

CE

R

Dis

tal H

andl

e A

ssem

bly

Fixt

ure

Bax

ano

n/a

10/2

2/14

E

Q01

78

0048

8 C

ER

C

NLR

Han

dle

Pre

ss B

lock

B

axan

o n/

a 10

/22/

14

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 39

of 2

21

Venta�Tran

sfer�Final�Che

cklist�1

2/1/14

��Sche

dule�A1�A�

�

Page

�4�o

f�11�

�

EQ o

r Tag

N

umbe

r A

sset

N

umbe

r Lo

catio

nD

escr

iptio

n M

anuf

actu

rer

Mod

el #

Tr

ansf

er

Dat

e E

Q01

78-0

2 00

489

CE

R

Han

dle

and

Butto

n P

ress

Ass

embl

y B

axan

o n/

a 10

/22/

14

EQ01

79

0000

6 C

ER

Com

pute

r and

Mon

itor

E

Q01

79

0009

0 C

ER

B

arco

de P

rinte

r S

ATO

G

L412

e 10

/22/

14

EQ

0179

-02

0012

6 C

ER

B

arco

de P

rinte

r S

ATO

G

L412

e 10

/22/

14

EQ

0181

-01

1021

5 O

CE

R

Rib

bon

Sub

stra

te C

urvi

ng T

ool

Bax

ano

n/a

10/2

2/14

E

Q01

81-0

2 10

216

OC

ER

R

ibbo

n S

ubst

rate

Cur

ving

Too

l B

axan

o n/

a 10

/22/

14

EQ

0181

-03

1021

7

OC

ER

R

ibbo

n S

ubst

rate

Cur

ving

Too

l B

axan

o n/

a 10

/22/

14

EQ

0183

00

474

CE

R

NLR

Han

dle

Sol

der S

uppo

rt B

lock

B

axan

o n/

a 10

/22/

14

EQ

0183

-02

0048

7 C

ER

N

LR H

andl

e S

olde

r Sup

port

Blo

ck

Bax

ano

n/a

10/2

2/14

E

Q01

86

0041

6 O

CE

R

Sha

ping

Blo

ck

Bax

ano

n/a

10/2

2/14

E

Q01

87

0045

9 C

ER

D

ista

l Han

dle

Tuni

ng F

ixtu

re

Bax

ano

n/a

10/2

2/14

E

Q01

89

0046

0 C

ER

D

ista

l Han

dle

Pul

l Tes

t Fix

ture

B

axan

o n/

a 10

/22/

14

EQ

0190

-01

0043

2 C

ER

O

PH

IR 1

50C

-SH

Hea

d O

PH

IR O

ptro

nics

15

0C-S

H H

ead

10/2

2/14

E

Q01

90-0

2 00

431

CE

R

OP

HIR

150

C-S

H H

ead

OP

HIR

Opt

roni

cs

150C

-SH

Hea

d 10

/22/

14

EQ

0192

-02

C

ER

R

ear C

ondu

ctor

s S

take

Pin

Driv

er

Bax

ano

n/a

10/2

2/14

EQ

0195

00

055

Pac

k Im

puls

e P

ouch

Sea

ler

Van

der

Stä

hl

Sci

entif

icM

S-3

50N

P 10

/22/

14

EQ

0195

-02

0021

5 P

ack

Impu

lse

Pou

ch S

eale

r V

an d

er S

tähl

S

cien

tific

MS

-350

NP

10/2

2/14

EQ

0200

00

472

CE

R

Wire

Crim

p Tu

be F

ixtu

re

Bax

ano

n/a

10/2

2/14

E

Q02

06

0044

6 C

ER

M

otor

ized

Tes

t Sta

nd (C

hatil

lon

Tens

ile T

este

r)

Cha

tillo

n TC

M20

1 10

/22/

14

EQ

0224

10

209

iO-T

ome

Sub

stra

te P

roxi

mal

For

min

g To

ol

Bax

ano

n/a

10/2

2/14

E

Q02

25

1021

0 iO

-Tom

e H

eat S

hiel

d B

axan

o n/

a 10

/22/

14

EQ

0226

-01

1020

8 iO

-Tom

e 12

mm

Wid

th B

umpe

r Pos

ition

ing

Fixt

ure

Bax

ano

n/a

10/2

2/14

E

Q02

26-0

2 10

211

iO-T

ome

10m

m W

idth

Bum

per P

ositi

onin

g Fi

xtur

e B

axan

o n/

a 10

/22/

14

EQ

0226

-03

1021

2 iO

-Tom

e 7.

5mm

Wid

th B

umpe

r Pos

ition

ing

Fixt

ure

Bax

ano

n/a

10/2

2/14

E

Q02

28

1020

7 iO

-Tom

e S

ubst

rate

Dis

tal E

nd F

orm

ing

Tool

B

axan

o n/

a 10

/22/

14

EQ

0231

-01

0042

1 O

CE

R

Pro

be S

haft

Ben

d Fi

xtur

e B

axan

o n/

a 10

/22/

14

EQ

0232

10

219

OC

ER

S

tyle

t Tip

Loc

atio

n G

o-N

o G

o G

age

Bax

ano

n/a

10/2

2/14

E

Q02

34

1020

6 C

ER

N

C P

ebax

Tub

e Le

ak T

estin

g Fi

xtur

e B

axan

o n/

a 10

/22/

14

EQ

0238

00

419

OC

ER

Irr

igat

ion

Can

nula

Sha

ft B

ende

r B

axan

o n/

a 10

/22/

14

EQ

0239

10

218

OC

ER

C

ontra

Irrig

atio

n C

annu

la S

haft

Tube

Fla

ttene

r B

axan

o n/

a 10

/22/

14

EQ

0240

00

422

OC

ER

Ip

si Ir

rigat

ion

Can

nula

Sha

ft Tu

be F

latte

ner

Bax

ano

n/a

10/2

2/14

EQ

0241

-01

0040

9 O

CE

R

Con

tra Ir

rigat

ion

Can

nula

te S

haft

Insp

ectio

n Fi

xtur

e B

axan

o n/

a 10

/22/

14

EQ

0242

00

407

OC

ER

Ip

si Ir

rigat

ion

Can

nula

Sha

ft In

spec

tion

Fixt

ure

Bax

ano

n/a

10/2

2/14

E

Q02

47-0

1 00

433

OC

ER

A

ir R

egul

ator

Mod

ular

Typ

e S

MC

A

R25

-N02

E-Z

10

/22/

14

EQ

0248

-02

0042

0 O

CE

R

Can

nula

Wire

Tip

Inse

rtion

Too

l B

axan

o n/

a 10

/22/

14

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 40

of 2

21

Venta�Tran

sfer�Final�Che

cklist�1

2/1/14

��Sche

dule�A1�A�

�

Page

�5�o

f�11�

�

EQ o

r Tag

N

umbe

r A

sset

N

umbe

r Lo

catio

nD

escr

iptio

n M

anuf

actu

rer

Mod

el #

Tr

ansf

er

Dat

e E

Q02

49

0041

8 O

CE

R

Con

tra Ir

rigat

ion

Can

nula

Cut

ting

Fixt

ure

Bax

ano

n/a

10/2

2/14

E

Q02

50

0041

7 O

CE

R

Ipsi

Irrig

atio

n C

annu

la C

uttin

g Fi

xtur

e B

axan

o n/

a 10

/22/

14

EQ

0258

10

213

CE

R

Rac

k &

Pin

ion

Pre

ss

Sch

mid

t N

o 3-

X1

10/2

2/14

E

Q02

62-0

1 00

436

OC

ER

C

ontra

Can

nula

Dis

tanc

e G

auge

B

axan

o n/

a 10

/22/

14

EQ

0262

-02

0043

6 O

CE

R

Con

tra C

annu

la D

ista

nce

Gau

ge

Bax

ano

n/a

10/2

2/14

E

Q02

62-0

3 00

436

OC

ER

C

ontra

Can

nula

Dis

tanc

e G

auge

B

axan

o n/

a 10

/22/

14

EQ

0262

-04

0043

6 O

CE

R

Con

tra C

annu

la D

ista

nce

Gau

ge

Bax

ano

n/a

10/2

2/14

E

Q02

63-0

1 00

435

OC

ER

Ip

si C

annu

la D

ista

nce

Gau

ge

Bax

ano

n/a

10/2

2/14

E

Q02

63-0

2 00

435

OC

ER

Ip

si C

annu

la D

ista

nce

Gau

ge

Bax

ano

n/a

10/2

2/14

E

Q02

63-0

3 00

435

OC

ER

Ip

si C

annu

la D

ista

nce

Gau

ge

Bax

ano

n/a

10/2

2/14

E

Q02

63-0

4 00

435

OC

ER

Ip

si C

annu

la D

ista

nce

Gau

ge

Bax

ano

n/a

10/2

2/14

E

Q02

70-0

1 00

400

OC

ER

C

ontra

Go

- No

Go

Leng

th G

auge

B

axan

o n/

a 10

/22/

14

EQ

0271

-01

1011

5 C

ER

S

tyle

t Crim

ping

Fix

ture

B

axan

o n/

a 10

/22/

14

EQ

0273

-01

1011

6 C

ER

S

tyle

t Len

gth

Go-

No

Go

Gag

e B

axan

o n/

a 10

/22/

14

EQ

0275

-01

0040

5 O

CE

R

Ipsi

Pro

be S

haft

Insp

ectio

n G

auge

B

axan

o n/

a 10

/22/

14

EQ

0282

-01

0041

1 O

CE

R

Con

tra S

haft

Go

- No

Go

Fixt

ure

Bax

ano

n/a

10/2

2/14

E

Q02

82-0

2 00

410

OC

ER

C

ontra

Sha

ft G

o - N

o G

o Fi

xtur

e B

axan

o n/

a 10

/22/

14

EQ

0286

-01

0041

5 O

CE

R

Pro

be S

Sha

ft B

endi

ng F

ixtu

re

Bax

ano

n/a

10/2

2/14

E

Q02

87-0

1 00

393

OC

ER

C

annu

la C

rush

ing

Tool

B

axan

o n/

a 10

/22/

14

EQ

0288

-01

1011

7 C

ER

P

EE

K C

rush

ing

and

Sw

agin

g To

ol

Bax

ano

n/a

10/2

2/14

E

Q02

88-0

2 00

223

CE

R

PE

EK

Cru

shin

g an

d S

wag

ing

Tool

B

axan

o n/

a 10

/22/

14

EQ

0295

-01

1011

8 C

ER

P

EE

K F

orm

ing

Man

drel

B

axan

o n/

a 10

/22/

14

EQ

0296

-01

1013

5 C

ER

P

robe

S P

lung

er D

eten

t For

min

g Fi

xtur

e B

axan

o n/

a 10

/22/

14

EQ

0298

-01

0022

2 C

ER

P

neum

atic

PE

EK

For

min

g To

ol

Bax

ano

n/a

10/2

2/14

E

Q02

98-0

2 10

119

CE

R

Pne

umat

ic P

EE

K F

orm

ing

Tool

B

axan

o n/

a 10

/22/

14

EQ

0307

-01

0039

2 O

CE

R

Ipsi

Pro

be T

R N

itino

l Sha

ft D

rillin

g Fi

xtur

e B

axan

o n/

a 10

/22/

14

EQ

0308

-01

0042

4 O

CE

R

Ipsi

Pro

be T

R S

haft

Ben

der

Bax

ano

n/a

10/2

2/14

E

Q03

09-0

1 00

402

OC

ER

Ip

si P

robe

TR

Sha

ft In

spec

tion

Fixt

ure

Bax

ano

n/a

10/2

2/14

E

Q03

10-0

1 00

499

CE

R

Ipsi

Pro

be T

R T

ip P

ress

ing

Fixt

ure

Bax

ano

n/a

10/2

2/14

E

Q03

11-0

1 00

500

CE

R

Ipsi

Pro

be T

R T

ip S

taki

ng F

ixtu

re

Bax

ano

n/a

10/2

2/14

E

Q03

14-0

1 10

120

CE

R

Pin

Gag

e .0

78 m

inus

M

eyer

.0

780Z

M

10/2

2/14

E

Q03

15-0

1 10

122

CE

R

Pin

Gag

e .0

80 m

inus

M

eyer

.0

800Z

M

10/2

2/14

E

Q03

17-0

1 00

403

OC

ER

Ip

si P

robe

TR

Sha

ft W

eldi

ng F

ixtu

re

Bax

ano

n/a

10/2

2/14

E

Q03

18-0

1 10

181

iO-T

ome

iO-T

ome

Bum

pers

Cut

ting

Fixt

ure

Bax

ano

n/a

10/2

2/14

E

Q03

23-0

1 00

425

OC

ER

Ip

si P

robe

-TR

L N

itino

l Sha

ping

Fix

ture

B

axan

o n/

a 10

/22/

14

EQ

0323

-02

0042

6 O

CE

R

Ipsi

Pro

be-T

RL

Niti

nol S

hapi

ng F

ixtu

re

Bax

ano

n/a

10/2

2/14

E

Q03

24-0

1 00

427

OC

ER

Ip

si P

robe

-TR

L N

iti S

haft

Trim

min

g Fi

xtur

e B

axan

o n/

a 10

/22/

14

EQ

0327

-01

1012

4 C

ER

P

robe

TR

L Ti

p P

ress

ing

Fixt

ure

Bax

ano

n/a

10/2

2/14

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 41

of 2

21

Venta�Tran

sfer�Final�Che

cklist�1

2/1/14

��Sche

dule�A1�A�

�

Page

�6�o

f�11�

�

EQ o

r Tag

N

umbe

r A

sset

N

umbe

r Lo

catio

nD

escr

iptio

n M

anuf

actu

rer

Mod

el #

Tr

ansf

er

Dat

e E

Q03

28-0

1 10

126

CE

R

Pro

be T

RL

Sta

king

Fix

ture

B

axan

o n/

a 10

/22/

14

EQ

0329

-01

1012

9 C

ER

S

tyle

t Crim

ping

Fix

ture

- 28

6.7m

m

Bax

ano

n/a

10/2

2/14

E

Q03

30-0

1 10

131

CE

R

Sty

let L

engt

h G

o-N

o G

o G

age

Bax

ano

n/a

10/2

2/14

E

Q03

31-0

1 10

128

CE

R

Ass

y, P

EE

K F

larin

g Fi

xtur

e, L

ong

Bax

ano

n/a

10/2

2/14

E

Q03

39-0

1 10

153

CE

R

Bla

de F

ram

e C

rimp

Sup

port

Blo

ck

Bax

ano

n/a

10/2

2/14

E

Q03

39-0

3 10

154

CE

R

Bla

de F

ram

e C

rimp

Sup

port

Blo

ck

Bax

ano

n/a

10/2

2/14

E

Q03

43-0

1 10

179

CE

R

Ferru

le C

rimp

Tool

Sup

port

Fixt

ure

Bax

ano

n/a

10/2

2/14

E

Q03

45-0

1 10

180

CE

R

Ferr

ule

Crim

p To

ol

Bax

ano

n/a

10/2

2/14

E

Q03

47-0

1 10

182

CE

R

iO-T

ome

Rig

ht B

umpe

r Cut

ter

Bax

ano

n/a

10/2

2/14

E

Q03

47-0

2 10

184

CE

R

iO-T

ome

Rig

ht B

umpe

r Cut

ter

Bax

ano

n/a

10/2

2/14

E

Q03

48-0

1 10

185

CE

R

iO-T

ome

Left

Bum

per C

utte

r B

axan

o n/

a 10

/22/

14

EQ

0348

-02

1018

8 C

ER

iO

-Tom

e Le

ft B

umpe

r Cut

ter

Bax

ano

n/a

10/2

2/14

E

Q03

51-0

1 10

189

CE

R

iOTo

me

Wid

th C

uttin

g Fi

xtur

e B

axan

o n/

a 10

/22/

14

EQ

0351

-02

1019

0 C

ER

iO

Tom

e W

idth

Cut

ting

Fixt

ure

Bax

ano

n/a

10/2

2/14

E

Q03

53-0

2 00

396

iO-T

ome

Sch

mid

t Pre

ss, L

arge

S

chm

idt

11F-

X5

10/2

2/14

E

Q04

45-0

1

0038

4 C

ER

M

in/M

ax D

igita

l The

rmom

eter

C

ontro

l Com

pany

15

551-

284

10/2

2/14

E

Q04

45-0

2 00

385

OC

ER

M

in/M

ax D

igita

l The

rmom

eter

C

ontro

l Com

pany

15

551-

249

10/2

2/14

EQ

0014

-04

0038

8 O

CE

R

Var

iabl

e S

peed

Grin

der

NS

K N

akni

sh In

c.

Ele

ctor

Em

ax

NE

129

10/2

7/14

EQ

0009

-01

0039

1 O

CE

R

12" C

alip

ers

Mitu

toyo

10

2057

10

/27/

14

EQ

0173

00

387

OC

ER

M

edia

Bla

st C

ham

ber

Sna

p O

n Y

A43

3 10

/27/

14

EQ

0081

-01

0043

8 O

CE

R

Pin

Gag

e S

et, .

011

- .06

1 M

eyer

n/

a 10

/27/

14

EQ

0082

-01

0043

9 O

CE

R

Pin

Gag

e S

et .0

115

- .06

15

Mey

er

n/a

10/2

7/14

E

Q04

13-0

1 00

412

OC

ER

C

ontra

TR

Pro

be B

end

insp

ectio

n Fi

xtur

e B

axan

o n/

a 10

/27/

14

EQ

0410

-01

0041

3 O

CE

R

Sha

ft W

eldi

ng F

ixtu

re

Bax

ano

n/a

10/2

7/14

E

Q01

61-0

1 00

443

OC

ER

C

lean

ing

Hol

der

Bax

ano

n/a

10/2

7/14

E

Q01

61-0

2 00

444

OC

ER

C

lean

ing

Hol

der

Bax

ano

n/a

10/2

7/14

E

Q01

61-0

3 00

445

OC

ER

C

lean

ing

Hol

der

Bax

ano

n/a

10/2

7/14

E

Q02

47-0

2 00

441

CE

R

Air

Reg

ulat

or, M

odul

ar

SM

C

n/a

10/2

7/14

E

Q00

48-0

3 00

458

CE

R

Rul

er, M

etal

, 19.

5"

Sta

rret

n/a

10/2

7/14

E

Q00

23-1

5 00

484

CE

R

Rul

er, M

etal

, 19.

5"

Sta

rret

n/a

10/2

7/14

E

Q00

48-0

1 00

459

CE

R

Rul

er, M

etal

, 19.

5"

Sta

rret

n/a

10/2

7/14

E

Q00

48-0

6 00

483

CE

R

Rul

er, M

etal

, 19.

5"

Sta

rret

n/a

10/2

7/14

E

Q02

33

0475

C

ER

C

rimpe

r, N

euro

Che

ck

Bax

ano

n/a

10/2

7/14

E

Q01

53

1020

5 C

ER

C

rimpe

r B

axan

o n/

a 10

/27/

14

EQ

0355

-01

1019

1 C

ER

10

mm

Bum

per P

ositi

onin

g Fi

xtur

e B

axan

o n/

a 10

/27/

14

EQ

0355

-02

1019

8 C

ER

10

mm

Bum

per P

ositi

onin

g Fi

xtur

e B

axan

o n/

a 10

/27/

14

EQ

0356

-01

1020

0 C

ER

7.

5mm

Bum

per P

ositi

onin

g Fi

xtur

e B

axan

o n/

a 10

/27/

14

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 42

of 2

21

Venta�Tran

sfer�Final�Che

cklist�1

2/1/14

��Sche

dule�A1�A�

�

Page

�7�o

f�11�

�

EQ o

r Tag

N

umbe

r A

sset

N

umbe

r Lo

catio

nD

escr

iptio

n M

anuf

actu

rer

Mod

el #

Tr

ansf

er

Dat

e E

Q03

56-0

2 10

201

CE

R

7.5m

m B

umpe

r Pos

ition

ing

Fixt

ure

Bax

ano

n/a

10/2

7/14

E

Q02

10

1020

3 C

ER

C

rimpe

r, iO

-Tom

e E

clip

se

n/a

10/2

7/14

E

Q00

32

1020

2 C

ER

C

rimpe

r, iO

-Tom

e E

clip

se

n/a

10/2

7/14

E

Q00

48-1

1 00

484

CE

R

Rul

er, M

etal

, 19.

5"

Sta

rret

n/a

10/2

7/14

E

Q00

97

0046

5

Hea

t Shi

eld

Fusi

ng T

ool

Bax

ano

n/a

10/2

7/14

E

Q02

11

1020

4 C

ER

Fl

atte

ning

Too

l B

axan

o n/

a 10

/27/

14

2 10

278

CE

R

Wire

cag

e ca

rt -

50"w

x 6

8"h

x 25

"d

n/a

n/a

10/2

2/14

3

1027

9 C

ER

W

ire c

age

cart

- 60"

w x

68"

h x

25"d

n/

a n/

a 10

/27/

14

4 10

220

CE

R

Wire

cag

e ca

rt - 3

8"w

x 6

8"h

x 25

"d

n/a

n/a

10/2

7/14

6

1029

7 C

ER

R

efrig

eato

r-Ad

hesi

ves-

17.

5"w

x 1

9"h

x 19

"d

n/a

n/a

10/2

7/14

7

1022

7 C

ER

W

orkb

ench

w/ri

ser 6

'w x

34"

h x

30"d

- N

C

n/a

n/a

10/2

7/14

8

1025

0 C

ER

W

orkb

ench

w/ri

ser -

8'w

x 3

4"h

x 30

"d -

NC

-1

n/a

n/a

10/2

7/14

9

1025

1 C

ER

W

orkb

ench

w/ri

ser -

8'w

x 3

4"h

x 30

"d -

NC

-2

n/a

n/a

10/2

7/14

10

10

252

CE

R

Wor

kben

ch w

/rise

r - 8

'w x

34"

h x

30"d

- N

C-3

n/

a n/

a 10

/27/

14

11

1023

9 C

ER

W

orkb

ench

w/ri

ser -

8'w

x 3

4"h

x 30

"d -

NC

-4

n/a

n/a

10/2

7/14

12

10

240

CE

R

Wor

kben

ch w

/rise

r - 8

'w x

34"

h x

30"d

- N

C-5

n/

a n/

a 10

/27/

14

13

1024

1 C

ER

W

orkb

ench

w/ri

ser -

6'w

x 3

4"h

x 30

"d -

NC

-6

n/a

n/a

10/2

7/14

14

10

238

CE

R

Wor

kben

ch w

/rise

r - 8

'w x

34"

h x

30"d

- P

robe

-1

n/a

n/a

10/2

7/14

15

10

237

CE

R

Wor

kben

ch w

/rise

r - 8

'w x

34"

h x

30"d

- P

robe

-2

n/a

n/a

10/2

7/14

16

10

236

CE

R

Wor

kben

ch w

/rise

r - 6

'w x

34"

h x

30"d

- P

robe

-3

n/a

n/a

10/2

7/14

17

10

260

CE

R

Wor

kben

ch w

/rise

r - 6

'w x

34"

h x

30"d

- M

BS

-1

n/a

n/a

10/2

7/14

18

10

259

CE

R

Wor

kben

ch w

/rise

r - 6

'w x

34"

h x

30"d

- M

BS

-2

n/a

n/a

10/2

7/14

19

10

258

CE

R

Wor

kben

ch w

/rise

r - 8

'w x

34"

h x

30"d

- M

BS

-3

n/a

n/a

10/2

7/14

20

10

221

CE

R

Wor

kben

ch n

o ris

er -

8'w

x 3

4"h

x 30

"d -

PK

G -1

n/

a n/

a 10

/27/

14

21

1022

2 C

ER

W

orkb

ench

w/ri

ser -

6'w

x 3

4"h

x 30

"d -

PK

G -

2 n/

a n/

a 10

/27/

14

22

1022

8 C

ER

W

orkb

ench

no

riser

- 8'

w x

34"

h x

30"d

- P

KG

-3

n/a

n/a

10/2

7/14

24

10

287

CE

R

Wire

rack

car

t,she

lf - 4

'w x

78"

h x

24"d

n/

a n/

a 10

/27/

14

25

1026

8 C

ER

W

ire ra

ck c

art,p

ush-

3'w

x 4

0"h

x 18

"d

n/a

n/a

10/2

7/14

26

10

275

CE

R

Mat

eria

l/kan

ban

cart/

whe

els

- 3'w

x 5

9"h

x 20

"d

n/a

n/a

10/2

7/14

27

10

276

CE

R

Mat

eria

l/kan

ban

cart/

whe

els

- 3'w

x 5

9"h

x 20

"d

n/a

n/a

10/2

7/14

28

10

274

CE

R

Mat

eria

l/kan

ban

cart/

whe

els

- 3'w

x 5

9"h

x 20

"d

n/a

n/a

10/2

7/14

29

10

277

CE

R

Mat

eria

l/kan

ban

cart/

whe

els

- 3'w

x 5

9"h

x 20

"d

n/a

n/a

10/2

7/14

30

10

224

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

31

10

223

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

32

10

261

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

33

10

263

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

34

10

254

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

35

10

256

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 43

of 2

21

Venta�Tran

sfer�Final�Che

cklist�1

2/1/14

��Sche

dule�A1�A�

�

Page

�8�o

f�11�

�

EQ o

r Tag

N

umbe

r A

sset

N

umbe

r Lo

catio

nD

escr

iptio

n M

anuf

actu

rer

Mod

el #

Tr

ansf

er

Dat

e 36

10

243

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

37

10

242

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

38

10

270

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

39

10

255

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

40

10

262

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

41

10

244

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

42

10

257

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

43

10

234

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

45

10

235

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

46

10

265

CE

R

Adj

usta

ble

foot

rest

-met

al

n/a

n/a

10/2

7/14

47

10

247

CE

R

Adj

usta

ble

foot

rest

-met

al

n/a

n/a

10/2

7/14

48

10

245

CE

R

Adj

usta

ble

foot

rest

-met

al

n/a

n/a

10/2

7/14

49

10

264

CE

R

Adj

usta

ble

foot

rest

-met

al

n/a

n/a

10/2

7/14

50

10

248

CE

R

Adj

usta

ble

foot

rest

-met

al

n/a

n/a

10/2

7/14

51

10

246

CE

R

Adj

usta

ble

foot

rest

-met

al

n/a

n/a

10/2

7/14

52

10

253

CE

R

Adj

usta

ble

foot

rest

-met

al

n/a

n/a

10/2

7/14

53

10

249

CE

R

Adj

usta

ble

foot

rest

-Pla

stic

n/

a n/

a 10

/27/

14

54

1029

2 C

ER

pr

od c

omm

unic

atio

n bo

ard

n/a

n/a

10/2

7/14

55

10

226

CE

R

Mag

nific

atio

n lig

hted

lens

es

n/a

n/a

10/2

7/14

56

10

301

OC

ER

P

arts

cle

anin

g be

nch

w/ri

ser-

8'w

x 3

4"h

x 36

"d

n/a

n/a

10/2

7/14

58

10

317

OC

ER

P

arts

cle

anin

g w

ire p

ush

cart

-34"

w x

34"

h x

18"d

n/

a n/

a 10

/27/

14

59

1031

9 O

CE

R

Farm

able

was

te c

an-r

ed

n/a

n/a

10/2

7/14

60

10

302

OC

ER

W

orkb

ench

w/ri

ser -

6'w

x 3

4"h

x 36

"d

n/a

n/a

10/2

7/14

61

10

271

OC

ER

W

orkb

ench

w/ri

ser -

6'w

x 3

4"h

x 36

"d

n/a

n/a

10/2

7/14

63

10

286

OC

ER

W

orkb

ench

no

riser

- 6'

w x

34"

h x

30"d

n/

a n/

a 10

/27/

14

64

1032

0 O

CE

R

Wor

kben

ch w

/rise

r - 6

'w x

34"

h x

36"d

n/

a n/

a 10

/27/

14

65

1028

5 O

CE

R

Tig

wel

ding

tabl

e - 3

'w x

33'

h x

3'd

n/a

n/a

10/2

7/14

66

10

285

OC

ER

N

one

clea

nroo

m c

hair/

blac

k pa

inte

d n/

a n/

a 10

/27/

14

67

1030

8 O

CE

R

Non

e cl

eanr

oom

cha

ir/bl

ack

pain

ted

n/a

n/a

10/2

7/14

68

10

303

OC

ER

N

one

clea

nroo

m c

hair/

blac

k pa

inte

d n/

a n/

a 10

/27/

14

69

1028

4 O

CE

R

Non

e cl

eanr

oom

cha

ir/bl

ack

pain

ted

n/a

n/a

10/2

7/14

70

10

315

OC

ER

C

lean

room

cha

ir n/

a n/

a 10

/27/

14

71

1030

6 O

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

75

10

316

OC

ER

C

lean

room

cha

ir n/

a n/

a 10

/27/

14

76

1030

5 O

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

77

10

299

OC

ER

Fu

rnac

e ta

ble

- 3'

w x

30"

h x

20"d

n/

a n/

a 10

/27/

14

78

1030

7 O

CE

R

Furn

ace

quen

ch b

ucke

t-sst

n/

a n/

a 10

/27/

14

79

1031

0 O

CE

R

Foot

rest

- pl

astic

n/

a n/

a 10

/27/

14

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 44

of 2

21

Venta�Tran

sfer�Final�Che

cklist�1

2/1/14

��Sche

dule�A1�A�

�

Page

�9�o

f�11�

�

EQ o

r Tag

N

umbe

r A

sset

N

umbe

r Lo

catio

nD

escr

iptio

n M

anuf

actu

rer

Mod

el #

Tr

ansf

er

Dat

e 80

10

311

OC

ER

E

quip

/fixt

ure

cabi

net-D

b. d

oor -

3'w

x 7

9"h

x 24

"d

n/a

n/a

10/2

7/14

81

10

300

OC

ER

E

quip

/sto

rage

/mat

eria

l - 3

'w x

6'h

x 1

8"d

n/a

n/a

10/2

7/14

82

10

312

O

CE

R

Equ

ip/s

tora

ge/m

ater

ial -

3'w

x 6

'h x

18"

d n/

a n/

a 10

/27/

14

83

1030

9 O

CE

R

Vac

uum

n/

a n/

a 10

/27/

14

94

1029

4 O

CE

R

Dou

ble

Doo

r Cab

inet

n/

a n/

a 10

/27/

14

97

1029

5 O

CE

R

Sm

all p

rodu

ct c

abin

et/D

b. d

oor -

4'w

x 7

8"h

x 24

"d

n/a

n/a

10/2

7/14

98

1029

3 O

CE

R

Indi

rect

mat

eria

l cab

inet

/Db.

doo

r - 3

'w x

79"

h x

24"d

n/

a n/

a 10

/27/

14

99

1029

4 O

CE

R

Dou

ble

Doo

r Cab

inet

n/

a n/

a 10

/27/

14

105

102

90

OC

ER

W

ire s

helf

cart/

lock

cas

ters

-6'w

x 6

9"h

x 24

"d

n/a

n/a

10/2

7/14

10

8 1

0291

O

CE

R

Wire

she

lf ca

rt/lo

ck c

aste

rs -4

'w x

69"

h x

24"d

n/

a n/

a 10

/27/

14

109

102

81

OC

ER

W

ire s

helf

cart/

lock

cas

ters

-5'w

x 6

9"h

x 24

"d

n/a

n/a

10/2

7/14

11

0 1

0273

O

CE

R

Wire

she

lf ca

rt/lo

ck c

aste

rs -4

'w x

78"

h x

24"d

n/

a n/

a 10

/27/

14

111

102

83

OC

ER

W

ire s

helf

cart/

lock

cas

ters

-4'w

x 7

8"h

x 24

"d

n/a

n/a

10/2

7/14

11

2 1

0282

O

CE

R

Wire

she

lf ca

rt/lo

ck c

aste

rs -4

'w x

69"

h x

24"d

n/

a n/

a 10

/27/

14

113

102

80

OC

ER

W

ire s

helf

cart/

lock

cas

ters

-5'w

x 6

9"h

x 24

"d

n/a

n/a

10/2

7/14

11

4 1

0296

O

CE

R

Adh

esiv

e m

ater

ial r

efrig

erat

or-M

agic

Che

f n/

a n/

a 10

/27/

14

115

102

88

OC

ER

H

eavy

dut

y co

rruga

ted

box

shel

f 6' x

7' x

31"

n/

a n/

a 10

/27/

14

116

102

89

OC

ER

H

eavy

dut

y co

rruga

ted

box

shel

f 6' x

7' x

31"

n/

a n/

a 10

/27/

14

117

102

67

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

11

8 1

0231

C

ER

C

lean

room

cha

ir n/

a n/

a 10

/27/

14

119

102

33

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

12

0 1

0266

C

ER

W

orkb

ench

w/ R

iser

8'

n/a

n/a

10/2

7/14

12

1 1

0230

C

ER

W

orkb

ench

w/ R

iser

8'

n/a

n/a

10/2

7/14

12

2 1

0229

C

ER

W

orkb

ench

w/ R

iser

8'

n/a

n/a

10/2

7/14

12

3 1

0232

C

ER

C

lean

room

cha

ir n/

a n/

a 10

/27/

14

124

102

25

CE

R

Cle

anro

om c

hair

n/a

n/a

10/2

7/14

12

5 1

0269

C

ER

W

orkb

ench

w/ R

iser

6'

n/a

n/a

10/2

7/14

12

6 1

0304

C

ER

C

lean

room

cha

ir n/

a n/

a 10

/27/

14

128

103

18

OC

ER

P

arts

Cle

anin

g B

ucke

t with

Hol

es

n/a

n/a

10/2

7/14

12

9 1

0313

O

CE

R

Flam

able

Cab

inet

n/

a n/

a 10

/27/

14

130

102

98

CE

R

Bro

ther

Prin

ters

n/

a n/

a 10

/27/

14

EQ

0001

-02

Bax

1032

1 Q

A L

ab

Cal

iper

, 6"

Mitu

toyo

50

0-19

6-20

12

/5/2

014

EQ

0002

-01

Bax

1032

2 Q

A L

ab

Mic

rom

eter

, 0-1

" M

ituto

yo

293-

340

12/5

/201

4 E

Q00

02-0

4 B

ax10

323

QA

Lab

M

icro

met

er, 0

-1"

Mitu

toyo

29

3-34

0 12

/5/2

014

EQ

0002

-05

Bax

1032

4 Q

A L

ab

Mic

rom

eter

, 0-1

" M

ituto

yo

293-

340

12/5

/201

4 E

Q00

05-0

6 B

ax10

325

QA

Lab

P

in G

ages

- .0

11 -

.060

" (M

inus

) M

eyer

Gag

e M

0 Z

- Min

us

12/5

/201

4

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 45

of 2

21

Venta�Tran

sfer�Final�Che

cklist�1

2/1/14

��Sche

dule�A1�A�

�

Page

�10�

of�1

1��

EQ o

r Tag

N

umbe

r A

sset

N

umbe

r Lo

catio

nD

escr

iptio

n M

anuf

actu

rer

Mod

el #

Tr

ansf

er

Dat

e E

Q00

06-0

3 B

ax10

326

QA

Lab

P

in G

ages

- .0

115

- .06

05" (

Min

us)

Mey

er G

age

M0

Z - M

inus

12

/5/2

014

EQ

0009

-02

Bax

1032

7 Q

A L

ab

Cal

iper

, 12"

M

ituto

yo

500-

193

12/5

/201

4 E

Q00

11-0

1 B

ax10

328

QA

Lab

P

in G

ages

: .0

610

- .25

00" (

Plu

s)

Fow

ler C

o.

n/a

12/5

/201

4 E

Q00

18-0

1 B

ax10

329

QA

Lab

R

uler

, Met

al 2

4"

Ledf

ord

Gag

e La

b 50

5-02

4 12

/5/2

014

EQ

0039

00

017

QA

Lab

Te

nsile

Tes

ter

Thw

ing-

Alb

ert

EJA

Vang

age

Ser

ies

1 12

/5/2

014

EQ

0040

-50

Bax

1033

0 Q

A L

ab

50N

Loa

d C

ell

Thw

ing-

Alb

ert

SM

T1-5

0N-5

34

12/5

/201

4 E

Q00

40-5

00

Bax

1033

1 Q

A L

ab

500N

Loa

d C

ell

Thw

ing-

Alb

ert

SM

T2-5

00-5

34

12/5

/201

4 E

Q00

40-1

000

Bax

1033

2 Q

A L

ab

1000

N L

oad

Cel

l Th

win

g-A

lber

t S

MT2

-100

0N-5

34

12/5

/201

4 E

Q00

48-0

4 B

ax10

333

QA

Lab

R

uler

, Met

al 1

8" (4

5 cm

) S

tarr

ett

C26

2-01

8 12

/5/2

014

EQ

0048

-07

Bax

1033

4 Q

A L

ab

Rul

er, M

etal

19.

5" (5

0 cm

) S

tarr

ett

C63

6 12

/5/2

014

EQ

0048

-08

Bax

1033

5 Q

A L

ab

Rul

er, M

etal

19.

5" (5

0 cm

) S

tarr

ett

C63

6 12

/5/2

014

EQ

0050

-01

0001

9 Q

A L

ab

Vid

eo M

icro

scop

e (R

OI)

Ram

Opt

ical

S

prin

t 100

12

/5/2

014

EQ

0050

-02

0019

8 Q

A L

ab

Vid

eo M

icro

scop

e (R

OI)

Ram

Opt

ical

S

tarli

te G

X S

yste

m

12/5

/201

4 E

Q00

64

Bax

1033

6 Q

A L

ab

Dep

th G

auge

M

ituto

yo

ID-C

1012

EB

S

12/5

/201

4 E

Q00

83-0

1 B

ax10

337

QA

Lab

P

in G

ages

: .0

615

- .25

05" (

Plu

s)

Mey

er

M15

Z (P

lus)

12

/5/2

014

EQ

0084

-06

Bax

1033

8 Q

A L

ab

Pin

Gag

e: .

008"

Cla

ss X

(Plu

s)

Ver

mon

t Gag

e n/

a 12

/5/2

014

EQ

0093

-02

Bax

1033

9 Q

A L

ab

Rul

er, M

etal

80"

(203

cm

) La

nce

TBLR

- 80

EM

12

/5/2

014

EQ

0104

-02

Bax

1034

0 Q

A L

ab

Fluk

e D

igita

l Mul

timet

er

Fluk

e 17

9 12

/5/2

014

EQ

0185

-01

Bax

1034

1 Q

A L

ab

Pin

Gag

es:

.061

0 - .

2500

" (M

inus

) M

eyer

Gag

e M

1 Z

- M

inus

12

/5/2

014

EQ

0185

-02

Bax

1034

2 Q

A L

ab

Pin

Gag

es:

.061

5 - .

2505

" (M

inus

) M

eyer

Gag

e M

15 Z

- M

inus

12

/5/2

014

EQ

0188

-02

Bax

1034

3 Q

A L

ab

Cyc

ling

Fixt

ure

Bax

ano

n/a

12/5

/201

4 E

Q01

98-0

1 B

ax10

344

QA

Lab

C

ontra

Sha

ft G

o / n

o-G

o G

age

Bax

ano

n/a

12/5

/201

4 E

Q01

98-0

2 B

ax10

345

QA

Lab

C

ontra

Sha

ft G

o / n

o-G

o G

age

Bax

ano

n/a

12/5

/201

4 E

Q01

99-0

1 B

ax10

346

QA

Lab

Ip

si S

haft

Go

/ no-

Go

Gag

e B

axan

o n/

a 12

/5/2

014

EQ

0199

-02

Bax

1034

7 Q

A L

ab

Ipsi

Sha

ft G

o / n

o-G

o G

age

Bax

ano

n/a

12/5

/201

4 E

Q02

20-0

1 B

ax10

348

QA

Lab

P

in G

ages

: .2

51 -

.500

" (M

inus

) M

eyer

Gag

e M

2 Z

- Min

us

12/5

/201

4 E

Q02

21-x

x B

ax10

349

QA

Lab

In

spec

tion

Man

drel

s B

axan

o n/

a 12

/5/2

014

EQ

0222

-01

Bax

1035

0 Q

A L

ab

Pro

be N

itino

l Sha

ft In

spec

tion

Fixt

ure

Bax

ano

n/a

12/5

/201

4 E

Q02

74-0

1 B

ax10

351

QA

Lab

W

ire 9

0 D

egre

e Fa

tigue

Tes

t Fix

ture

B

axan

o n/

a 12

/5/2

014

EQ

0292

-01

Bax

1035

2 Q

A L

ab

Pro

be S

kive

Tes

t Fix

ture

B

axan

o n/

a 12

/5/2

014

EQ

0337

-01

Bax

1035

3 Q

A L

ab

Go

- No-

Go

Gag

e P

lung

er B

otto

m In

sert

Ope

ning

B

axan

o n/

a 12

/5/2

014

EQ

0359

-01

Bax

1035

4 Q

A L

ab

Pin

Gag

e .0

100

Plu

s C

lass

X

Mey

er G

age

1411

0010

00

12/5

/201

4 E

Q03

59-0

2 B

ax10

355

QA

Lab

P

in G

age

.010

0 P

lus

Cla

ss X

M

eyer

Gag

e 14

1100

1000

12

/5/2

014

EQ

0362

-01

Bax

1035

6 Q

A L

ab

Pin

Gag

es:

.251

- .5

00" (

Plus

) M

eyer

Gag

e M

2 C

lass

Z -

Plu

s 12

/5/2

014

EQ

0365

-01

Bax

1035

7 Q

A L

ab

Pin

Gag

es:

.501

- .6

25" (

Min

us)

Mey

er G

age

M3

Cla

ss Z

- M

inus

12

/5/2

014

EQ

0365

-02

Bax

1035

8 Q

A L

ab

Pin

Gag

es:

.626

- .7

50" (

Min

us)

Mey

er G

age

M4

CLZ

- M

inus

12

/5/2

014

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 46

of 2

21

Venta�Tran

sfer�Final�Che

cklist�1

2/1/14

��Sche

dule�A1�A�

�

Page

�11�

of�1

1��

EQ o

r Tag

N

umbe

r A

sset

N

umbe

r Lo

catio

nD

escr

iptio

n M

anuf

actu

rer

Mod

el #

Tr

ansf

er

Dat

e E

Q00

01-0

2 B

ax10

321

QA

Lab

C

alip

er, 6

" M

ituto

yo

500-

196-

20

12/5

/201

4 E

Q00

02-0

1 B

ax10

322

QA

Lab

M

icro

met

er, 0

-1"

Mitu

toyo

29

3-34

0 12

/5/2

014

EQ

0002

-04

Bax

1032

3 Q

A L

ab

Mic

rom

eter

, 0-1

" M

ituto

yo

293-

340

12/5

/201

4 E

Q00

02-0

5 B

ax10

324

QA

Lab

M

icro

met

er, 0

-1"

Mitu

toyo

29

3-34

0 12

/5/2

014

EQ

0005

-06

Bax

1032

5 Q

A L

ab

Pin

Gag

es -

.011

- .0

60" (

Min

us)

Mey

er G

age

M0

Z - M

inus

12

/5/2

014

EQ

0006

-03

Bax

1032

6 Q

A L

ab

Pin

Gag

es -

.011

5 - .

0605

" (M

inus

) M

eyer

Gag

e M

0 Z

- Min

us

12/5

/201

4 E

Q00

09-0

2 B

ax10

327

QA

Lab

C

alip

er, 1

2"

Mitu

toyo

50

0-19

3 12

/5/2

014

EQ

0011

-01

Bax

1032

8 Q

A L

ab

Pin

Gag

es:

.061

0 - .

2500

" (P

lus)

Fo

wle

r Co.

n/

a 12

/5/2

014

EQ

0018

-01

Bax

1032

9 Q

A L

ab

Rul

er, M

etal

24"

Le

dfor

d G

age

Lab

505-

024

12/5

/201

4 �

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 47

of 2

21

Sch

edul

e A

-1B

uct L

ine-

Gre

g Fe

edba

ckSy

s N

oVe

ndor

Des

crip

tion

In S

vc

Dat

eC

ount

y A

cqui

red

Valu

e

B10

062

AIM

Pla

stic

sM

olds

05/3

1/13

Clin

ton

Tow

nshi

p - A

IM P

last

ic3,

834.

74

B10

063

AIM

Pla

stic

sM

olds

05/3

1/13

Clin

ton

Tow

nshi

p - A

IM P

last

ic5,

941.

39

B10

067

AIM

Pla

stic

sM

olds

05/3

1/13

Clin

ton

Tow

nshi

p - A

IM P

last

ic57

3.58

B10

068

AIM

Pla

stic

sM

olds

05/3

1/13

Clin

ton

Tow

nshi

p - A

IM P

last

ic6,

449.

38

B10

069

AIM

Pla

stic

sM

olds

05/3

1/13

Clin

ton

Tow

nshi

p - A

IM P

last

ic1,

491.

28

B10

071

AIM

Pla

stic

sM

olds

05/3

1/13

Clin

ton

Tow

nshi

p - A

IM P

last

ic82

5.00

B10

072

AIM

Pla

stic

sM

olds

- ta

x05

/31/

13C

linto

n To

wns

hip

- AIM

Pla

stic

76.3

5

B

1008

2A

IM P

last

ics

Pad

Prin

t Pla

tes

(inc

tax)

05/3

1/13

Clin

ton

Tow

nshi

p - A

IM P

last

ic61

9.14

B10

059

AIM

Pla

stic

sS

ingl

e C

avity

Alu

min

um M

old

05/3

1/13

Clin

ton

Tow

nshi

p - A

IM P

last

ic78

0.00

B10

116

Del

ta P

acifi

c P

rodu

cts

1-C

avity

Mol

d (iO

-Tom

e B

umpe

r)05

/31/

13A

lmed

a - D

elta

Pac

ific

3,90

1.50

B

1009

8D

elta

Pac

ific

Pro

duct

s3-

Cav

ity F

amily

(1+1

+1) I

njec

ting

Mol

d w

ith 6

Har

dene

d S

lides

05/3

1/13

Alm

eda

- Del

ta P

acifi

c7,

363.

64

B10

099

Del

ta P

acifi

c P

rodu

cts

3-C

avity

Fam

ily (1

+1+1

) Inj

ectin

g M

old,

Sel

f Con

tain

ed B

ased

, 05

/31/

13A

lmed

a - D

elta

Pac

ific

7,55

5.54

B

1008

1D

elta

Pac

ific

Pro

duct

sC

avity

mol

d P

O 3

119

05/3

1/13

Ala

med

a - D

elta

Pac

ific

7,57

4.24

B

1006

5D

elta

Pac

ific

Pro

duct

sM

olds

05/3

1/13

Alm

eda

- Del

ta P

acifi

c5,

425.

84

B10

158

Del

ta P

acifi

c P

rodu

cts

Pro

be S

Too

ling

(Han

dle

Top

& B

otto

m)

05/3

1/13

Alm

eda

- Del

ta P

acifi

c22

,606

.24

0006

49P

robe

Han

dle

Mol

d10

/01/

13A

lmed

a - D

elta

Pac

ific

2,80

0.00

00

0656

Pro

be T

R H

andl

e C

hang

es11

/01/

13A

lmed

a - D

elta

Pac

ific

5,87

2.50

B

1006

6D

elta

Pac

ific

Pro

duct

sTo

olin

g py

mt -

nee

d m

ore

desc

riptio

n05

/31/

13A

lmed

a - D

elta

Pac

ific

6,98

0.82

B

1008

8M

P&

EM

P&

E05

/31/

13M

N -

MP

&E

865.

13

B

1016

3E

xtru

sion

Too

l - R

M09

5405

/31/

13M

N -

MP

&E

3,80

0.00

B

1010

9M

P&

ETo

olin

g fo

r Ext

rude

d B

umpe

r. R

esid

es in

MN

05/3

1/13

MN

- M

P&

E1,

013.

84

B10

149

Phi

llips

Pla

stic

sC

eram

ic S

ette

rs fo

r MIM

Fur

nace

Pro

cess

ing

05/3

1/13

Vash

on Is

land

WA

- Saw

bone

s8,

541.

53

B10

113

Phi

llips

Pla

stic

sP

O 3

701

Sin

gleM

old

cavi

ty fo

r RM

1356

05/3

1/13

Vash

on Is

land

WA

- Saw

bone

s7,

875.

00

B10

122

Phi

llips

Pla

stic

s10

mm

Bla

de R

ung

Mol

d05

/31/

13H

udso

n W

I - P

hilli

ps P

last

ics

3,48

9.90

B

1010

5P

hilli

ps P

last

ics

1-C

avity

Too

l Bui

ld P

robe

MIM

Dis

sect

ingT

ip

05/3

1/13

Hud

son

WI -

Phi

llips

Pla

stic

s13

,929

.93

B10

104

Phi

llips

Pla

stic

s1-

Cav

ity T

ool B

uild

/MIM

Bla

de R

ung

(715

mm

Too

l)05

/31/

13H

udso

n W

I - P

hilli

ps P

last

ics

13,7

19.9

3

B

1010

6P

hilli

ps P

last

ics

2-C

avity

Mol

d/M

IM S

traig

ht B

lank

Run

g05

/31/

13H

udso

n W

I - P

hilli

ps P

last

ics

15,1

55.0

7

B

1011

8P

hilli

ps P

last

ics

MB

S M

IM B

lade

Run

g 10

mm

Too

ling

05/3

1/13

Hud

son

WI -

Phi

llips

Pla

stic

s18

,946

.57

B10

119

Phi

llips

Pla

stic

sM

BS

MIM

Bla

de R

ung

5.5m

m T

oolin

g05

/31/

13H

udso

n W

I - P

hilli

ps P

last

ics

18,9

46.5

7

B

1012

0P

hilli

ps P

last

ics

MB

S M

IM D

ista

l Tap

ered

Run

g 1-

8 To

olin

g05

/31/

13H

udso

n W

I - P

hilli

ps P

last

ics

45,2

40.0

0

B

1010

3P

hilli

ps P

last

ics

MIM

Sin

terin

g Fi

xure

s fo

r All

Par

ts05

/31/

13H

udso

n W

I - P

hilli

ps P

last

ics

1,95

9.93

B

1013

9P

hilli

ps P

last

ics

Sin

terin

g Fi

xtur

e/S

ette

r for

MIM

Par

ts fo

r MB

S05

/31/

13H

udso

n W

I - P

hilli

ps P

last

ics

3,70

0.00

B

1012

4P

hilli

ps P

last

ics

Tool

Bui

ld 1

0MM

Tap

ered

Run

g P

art#

RM

1669

-01

to -0

505

/31/

13H

udso

n W

I - P

hilli

ps P

last

ics

33,3

33.4

4

in

San

Jos

e00

0509

QA

DQ

AD

Lic

ense

5 U

sers

05/0

1/13

Wak

e 20

1310

,538

.00

t-Ser

ver R

eloc

ated

to R

DU

B10

138

QA

DQ

AD

Sof

twar

e an

d Im

plem

enta

tion

Cos

ts05

/31/

13S

anta

Cla

ra19

,933

.32

B10

150

Saw

bone

sD

istri

buto

r Bon

es M

odel

on

Bas

e M

old

05/3

1/13

Vash

on Is

land

WA

- Saw

bone

s3,

826.

53

B10

147

Saw

bone

sLu

mba

r Cov

er L

a Ill

iac

1513

-64

Tool

/Mol

d05

/31/

13Va

shon

Isla

nd W

A - S

awbo

nes

2,56

2.50

B

1014

4S

awbo

nes

Lum

bar L

1 To

ol/M

old

05/3

1/13

Vash

on Is

land

WA

- Saw

bone

s2,

880.

00

B10

145

Saw

bone

sLu

mba

r Ste

nosi

s M

odel

Too

l/Mol

d05

/31/

13Va

shon

Isla

nd W

A - S

awbo

nes

3,33

3.20

B

1016

1-1

Saw

bone

sN

ew L

umba

r Spi

ne M

odel

Mol

d/To

ol05

/31/

13Va

shon

Isla

nd W

A - S

awbo

nes

12,8

79.8

4

B

1015

2S

awbo

nes

Sha

ver R

eplic

a M

old

for D

istri

buto

r Mod

el05

/31/

13Va

shon

Isla

nd W

A - S

awbo

nes

4,44

3.19

00

0676

Saw

bone

sD

epos

it fo

r a M

olde

l and

Mol

ds8/

1/14

Vash

on Is

land

WA

- Saw

bone

s7,

175.

00

n To

ol ~

4k A

cqui

red

Tool

TAC

TX C

regg

ana

Pro

duct

: Pro

bes

B10

077

Tech

-Etc

hM

olds

05/3

1/13

Ply

mou

th -

Tech

-Etc

h29

3.48

B10

078

Tech

-Etc

hM

olds

05/3

1/13

Ply

mou

th -

Tech

-Etc

h29

3.28

Was

not

on

list-F

ully

dep

reci

ated

o/Tr

aini

ng p

rodu

cts

Add

ress

is c

orre

ct

BO

NE

S; A

cqui

red

Valu

e ~4

5kg

Mod

el fo

r iO

Pro

duct

s

min

gToo

ling

~20k

Acq

uire

d Va

lue

Mol

d To

olin

g ~>

250k

Acq

uire

d Va

lue

264

Sta

rks

Driv

e C

linto

n Tw

p M

I 480

36cr

oBla

de S

have

r, N

euro

chec

k

Mol

d To

olin

g ~2

00k

Acq

uire

d Va

lue

170

Cen

tral A

ve. U

nion

City

CA

945

87s:

Dis

tal H

andl

e, P

robe

s

by M

PE

Tec

h D

evic

e. A

cqui

red

Valu

e ~8

kD

rive

Ede

n P

rairi

e M

N 5

5346

tion

Mol

d To

olin

g ~6

00k

Acq

uire

d Va

lue

2 Te

chno

logy

Driv

e E

ast M

enom

onie

WI

5475

1P

robe

tip,

Mic

robl

ade

Sha

ver

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 48

of 2

21

Sch

edul

e A

-1B

B10

079

Tech

-Etc

hM

olds

05/3

1/13

Ply

mou

th -

Tech

-Etc

h61

0.72

B10

080

Tech

-Etc

hM

olds

05/3

1/13

Ply

mou

th -

Tech

-Etc

h42

6.72

B10

108

Tech

-Etc

hTo

olin

g fo

r Sel

ectiv

e G

old

Pla

te C

ondu

ctor

05/3

1/13

Ply

mou

th -

Tech

-Etc

h1,

136.

74

lue

was

val

ue o

f ass

et a

t tim

e of

Bax

ano/

Tran

s1 M

erge

in 2

013.

Orig

inal

pur

chas

ed c

apita

l val

ue w

as s

igni

fican

tly g

reat

er th

an A

cqui

red

Valu

e.

Ald

rin R

oad

Ply

mou

th M

A 02

360

oduc

t: N

euro

chec

k

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 49

of 2

21

SL1 1342200v6 109188.00001

Schedule A-2

Owned Intellectual Property

U.S. Patents

� File�ref.�#� Title� App.�No.� App.�Date� Patent�No.� Patent�Date� Esp�Date

52�

10376�700.201�

DEVICES�AND�METHODS�FOR�SELECTIVE�SURGICAL�REMOVAL�OF�TISSUE�

11/250,332 10/15/2005 7,738,968� 6/15/2010� 7/31/2027

53�

10376�700.202�


11/250,369 10/15/2005 7,555,343� 6/30/2009� 3/5/2027

54�10376�700.204�

DEVICES�AND�METHODS�FOR�TISSUE�ACCESS�

11/251,205 10/15/2005 7,918,849� 4/5/2011� 10/01/2029

55�10376�700.206�

DEVICES�AND�METHODS�FOR�TISSUE�ACCESS�

11/251,186 10/15/2005 7,963,915� 6/21/2011� 08/16/2029

56�10376�700.207�

DEVICES�AND�METHODS�FOR�TISSUE�MODIFICATION�

11/251,165 10/15/2005 7,553,307� 6/30/2009� 02/25/2027

57�10376�700.208�


11/251,204 10/15/2005 7,740,631� 6/22/2010� 02/23/2029

58�10376�700.209�


11/251,199 10/15/2005 8,192,435� 6/5/2012� 01/28/2027

59�10376�700.307�


12/428,369 4/22/2009 8,221,397� 7/17/2012� 11/23/2026

60�

10376�700.310�


13/430,500 3/26/2012 8,579,902� 11/12/2013� 12/08/2025

61�

10376�700.401�


12/357,289 1/21/2009 7,738,969� 6/15/2010� 10/15/2025

62�10376�700.402�

SPINAL�ACCESS�AND�NEURAL�LOCALIZATION�

12/504,545 7/16/2009 8,419,653� 4/16/2013� 11/06/2026

63�

10376�700.501�

MECHANICAL�TISSUE�MODIFICATION�DEVICES�AND�METHODS�

11/405,848 4/17/2006 8,430,881� 4/30/2013� 06/14/2027

64�10376�700.502�

POWERED�TISSUE�MODIFICATION�DEVICES�AND�METHODS�

11/406,486 4/17/2006 7,938,830� 5/10/2011� 08/12/2027

65�10376�700.504�

FLEXIBLE�TISSUE�RASP� 11/429,377 5/4/2006 8,048,080� 11/1/2011� 12/29/2027

66�10376�700.505�

SPINAL�ACCESS�AND�NEURAL�LOCALIZATION�

11/457,416 7/13/2006 7,578,819� 8/25/2009� 10/15/2025

67�10376�700.506�

TISSUE�REMOVAL�WITH�AT�LEAST�PARTIALLY�FLEXIBLE�DEVICES�

11/687,548 3/16/2007 8,062,300� 11/22/2011� 03/24/2028

68�10376�700.507�

FLEXIBLE�TISSUE�REMOVAL�DEVICES�AND�METHODS�

11/687,558 3/16/2007 8,062,298� 11/22/2011� 01/19/2028

69�10376�700.509�

TISSUE�MODIFICATION�DEVICES 12/324,147 11/26/2008 8,192,436� 6/5/2012� 12/08/2028�

70�10376�700.US1�

METHODS�AND�APPARATUS�FOR�TISSUE�MODIFICATION�

11/375,265 3/13/2006 7,887,538� 2/15/2011� 01/08/2027


SL1 1342200v6 109188.00001

71�10376�706.201�

TISSUE�ACCESS�GUIDEWIRE�SYSTEM�AND�METHOD�

11/468,247 8/29/2006 7,857,813� 12/28/2010� 05/16/2028

72�10376�706.501�

GUIDEWIRE�EXCHANGE�SYSTEMS�TO�TREAT�SPINAL�STENOSIS�

12/127,535 5/27/2008 8,257,356� 9/4/2012� 08/09/2028

73�

10376�719.200�

METHOD,�SYSTEM,�AND�APPARATUS�FOR�NEURAL�LOCALIZATION�

12/060,229 3/31/2008 7,959,577� 6/14/2011� 06/27/2028

74�

10376�719.400�

METHOD,�SYSTEM,�AND�APPARATUS�FOR�NEURAL�LOCALIZATION�

13/090,944 4/20/2011 8,303,516� 11/6/2012� 03/31/2028

75�

10376�727.200�

MULTIPLE�PATHWAYS�FOR�SPINAL�NERVE�ROOT�DECOMPRESSION�FROM�A�SINGLE�ACCESS�POINT�

12/352,978 1/13/2009 8,092,456� 1/10/2012� 05/08/2026

76�

10376�727.300�

MULTIPLE�PATHWAYS�FOR�SPINAL�NERVE�ROOT�DECOMPRESSION�FROM�A�SINGLE�ACCESS�POINT�

13/312,272 12/6/2011 8,366,712� 2/5/2013� 10/15/2025

77�10376�730.200�

SURGICAL�TOOLS�FOR�TREATMENT�OF�SPINAL�STENOSIS�

12/824,043 6/25/2010 8,394,102� 3/12/2013� 01/30/2031

78�10376�731.200�

TISSUE�MODIFICATION�DEVICES�AND�METHODS�

12/773,595 5/4/2010 8,409,206� 4/2/2013� 07/01/2029

79�10376�731.500�

TISSUE�MODIFICATION�DEVICES�AND�METHODS�

13/338,103 12/27/2011 8,398,641� 3/19/2013� 07/01/2029

80�10376�706.301�

TISSUE�ACCESS�GUIDEWIRESYSTEM�AND�METHOD�

12/917,253 11/1/2010 8,551,097� 10/8/2013� 08/29/2026

81�

10376�706.502�

ACCESS�AND�TISSUE�MODIFICATION�SYSTEMS�AND�METHODS�

13/588,969 8/17/2012 8,568,416� 10/29/2013� 10/14/2025

82�10376�700.310�


13/430,500 3/26/2012 8,579,902� 11/12/2013� 12/8/2025

83�10376�700.309�

FLEXIBLE�TISSUE�REMOVAL�DEVICES�AND�METHODS�

13/267,683 10/6/2011 8,585,704��

11/19/2013� 05/09/2026

84�10376�700.514�

METHODS,�SYSTEMS�AND�DEVICES�FOR�CARPAL�TUNNEL�RELEASE�

13/112,886 5/20/2011 8,617,163� 12/31/2013� 09/14/2026

85�10376�700.515�

METHODS,�SYSTEMS�AND�DEVICES�FOR�CARPAL�TUNNEL�RELEASE�

13/112,918 5/20/2011 8,613,745� 12/24/2013� 09/14/2026

86�10376�700.311�


13/484,744 5/31/2012 8,647,346� 02/11/2014� 10/15/2025

87�10376�700.304�

FLEXIBLE�TISSUE�RASP� 13/243,095 9/23/2011 8,652,138� 2/18/2014� 10/15/2025

88�10376�700.403�

TISSUE�MODIFICATION�DEVICES 13/232,882 9/14/2011 8,662,228��

3/4/2014� 12/07/2027

93�10376�729.500�

FLEXIBLE�NEURAL�LOCALIZATION�DEVICES�AND�METHODS�

13/340,363 12/29/2011 8,801,626� 8/12/2014� �

94�10376�706.401�

TISSUE�ACCESS�GUIDEWIRE�SYSTEM�AND�METHOD�

14/023,893 9/11/2013 8,845,637�9/30/2014� �

95�10376�725.300�

TISSUE�MODIFICATION�DEVICES 13/007,381 1/14/2011 8.845,639�9/30/2014� �


SL1

134

2200

v6 1

0918

8.00

001

Fore

ign

Issu

ed P

aten

ts

File

�Ref

.�no.

�Ti

tle�

App.

�No.

�Ap

p.�D

ate�

Nat

.�Dat

ePa

tent

�No.

�Pa

tent

�Da

te�

1037

6�70

0.DE

5�TI

SSU

E�RE

MO

VAL�

DEVI

CES�

AND�

MET

HODS

�10

0750

66.0

�12

/7/2

007�

��EP

�224

1274

�2/

1/20

12�

1037

6�70

0.FR

5�TI

SSU

E�RE

MO

VAL�

DEVI

CES�

AND�

MET

HODS

�10

0750

66.0

�12

/7/2

007�

��22

4127

4�2/

1/20

12�

1037

6�70

0.GB

5�TI

SSU

E�RE

MO

VAL�

DEVI

CES�

AND�

MET

HODS

�10

0750

66.0

�12

/7/2

007�

��22

4127

4�2/

1/20

12�

1037

6�70

0.IT

5�TI

SSU

E�RE

MO

VAL�

DEVI

CES�

AND�

MET

HODS

�10

0750

66.0

�12

/7/2

007�

��22

4127

4�2/

1/20

12�

U.S

. Pen

ding

Pat

ent A

pplic

atio

ns

File

�Ref

.�no.

�Ti

tle�

App.

�No.

�Ap

p.�D

ate�

Pub.

�No.

�Pu

b.�D

ate�

Stat

us�

10376�700.404�

�FL

EXIB

LE�T

ISSU

E�RA

SP�

�14

/180

,221

02/1

3/20

14�

2014

0163

562�

6/12

/201

4pend

ing�

10376�700.314�

FLEX

IBLE

�TIS

SUE�

REM

OVA

L�DE

VICE

S�AN

D�M

ETHO

DS�

�

14/0

82,0

5211

/15/

2013

�20

1400

7409

7�3/

13/2

014

pend

ing�

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 52

of 2

21

SL1

134

2200

v6 1

0918

8.00

001

Add

ition

al P

aten

ts:1

US

2011

-006

0314

A1

- D

EV

ICE

S A

ND

ME

TH

OD

S FO

R T

RE

AT

ING

TIS

SUE

US

2011

-016

0731

A1

- DE

VIC

ES

AN

D M

ET

HO

DS

FOR

TIS

SUE

AC

CE

SS

US

2011

-006

0314

A1

- D

EV

ICE

S A

ND

ME

TH

OD

S FO

R T

RE

AT

ING

TIS

SUE

US

2012

-019

1003

A1

- FL

EX

IBL

E N

EU

RA

L L

OC

AL

IZA

TIO

N D

EV

ICE

S A

ND

ME

TH

OD

S

US

2013

-015

0855

A1

- MU

LT

IPL

E P

AT

HW

AY

S FO

R S

PIN

AL

NE

RV

E R

OO

T D

EC

OM

PRE

SSIO

N F

RO

M A

SIN

GL

E

AC

CE

SS P

OIN

T

US

2013

-015

0856

A1_

TIS

SUE

MO

DIF

ICA

TIO

N D

EV

ICE

S A

ND

ME

TH

OD

S

US

2013

-031

0837

A1

- PO

WE

RE

D T

ISSU

E M

OD

IFIC

AT

ION

DE

VIC

ES

AN

D M

ET

HO

DS

US

2014

-018

0293

A1

- TIS

SUE

MO

DIF

ICA

TIO

N D

EV

ICE

S

US

2014

-010

7709

A1

- AC

CE

SS A

ND

TIS

SUE

MO

DIF

ICA

TIO

N S

YST

EM

S A

ND

ME

TH

OD

S

WO

200

8/02

7926

- T

ISSU

E A

CC

ESS

GU

IDE

WIR

E S

YST

EM

AN

D M

ET

HO

D

JP

2010

5023

05 (A

) E

P205

6710

(A2)

C

A26

6186

9 (A

1)

AU

2007

2892

43 (A

1)

AU

2007

2892

43 (B

2)

WO

200

7/10

6740

- M

ET

HO

DS

AN

D A

PPA

RA

TU

S FO

R T

ISSU

E M

OD

IFIC

AT

ION

WO

200

6/04

4727

- D

EV

ICE

S A

ND

ME

TH

OD

S FO

R T

ISSU

E R

EM

OV

AL

JP20

1217

9371

(A)

JP5

6071

00 (B

2)

JP20

0851

6694

(A)

JP5

2430

34 (B

2)

EP1

7991

29 (A

2)

EP1

7991

29 (A

4)

C

A25

8390

6 A

1)

CA

2583

906

(C)

AU

2005

2955

89 (A

1)

AU

2005

2955

89 (B

2)

WO

201

0/00

9093

- T

ISSU

E M

OD

IFIC

AT

ION

DE

VIC

ES

M

X20

1100

0510

(A)

EP2

3284

89 (A

2)

EP2

3284

89 (A

4)

CA

2730

732

(A1)

A

U20

0927

1047

(A1)

A

U20

0927

1047

1 Th

e Se

ller h

as n

ot p

aid

the

asso

ciat

ed re

gistr

atio

n an

d/or

mai

nten

ance

fees

for a

ny o

f the

pat

ents

list

ed b

elow

, nor

has

it, s

ince

Aug

ust 2

014,

oth

erw

ise

enfo

rced

any

such

pat

ents

.

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 53

of 2

21

SL1

134

2200

v6 1

0918

8.00

001

Fede

ral T

rade

mar

ks

MA

RK

A

PP. N

O.

FIL

ING

D

AT

E

RE

G. N

O.

RE

G. D

AT

E

CL

ASS

C

LA

SS:

GO

OD

S/SE

RV

ICE

S ST

AT

US

iO-F

lex

77/8

17,7

65

01-S

ept-2

009

3894

968

21-D

ec-2

010

10

10:

Surg

ical

and

med

ical

dev

ices

and

inst

rum

ents

, na

mel

y, su

rgic

al in

stru

men

ts fo

r acc

essi

ng,

loca

lizin

g an

d m

odify

ing

tissu

e; S

urgi

cal a

nd

med

ical

syst

ems,

com

pris

ed o

f a se

t of m

inim

ally

in

vasi

ve su

rgic

al in

stru

men

ts u

sed

in se

quen

ce fo

r ac

cess

ing,

loca

lizin

g an

d m

odify

ing

tissu

e

RE

GIS

TER

ED

iO-F

lex

77/8

17,7

82

01-S

ept-2

009

3887

573

07-D

ec-2

010

44

44:

Med

ical

serv

ices

R

EG

IST

ERE

D

iO-F

lex

77/8

17,7

91

01-S

ept-2

009

3894

969

21-D

ec-2

010

10

10:

Surg

ical

and

med

ical

dev

ices

and

inst

rum

ents

, na

mel

y, su

rgic

al in

stru

men

ts fo

r acc

essi

ng,

loca

lizin

g an

d m

odify

ing

tissu

e; S

urgi

cal a

nd

med

ical

syst

ems,

com

pris

ed o

f a se

t of m

inim

ally

in

vasi

ve su

rgic

al in

stru

men

ts u

sed

in se

quen

ce fo

r ac

cess

ing,

loca

lizin

g an

d m

odify

ing

tissu

e

RE

GIS

TER

ED

iO-F

lex

77/8

17,7

94

01-S

ept-2

009

3887

574

07-D

ec-2

010

44

44:

Med

ical

serv

ices

R

EG

IST

ERE

D

iO-F

lex

77/8

17,8

29

01-S

ept-2

009

3894

970

21-D

ec-2

010

10

10:

Surg

ical

and

med

ical

dev

ices

and

inst

rum

ents

, na

mel

y, su

rgic

al in

stru

men

ts fo

r acc

essi

ng,

loca

lizin

g an

d m

odify

ing

tissu

e; S

urgi

cal a

nd

med

ical

syst

ems,

com

pris

ed o

f a se

t of m

inim

ally

in

vasi

ve su

rgic

al in

stru

men

ts u

sed

in se

quen

ce fo

r ac

cess

ing,

loca

lizin

g an

d m

odify

ing

tissu

e

RE

GIS

TER

ED

iO-F

lex

77/8

17,8

33

01-S

ept-2

009

3894

971

21-D

ec-2

010

44

44:

Med

ical

serv

ices

R

EG

IST

ERE

D

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 54

of 2

21

SL1

134

2200

v6 1

0918

8.00

001

MA

RK

A

PP. N

O.

FIL

ING

D

AT

E

RE

G. N

O.

RE

G. D

AT

E

CL

ASS

C

LA

SS:

GO

OD

S/SE

RV

ICE

S ST

AT

US

MIC

RO

BLA

DE

SHA

VER

A

XIA

MD

.138

T 77

/817

,695

01

-Sep

t-200

9 39

2128

6 15

-Feb

-201

1 10

10

: Su

rgic

al an

d m

edic

al d

evic

es an

d in

stru

men

ts,

nam

ely,

surg

ical

inst

rum

ents

for a

cces

sing

and

m

odify

ing

soft

tissu

e an

d bo

ne

RE

GIS

TER

ED

MIC

RO

BLA

DE

SHA

VER

77

/817

,698

01

-Sep

t-200

9 39

2651

4 01

-Mar

-201

1 44

44

: M

edic

al se

rvic

es

RE

GIS

TER

ED

NEU

RO

CH

ECK

A

XIA

MD

.139

T 77

/817

,683

01

-Sep

t-200

9 3,

958,

689

10-M

ay-2

011

10

10:

Surg

ical

and

med

ical

dev

ices

and

inst

rum

ents

, na

mel

y, su

rgic

al in

stru

men

ts fo

r acc

essi

ng a

nd

loca

lizin

g tis

sue

RE

GIS

TER

ED

NEU

RO

CH

ECK

77

/817

,687

01

-Sep

t-200

9 40

7454

7 20

-Dec

-201

1 44

44

: Pr

ovid

ing

med

ical

info

rmat

ion

conc

erni

ng th

e us

e of

surg

ical

dev

ices

and

inst

rum

ents

R

EG

IST

ERE

D

IO-T

OM

E 85

/082

,846

12-J

ul-2

010

4415

146

10/0

8/20

13

10 &

41

10: S

urgi

cal a

nd m

edic

al d

evic

es an

d in

stru

men

ts,

nam

ely,

surg

ical

inst

rum

ents

for a

cces

sing

and

m

odify

ing

soft

tissu

e an

d bo

ne.

41: E

duca

tion,

nam

ely,

pro

vidi

ng c

lass

es,

sem

inar

s, co

nfer

ence

s and

wor

ksho

ps a

nd

train

ing

serv

ices

all

in th

e m

edic

al fi

eld.

RE

GIS

TER

ED

Fore

ign

Tra

dem

arks

MA

RK

TE

RR

ITO

RY

APP

. NO

. FI

LIN

G

DA

TE

REG

. NO

. R

EG. D

ATE

C

LASS

ES

CLA

SS:

GO

OD

S/SE

RV

ICES

ST

ATU

S

iO-F

lex

Euro

pean

C

omm

unity

89

1905

2

01-M

ar-2

010

8919

052

13-O

ct-2

010

10 &

44

10: S

urgi

cal a

nd m

edic

al d

evic

es

and

inst

rum

ents

, nam

ely,

sur

gica

l in

stru

men

ts fo

r acc

essi

ng,

loca

lizin

g an

d m

odify

ing

tissu

e;

REG

ISTE

RED

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 55

of 2

21

SL1

134

2200

v6 1

0918

8.00

001

MA

RK

TE

RR

ITO

RY

APP

. NO

. FI

LIN

G

DA

TE

REG

. NO

. R

EG. D

ATE

C

LASS

ES

CLA

SS:

GO

OD

S/SE

RV

ICES

ST

ATU

S

Surg

ical

and

med

ical

sys

tem

s,

com

pris

ed o

f a s

et o

f min

imal

ly

inva

sive

sur

gica

l ins

trum

ents

use

d in

seq

uenc

e fo

r acc

essi

ng,

loca

lizin

g an

d m

odify

ing

tissu

e

44: M

edic

al s

ervi

ces.

IO-T

OM

E Eu

rope

an

Uni

on

9647

389

10-Ja

n-20

11

9647

389

16-Ju

n-20

11

10, 4

1, 4

4 10

: Sur

gica

l and

med

ical

dev

ices

, m

achi

nes,

inst

rum

ents

, app

arat

us

and

syst

ems;

sur

gica

l and

med

ical

de

vice

s an

d in

stru

men

ts, n

amel

y,

surg

ical

inst

rum

ents

for a

cces

sing

an

d m

odify

ing

soft

tissu

e an

d bo

ne.

41: E

duca

tion;

Pro

vidi

ng o

f tr

aini

ng; e

duca

tion

and

trai

ning

se

rvic

es in

the

med

ical

fiel

d.

44: M

edic

al S

ervi

ces;

pro

vidi

ng

med

ical

info

rmat

ion.

REG

ISTE

RED

Trad

emar

ks2 �

�85

6545

90�

4285

902�

IO�F

LEXI

BILI

TY�

8557

1995

�43

2698

0�IO

�CO

NN

ECT�

7781

7743

�38

8757

2�IN

SIDE

�OU

T.�T

HE�IN

TUIT

IVE�

DIRE

CTIO

N�

2 Th

e Se

ller h

as n

ot p

aid

the

asso

ciat

ed re

gist

ratio

n an

d/or

mai

nten

ance

fees

for a

ny o

f the

trad

emar

ks li

sted

bel

ow, n

or h

as it

, sin

ce A

ugus

t 201

4, o

ther

wis

e en

forc

ed a

ny su

ch tr

adem

arks

. C

ase

14-1

2545

-CS

S

Doc

191

F

iled

12/3

1/14

P

age

56 o

f 221

SL1

134

2200

v6 1

0918

8.00

001

7781

7742

�39

5869

3�IN

SIDE

�OU

T.�T

HE�IN

TUIT

IVE�

DIRE

CTIO

N�

7781

7733

�38

9496

7�SU

RGER

Y�FR

OM

�THE

�INSI

DE�O

UT�

7781

7727

�39

5869

2�SU

RGER

Y�FR

OM

�THE

�INSI

DE�O

UT�

7781

7720

�38

8757

1�DI

SCO

VER�

THE�

UPS

IDE�

OF�

THE�

INSI

DE�O

UT�

7781

7715

�39

5869

1�DI

SCO

VER�

THE�

UPS

IDE�

OF�

THE�

INSI

DE�O

UT�

7781

7707

�38

8757

0�PR

ECIS

ION

�DEC

OM

PRES

SIO

N�F

ROM

�THE

�INSI

DE�

OU

T�77

8177

02�

3958

690�

PREC

ISIO

N�D

ECO

MPR

ESSI

ON

�FRO

M�T

HE�IN

SIDE

�O

UT�

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 57

of 2

21

SL1 1342200v6 109188.00001

�

Schedule A-3

Assigned Contracts

None.


SL1 1342200v6 109188.00001

Schedule A-4

Governmental Authorizations*

US Product 510k # Class Product Code iO-Flex K100958, K063231 II HAE

Neurocheck K092729, K081742 II ETN Catheter K102594 II BSO

Neurocheck�with�wire��K113533�and�K110696�iO�Tome��K113073�Baxano�Ultra�Low�Profile�Rongeur�K080494�Microblade�Shaver�and�Accessories�K063231�Ultra�Low�Profile�Rongeur�K062711�K110696��*Please note that the Bone Graft Harvester did not require a 510(k) registration

CanadaProduct Registration

#Class Registration

Holder First Issue Registration

Agent Frequency

for Renewal iO-Flex 88060 3 of 4 Baxano

Surgical 1/13/2012 Baxano

Surgical Annual

EUProduct Registration

#Class Registration

Holder First Issue Notified

Body Expiry

iO-Flex 41314965 IIb Baxano Surgical

Transferred from BSi

Intertek 3/9/2015 (EC Cert)

DubaiiO-Flex Approved

Turkey TITUBB Database Listings

iO-Wire 00814864010545 iO-CP45 00814864010552 iO-IP 00814864010569 iO-IP-TR 00814864010576 iO-NCW 00814864010583 iO-DH 00814864010590 iO-MBS5.5 00814864010606 iO-MBS7.5sc 00814864010613 iO-MBS10sc 00814864010620 iO-MBS12sc 00814864010637 iO-Tome7.5 00814864010644 iO-Tome10 00814864010651 iO-IC 00814864010668 iO-CC 00814864010675


SL1 1342200v6 109188.00001

Schedule A-5

Other Assets

None


SL1 1342200v6 109188.00001

EXHIBIT B

ASSIGNMENT, DELEGATION AND ASSUMPTION AGREEMENT

ASSIGNMENT, DELEGATION AND ASSUMPTION AGREEMENT (“Agreement”) dated as of [__________] by and between Baxano Surgical, Inc., a Delaware corporation (“Assignor”), and [__________________] a [__________] (“Assignee”).

BACKGROUND

A. Assignee and Assignor have entered into an Asset Purchase Agreement dated as of [___________] (together with the Exhibits and Schedules thereto, the “Purchase Agreement”) providing for, among other things, the sale, transfer, conveyance, assignment, and delivery by Assignor to Assignee of certain assets of Assignor (collectively, the “Acquired Assets”) that are owned or used by Assignor in connection with the Business.

B. In connection with the sale and purchase of the Acquired Assets pursuant to the Purchase Agreement, Assignor is to assign and delegate, and Assignee is to assume, the Assigned Contracts. Closing is being held on the date hereof under the Purchase Agreement.

NOW, THEREFORE, pursuant to and in consideration of the Purchase Agreement and the mutual covenants and agreements set forth therein and herein, Assignor and Assignee, each intending to be legally bound, agree as follows:

1. Incorporation of Background; Defined Terms. The Background provisions set forth above (including, without limitation, all of the defined terms set forth therein) are hereby incorporated by reference into this Agreement and made a part hereof as if set forth in their entirety in this Section 1. Capitalized terms used herein which are not otherwise defined shall have the respective meanings assigned to them in the Purchase Agreement.

2. Assignment of Rights. Assignor hereby sells, transfers, conveys, and assigns to Assignee all of Assignor’s right, title and interest in, to and under all of the Assigned Contracts, each of which are identified on Schedule 2 attached hereto.

3. Delegation of Duties. Assignor hereby delegates to Assignee all of Assignor’s duties and liabilities under the Assigned Contracts.

4. Assumption of Liabilities. In partial consideration for the sale of the Acquired Assets by Assignor pursuant to the Purchase Agreement, Assignee hereby undertakes and agrees to assume, discharge, or perform as the case may be, all duties, obligations, and liabilities of Assignor under the Assigned Contracts which are to be performed after, and relate to the period after, the date hereof or which are otherwise assigned to and assumed by the Purchaser under or pursuant to the Purchaser Agreement or the Sale Order.

5. Assignment of Governmental Authorizations; Etc. Assignor hereby assigns, sells, transfers, and sets over to Assignee all of Assignor’s right, title and interest in, to, and under all of the Governmental Authorizations which are listed on Schedule 5 attached hereto, but only to the extent that any of the foregoing may be legally sold, transferred, conveyed, assigned and


SL1 1342200v6 109188.00001

delivered by Assignor to Assignee without any action by any such applicable federal, state, or local government or regulatory body.

6. Binding Effect. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.

7. Governing Law. This Agreement shall be governed by, and construed in accordance with, the domestic, internal laws of the State of Delaware, without regard to its rules pertaining to the conflict of laws.

8. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed to be an original of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement. Any party to this Agreement may deliver an executed counterpart hereof by facsimile transmission or electronic mail (as a Portable Document Format (PDF) file) to the other party hereto and any such delivery shall have the same force and effect as the manual delivery of an original executed counterpart of this Agreement.

Remainder of Page Intentionally Left Blank Signature Page Follows


SL1 1342200v6 109188.00001

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their duly authorized officers the day and year first above written.

BAXANO SURGICAL, INC.

By _________________________________________ [_______________], [__________]

“Assignor”

[__________________________]

By _________________________________________ Name: Title:

“Assignee”


SL1 1342200v6 109188.00001

EXHIBIT C

BILL OF SALE

January ___, 2015

KNOW ALL BY THESE PRESENTS that BAXANO SURGICAL, INC., a Delaware corporation (the “Seller”), for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, has granted, bargained, sold, conveyed, transferred, assigned and delivered, and by this Bill of Sale hereby grants, bargains, sells, conveys, transfers, assigns and delivers, to ExWorks Capital Fund I, L.P (“Purchaser”), its successors and assigns, all of the Seller’s right, title and interest in and to the Acquired Assets. As used herein, the term “Acquired Assets” has the meaning given to such term in that certain Asset Purchase Agreement, dated as of December 31 , 2014, by and between the Seller and Purchaser (together with the Exhibits and Schedules thereto, the “Purchase Agreement”), which Purchase Agreement is incorporated herein by this reference.

EXCLUDING, HOWEVER, the “Excluded Assets” (as such term is defined in the Purchase Agreement).

TO HAVE AND TO HOLD the Acquired Assets unto Purchaser, its successors and assigns, forever.

This Bill of Sale is being executed and delivered by the Seller to the Purchaser under and pursuant to Section 8.2(a) of the Purchase Agreement and is subject to the terms and conditions of the Purchase Agreement in all respects.

Remainder of Page Intentionally Left Blank

Signature Page Follows


SL1 1342200v6 109188.00001

IN WITNESS WHEREOF, Seller has executed and delivered this Bill of Sale as of the date and year first set forth above.


By _______________________________________________ Name: Title:


SL1 1342200v6 109188.00001

EXHIBIT D

DEPOSIT ESCROW AGREEMENT

This Escrow Agreement (this “Agreement”) is entered into as of December 31, 2014, by and among Stevens & Lee, P.C., as escrow agent (“Escrow Agent”), Baxano Surgical, Inc. (“Baxano”), and ExWorks Capital Fund I, L.P. (the “Purchaser,” and, collectively with Baxano, the “Principals”). The Escrow Agent and the Principals may be referred to herein as a “Party” and collectively, the “Parties”.

WHEREAS, pursuant to that certain Asset Purchase Agreement of even date herewith (the “Purchase Agreement”), the Purchaser has offered to purchase certain assets of Baxano.

WHEREAS, pursuant to the Purchase Agreement, the Purchaser is required to provide a Deposit (as defined in the Purchase Agreement.)

WHEREAS, the Principals have requested that the Escrow Agent serve as escrow agent for the Deposit.

WHEREAS, the Escrow Agent has agreed to act as escrow agent during the term of this Agreement, on the terms and subject to the conditions set forth in this Agreement.

NOW, THEREFORE, in consideration of the representations, warranties and covenants herein contained, and intending to be legally bound, the Parties agree as follows:

1. Appointment. The Principals hereby constitute and appoint the Escrow Agent as escrow agent hereunder, and the Escrow Agent hereby agrees to assume and perform the duties of the escrow agent hereunder. The Escrow Agent is not charged with knowledge of the terms or provisions of any agreements between the Principals or with any duties or responsibilities except as expressly stated in this Agreement.

2. Escrow Funds. Upon the execution hereof Purchaser shall cause to be delivered to the Escrow Agent the amount of $400,000 in immediately available funds (the “Escrow Funds”).

3. Investments.

(a) The Escrow Agent is authorized and directed to deposit, transfer, hold and invest the Escrow Funds in its Interest on Lawyers Trust Funds account.

(b) The Escrow Agent is hereby authorized and directed to make any payments or distributions required under this Agreement. The Parties acknowledge that the Escrow Agent is not providing investment supervision, recommendations, or advice.

4. Disbursements. The Escrow Agent shall disburse the Escrow Funds only pursuant to (a) a joint written direction from the Principals (a “Joint Instruction Letter”), or (b) an order of a court of competent jurisdiction. The Escrow Agent shall not be responsible for verifying


SL1 1342200v6 109188.00001

the accuracy or completeness of any Joint Instruction Letter or the compliance of such Joint Instruction Letter with the terms of this Agreement or any agreement between the Principals. The Escrow Agent shall not be liable for any action taken in respect of the distribution of Escrow Funds in accordance with this Section 4.

5. No Security Interest; Escrow Agent Priority of Payment. Escrow Agent hereby disclaims any security interest in any portion of the Escrow Funds and agrees to keep the Escrow Funds free and clear of liens in favor of Escrow Agent while such Escrow Funds remain in the Escrow Account.

6. Termination. This Agreement shall terminate upon the distribution of all of the Escrow Funds held by the Escrow Agent pursuant to this Agreement.

7. Compensation. The Escrow Agent’s services hereunder shall be provided without charge.

8. Exculpatory Provisions. The Escrow Agent shall be obligated only to perform such duties as are specifically set forth in this Agreement and may rely and shall be protected in relying on any instrument reasonably believed to be genuine and to have been signed or presented by the proper Party or Parties. The Escrow Agent shall not be liable for forgeries or false impersonations. The Escrow Agent shall not be liable for any act done or omitted hereunder as escrow agent except for actions or omissions that are finally determined by a court of competent jurisdiction to constitute fraud, gross negligence or willful misconduct. The Escrow Agent shall in no case or event incur liability for any punitive, incidental or consequential losses or damages of any kind whatsoever (including without limitation lost profits), even if the Escrow Agent has been advised of the possibility of such losses or damages and regardless of the form of action. The Escrow Agent shall be entitled to rely on and shall not be liable for any action taken or omitted to be taken by the Escrow Agent in accordance with the advice of counsel or other professionals retained or consulted by the Escrow Agent. Any act done or omitted pursuant to the advice or opinion of counsel (including counsel employed by the Escrow Agent) shall be conclusive evidence of the good faith of the Escrow Agent.

9. Alteration of Duties. The duties of the Escrow Agent may only be altered, amended, modified or revoked pursuant to a writing signed by all the Parties.

10. Resignation or Removal of the Escrow Agent. The Escrow Agent may resign as escrow agent at any time with or without cause by giving at least sixty (60) days’ prior written notice to each of the Principals, such resignation to be effective sixty (60) days following the date such notice is given or upon the earlier appointment of a successor escrow agent. In addition, the Principals may jointly remove the Escrow Agent as escrow agent at any time with or without cause, by an instrument executed by the Principals, which instrument shall designate the effective date of such removal. In the event of any such resignation or removal, a successor escrow agent shall be appointed by the Principals. If, however, the Principals shall fail to name such a successor escrow agent within thirty (30) days after the notice of resignation from the Escrow Agent, the Escrow Agent may apply to a court of competent jurisdiction for appointment of a successor escrow agent. Any such successor escrow agent shall deliver to the Principals a written instrument


SL1 1342200v6 109188.00001

accepting such appointment, and thereupon it shall succeed to all the rights and duties of the Escrow Agent hereunder and shall be entitled to receive and safeguard the Escrow Funds.

11. Further Instruments. If the Escrow Agent reasonably requires other or further instruments in connection with the performance of its duties hereunder, the Principals shall join in furnishing such instruments.

12. Indemnification. The Principals, jointly and severally, shall reimburse and indemnify the Escrow Agent for, and hold it harmless against, any loss, damages, cost or expense, including, without limitation, reasonable attorneys’ fees, reasonably incurred by the Escrow Agent in connection with the performance of its duties and obligations under this Agreement, as well as the reasonable costs and expenses of defending against any claim or liability relating to this Agreement; provided, that notwithstanding the foregoing, neither Principal shall be required to indemnify the Escrow Agent for any such loss, liability, cost or expense arising as a result of the Escrow Agent’s gross negligence or willful misconduct as finally determined by a court of competent jurisdiction. The provisions of this paragraph shall survive the termination of this Agreement and the resignation or removal of the Escrow Agent for any reason.

13. Disagreements. If any conflict, disagreement or dispute arises between, among, or involving any of the Parties concerning the meaning or validity of any provision hereunder or concerning any other matter relating to this Agreement, or the Escrow Agent is in doubt as to the action to be taken hereunder, the Escrow Agent is authorized to retain the Escrow Funds until the Escrow Agent (a) receives a final non-appealable order of a court of competent jurisdiction or a final non-appealable arbitration decision directing delivery of the Escrow Funds, (b) receives a written agreement executed by each of the Principals directing delivery of the Escrow Funds, in which event the Escrow Agent shall be authorized to disburse the Escrow Funds in accordance with such final court order, arbitration decision, or agreement, or (c) files an interpleader action in any court of competent jurisdiction, and upon the filing thereof, the Escrow Agent shall be relieved of all liability as to the Escrow Funds and shall be entitled to recover attorneys’ fees, expenses and other costs incurred in commencing and maintaining any such interpleader action. The Escrow Agent shall be entitled to act on any such agreement, court order, or arbitration decision without further question, inquiry, or consent.

14. Notices. Any notice given hereunder shall be in writing and shall be deemed effective upon the earliest of (a) personal delivery, (b) electronic or facsimile delivery, and (c) the third day after mailing by certified or registered mail, postage prepaid as follows:

To Purchaser: With a copy(which copy shall not constitute notice) to:

Andy Hall ExWorks Capital Fund I, L.P. 333 W. Wacker Drive, Suite 1620 Chicago, IL 60606


SL1 1342200v6 109188.00001

With a copy to:

And a copy to:

And a copy to:

Donald F. Baty, Esquire Honigman Miller Schwartz and Cohn LLP 2290 First National Building 660 Woodward Avenue Detroit, MI 48226

Michael F. Rozmajzl Amendia, Inc. 1755 West Oak Parkway Marietta, GA 30062

Michael A. Steel Brennan, Manna & Diamond, LLC 75 East Market Street Akron, Ohio 44308

To Baxano:

Baxano Surgical, Inc. 110 Horizon Drive, Suite 230 Raleigh, N.C., 27615 Attn: John L. Palmer Email:[email protected]: (215) 475-4714

To the Escrow Agent: Stevens & Lee, P.C. 1818 Market Street 29th Floor Philadelphia, Pennsylvania, 19103 Attention: Robert Lapowsky Email: [email protected] Facsimile: (610) 371-7958

With a copy (which copy shall not constitute notice) to:

Stevens & Lee, P.C. 1818 Market Street 29th Floor Philadelphia, Pennsylvania, 19103 Attention: Robert Lapowsky Email: [email protected] Facsimile: (610) 371-7958

15. Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the Commonwealth of Pennsylvania. Each of the Parties hereby (a) irrevocably and unconditionally submits to the jurisdiction of (i) the United States Bankruptcy Court for the District of Delaware or, (ii) if such court declines to exercise jurisdiction, the courts of the State of Delaware and the United States District Court for the District of Delaware, and (b) irrevocably agrees that all actions or proceedings arising out of or related to this Agreement


SL1 1342200v6 109188.00001

shall be litigated exclusively in such courts. Each of the Parties agrees not to commence any legal proceedings related hereto except in such courts. Each of the Parties hereby irrevocably waives any objection which he or it may now or hereafter have to the laying of venue of any such proceeding in any such court and hereby irrevocably waives and agrees not to plead or claim that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.

16. Waiver of Jury Trial. EACH OF THE PARTIES HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL ACTION, SUIT OR PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

17. Tax Matters.

(a) Reporting. The Principals agree that, for tax reporting purposes, all interest and other income from investment of the Escrow Funds, if any, shall, as of the end of each calendar year and to the extent required by the Internal Revenue Service, be reported as having been earned by the Principal to whom it is actually disbursed, in the year in which disbursed.

(b) Certification of Tax Identification Numbers. The Principals shall provide the Escrow Agent with certified tax identification numbers by furnishing appropriate forms W-9 or W-8 and other forms and documents as the Escrow Agent may reasonably request. The Principals understand that if such tax documentation is not certified to the Escrow Agent, the Escrow Agent may be required by the Internal Revenue Code of 1986, as amended, to withhold a portion of any interest or other income earned on the investment of monies or other property held by the Escrow Agent pursuant to this Agreement.

(c) Tax Allocation. To the extent the Escrow Agent becomes liable for the payment of any taxes in respect of income derived from the investment of funds or payments made hereunder, the Escrow Agent shall satisfy such liability to the extent possible from the Escrow Fund. The Principals, jointly and severally, agree to indemnify and hold harmless the Escrow Agent from and against any taxes, additions for late payment, interest, penalties and other expenses that may be assessed against the Escrow Agent on or with respect to any payment or other activities under this Agreement unless any such tax, addition for late payment, interest, penalties and other expenses shall arise out of or be caused by the actions of, or failure to act by, the Escrow Agent.

18. Conflict Waiver. The Principals acknowledge that (a) Stevens & Lee, P.C.serves as counsel to Baxano in its pending bankruptcy proceeding and in connection with the transaction between the Principals described in the Purchase Agreement (the “Transaction”), and (b) Stevens & Lee, P.C. has agreed to serve as Escrow Agent solely to facilitate the Transaction. Purchaser hereby waives any conflict of interest that exists, or may in the future arise, as a result of Stevens & Lee’s service as Escrow Agent hereunder and Stevens & Lee’s representation of Baxano in connection with the Transaction and any related transactions or litigation. The Purchaser agrees that the service by Stevens & Lee, P.C. as Escrow Agent hereunder shall not preclude the continued representation of Baxano


SL1 1342200v6 109188.00001

by Stevens & Lee, P.C. in connection with the Baxano bankruptcy proceedings, the Transaction or any related transactions or litigation.

19. Amendments and Waivers; Entire Agreement. No amendment of any provision of this Agreement shall be valid unless the same shall be in writing and signed by each of the Parties. No waiver by any Party of any right or remedy hereunder shall be valid unless the same shall be in writing and signed by the Party giving such waiver. No waiver by any Party with respect to any default hereunder shall be deemed to extend to any prior or subsequent default hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence. The Escrow Agent is bound only by the terms of this Agreement.

20. Succession and Assignment. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns. No Party may assign any of its rights or delegate any of its performance obligations hereunder without the prior written approval of the other Parties. Any purported assignment of rights or delegation of performance obligations in violation of this Section is void.

21. Parties in Interest. Nothing expressed or implied in this Agreement is intended to or shall be construed to confer upon or give any party other than the parties hereto and their permitted successors and assigns, any rights or remedies under or by reason of this Agreement or any transaction contemplated hereby.

22. Invalidity of Provisions. Each of the provisions contained in this Agreement is distinct and severable and a declaration of invalidity or unenforceability of any such provision or part thereof by a court of competent jurisdiction shall not affect the validity or enforceability of any other provision hereof.

23. Section Headings. The section headings contained in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement. Unless otherwise expressly indicated, any reference in this Agreement to a “Section”, “clause” or other division means a Section, clause or division of this Agreement.

24. Counterparts. This Agreement may be executed by facsimile, electronic or pdf signature and in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.

[Remainder of Page Intentionally Left Blank]


SL1 1342200v6 109188.00001

EXHIBIT E

SALE ORDER

IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE

�In�re:��Baxano�Surgical,�Inc.,3�� Debtor.��

�Chapter 11

Case No. 14-12545 (CSS)

Re: Docket No. 43, 147

ORDER PURSUANT TO BANKRUPTCY CODE SECTIONS 105(A), 363, 365, 503AND BANKRUPTCY RULES 2002, 6004, 6006 (I) APPROVING THE SALE OF

THE DEBTOR’S ASSETS FREE AND CLEAR OF ALL LIENS, CLAIMS, ENCUMBRANCES AND INTERESTS; (II) AUTHORIZING THE ASSUMPTION

AND ASSIGNMENT OF CERTAIN EXECUTORY CONTRACTS AND UNEXPIRED LEASES; AND (Ill) GRANTING CERTAIN RELATED RELIEF

Upon the motion (the “Sale Motion”)4 of the Debtor (D.I. 43) for, among other things,

entry of an order, pursuant to sections 105(a), 363, 365 and 503 of title 11 of the United States

Code (the “Bankruptcy Code”) and Rules 2002, 6004 and 6006 of the Federal Rules of Bankruptcy

Procedure (the “Bankruptcy Rules”), (i) approving the sale of substantially all of the Debtor’s

assets (the “Sale”) free and clear of all Interests (defined below), other than Assumed Liabilities,

and authorizing the assumption and assignment of certain executory contracts, in each case as set

forth in that certain Asset Purchase Agreement attached hereto as Exhibit “A” (as may be

amended, supplemented or restated, the “Asset Purchase Agreement”), and (ii) granting certain

related relief; and the Court having held a hearing on January 27, 2015 (the “Sale Hearing”) to

1 The Debtor’s last four digits of taxpayer identification number are as follows: 9022. The address of the Debtor’s corporate headquarters is 110 Horizon Drive, Suite 230, Raleigh, North Carolina.

2 Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Motion, the Sale Procedures Order, the Bidding Procedures or the Asset Purchase Agreement, as applicable.


SL1 1342200v6 109188.00001

approve the Sale; and the Court having reviewed and considered (a) the Motion, (b) the objections

to the Sale Motion, if any, and (c) the arguments of counsel made, and the evidence proffered or

adduced at the Sale Hearing; and it appearing that the relief requested in the Sale Motion is in the

best interests of the Debtor, its estate and creditors and other parties in interest; and upon the record

of the Sale Hearing and after due deliberation thereon; and good cause appearing therefore,

IT IS HEREBY FOUND AND DETERMINED THAT:5

A. This Court has jurisdiction over the Sale Motion, the transactions contemplated

by the Asset Purchase Agreement and any other ancillary documents and agreements related

thereto pursuant to 28 U.S.C. §§ 157 and 1334. Venue is proper pursuant to 28 U.S.C. §§ 1408

and 1409. This is a core proceeding under 28 U.S.C. §157(b)(2)(A), (M), (N) and (O).

B. Proper, timely, adequate and sufficient notice of the Sale Motion, the hearing

on the Sale Motion, the sale of the Acquired Assets to ExWorks Capital Fund I, L.P (the

“Purchaser”) and the Debtor’s assumption and assignment of the contracts listed on Exhibit “B”

hereto (the “Assigned Contracts”) to the Purchaser, has been provided in accordance with

sections 102(1), 363 and 365 of the Bankruptcy Code and Fed. R. Bankr. P. 2002, 6004, 6006 and

9014, the applicable Local Rules of the United States Bankruptcy Court for the District of

Delaware (the “Local Rules”) and the order of this Court dated December 12, 2014 (the “Sale

Procedures Order”), and no other or further notice of the Sale Motion, the hearing on the Sale

Motion, or of the entry of this Order is required.

C. A reasonable opportunity to object or be heard regarding the relief requested in

the Sale Motion has been afforded to all interested persons and entities, including (a) all entities

3 Findings of fact shall be construed as conclusions of law and conclusions of law shall be construed as findings of fact when appropriate.


SL1 1342200v6 109188.00001

known to have expressed an interest in a transaction with respect to some or all of the Acquired

Assets at any time; (b) all entities known to have asserted any lien, claim, interest or encumbrance

in or upon any of the Acquired Assets; (c) all federal, state and local regulatory or taxing

authorities or recording offices which have a reasonably known interest in the relief requested by

this Motion; (d) the United States Attorney’s office; (e) the Securities and Exchange Commission;

(f) the Internal Revenue Service; (g) legal and financial advisors to any statutory committee

appointed in this case; (h) the parties included on the Debtor’s list of twenty (20) largest unsecured

creditors; and (i) those parties who have filed the appropriate notice requesting notice of all

pleadings filed in the Chapter 11 Case; and (j) all counterparties to the Assigned Contracts ; (k) all

other known creditors of the Debtor; and (l) the Office of the United States Trustee.

D. The Bidding Procedures afforded a full, fair and reasonable opportunity for any

Qualified Bidder to make a Qualified Bid to purchase the Acquired Assets which was higher and

better than the offer documented in the Asset Purchase Agreement, and no such higher or better

offer has been made. The Purchaser complied with the Bidding Procedures Order.

E. The Debtor has full power and authority to execute the Asset Purchase

Agreement and all other documents contemplated thereby and consummate the transactions

contemplated therein, including the sale of the Acquired Assets and assumption and assignment of

the Assigned Contracts, and no consents or approvals, other than the approval of this Court are

required for the Debtor to consummate such transactions.

F. The Debtor has adequately marketed all of its assets. The Debtor has

demonstrated that it is an exercise of its sound business judgment to, in connection with the

consummation of the Asset Purchase Agreement, sell the Acquired Assets to Purchaser and

assume and assign the Assigned Contracts, if any, to the Purchaser and that approval of the Asset


SL1 1342200v6 109188.00001

Purchase Agreement and sale of the Acquired Assets and assumption and assignment of the

Assigned Contracts pursuant thereto is in the best interests of the Debtor, its estate, and its

creditors.

G. The sale must be completed immediately in order to preserve the value of the

Acquired Assets and, as a result, good and sufficient business justification exists for the immediate

sale of the Acquired Assets to Purchaser and assumption and assignment of the Assigned

Contracts to the Purchaser outside of a plan of reorganization. The transactions set forth in the

Asset Purchase Agreement will provide a greater recovery for the Debtor’s creditors than would be

provided by any other practical available alternative, including, without limitation, liquidation

under Chapter 7 or Chapter 11 of the Bankruptcy Code.

H. No insiders of the Debtor are receiving or retaining any benefit, property or

payments in connection with the sale of the Acquired Assets or assumption and assignment of the

Assigned Contracts except to the extent (i) such insiders have allowed claims against the Debtor

and, as a result, may participate in a distribution of sale proceeds, (ii) such insiders are to be

employed by the Purchaser following closing or otherwise have an interest in Purchaser, as

disclosed by Purchaser to the Debtor in connection with the sale process and on the record at the

hearing on the Sale Motion, or (iii) otherwise disclosed on the record at the hearing on the Sale

Motion.

I. The Purchaser has disclosed that it is purchasing the Acquired Assets with the

intent of re-selling the Acquired Assets to Amendia, Inc. (“Amendia”) under a separate agreement

between the Purchaser and Amendia. Even though Amendia was a potential bidder to purchase the

Acquired Assets directly from the Debtor, the Asset Purchase Agreement was negotiated,

proposed and entered into by the Debtor and the Purchaser without collusion, in good faith, and as


SL1 1342200v6 109188.00001

a result of arm’s length bargaining. The Purchaser is a good faith purchaser under section 363(m)

of the Bankruptcy Code and, as such, is entitled to the protections afforded thereby. Neither the

Debtor nor the Purchaser nor Amendia have engaged in any conduct that would cause or permit a

sale pursuant to the Asset Purchase Agreement (including the assumption and assignment of the

Assigned Contracts) to be avoided under section 363(n) of the Bankruptcy Code.

J. In the absence of a stay pending appeal, the Purchaser will be acting in good

faith within the meaning of section 363(m) of the Bankruptcy Code in closing the transactions

contemplated by the Asset Purchase Agreement (including the assumption and assignment of the

Assigned Contracts) at any time after the entry of this Order, provided the Purchaser shall not be

obligated to close until all applicable conditions to closing under the Asset Purchase Agreement

have been satisfied or waived as provided in such agreement.

K. The consideration provided by the Purchaser for the Acquired Assets and the

assumption and assignment of the Assigned Contracts pursuant to the Asset Purchase Agreement

constitutes the best and highest offer for the Acquired Assets and Assigned Contracts and

reasonably equivalent value and fair consideration (as those terms are defined in each of the

Uniform Fraudulent Transfer Act, Uniform Fraudulent Conveyance Act and Section 548 of the

Bankruptcy Code) under the Bankruptcy Code and under the laws of the United States, any state,

territory or possession thereof or the District of Columbia.

L. The Debtor may sell the Acquired Assets and assign the Assigned Contracts

free and clear of all (i) mortgages, security interests, conditional sale or other title retention

agreements, pledges, Liens, judgments, demands, Encumbrances and claims (as these terms are

defined in the Bankruptcy Code and the Asset Purchase Agreement), (ii) rights or options to effect

any forfeiture, modification, repurchase, or termination of the Debtor’s or the Purchaser’s interest


SL1 1342200v6 109188.00001

in the Acquired Assets, regardless whether such are “claims” as that term is defined in the

Bankruptcy Code, (iii) liability related to benefits, underfunding, termination and/or termination

premiums, regardless when such claims are deemed to have accrued and regardless whether such

would be considered “claims” as such term is defined in the Bankruptcy Code, to the Pension

Benefit Guaranty Corporation, (iv) claims in respect of taxes, (v) claims based on any successor or

transferee liability, (vi) claims in respect of that certain Corporate Integrity Agreement dated

June 24, 2013 by and between the Office of Inspector General of the Department of Health and

Human Services and the Debtor, and (vii) easements, restrictions, rights of first refusal or charges

of any kind or nature, if any, including, but not limited to, any restriction on the use, voting,

transfer, receipt of income or other exercise of any attributes of ownership, regardless whether

such are “claims” as that term is defined in the Bankruptcy Code, (collectively, items (i) to

(vii) above are referred to as “Interests”), because each entity with an Interest in any of the

Acquired Assets and/or the Assigned Contracts, including specifically Hercules Technology

Growth Capital, Inc., has consented to such sale, is deemed to have consented to such sale or could

be compelled in a legal or equitable proceeding to accept a money satisfaction of such Interest and

because all such Interests will attach to the proceeds of the sale as provided in paragraph 9 below.

M. The Debtor has good title to the Acquired Assets and the Assigned Contracts

and, accordingly, assumption and assignment of the Assigned Contracts and the transfer of the

Acquired Assets to Purchaser pursuant to the Asset Purchase Agreement will be a legal, valid, and

effective transfer of the Acquired Assets and assumption and assignment of the Assigned

Contracts.

N. The Purchaser has provided adequate assurance of future performance under

the Assigned Contracts, as required by Section 365(f)(2)(B) of the Bankruptcy Code.


SL1 1342200v6 109188.00001

O. Upon the assumption and assignment of the Assigned Contracts, as provided

herein, the Purchaser shall succeed to all of the right, title and interest of the Debtor under the

Assigned Contracts including, without limitation, the right to exercise renewal options which,

pursuant to the terms of the applicable Assigned Contract, are not exercisable by assignees of the

Debtor, the Court having found that such provisions constitute unenforceable restrictions on

assignment pursuant to Section 365(f)(3) of the Bankruptcy Code.

NOW, THEREFORE, IT IS HEREBY ADJUDGED, ORDERED, AND

DECREED THAT:

1. The Sale Motion, and the relief sought therein is granted, in all respects.

2. All objections to the Sale Motion or the relief requested therein that have not

been withdrawn with prejudice, waived, or settled, and all reservations of rights included therein,

are overruled on the merits.

3. The Asset Purchase Agreement, and all of the terms and conditions thereof

including the assumption and assignment of the Assigned Contracts, is hereby approved.

4. Pursuant to sections 105(a), 363(b) and 365 of the Bankruptcy Code, the Debtor

is authorized and directed to take all actions necessary to consummate the sale of the Acquired

Assets to the Purchaser and assumption and assignment of the Assigned Contracts to the Purchaser

pursuant to and in accordance with the terms and conditions of the Asset Purchase Agreement and

any ancillary documents thereto.

5. As of the date of closing under the Asset Purchase Agreement (the “Closing

Date”), in accordance with sections 363 and 365 of the Bankruptcy Code, (i) the Assigned

Contracts shall be deemed to have been assumed by the Debtor and assigned to the Purchaser,

(ii) the Purchaser shall be fully and irrevocably vested with all right, title and interest of the Debtor


SL1 1342200v6 109188.00001

under the Assigned Contracts, (iii) the Purchaser shall be deemed to be substituted for the Debtor

as a party to the applicable Assigned Contracts, and (iv) the Debtor shall be relieved, pursuant to

section 365(k) of the Bankruptcy Code, from any further liability under the Assigned Contracts.

6. The Assigned Contracts will be transferred to, and remain in full force and effect

for the benefit of, the Purchaser in accordance with their respective terms, notwithstanding any

provision in any such Assigned Contract (including those of the types described in

Sections 365(e)(1) and (f) of the Bankruptcy Code) that prohibits, restricts or conditions such

assignment or transfer. There will be no rent accelerations, assignment fees, increases or any other

fees charged to Purchaser as a result of the assumption or assignment of the Assigned Contracts.

No Assigned Contract may be terminated, or the rights of any party modified in any respect,

including pursuant to any “change of control” clause, by any other party thereto as a result of the

transactions contemplated by the Asset Purchase Agreement.

7. Promptly after the Closing Date, (i) Purchaser shall pay to the non-debtor party

to each Assigned Contract as to which a Liquidated Cure Amount is stated on Exhibit “B” hereto

and which is not a Previously Assumed Assigned Contract the amount of such Liquidated Cure

Amount, (ii) Seller shall pay to the non-debtor party to each Assigned Contract as to which a

Liquidated Cure Amount is stated on Exhibit “B” hereto and which is a Previously Assumed

Assigned Contract the amount of such Liquidated Cure Amount (iii) Purchaser shall pay to the

Escrow Agent the “Reserve Amount,” if any, stated on Exhibit “B,” on account of each Assigned

Contract as to which no Liquidated Cure Amount exists on the date of this Order and which is not

a Previously Assumed Contract, and (iv) Seller shall pay to the Escrow Agent the “Reserve

Amount” stated on Exhibit “B,” on account of each Assigned Contract as to which no Liquidated

Cure Amount exists on the date of this Order and which is a Previously Assumed Contract. As to


SL1 1342200v6 109188.00001

any Assigned Contract as to which a Liquidated Cure Amount does not exist as of the Closing

Date, the Escrow Agent shall pay the Liquidated Cure Amount to the applicable counterparty

promptly following the existence of a Liquidated Cure Amount and promptly return to the

Purchaser or Seller, as applicable, the amount, if any, by which the Reserve Amount paid by the

Purchaser or Seller exceeds the Liquidated Cure Amount. Any amounts returned to the Seller shall

be disbursed as stated in paragraph 28 of the Final Order (I) Authorizing Debtor to Obtain

Financing Pursuant to 11 U.S.C. §§ 105, 362, 363 and 364, (II) Granting Liens and Superpriority

Claims to Postpetition Lender Pursuant to 11 U.S.C. §§ 364 and 507, (III) Authorizing Use of

Cash Collateral Pursuant to 11 U.S.C. § 363, and (IV) Providing Adequate Protection to

Prepetition Secured Lender Pursuant to 11 U.S.C. §§ 361, 362, 363, 364 and 507. The Reserve

Amount for each Assigned Contract is equal to the maximum amount claimed by the applicable

non-debtor party as necessary to cure all defaults under the related Assigned Contracts required to

be cured pursuant to Section 365(b)(1)(A) of the Bankruptcy Code and to compensate such

non-debtor party for all actual pecuniary loss related to such defaults pursuant to pursuant to

Section 365(b)(1)(B) of the Bankruptcy Code, or such lesser amount as the Court may determine

constitutes an adequate reserve for payment of such amounts.

8. Upon payment of the Liquidated Cure Amounts to the applicable non-debtor

parties, (i) all defaults, whether monetary or non-monetary, under the related Assigned Contracts

required to be cured pursuant to Section 365(b)(1)(A) of the Bankruptcy Code shall be deemed

cured and all amounts due to the non-debtor parties to such Assigned Contracts pursuant to

Section 365(b)(1)(B) on account of any pecuniary loss resulting from such defaults shall be

deemed paid in full, and (ii) each non-debtor party to such Assigned Contracts shall be enjoined

from seeking to terminate such Assigned Contract or enforce any other remedies under such


SL1 1342200v6 109188.00001

Assigned Contract against the Purchaser on account of defaults, whether monetary or

non-monetary, by any Debtor, including defaults as to which, pursuant to Section 365(b)(1)(A) of

the Bankruptcy Code, cure is not required. Upon payment of the applicable Liquidated Cure

Amounts, each non-debtor party to an Assigned Contract shall be forever barred, estopped and

permanently enjoined from asserting against the Purchaser any default based on any known and

unknown fact and circumstances existing as of the date of the Sale Hearing regardless of whether

such default was raised or asserted prior to or at the Sale Hearing.

9. Upon payment of the Reserve Amounts to the Escrow Agent, the non-debtor

parties to each applicable Assigned Contract shall be (i) limited to recourse against the Reserve

Amount attributed to its Assigned Contract on account of all defaults under such Assigned

Contract required to be cured pursuant to Section 365(b)(1)(A) of the Bankruptcy Code and all

pecuniary loss resulting from such defaults due to such non-debtor party pursuant to

Section 365(b)(1)(B) of the Bankruptcy Code, and (ii) enjoined from seeking (A) recourse against

the Purchaser on account of any defaults, whether monetary or non-monetary, by the Debtor under

such Assigned Contract required to be cured pursuant to Section 365(b)(1)(A) of the Bankruptcy

Code and/or any pecuniary loss resulting from such defaults due to such non-debtor party pursuant

to Section 365(b)(1)(B) of the Bankruptcy Code, and/or (B) to terminate such Assigned Contract

or enforce any other remedies under such Assigned Contract against Purchaser on account of

defaults by the Debtor, including defaults as to which, pursuant to Section 365(b)(1)(A) of the

Bankruptcy Code, cure is not required.

10. Pursuant to sections 105(a) and 363(f) of the Bankruptcy Code, upon the

closing under the Asset Purchase Agreement, the Acquired Assets and the Assigned Contracts

shall be free and clear of all Interests other than Assumed Liabilities, with all such divested


SL1 1342200v6 109188.00001

Interests to attach to the proceeds of the sale in the order of their priority, with the same validity,

force and effect (if any) which they now have against the Acquired Assets.

11. Transfer of the Acquired Assets and assumption and assignment of the

Assigned Contracts will not subject the Purchaser to any liability for claims against the Debtor or

the Debtor’s predecessors or affiliates of any kind or character, whether known or unknown, now

existing or hereafter occurring, whether fixed or contingent, based, in whole or in part, directly or

indirectly, on any theory of law, including, without limitation, any theory of successor, vicarious

or transferee liability. No persons or entities will assert against the Purchaser any liability, debt,

claim or obligation arising from, related to or in connection with the ownership or operation of the

Acquired Assets prior to the Closing Date.

12. Effective on the Closing Date, all persons and entities are forever prohibited

and enjoined, to the maximum extent permitted by the powers vested in this Court under the

Bankruptcy Code, from commencing or continuing any action or proceeding, at law or in equity,

against the Purchaser or the Acquired Assets with respect to any claim (as defined in the

Bankruptcy Code), including claims based on successor liability against Purchaser.

13. As of the Closing Date, each of the Debtor’s creditors is authorized and

directed to execute such documents and take all other actions as may be necessary to release its

Interests in the Acquired Assets (including the Assigned Contracts) as such Interests may have

been recorded or may otherwise exist.

14. Each and every federal, state and local governmental agency or department be,

and hereby is, authorized to accept any and all documents and instruments necessary and

appropriate to consummate the transactions contemplated by the Asset Purchase Agreement.


SL1 1342200v6 109188.00001

15. If any person or entity that has filed financing statements or other documents or

agreements evidencing Interests, other than Assumed Liabilities, in the Acquired Assets

(including the Assigned Contracts) shall not have delivered to the Debtor prior to the Closing

Date, in proper form for filing and executed by the appropriate parties, termination statements,

instruments of satisfaction and releases of all such Interests, the Debtor and/or Purchaser are

hereby authorized to execute and file such statements, instruments, releases and other documents

on behalf of the person or entity with respect to the Acquired Assets and the Assigned Contracts.

The foregoing notwithstanding, the provision of this Order authorizing the sale of the Acquired

Assets and assignment of the Assigned Contracts free and clear of all Interests other than Assumed

Liabilities shall be self-executing, and notwithstanding the failure of the Debtor, the Purchaser or

any other party to execute, file or obtain releases, termination statements, assignments, consents or

other instruments to effectuate, consummate and/or implement the provisions hereof or in the

Asset Purchase Agreement with respect to the sale of the Acquired Assets and/or assumption and

assignment of the Assigned Contracts, all Interests other than Assumed Liabilities in or against the

Acquired Assets and/or the Assigned Contracts shall be deemed divested on the Closing Date.

This Sale Approval Order is deemed to be in recordable form sufficient to be placed in the filing or

recording system of each and every federal, state or local government agency, department or

office.

16. All entities that are presently, or on the Closing Date may be, in possession of

some or all of the Acquired Assets are hereby ordered and directed to surrender possession of the

Acquired Assets to Purchaser on the Closing Date.

17. The Acquired Assets may remain at the Seller’s Facilities for up to 30 days

after the Closing Date at no cost to Purchaser as further detailed in the Asset Purchase Agreement.


SL1 1342200v6 109188.00001

18. To the extent provided by section 525 of the Bankruptcy Code, no

governmental unit may deny, revoke, suspend, or refuse to renew any permit, license, or similar

grant relating to the operation of the Acquired Assets on account of the filing or pendency of this

chapter 11 case or the consummation of the Asset Purchase Agreement and the assumption and

assignment of the Assigned Contracts

19. As of the Closing Date, all agreements of any kind whatsoever and all orders of

this Court entered prior to the date hereof shall be deemed amended and/or modified to the extent

required to permit the consummation of the transactions contemplated by the Asset Purchase

Agreement.

20. The gross proceeds from the Sale payable to the Debtor shall be distributed as

follows:

a) First, to pay all Liquidated Cure Amounts and Reserve Amounts as to

which the Seller is responsible for payment;

b) Second, to pay amounts due to Houlihan Lokey Capital, Inc.

(“Houlihan”), to the extent such amounts are payable under that

certain order of this Court approving the retention of Houlihan

(D.I. 177);

c) Third, to pay any Bid Protections (as defined in the Sale Procedures

Order) owing on account of sale of the Acquired Assets; and

d) Fourth, as provided in the Disposition of Collateral paragraph of the

Final Order (I) Authorizing Debtor to Obtain Financing Pursuant to

11 U.S.C. §§ 105, 362, 363 and 364, (II) Granting Liens and


SL1 1342200v6 109188.00001

Superpriority Claims to Postpetition Lender Pursuant to 11 U.S.C.

§§ 364 and 507, (III) Authorizing Use of Cash Collateral Pursuant to

11 U.S.C. § 363, and (IV) Providing Adequate Protection to

Prepetition Secured Lender Pursuant to 11 U.S.C. §§ 361, 362, 363,

364 and 507 (the “DIP/Cash Collateral Order”);

21. Subject to further Court order and the terms of the Asset Purchase Agreement,

the Debtor is authorized to and shall take appropriate measures to maintain and preserve, until the

earliest of (i) consummation of any plan for the Debtor, (ii) conversion of the Debtor’s chapter 11

case to a case under chapter 7 of the Bankruptcy Code, and (iii) dismissal of the Debtor’s

bankruptcy case, the books, records, and any other documentation, including tapes or other audio

or digital recordings and data in, or retrievable from, computers or servers relating to or reflecting

the records held by the Debtor or its affiliates relating to the Debtor’s business.

22. No law of any state or other jurisdiction relating to bulk sales or similar laws

shall apply in any way to the transaction contemplated by the Asset Purchase Agreement,

including, without limitation, the assumption and assignment of the Assigned Contracts, the Sale

Motion, and this Order.

23. This Court shall retain jurisdiction (a) to enforce and implement the terms and

provisions of the Asset Purchase Agreement, all amendments thereto, any waivers and consents

thereunder and each of the agreements executed in connection therewith, (b) to compel delivery of

the Acquired Assets and assumption and assignment of the Assigned Contracts to the Purchaser,

(c) to resolve any disputes arising under or related to the Asset Purchase Agreement, except as

otherwise provided therein, and (d) to interpret, implement and enforce the provisions of this

Order.


SL1 1342200v6 109188.00001

24. Nothing contained in any plan of reorganization confirmed in this case or the

order confirming any plan of reorganization shall conflict with or derogate from the provisions of

the Asset Purchase Agreement or the terms of this Order. Further, the provisions of this Order and

any actions taken pursuant hereto shall survive the entry of any order which may be entered

confirming any plan of reorganization for the Debtor or converting the Debtor’s case from

chapter 11 to a case under chapter 7 of the Bankruptcy Code.

25. The terms and provisions of the Asset Purchase Agreement, together with the

terms and provisions of this Order, shall be binding in all respects upon, and shall inure to the

benefit of, the Debtor, its estate, its creditors, and the Purchaser and its affiliates, successors and

assigns, and any affected third parties including, but not limited to, all persons asserting a claim

against the Debtor’s estate and/or Interest in the Acquired Assets and/or the Assigned Contracts

and any trustee appointed for the Debtor under any chapter of the Bankruptcy Code.

26. The Asset Purchase Agreement and any related agreements, documents or

other instruments may, with the consent of Hercules and in consultation with the Committee, be

modified, amended or supplemented by the parties thereto, in a writing signed by both parties, and

in accordance with the terms thereof without further order of the Court, provided that any such

modification, amendment or supplement is not material.

27. The failure specifically to include any particular provision of the Asset

Purchase Agreement in this Order shall not diminish or impair the effectiveness of such provision,

it being the intent of the Court that the Asset Purchase Agreement be authorized and approved in

its entirety.

28. Notwithstanding the provisions of Fed. R. Bankr. P. 6004 (h), 6006(d)

and 7062, this Order shall be effective and enforceable immediately upon entry.


SL1 1342200v6 109188.00001

Dated: ___________, 2014 Wilmington, Delaware

Christopher S. Sontchi UNITED STATES BANKRUPTCY JUDGE


SL1 1342200v6 109188.00001

EXHIBIT “A”



SL1 1342200v6 109188.00001

EXHIBIT “B”

ASSIGNED CONTRACTS AND CURE AMOUNTS

NOT APPLICABLE – NO ASSIGNED CONTRACTS

CONTRACT COUNTERPARTY LIQUIDATED CURE AMOUNT

RESERVEAMOUNT


SL1 1342200v6 109188.00001

EXHIBIT F

ASSIGNMENT OF TRADEMARKS

THIS ASSIGNMENT made as of the ___ day of January, 2015, by BAXANO SURGICAL, INC., a Delaware corporation (“Assignor”), to ExWorks Capital Fund I, L.P., (“Assignee”) with a place of business at 333 W. Wacker Drive, Suite 1620, Chicago, IL 60606.

WHEREAS, Assignor owns all of the right, title and interest in and to the registered trademarks and applications for trademark registration listed on Schedule A attached hereto (collectively, the “Trademarks”) which Trademarks relate to a business that Assignor has sold, assigned, transferred and set over to Assignee; and

WHEREAS, Assignor has agreed to assign, transfer and convey all of its right, title and interest in and to the Trademarks, and each of them, to Assignee.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor does hereby assign unto Assignee, all of the right, title and interest of Assignor in and to the Trademarks and all goodwill associated therewith or related thereto.

FURTHER, Assignor does hereby assign to Assignee, all income, royalties or payments due or payable in respect of the Trademarks as of the date hereof or thereafter, including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Trademarks, with right to sue for, and collect the same for Assignee’s own use and enjoyment and for the use and enjoyment of its successors, assigns or other legal representatives.

Assignor requests that the Register of Trademarks or corresponding agencies in all applicable jurisdictions record Assignee as the assignee and owner of each of the Trademarks and registrations therefor.


SL1 1342200v6 109188.00001

IN WITNESS WHEREOF, Assignor has executed this instrument.


By: ______________________________ , its [______________]

STATE OF _________________ )

) SS.

COUNTY OF __________ )

On this date, the person executing this document, who acknowledged himself to be ________________, the ____________ of Baxano Surgical, Inc., a Delaware corporation, with the authority to execute the same, personally appeared before me and executed the document in my presence.

Subscribed and sworn to before me this __ day of ______________, 201__.

_________________________________ Notary Public

My Commission Expires: ____________


SL1 1342200v6 109188.00001

SCHEDULE A


SL1 1342200v6 109188.00001

EXHIBIT G

ASSIGNMENT OF PATENTS

THIS ASSIGNMENT made as of the ___ day of January, 2015, by BAXANO SURGICAL, INC., a Delaware corporation (“Assignor”), to ExWorks Capital Fund I, L.P. (“Assignee”).

WHEREAS, Assignor owns all of the right, title and interest in and to the patents, patent applications and patent disclosures listed on Schedule A attached hereto, together with all continuations (in whole or in part), divisionals, extensions, reissuances, revisions and reexaminations thereof (collectively, the “Patents”).

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor hereby sells, assigns, transfers and sets over to Assignee the entire right, title and interest of Assignor in and to the Patents and the inventions claimed therein (collectively, the “Patent Rights”), for the United States and for all foreign countries, including, without limitation, any applications and registrations therefor, any renewals and extensions of the registrations, and all other corresponding rights that are or may be secured under the laws of the United States or any foreign country, now or hereafter in effect, for Assignee’s own use and enjoyment, and for the use and enjoyment of Assignee’s successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made, together with all income, royalties or payments due or payable as of the date hereof or thereafter, including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Patent Rights, with right to sue for, and collect the same for Assignee’s own use and enjoyment and for the use and enjoyment of its successors, assigns or other legal representatives.

Assignor hereby requests the Commissioner for Patents record Assignee as the assignee and owner of the Patents and Patent Rights.


SL1 1342200v6 109188.00001

IN WITNESS WHEREOF, Assignor has executed this instrument.


By: ______________________________ , its [______________]

STATE OF ___________ )

) SS.

COUNTY OF __________ )

On this date, the person executing this document, who acknowledged himself to be ________________, the ____________ of Baxano Surgical, Inc., a Delaware corporation, with the authority to execute the same, personally appeared before me and executed the document in my presence.

Subscribed and sworn to before me this __ day of _____________, 201___.

_________________________________ Notary Public

My Commission Expires: ____________


SL1 1342200v6 109188.00001

[ACCEPTANCE OF ASSIGNMENT]6

The Assignee hereby accepts the foregoing assignment.

[PURCHASER]

By: ____________________________

Its: _____________________________

6 To be included for any foreign patent assignments.


SL1 1342200v6 109188.00001

SCHEDULE A


SL1 1342200v6 109188.00001

SCHEDULES TO THE


DATED AS OF DECEMBER 31, 2014

BY AND BETWEEN

BAXANO SURGICAL, INC.,

as Seller,

AND


as Purchaser


1 SL1 1342200v6 109188.00001

SCHEDULESTO THE

ASSET PURCHASE AGREEMENT DATED AS OF DECEMBER 31, 2014

BY AND BETWEEN


AND


1. Asset Purchase Agreement; Defined Terms. Attached hereto are the Schedules (the “Schedules”) to the Asset Purchase Agreement dated as of December 31, 2014 (the “Agreement”)by and between Baxano Surgical, Inc., a Delaware corporation, successor to each of TranS1, Inc. and Baxano, Inc. (“Seller”), and Exworks Capital Fund I, L.P. (“Purchaser”). Pursuant to the Agreement, among other things, Purchaser shall purchase from the Seller, and the Seller shall sell, certain assets of the Seller. The inclusion of an item in any Schedule as an exception to a representation or warranty shall not be deemed an admission that such item represents a material exception or material fact, event or circumstance. The information contained in any Schedule is disclosed solely for the purposes of the Agreement, and any descriptions or summaries of any agreements or documents in the Schedules are summaries only and are qualified in their entirety by the specific terms of such agreements or documents. No disclosure in the Schedules relating to any possible breach or violation of any agreement or Law shall be construed as an admission or indication that any such breach or violation exists or has actually occurred. Where the representations and warranties in the Agreement contain specific dollar thresholds, the items, contracts and other matters listed in response thereto may include items, agreements and other matters that are below such dollar thresholds. Any disclosure set forth in one Section or Paragraph of a Schedule shall apply to (A) the representations and warranties contained in the Section of the Agreement to which it corresponds in number; (B) any representation and warranty or Schedule (or Section or Paragraph thereof) to which it is referred by cross reference; and (C) any other representation or warranty set forth in the Agreement, to the extent it is reasonably apparent that such disclosure is intended to qualify such other representation or warranty. Any capitalized terms used herein or in any Schedule that are not defined therein, but which are defined in the Agreement, shall have the meaning given to those terms in the Agreement. Any capitalized term defined in any Schedule shall have the same meaning when used in any other Schedule, unless otherwise indicated or the context clearly requires otherwise.

2. Exhibits. Each Exhibit attached to, or delivered together with, any Schedule is incorporated by reference into, and made a part of, such Schedule, as if such Exhibit were set forth in its entirety in such Schedule.


2 SL1 1342200v6 109188.00001

3. Captions. The headings or other captions set forth in any Schedule are provided for convenience of reference only and shall not affect the construction or interpretation, or modify any, of the representations and warranties made by any Seller pursuant to the Agreement or any of the qualifications or exceptions set forth in the Agreement relating to such representations and warranties including, without limitation, any qualifications based on the Seller’s Knowledge.


1(a)-1 SL1 1342200v6 109188.00001

Schedule 1(a)

Permitted Liens and Encumbrances

None.


4.9-1 SL1 1342200v6 109188.00001

Schedule 4.9

Listing and Location of Inventory as December 31, 2014

See attached.


iO Finished Goods Inventory - 12/30/14

Page 1 or 54

Item Number Description # at Location Location Description Lot/Serial Expire Date

FG0973-01 Neuro Check FG 1 301 N. CAROLINA HOLD 100976 9/30/14

FG0973-01 Neuro Check FG 1 301 N. CAROLINA HOLD 101892 8/31/15

FG0973-01 Neuro Check FG 59 400 Sterile - SJ 103166

FG0973-01 Neuro Check FG 1 501 N. CAROLINA FG 102714 3/31/16




FG0973-01 Neuro Check FG 1 600 Evaluation Products - SJ 102105 9/30/15

FG0973-01 Neuro Check FG 1 700 Demo Products - SJ 100884 8/31/14

FG0973-01 Neuro Check FG 1 700 Demo Products - SJ 101361 2/28/15

FG0973-01 Neuro Check FG 1 D101 KNS Medical Distribution 102994 8/28/16



FG0973-01 Neuro Check FG 1 D102 City Surgical 102714 3/31/16





FG0973-01 Neuro Check FG 1 D103 Bahler Medical 101546 5/31/15



FG0973-01 Neuro Check FG 1 D105 Inline Spine 103062 9/28/16

FG0973-01 Neuro Check FG 6 D105 Inline Spine 103147 9/28/16

FG0973-01 Neuro Check FG 2 D107 Fusion Medical 102994 8/28/16

FG0973-01 Neuro Check FG 1 D107 Fusion Medical 103049 8/28/16

FG0973-01 Neuro Check FG 1 D111 Davey Medical 101701 7/31/15

FG0973-01 Neuro Check FG 1 D114 Medifuse Surgical, LLC. 103062 9/28/16

FG0973-01 Neuro Check FG 1 D116 Greg Stenzel 101985 9/30/15

FG0973-01 Neuro Check FG 2 D116 Greg Stenzel 102291 11/30/15

FG0973-01 Neuro Check FG 3 D117 Brannon Wyatt 103062 9/28/16

FG0973-01 Neuro Check FG 3 D117 Brannon Wyatt 103147 9/28/16

FG0973-01 Neuro Check FG 1 D118 Amanda Turko 101404 3/31/15




FG0973-01 Neuro Check FG 1 D119 Align Alternatives 102911 6/30/16





FG0973-01 Neuro Check FG 2 D120 Choice Spine 103147 9/28/16

FG0973-01 Neuro Check FG 5 D123 MetaGen 103147 9/28/16

FG0973-01 Neuro Check FG 2 D125 Charles Pierce Martin 102643 2/29/16



FG0973-01 Neuro Check FG 1 D126 Goalline Medical, LLC 102212 10/31/15



FG0973-01 Neuro Check FG 1 D131 Duke Medical, LLC 101701 7/31/15






Page 2 or 54


FG0973-01 Neuro Check FG 3 D134 Advanced Medical SW 103147 9/28/16

FG0973-01 Neuro Check FG 1 D137 BIOlympic Medical 102911 6/30/16

FG0973-01 Neuro Check FG 1 D140 Long Medical Specialties 102911 6/30/16

FG0973-01 Neuro Check FG 2 D140 Long Medical Specialties 103147 9/28/16

FG0973-01 Neuro Check FG 2 D144 Innovative Surgical LLC. 103147 9/28/16

FG0973-01 Neuro Check FG 2 D155 Minivasive - B. Manning 103062 9/28/16

FG0973-01 Neuro Check FG 1 D155 Minivasive - B. Manning 103147 9/28/16

FG0973-01 Neuro Check FG 1 D167 MetaGen-SBrown 101431 4/30/15

FG0973-01 Neuro Check FG 1 D167 MetaGen-SBrown 103147 9/28/16

FG0973-01 Neuro Check FG 2 D174 KRP Medical-KCorrado 102994 8/28/16

FG0973-01 Neuro Check FG 4 D176 Ross Medical-RTate 102994 8/28/16

FG0973-01 Neuro Check FG 3 D176 Ross Medical-RTate 103062 9/28/16

FG0973-01 Neuro Check FG 1 D177 Carolina Surgi-PTracy 102643 2/29/16




FG0973-01 Neuro Check FG 1 D181 OrthoMed-MSalinas 102714 3/31/16

FG0973-01 Neuro Check FG 1 D187 Biotech Solutions-JNalli 102540 1/31/16




FG0973-01 Neuro Check FG 1 D188 INNOTEK-DTouhey 102994 8/28/16

FG0973-01 Neuro Check FG 5 D188 INNOTEK-DTouhey 103147 9/28/16

FG0973-01 Neuro Check FG 4 D191 Mesa Medical-SPutman 101014 10/31/14

FG0973-01 Neuro Check FG 1 D194 Horse Creek Med-TOakes 102714 3/31/16



FG0973-01 Neuro Check FG 2 D195 Med-Adv.-Faulkner/Benton 102994 8/28/16

FG0973-01 Neuro Check FG 1 D198 Axial Systems-JWing 102864 5/31/16

FG0973-01 Neuro Check FG 6 D198 Axial Systems-JWing 102932 7/28/16

FG0973-01 Neuro Check FG 1 D199 Innotek - K. Nevel 102643 2/29/16

FG0973-01 Neuro Check FG 1 d199 Innotek - K. Nevel 102994 8/28/16

FG0973-01 Neuro Check FG 1 D199 Innotek - K. Nevel 103147 9/28/16

FG0973-01 Neuro Check FG 1 D200 2K Spine -T Schultz 102748 4/30/16

FG0973-01 Neuro Check FG 3 D203 AG Distribu-AGuidacan 103147 9/28/16

FG0973-01 Neuro Check FG 4 D206 Patton Medical-APatton 103062 9/28/16

FG0973-01 Neuro Check FG 4 D206 Patton Medical-APatton 103147 9/28/16

FG0973-01 Neuro Check FG 2 D208 Team Harmony-SWilson 103062 9/28/16

FG0973-01 Neuro Check FG 2 D210 Elite Spine-PHarmon 103147 9/28/16

FG0973-01 Neuro Check FG 1 D212 Sand Medical-REstrada 102540 1/31/16

FG0973-01 Neuro Check FG 2 D212 Sand Medical-REstrada 102748 4/30/16

FG0973-01 Neuro Check FG 2 D217 Freestone Med-JDoub 102291 11/30/15

FG0973-01 Neuro Check FG 2 D217 Freestone Med-JDoub 102911 6/30/16

FG0973-01 Neuro Check FG 1 D220 Northstate-EAlexander 101286 1/31/15




FG0973-01 Neuro Check FG 1 D222 Northstate-SAllen 101805 8/31/15

FG0973-01 Neuro Check FG 1 D222 Northstate-SAllen 102291 11/30/15

FG0973-01 Neuro Check FG 1 D223 KNS-JPugliese 102714 3/31/16

FG0973-01 Neuro Check FG 1 D223 KNS-JPugliese 102803 5/31/16

FG0973-01 Neuro Check FG 1 D224 Northstate-TCoppedge 101361 2/28/15



Page 3 or 54




FG0973-01 Neuro Check FG 2 D225 Advanced Medical-KMorin 102932 7/28/16



FG0973-01 Neuro Check FG 2 D227 True North-DBrown 103062 9/28/16

FG0973-01 Neuro Check FG 2 D227 True North-DBrown 103147 9/28/16

FG0973-01 Neuro Check FG 1 D229 Kevin Kearney 102346 11/30/15

FG0973-01 Neuro Check FG 1 D229 Kevin Kearney 102540 1/31/16

FG0973-01 Neuro Check FG 1 D230 Touchstone-RWeaver 102346 11/30/15




FG0973-01 Neuro Check FG 1 D231 QB Medical-PParsons 102291 11/30/15

FG0973-01 Neuro Check FG 4 D231 QB Medical-PParsons 102643 2/29/16

FG0973-01 Neuro Check FG 1 D240 7 Spine Group-THenderson 101492 4/30/15

FG0973-01 Neuro Check FG 2 D241 Corvus Med-JeUnderwood 101892 8/31/15

FG0973-01 Neuro Check FG 2 D241 Corvus Med-JeUnderwood 102540 1/31/16

FG0973-01 Neuro Check FG 1 D242 Elite Spine-BBooker 103049 8/28/16



FG0973-01 Neuro Check FG 1 D243 Corvus Medical-TKline 102748 4/30/16



FG0973-01 Neuro Check FG 1 D245 Jennifer Wyatt 102911 6/30/16

FG0973-01 Neuro Check FG 2 D245 Jennifer Wyatt 103147 9/28/16

FG0973-01 Neuro Check FG 3 D248 CLIP MEDICAL - DUBAI 102212 10/31/15

FG0973-01 Neuro Check FG 1 D255 A2 MEDICAL 102911 6/30/16

FG0973-01 Neuro Check FG 2 D255 A2 MEDICAL 103147 9/28/16

FG0973-01 Neuro Check FG 1 D260 STIRLING SURGICAL - CURT 102911 6/30/16

FG0973-01 Neuro Check FG 3 D260 STIRLING SURGICAL - CURT 102994 8/28/16

FG0973-01 Neuro Check FG 2 D268 BLACK DIAMOND 102994 8/28/16

FG0973-01 Neuro Check FG 1 D270 Med Advise -DTighe 103062 9/28/16

FG0973-01 Neuro Check FG 2 D270 Med Advise -DTighe 103147 9/28/16

FG0973-01 Neuro Check FG 3 D271 KML Medical - KCook 103147 9/28/16

FG0973-01 Neuro Check FG 1 D274 CBR Medical-RDobson 101892 8/31/15

FG0973-01 Neuro Check FG 2 D274 CBR Medical-RDobson 102864 5/31/16

FG0973-01 Neuro Check FG 2 D277 Sand Med-B Ledford 102748 4/30/16

FG0973-01 Neuro Check FG 1 D277 Sand Med-B Ledford 103049 8/28/16

FG0973-01 Neuro Check FG 1 D280 Nicole Juber 102932 7/28/16



FG0973-01 Neuro Check FG 1 D281 Susan Rains 103049 8/28/16

FG0973-01 Neuro Check FG 2 D282 Weisz Surgical-PWeisz 102803 5/31/16



FG0973-01 Neuro Check FG 3 D285 Touchstone-BDoyle 103062 9/28/16

FG0973-01 Neuro Check FG 1 D285 Touchstone-BDoyle 103147 9/28/16

FG0973-01 Neuro Check FG 2 D286 Tolan Mai 103147 9/28/16

FG0973-01 Neuro Check FG 1 D290 IoliteMedical-PGeiger 101892 8/31/15

FG0973-01 Neuro Check FG 3 D290 IoliteMedical-PGeiger 102994 8/28/16

FG0973-01 Neuro Check FG 1 D296 Denise Sheppard 103049 8/28/16



Page 4 or 54


FG0973-01 Neuro Check FG 3 D296 Denise Sheppard 103062 9/28/16

FG0973-01 Neuro Check FG 1 D297 Synergy Surgical 103062 9/28/16

FG0973-01 Neuro Check FG 4 D297 Synergy Surgical 103147 9/28/16

FG0973-01 Neuro Check FG 1 D298 Emmerson Med. -THamilton 103062 9/28/16

FG0973-01 Neuro Check FG 3 D298 Emmerson Med. -THamilton 103147 9/28/16

FG0973-01 Neuro Check FG 1 D299 Innotek/Moore Med CZeise 101892 8/31/15



FG0973-01 Neuro Check FG 2 D300 Medical Innovation-RMaly 103062 9/28/16

FG0973-01 Neuro Check FG 1 D301 Elite Spine-DBalsamo 102714 3/31/16



FG0973-01 Neuro Check FG 1 D307 Synergy Surgical-SKlein 101701 7/31/15




FG0973-01 Neuro Check FG 1 D309 Central Valley -R. Green 103147 9/28/16

FG0973-01 Neuro Check FG 1 D310 Resurrection A. Gratsias 101546 5/31/15




FG0973-01 Neuro Check FG 1 D311 Minivasive - Chris Rutt 103062 9/28/16

FG0973-01 Neuro Check FG 2 D311 Minivasive - Chris Rutt 103147 9/28/16

FG0973-01 Neuro Check FG 2 D315 PAL Medical - M. Balleux 102994 8/28/16

FG0973-01 Neuro Check FG 1 D316 Elite Spine CA - AGarcia 103062 9/28/16

FG0973-01 Neuro Check FG 4 D316 Elite Spine CA - AGarcia 103147 9/28/16

FG0973-01 Neuro Check FG 1 D317 Innotek Medical - TMoore 103147 9/28/16

FG0973-01 Neuro Check FG 2 D318 Fidelis Surgical - Ligon 103049 8/28/16

FG0973-01 Neuro Check FG 3 D321 Spinal Restorative- Lacy 103062 9/28/16

FG0973-01 Neuro Check FG 2 D321 Spinal Restorative- Lacy 103147 9/28/16

FG0973-01 Neuro Check FG 2 D322 Innotek - M. Swanson 103062 9/28/16

FG0973-01 Neuro Check FG 1 D322 Innotek - M. Swanson 103147 9/28/16

FG0973-01 Neuro Check FG 4 D328 Bahler - J. McNamara 103147 9/28/16

FG0973-01 Neuro Check FG 1 iO-Loan1 iO-Loaner # 1 103147 9/28/16







FG0973-01 Neuro Check FG 2 iO-Loan8 iO-Loan8 102411 12/31/15

FG0973-01 Neuro Check FG 1 P103 Bob Cook 101361 2/28/15




FG0973-01 Neuro Check FG 1 S157 JOHN DIETERLY 103049 8/28/16

FG0973-01 Neuro Check FG 5 S157 JOHN DIETERLY 103147 9/28/16

FG0973-01 Neuro Check FG 1 S163 KATRYN FERNALD 102911 6/30/16

FG0973-01 Neuro Check FG 1 S169 MATT HART 102932 7/28/16



FG0973-01 Neuro Check FG 1 S175 STEVEN GREEN 102932 7/28/16



Page 5 or 54


FG0973-01 Neuro Check FG 2 S175 STEVEN GREEN 103147 9/28/16

FG0973-01 Neuro Check FG 1 S176 SCOTT HEYMOSS 102932 7/28/16

FG0973-01 Neuro Check FG 3 S176 SCOTT HEYMOSS 102994 8/28/16

FG0973-01 Neuro Check FG 1 S180 Greg Pellatt 103062 9/28/16

FG0973-01 Neuro Check FG 2 S180 Greg Pellatt 103147 9/28/16

FG0973-01 Neuro Check FG 1 S185 MICHAEL DEFAZIO 102994 8/28/16



FG0973-01 Neuro Check FG 3 S186 KATIE MORONI 103049 8/28/16

FG0973-01 Neuro Check FG 2 S186 KATIE MORONI 103062 9/28/16

FG0973-01 Neuro Check FG 1 S192 ANDREW PINCKNEY 103062 9/28/16

FG0973-01 Neuro Check FG 6 S192 ANDREW PINCKNEY 103147 9/28/16

FG0973-01 Neuro Check FG 1 S193 APRIL SPILLANE 102932 7/28/16



FG0973-01 Neuro Check FG 1 S204 Tanner Michael Shaw 102932 7/28/16



FG1117-01 Ipsi Probe FG 2 301 N. CAROLINA HOLD 100921 9/30/14

FG1117-01 Ipsi Probe FG 1 301 N. CAROLINA HOLD 101027 10/31/14

FG1117-01 Ipsi Probe FG 4 D191 Mesa Medical-SPutman 101027 10/31/14

FG1117-02 Contra Probe FG 1 180 SHIPPING TO RALEIGH 103063 9/28/16

FG1117-02 Contra Probe FG 1 301 N. CAROLINA HOLD 100792 7/31/14













FG1117-02 Contra Probe FG 25 400 Sterile - SJ 103168

FG1117-02 Contra Probe FG 1 501 N. CAROLINA FG 101143 11/30/14







FG1117-02 Contra Probe FG 1 700 Demo Products - SJ 100419

FG1117-02 Contra Probe FG 4 700 Demo Products - SJ 100503 3/31/14










Page 6 or 54








FG1117-02 Contra Probe FG 1 D101 KNS Medical Distribution 101143 11/30/14



FG1117-02 Contra Probe FG 1 D102 City Surgical 101132 11/30/14




FG1117-02 Contra Probe FG 1 D105 Inline Spine 101349 2/28/15

FG1117-02 Contra Probe FG 4 D107 Fusion Medical 102593 2/29/16

FG1117-02 Contra Probe FG 2 D111 Davey Medical 102749 4/30/16

FG1117-02 Contra Probe FG 2 D114 Medifuse Surgical, LLC. 101349 2/28/15

FG1117-02 Contra Probe FG 1 D114 Medifuse Surgical, LLC. 102517 1/31/16

FG1117-02 Contra Probe FG 1 D116 Greg Stenzel 101844 8/31/15

FG1117-02 Contra Probe FG 1 D116 Greg Stenzel 102161 10/31/15

FG1117-02 Contra Probe FG 2 D118 Amanda Turko 101287 1/31/15

FG1117-02 Contra Probe FG 2 D119 Align Alternatives 101091 11/30/14






FG1117-02 Contra Probe FG 1 D123 MetaGen 102161 10/31/15

FG1117-02 Contra Probe FG 1 D125 Charles Pierce Martin 102749 4/30/16

FG1117-02 Contra Probe FG 1 D126 Goalline Medical, LLC 101143 11/30/14

FG1117-02 Contra Probe FG 1 D126 Goalline Medical, LLC 102986 7/28/16

FG1117-02 Contra Probe FG 1 D132 Axial Systems 101469 4/30/15

FG1117-02 Contra Probe FG 7 D134 Advanced Medical SW 101143 11/30/14



FG1117-02 Contra Probe FG 1 D155 Minivasive - B. Manning 101132 11/30/14

FG1117-02 Contra Probe FG 1 D155 Minivasive - B. Manning 102161 10/31/15

FG1117-02 Contra Probe FG 2 D167 MetaGen-SBrown 102986 7/28/16

FG1117-02 Contra Probe FG 2 D174 KRP Medical-KCorrado 102593 2/29/16

FG1117-02 Contra Probe FG 1 D176 Ross Medical-RTate 101349 2/28/15




FG1117-02 Contra Probe FG 1 D177 Carolina Surgi-PTracy 101844 8/31/15



FG1117-02 Contra Probe FG 1 D188 INNOTEK-DTouhey 101132 11/30/14



FG1117-02 Contra Probe FG 2 D191 Mesa Medical-SPutman 100989 10/31/14

FG1117-02 Contra Probe FG 1 D194 Horse Creek Med-TOakes 102517 1/31/16

FG1117-02 Contra Probe FG 1 D195 Med-Adv.-Faulkner/Benton 101049 10/31/14



Page 7 or 54


FG1117-02 Contra Probe FG 3 D195 Med-Adv.-Faulkner/Benton 102986 7/28/16

FG1117-02 Contra Probe FG 1 D198 Axial Systems-JWing 101844 8/31/15



FG1117-02 Contra Probe FG 2 D206 Patton Medical-APatton 101287 1/31/15

FG1117-02 Contra Probe FG 2 D208 Team Harmony-SWilson 101132 11/30/14

FG1117-02 Contra Probe FG 2 D208 Team Harmony-SWilson 102414 12/31/15

FG1117-02 Contra Probe FG 2 D210 Elite Spine-PHarmon 102986 7/28/16

FG1117-02 Contra Probe FG 2 D212 Sand Medical-REstrada 102414 12/31/15

FG1117-02 Contra Probe FG 2 D217 Freestone Med-JDoub 101469 4/30/15

FG1117-02 Contra Probe FG 2 D220 Northstate-EAlexander 101210 12/31/14

FG1117-02 Contra Probe FG 2 D222 Northstate-SAllen 101210 12/31/14

FG1117-02 Contra Probe FG 2 D223 KNS-JPugliese 101210 12/31/14

FG1117-02 Contra Probe FG 1 D224 Northstate-TCoppedge 101210 12/31/14




FG1117-02 Contra Probe FG 1 D225 Advanced Medical-KMorin 101469 4/30/15

FG1117-02 Contra Probe FG 2 D225 Advanced Medical-KMorin 102517 1/31/16

FG1117-02 Contra Probe FG 1 D227 True North-DBrown 101287 1/31/15

FG1117-02 Contra Probe FG 1 D229 Kevin Kearney 101210 12/31/14

FG1117-02 Contra Probe FG 1 D229 Kevin Kearney 102414 12/31/15

FG1117-02 Contra Probe FG 1 D230 Touchstone-RWeaver 102593 2/29/16

FG1117-02 Contra Probe FG 2 D231 QB Medical-PParsons 101287 1/31/15

FG1117-02 Contra Probe FG 2 D231 QB Medical-PParsons 102414 12/31/15

FG1117-02 Contra Probe FG 2 D240 7 Spine Group-THenderson 101349 2/28/15

FG1117-02 Contra Probe FG 1 D242 Elite Spine-BBooker 102161 10/31/15

FG1117-02 Contra Probe FG 1 D243 Corvus Medical-TKline 101844 8/31/15

FG1117-02 Contra Probe FG 1 D245 Jennifer Wyatt 101349 2/28/15



FG1117-02 Contra Probe FG 3 D248 CLIP MEDICAL - DUBAI 101844 8/31/15

FG1117-02 Contra Probe FG 3 D248 CLIP MEDICAL - DUBAI 102414 12/31/15

FG1117-02 Contra Probe FG 1 D252 SPINE NET - GERMANY 102517 1/31/16

FG1117-02 Contra Probe FG 3 D255 A2 MEDICAL 102161 10/31/15

FG1117-02 Contra Probe FG 2 D260 STIRLING SURGICAL - CURT 102593 2/29/16

FG1117-02 Contra Probe FG 2 D268 BLACK DIAMOND 101702 7/31/15

FG1117-02 Contra Probe FG 1 D270 Med Advise -DTighe 101469 4/30/15



FG1117-02 Contra Probe FG 2 D271 KML Medical - KCook 102161 10/31/15

FG1117-02 Contra Probe FG 2 D274 CBR Medical-RDobson 101702 7/31/15

FG1117-02 Contra Probe FG 1 D275 Spinal Restorat- Lorenzo 101702 7/31/15

FG1117-02 Contra Probe FG 1 D277 Sand Med-B Ledford 101287 1/31/15

FG1117-02 Contra Probe FG 1 D277 Sand Med-B Ledford 102414 12/31/15

FG1117-02 Contra Probe FG 2 D280 Nicole Juber 102051 9/30/15

FG1117-02 Contra Probe FG 1 D281 Susan Rains 101287 1/31/15

FG1117-02 Contra Probe FG 2 D281 Susan Rains 102051 9/30/15

FG1117-02 Contra Probe FG 2 D282 Weisz Surgical-PWeisz 101844 8/31/15

FG1117-02 Contra Probe FG 1 D285 Touchstone-BDoyle 102986 7/28/16

FG1117-02 Contra Probe FG 1 D285 Touchstone-BDoyle 103063 9/28/16

FG1117-02 Contra Probe FG 1 D286 Tolan Mai 101844 8/31/15



Page 8 or 54


FG1117-02 Contra Probe FG 2 D290 IoliteMedical-PGeiger 102517 1/31/16

FG1117-02 Contra Probe FG 2 D296 Denise Sheppard 101349 2/28/15

FG1117-02 Contra Probe FG 3 D296 Denise Sheppard 102749 4/30/16

FG1117-02 Contra Probe FG 1 D297 Synergy Surgical 101287 1/31/15

FG1117-02 Contra Probe FG 2 D297 Synergy Surgical 101349 2/28/15

FG1117-02 Contra Probe FG 1 D298 Emmerson Med. -THamilton 101469 4/30/15



FG1117-02 Contra Probe FG 2 D299 Innotek/Moore Med CZeise 101287 1/31/15

FG1117-02 Contra Probe FG 2 D300 Medical Innovation-RMaly 101844 8/31/15

FG1117-02 Contra Probe FG 2 D301 Elite Spine-DBalsamo 102414 12/31/15

FG1117-02 Contra Probe FG 1 D304 CREAMER MEDICAL -Denmark 102517 1/31/16

FG1117-02 Contra Probe FG 2 D307 Synergy Surgical-SKlein 102517 1/31/16

FG1117-02 Contra Probe FG 2 D310 Resurrection A. Gratsias 101702 7/31/15




FG1117-02 Contra Probe FG 1 D311 Minivasive - Chris Rutt 102593 2/29/16

FG1117-02 Contra Probe FG 1 D312 HEIDI THOMPSON -PER DIEM 101210 12/31/14

FG1117-02 Contra Probe FG 2 D315 PAL Medical - M. Balleux 102749 4/30/16

FG1117-02 Contra Probe FG 4 D316 Elite Spine CA - AGarcia 103063 9/28/16

FG1117-02 Contra Probe FG 2 D317 Innotek Medical - TMoore 102749 4/30/16

FG1117-02 Contra Probe FG 2 D318 Fidelis Surgical - Ligon 103063 9/28/16

FG1117-02 Contra Probe FG 1 D320 Dominic D'Abate 101469 4/30/15

FG1117-02 Contra Probe FG 1 D320 Dominic D'Abate 102051 9/30/15

FG1117-02 Contra Probe FG 2 D321 Spinal Restorative- Lacy 103063 9/28/16

FG1117-02 Contra Probe FG 3 D322 Innotek - M. Swanson 102414 12/31/15

FG1117-02 Contra Probe FG 1 D322 Innotek - M. Swanson 102986 7/28/16

FG1117-02 Contra Probe FG 2 D324 Tyler Unzicker 101210 12/31/14

FG1117-02 Contra Probe FG 2 D328 Bahler - J. McNamara 102749 4/30/16

FG1117-02 Contra Probe FG 1 iO-Loan1 iO-Loaner # 1 101349 2/28/15









FG1117-02 Contra Probe FG 2 iO-Loan8 iO-Loan8 102414 12/31/15

FG1117-02 Contra Probe FG 1 P103 Bob Cook 102517 1/31/16

FG1117-02 Contra Probe FG 1 P103 Bob Cook 102749 4/30/16

FG1117-02 Contra Probe FG 1 S157 JOHN DIETERLY 101844 8/31/15



FG1117-02 Contra Probe FG 1 S163 KATRYN FERNALD 101349 2/28/15



FG1117-02 Contra Probe FG 1 S169 MATT HART 102517 1/31/16



FG1117-02 Contra Probe FG 3 S175 STEVEN GREEN 102593 2/29/16



Page 9 or 54


FG1117-02 Contra Probe FG 1 S176 SCOTT HEYMOSS 101469 4/30/15

FG1117-02 Contra Probe FG 2 S176 SCOTT HEYMOSS 102414 12/31/15

FG1117-02 Contra Probe FG 1 S180 Greg Pellatt 102161 10/31/15

FG1117-02 Contra Probe FG 2 S180 Greg Pellatt 102749 4/30/16

FG1117-02 Contra Probe FG 2 S185 MICHAEL DEFAZIO 102051 9/30/15

FG1117-02 Contra Probe FG 1 S186 KATIE MORONI 101469 4/30/15



FG1117-02 Contra Probe FG 1 S192 ANDREW PINCKNEY 102051 9/30/15




FG1117-02 Contra Probe FG 1 S193 APRIL SPILLANE 101210 12/31/14

FG1117-02 Contra Probe FG 2 S204 Tanner Michael Shaw 102593 2/29/16

FG1117-02 Contra Probe FG 3 S204 Tanner Michael Shaw 102749 4/30/16

FG1117-02 Contra Probe FG 1 S207 PAT FORDE 101091 11/30/14

FG1117-02 Contra Probe FG 1 S207 PAT FORDE 101210 12/31/14

FG1117-05 Ipsi Probe S FG 13 180 SHIPPING TO RALEIGH 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 501 N. CAROLINA FG 101986 9/30/15



FG1117-05 Ipsi Probe S FG 4 700 Demo Products - SJ 101305

FG1117-05 Ipsi Probe S FG 9 700 Demo Products - SJ 101405 3/31/14



FG1117-05 Ipsi Probe S FG 1 D101 KNS Medical Distribution 102987 7/28/16



FG1117-05 Ipsi Probe S FG 2 D102 City Surgical 101893 8/31/15







FG1117-05 Ipsi Probe S FG 1 D103 Bahler Medical 101514 5/31/15



FG1117-05 Ipsi Probe S FG 4 D105 Inline Spine 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 D107 Fusion Medical 102987 7/28/16

FG1117-05 Ipsi Probe S FG 2 D107 Fusion Medical 103011 8/28/16

FG1117-05 Ipsi Probe S FG 2 D111 Davey Medical 103011 8/28/16

FG1117-05 Ipsi Probe S FG 2 D114 Medifuse Surgical, LLC. 102595 2/29/16

FG1117-05 Ipsi Probe S FG 1 D116 Greg Stenzel 101986 9/30/15

FG1117-05 Ipsi Probe S FG 2 D116 Greg Stenzel 102347 11/30/15

FG1117-05 Ipsi Probe S FG 1 D117 Brannon Wyatt 103064 9/28/16

FG1117-05 Ipsi Probe S FG 3 D117 Brannon Wyatt 103148 9/28/16

FG1117-05 Ipsi Probe S FG 2 D118 Amanda Turko 102883 6/30/16

FG1117-05 Ipsi Probe S FG 2 D118 Amanda Turko 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 D119 Align Alternatives 102693 3/31/16





Page 10 or 54





FG1117-05 Ipsi Probe S FG 2 D120 Choice Spine 103148 9/28/16

FG1117-05 Ipsi Probe S FG 7 D123 MetaGen 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 D125 Charles Pierce Martin 102940 7/28/16

FG1117-05 Ipsi Probe S FG 4 D125 Charles Pierce Martin 103148 9/28/16

FG1117-05 Ipsi Probe S FG 2 D126 Goalline Medical, LLC 102693 3/31/16

FG1117-05 Ipsi Probe S FG 3 D126 Goalline Medical, LLC 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 D131 Duke Medical, LLC 102441 12/31/15



FG1117-05 Ipsi Probe S FG 1 D134 Advanced Medical SW 102913 7/31/16

FG1117-05 Ipsi Probe S FG 2 D134 Advanced Medical SW 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 D137 BIOlympic Medical 102913 7/31/16



FG1117-05 Ipsi Probe S FG 1 D140 Long Medical Specialties 102213 11/30/15

FG1117-05 Ipsi Probe S FG 1 D140 Long Medical Specialties 103148 9/28/16

FG1117-05 Ipsi Probe S FG 2 D144 Innovative Surgical LLC. 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 D155 Minivasive - B. Manning 102940 7/28/16

FG1117-05 Ipsi Probe S FG 1 D155 Minivasive - B. Manning 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 D167 MetaGen-SBrown 103148 9/28/16

FG1117-05 Ipsi Probe S FG 2 D174 KRP Medical-KCorrado 102987 7/28/16

FG1117-05 Ipsi Probe S FG 1 D176 Ross Medical-RTate 101893 8/31/15



FG1117-05 Ipsi Probe S FG 1 D177 Carolina Surgi-PTracy 101703 7/31/15

FG1117-05 Ipsi Probe S FG 1 D177 Carolina Surgi-PTracy 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 D181 OrthoMed-MSalinas 102883 6/30/16

FG1117-05 Ipsi Probe S FG 1 D187 Biotech Solutions-JNalli 102347 11/30/15






FG1117-05 Ipsi Probe S FG 1 D188 INNOTEK-DTouhey 102693 3/31/16



FG1117-05 Ipsi Probe S FG 1 D194 Horse Creek Med-TOakes 103011 8/28/16



FG1117-05 Ipsi Probe S FG 2 D195 Med-Adv.-Faulkner/Benton 102883 6/30/16

FG1117-05 Ipsi Probe S FG 1 D198 Axial Systems-JWing 101514 5/31/15


FG1117-05 Ipsi Probe S FG 2 d198 Axial Systems-JWing 102533 1/31/16


FG1117-05 Ipsi Probe S FG 1 D199 Innotek - K. Nevel 102595 2/29/16



FG1117-05 Ipsi Probe S FG 1 D200 2K Spine -T Schultz 102693 3/31/16

FG1117-05 Ipsi Probe S FG 1 D203 AG Distribu-AGuidacan 102750 4/30/16



Page 11 or 54





FG1117-05 Ipsi Probe S FG 4 D206 Patton Medical-APatton 103064 9/28/16

FG1117-05 Ipsi Probe S FG 4 D206 Patton Medical-APatton 103148 9/28/16

FG1117-05 Ipsi Probe S FG 2 D208 Team Harmony-SWilson 103148 9/28/16

FG1117-05 Ipsi Probe S FG 2 D210 Elite Spine-PHarmon 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 D212 Sand Medical-REstrada 101514 5/31/15



FG1117-05 Ipsi Probe S FG 1 D217 Freestone Med-JDoub 101703 7/31/15




FG1117-05 Ipsi Probe S FG 3 D220 Northstate-EAlexander 102913 7/31/16

FG1117-05 Ipsi Probe S FG 1 D222 Northstate-SAllen 101794 7/31/15

FG1117-05 Ipsi Probe S FG 2 D222 Northstate-SAllen 102693 3/31/16

FG1117-05 Ipsi Probe S FG 1 D223 KNS-JPugliese 102693 3/31/16



FG1117-05 Ipsi Probe S FG 1 D224 Northstate-TCoppedge 102138 10/31/15



FG1117-05 Ipsi Probe S FG 1 D225 Advanced Medical-KMorin 102883 6/30/16




FG1117-05 Ipsi Probe S FG 1 D227 True North-DBrown 103011 8/28/16

FG1117-05 Ipsi Probe S FG 2 D227 True North-DBrown 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 D229 Kevin Kearney 102441 12/31/15

FG1117-05 Ipsi Probe S FG 3 D229 Kevin Kearney 102533 1/31/16

FG1117-05 Ipsi Probe S FG 1 D230 Touchstone-RWeaver 102987 7/28/16



FG1117-05 Ipsi Probe S FG 2 D231 QB Medical-PParsons 102213 11/30/15

FG1117-05 Ipsi Probe S FG 5 D231 QB Medical-PParsons 102595 2/29/16

FG1117-05 Ipsi Probe S FG 1 D241 Corvus Med-JeUnderwood 102052 9/30/15



FG1117-05 Ipsi Probe S FG 2 D242 Elite Spine-BBooker 103011 8/28/16

FG1117-05 Ipsi Probe S FG 1 D242 Elite Spine-BBooker 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 D243 Corvus Medical-TKline 102750 4/30/16



FG1117-05 Ipsi Probe S FG 2 D245 Jennifer Wyatt 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 D248 CLIP MEDICAL - DUBAI 102213 11/30/15

FG1117-05 Ipsi Probe S FG 2 D248 CLIP MEDICAL - DUBAI 102595 2/29/16

FG1117-05 Ipsi Probe S FG 1 D255 A2 MEDICAL 102213 11/30/15



FG1117-05 Ipsi Probe S FG 1 D260 STIRLING SURGICAL - CURT 102913 7/31/16

FG1117-05 Ipsi Probe S FG 3 D260 STIRLING SURGICAL - CURT 102987 7/28/16



Page 12 or 54


FG1117-05 Ipsi Probe S FG 3 D268 BLACK DIAMOND 102595 2/29/16

FG1117-05 Ipsi Probe S FG 1 D268 BLACK DIAMOND 102987 7/28/16

FG1117-05 Ipsi Probe S FG 1 D270 Med Advise -DTighe 103064 9/28/16

FG1117-05 Ipsi Probe S FG 3 D270 Med Advise -DTighe 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 D271 KML Medical - KCook 102913 7/31/16



FG1117-05 Ipsi Probe S FG 2 D274 CBR Medical-RDobson 102804 5/31/16

FG1117-05 Ipsi Probe S FG 1 D275 Spinal Restorat- Lorenzo 102533 1/31/16

FG1117-05 Ipsi Probe S FG 2 D277 Sand Med-B Ledford 102750 4/30/16

FG1117-05 Ipsi Probe S FG 1 D277 Sand Med-B Ledford 103011 8/28/16

FG1117-05 Ipsi Probe S FG 1 D280 Nicole Juber 102913 7/31/16




FG1117-05 Ipsi Probe S FG 2 D281 Susan Rains 103011 8/28/16

FG1117-05 Ipsi Probe S FG 3 D282 Weisz Surgical-PWeisz 102693 3/31/16



FG1117-05 Ipsi Probe S FG 1 D285 Touchstone-BDoyle 103011 8/28/16



FG1117-05 Ipsi Probe S FG 1 D286 Tolan Mai 103064 9/28/16

FG1117-05 Ipsi Probe S FG 2 D286 Tolan Mai 103148 9/28/16

FG1117-05 Ipsi Probe S FG 2 D290 IoliteMedical-PGeiger 102987 7/28/16

FG1117-05 Ipsi Probe S FG 2 D290 IoliteMedical-PGeiger 103064 9/28/16

FG1117-05 Ipsi Probe S FG 1 D296 Denise Sheppard 103064 9/28/16

FG1117-05 Ipsi Probe S FG 1 D297 Synergy Surgical 102595 2/29/16




FG1117-05 Ipsi Probe S FG 4 D298 Emmerson Med. -THamilton 103064 9/28/16

FG1117-05 Ipsi Probe S FG 1 D299 Innotek/Moore Med CZeise 101893 8/31/15



FG1117-05 Ipsi Probe S FG 2 D300 Medical Innovation-RMaly 103064 9/28/16

FG1117-05 Ipsi Probe S FG 1 D301 Elite Spine-DBalsamo 102693 3/31/16



FG1117-05 Ipsi Probe S FG 2 D307 Synergy Surgical-SKlein 102213 11/30/15

FG1117-05 Ipsi Probe S FG 5 D307 Synergy Surgical-SKlein 103064 9/28/16

FG1117-05 Ipsi Probe S FG 1 D310 Resurrection A. Gratsias 102913 7/31/16



FG1117-05 Ipsi Probe S FG 1 D311 Minivasive - Chris Rutt 102913 7/31/16



FG1117-05 Ipsi Probe S FG 1 D312 HEIDI THOMPSON -PER DIEM 102913 7/31/16

FG1117-05 Ipsi Probe S FG 2 D315 PAL Medical - M. Balleux 103011 8/28/16

FG1117-05 Ipsi Probe S FG 1 D316 Elite Spine CA - AGarcia 102987 7/28/16





Page 13 or 54


FG1117-05 Ipsi Probe S FG 1 D317 Innotek Medical - TMoore 103011 8/28/16

FG1117-05 Ipsi Probe S FG 2 D318 Fidelis Surgical - Ligon 103011 8/28/16

FG1117-05 Ipsi Probe S FG 1 D320 Dominic D'Abate 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 D321 Spinal Restorative- Lacy 103011 8/28/16



FG1117-05 Ipsi Probe S FG 4 D322 Innotek - M. Swanson 103064 9/28/16

FG1117-05 Ipsi Probe S FG 1 D324 Tyler Unzicker 103064 9/28/16

FG1117-05 Ipsi Probe S FG 4 D328 Bahler - J. McNamara 103148 9/28/16

FG1117-05 Ipsi Probe S FG 2 iO-Loan2 iO-Loaner # 2 103148 9/28/16






FG1117-05 Ipsi Probe S FG 2 iO-Loan8 iO-Loan8 102533 1/31/16

FG1117-05 Ipsi Probe S FG 1 P103 Bob Cook 101893 8/31/15



FG1117-05 Ipsi Probe S FG 1 S157 JOHN DIETERLY 102595 2/29/16



FG1117-05 Ipsi Probe S FG 1 S163 KATRYN FERNALD 102804 5/31/16

FG1117-05 Ipsi Probe S FG 1 S163 KATRYN FERNALD 102913 7/31/16

FG1117-05 Ipsi Probe S FG 3 S169 MATT HART 102750 4/30/16



FG1117-05 Ipsi Probe S FG 1 S175 STEVEN GREEN 102940 7/28/16

FG1117-05 Ipsi Probe S FG 2 S175 STEVEN GREEN 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 S176 SCOTT HEYMOSS 102750 4/30/16



FG1117-05 Ipsi Probe S FG 1 S180 Greg Pellatt 103064 9/28/16

FG1117-05 Ipsi Probe S FG 2 S180 Greg Pellatt 103148 9/28/16

FG1117-05 Ipsi Probe S FG 2 S185 MICHAEL DEFAZIO 103064 9/28/16

FG1117-05 Ipsi Probe S FG 1 S185 MICHAEL DEFAZIO 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 S186 KATIE MORONI 102883 6/30/16

FG1117-05 Ipsi Probe S FG 3 S186 KATIE MORONI 103011 8/28/16

FG1117-05 Ipsi Probe S FG 1 S192 ANDREW PINCKNEY 102595 2/29/16

FG1117-05 Ipsi Probe S FG 6 S192 ANDREW PINCKNEY 103148 9/28/16

FG1117-05 Ipsi Probe S FG 2 S193 APRIL SPILLANE 102987 7/28/16

FG1117-05 Ipsi Probe S FG 1 S193 APRIL SPILLANE 103148 9/28/16

FG1117-05 Ipsi Probe S FG 1 S204 Tanner Michael Shaw 102987 7/28/16

FG1117-05 Ipsi Probe S FG 1 S204 Tanner Michael Shaw 103011 8/28/16

FG1117-09 Ipsi Probe TRL FG 1 301 N. CAROLINA HOLD 102418 12/31/15

FG1117-09 Ipsi Probe TRL FG 1 301 N. CAROLINA HOLD 102519 1/31/16

FG1117-09 Ipsi Probe TRL FG 1 501 N. CAROLINA FG 102941 7/28/16

FG1117-09 Ipsi Probe TRL FG 2 501 N. CAROLINA FG 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 43 501 N. CAROLINA FG 103162

FG1117-09 Ipsi Probe TRL FG 1 700 Demo Products - SJ 101849 9/30/15





Page 14 or 54


FG1117-09 Ipsi Probe TRL FG 5 D101 KNS Medical Distribution 102418 12/31/15

FG1117-09 Ipsi Probe TRL FG 1 D101 KNS Medical Distribution 102644 2/29/16

FG1117-09 Ipsi Probe TRL FG 1 D102 City Surgical 102164 10/31/15

FG1117-09 Ipsi Probe TRL FG 3 D102 City Surgical 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 2 D103 Bahler Medical 102249 11/30/15

FG1117-09 Ipsi Probe TRL FG 4 D107 Fusion Medical 102941 7/28/16

FG1117-09 Ipsi Probe TRL FG 1 D114 Medifuse Surgical, LLC. 102897 6/30/16

FG1117-09 Ipsi Probe TRL FG 1 D117 Brannon Wyatt 101443 5/31/15

FG1117-09 Ipsi Probe TRL FG 1 D118 Amanda Turko 102644 2/29/16

FG1117-09 Ipsi Probe TRL FG 1 D119 Align Alternatives 101849 9/30/15



FG1117-09 Ipsi Probe TRL FG 2 D120 Choice Spine 102249 11/30/15

FG1117-09 Ipsi Probe TRL FG 1 D123 MetaGen 103162

FG1117-09 Ipsi Probe TRL FG 1 D125 Charles Pierce Martin 102897 6/30/16

FG1117-09 Ipsi Probe TRL FG 3 D125 Charles Pierce Martin 103162

FG1117-09 Ipsi Probe TRL FG 1 D126 Goalline Medical, LLC 102249 11/30/15

FG1117-09 Ipsi Probe TRL FG 1 D126 Goalline Medical, LLC 102418 12/31/15

FG1117-09 Ipsi Probe TRL FG 2 D131 Duke Medical, LLC 102249 11/30/15

FG1117-09 Ipsi Probe TRL FG 2 D174 KRP Medical-KCorrado 102941 7/28/16

FG1117-09 Ipsi Probe TRL FG 2 D176 Ross Medical-RTate 102164 10/31/15



FG1117-09 Ipsi Probe TRL FG 1 D187 Biotech Solutions-JNalli 101847 8/31/15

FG1117-09 Ipsi Probe TRL FG 1 D187 Biotech Solutions-JNalli 102164 10/31/15

FG1117-09 Ipsi Probe TRL FG 2 D188 INNOTEK-DTouhey 101847 8/31/15





FG1117-09 Ipsi Probe TRL FG 1 D188 INNOTEK-DTouhey 103162

FG1117-09 Ipsi Probe TRL FG 2 D194 Horse Creek Med-TOakes 102644 2/29/16

FG1117-09 Ipsi Probe TRL FG 1 D198 Axial Systems-JWing 102644 2/29/16



FG1117-09 Ipsi Probe TRL FG 1 D203 AG Distribu-AGuidacan 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 1 D203 AG Distribu-AGuidacan 103162

FG1117-09 Ipsi Probe TRL FG 2 D206 Patton Medical-APatton 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 2 D210 Elite Spine-PHarmon 103162

FG1117-09 Ipsi Probe TRL FG 2 D217 Freestone Med-JDoub 102249 11/30/15

FG1117-09 Ipsi Probe TRL FG 3 D222 Northstate-SAllen 102164 10/31/15

FG1117-09 Ipsi Probe TRL FG 2 D223 KNS-JPugliese 102644 2/29/16

FG1117-09 Ipsi Probe TRL FG 2 D223 KNS-JPugliese 102897 6/30/16

FG1117-09 Ipsi Probe TRL FG 1 D224 Northstate-TCoppedge 101443 5/31/15



FG1117-09 Ipsi Probe TRL FG 1 D227 True North-DBrown 102249 11/30/15



FG1117-09 Ipsi Probe TRL FG 1 D229 Kevin Kearney 102418 12/31/15

FG1117-09 Ipsi Probe TRL FG 1 D230 Touchstone-RWeaver 102249 11/30/15

FG1117-09 Ipsi Probe TRL FG 2 D230 Touchstone-RWeaver 102897 6/30/16



Page 15 or 54


FG1117-09 Ipsi Probe TRL FG 2 D241 Corvus Med-JeUnderwood 102249 11/30/15

FG1117-09 Ipsi Probe TRL FG 1 D242 Elite Spine-BBooker 102941 7/28/16

FG1117-09 Ipsi Probe TRL FG 1 D242 Elite Spine-BBooker 103162

FG1117-09 Ipsi Probe TRL FG 1 D243 Corvus Medical-TKline 102164 10/31/15



FG1117-09 Ipsi Probe TRL FG 2 D255 A2 MEDICAL 102249 11/30/15

FG1117-09 Ipsi Probe TRL FG 1 D255 A2 MEDICAL 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 2 D260 STIRLING SURGICAL - CURT 102897 6/30/16

FG1117-09 Ipsi Probe TRL FG 1 D268 BLACK DIAMOND 101849 9/30/15

FG1117-09 Ipsi Probe TRL FG 1 D268 BLACK DIAMOND 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 1 D270 Med Advise -DTighe 103162

FG1117-09 Ipsi Probe TRL FG 1 D271 KML Medical - KCook 102249 11/30/15

FG1117-09 Ipsi Probe TRL FG 1 D271 KML Medical - KCook 102519 1/31/16

FG1117-09 Ipsi Probe TRL FG 2 d275 Spinal Restorat- Lorenzo 101849 9/30/15

FG1117-09 Ipsi Probe TRL FG 3 D282 Weisz Surgical-PWeisz 102418 12/31/15

FG1117-09 Ipsi Probe TRL FG 1 D285 Touchstone-BDoyle 102164 10/31/15



FG1117-09 Ipsi Probe TRL FG 2 D286 Tolan Mai 102249 11/30/15

FG1117-09 Ipsi Probe TRL FG 2 D290 IoliteMedical-PGeiger 102897 6/30/16

FG1117-09 Ipsi Probe TRL FG 4 D290 IoliteMedical-PGeiger 102941 7/28/16

FG1117-09 Ipsi Probe TRL FG 2 D296 Denise Sheppard 102519 1/31/16



FG1117-09 Ipsi Probe TRL FG 1 D297 Synergy Surgical 102644 2/29/16

FG1117-09 Ipsi Probe TRL FG 1 D307 Synergy Surgical-SKlein 102164 10/31/15



FG1117-09 Ipsi Probe TRL FG 1 D309 Central Valley -R. Green 102249 11/30/15

FG1117-09 Ipsi Probe TRL FG 1 D309 Central Valley -R. Green 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 1 D310 Resurrection A. Gratsias 102249 11/30/15



FG1117-09 Ipsi Probe TRL FG 2 D310 Resurrection A. Gratsias 103162

FG1117-09 Ipsi Probe TRL FG 2 D315 PAL Medical - M. Balleux 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 4 D316 Elite Spine CA - AGarcia 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 1 D316 Elite Spine CA - AGarcia 103162

FG1117-09 Ipsi Probe TRL FG 2 D317 Innotek Medical - TMoore 102897 6/30/16

FG1117-09 Ipsi Probe TRL FG 2 D318 Fidelis Surgical - Ligon 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 2 D320 Dominic D'Abate 101849 9/30/15

FG1117-09 Ipsi Probe TRL FG 1 D321 Spinal Restorative- Lacy 102644 2/29/16

FG1117-09 Ipsi Probe TRL FG 1 D321 Spinal Restorative- Lacy 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 2 D322 Innotek - M. Swanson 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 1 D322 Innotek - M. Swanson 103162

FG1117-09 Ipsi Probe TRL FG 2 D328 Bahler - J. McNamara 103162

FG1117-09 Ipsi Probe TRL FG 1 iO-Loan3 iO-Loaner # 3 103012 8/28/16





FG1117-09 Ipsi Probe TRL FG 2 iO-Loan8 iO-Loan8 102941 7/28/16



Page 16 or 54


FG1117-09 Ipsi Probe TRL FG 1 P103 Bob Cook 102249 11/30/15

FG1117-09 Ipsi Probe TRL FG 1 P103 Bob Cook 102644 2/29/16

FG1117-09 Ipsi Probe TRL FG 2 S157 JOHN DIETERLY 101849 9/30/15




FG1117-09 Ipsi Probe TRL FG 2 S163 KATRYN FERNALD 102164 10/31/15

FG1117-09 Ipsi Probe TRL FG 2 S169 MATT HART 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 1 S169 MATT HART 103162

FG1117-09 Ipsi Probe TRL FG 1 S175 STEVEN GREEN 102897 6/30/16

FG1117-09 Ipsi Probe TRL FG 2 S175 STEVEN GREEN 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 1 S176 SCOTT HEYMOSS 102941 7/28/16

FG1117-09 Ipsi Probe TRL FG 3 S180 Greg Pellatt 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 1 S185 MICHAEL DEFAZIO 102644 2/29/16

FG1117-09 Ipsi Probe TRL FG 2 S185 MICHAEL DEFAZIO 103012 8/28/16

FG1117-09 Ipsi Probe TRL FG 1 S185 MICHAEL DEFAZIO 103162

FG1117-09 Ipsi Probe TRL FG 1 S186 KATIE MORONI 102644 2/29/16



FG1117-09 Ipsi Probe TRL FG 1 S192 ANDREW PINCKNEY 102644 2/29/16



FG1117-09 Ipsi Probe TRL FG 3 S192 ANDREW PINCKNEY 103162

FG1117-09 Ipsi Probe TRL FG 1 S193 APRIL SPILLANE 102418 12/31/15

FG1117-09 Ipsi Probe TRL FG 2 S193 APRIL SPILLANE 102897 6/30/16

FG1117-09 Ipsi Probe TRL FG 1 S204 Tanner Michael Shaw 102249 11/30/15



FG1117-09 Ipsi Probe TRL FG 2 S207 PAT FORDE 102249 11/30/15

FG1134 Distal Handle FG 5 110 Test Sample - SJ 102884

FG1134 Distal Handle FG 5 110 Test Sample - SJ 103093

FG1134 Distal Handle FG 1 180 SHIPPING TO RALEIGH 102995 8/28/16

FG1134 Distal Handle FG 1 301 N. CAROLINA HOLD 100925 9/30/14




FG1134 Distal Handle FG 70 400 Sterile - SJ 103170

FG1134 Distal Handle FG 1 501 N. CAROLINA FG 102435

FG1134 Distal Handle FG 1 501 N. CAROLINA FG 102733 4/30/16




FG1134 Distal Handle FG 2 700 Demo Products - SJ 100759 6/30/14



FG1134 Distal Handle FG 1 D101 KNS Medical Distribution 102053 9/30/15




FG1134 Distal Handle FG 1 D102 City Surgical 102669 3/31/16





Page 17 or 54




FG1134 Distal Handle FG 3 D103 Bahler Medical 101547 5/31/15



FG1134 Distal Handle FG 2 D105 Inline Spine 103050 8/28/16

FG1134 Distal Handle FG 5 D105 Inline Spine 103093 9/28/16

FG1134 Distal Handle FG 1 D107 Fusion Medical 102914 6/30/16

FG1134 Distal Handle FG 2 D107 Fusion Medical 102995 8/28/16

FG1134 Distal Handle FG 4 D111 Davey Medical 102866 5/31/16

FG1134 Distal Handle FG 1 D114 Medifuse Surgical, LLC. 103050 8/28/16

FG1134 Distal Handle FG 2 D116 Greg Stenzel 102139 10/31/15

FG1134 Distal Handle FG 2 D116 Greg Stenzel 102348 11/30/15

FG1134 Distal Handle FG 4 D117 Brannon Wyatt 103050 8/28/16

FG1134 Distal Handle FG 2 D118 Amanda Turko 102669 3/31/16

FG1134 Distal Handle FG 2 D118 Amanda Turko 103093 9/28/16

FG1134 Distal Handle FG 1 D119 Align Alternatives 102995 8/28/16



FG1134 Distal Handle FG 1 D120 Choice Spine 103050 8/28/16

FG1134 Distal Handle FG 1 D120 Choice Spine 103093 9/28/16

FG1134 Distal Handle FG 1 D123 MetaGen 103050 8/28/16

FG1134 Distal Handle FG 3 D123 MetaGen 103093 9/28/16

FG1134 Distal Handle FG 2 D125 Charles Pierce Martin 103050 8/28/16

FG1134 Distal Handle FG 3 D125 Charles Pierce Martin 103093 9/28/16

FG1134 Distal Handle FG 1 D126 Goalline Medical, LLC 102914 6/30/16



FG1134 Distal Handle FG 1 D131 Duke Medical, LLC 101806 8/31/15




FG1134 Distal Handle FG 1 D134 Advanced Medical SW 103050 8/28/16

FG1134 Distal Handle FG 2 D134 Advanced Medical SW 103093 9/28/16

FG1134 Distal Handle FG 11 D137 BIOlympic Medical 103050 8/28/16

FG1134 Distal Handle FG 1 D140 Long Medical Specialties 102884 6/30/16



FG1134 Distal Handle FG 1 D144 Innovative Surgical LLC. 103050 8/28/16

FG1134 Distal Handle FG 2 D144 Innovative Surgical LLC. 103093 9/28/16

FG1134 Distal Handle FG 3 D155 Minivasive - B. Manning 103050 8/28/16

FG1134 Distal Handle FG 1 D167 MetaGen-SBrown 102053 9/30/15

FG1134 Distal Handle FG 2 D167 MetaGen-SBrown 103093 9/28/16

FG1134 Distal Handle FG 2 D174 KRP Medical-KCorrado 102995 8/28/16

FG1134 Distal Handle FG 3 D176 Ross Medical-RTate 101894 8/31/15



FG1134 Distal Handle FG 1 D177 Carolina Surgi-PTracy 102669 3/31/16

FG1134 Distal Handle FG 2 D177 Carolina Surgi-PTracy 103050 8/28/16

FG1134 Distal Handle FG 1 D181 OrthoMed-MSalinas 102884 6/30/16

FG1134 Distal Handle FG 1 D187 Biotech Solutions-JNalli 102435 12/31/15




Page 18 or 54




FG1134 Distal Handle FG 1 D188 INNOTEK-DTouhey 102733 4/30/16



FG1134 Distal Handle FG 4 D191 Mesa Medical-SPutman 100975 9/30/14

FG1134 Distal Handle FG 1 D194 Horse Creek Med-TOakes 102884 6/30/16



FG1134 Distal Handle FG 1 D195 Med-Adv.-Faulkner/Benton 102914 6/30/16

FG1134 Distal Handle FG 2 D195 Med-Adv.-Faulkner/Benton 102995 8/28/16

FG1134 Distal Handle FG 1 D196 Bahler Medical-BHauk 101362 2/28/15

FG1134 Distal Handle FG 1 D198 Axial Systems-JWing 102783 4/30/16

FG1134 Distal Handle FG 6 D198 Axial Systems-JWing 102914 6/30/16

FG1134 Distal Handle FG 1 D199 Innotek - K. Nevel 102669 3/31/16

FG1134 Distal Handle FG 1 D199 Innotek - K. Nevel 103050 8/28/16

FG1134 Distal Handle FG 1 D200 2K Spine -T Schultz 102733 4/30/16

FG1134 Distal Handle FG 2 D203 AG Distribu-AGuidacan 103050 8/28/16

FG1134 Distal Handle FG 1 D203 AG Distribu-AGuidacan 103093 9/28/16

FG1134 Distal Handle FG 8 D206 Patton Medical-APatton 103050 8/28/16

FG1134 Distal Handle FG 2 D208 Team Harmony-SWilson 103050 8/28/16

FG1134 Distal Handle FG 2 D210 Elite Spine-PHarmon 103093 9/28/16

FG1134 Distal Handle FG 1 D212 Sand Medical-REstrada 102245 11/30/15



FG1134 Distal Handle FG 2 D217 Freestone Med-JDoub 102348 11/30/15

FG1134 Distal Handle FG 1 D217 Freestone Med-JDoub 102914 6/30/16

FG1134 Distal Handle FG 1 D220 Northstate-EAlexander 101269 1/31/15

FG1134 Distal Handle FG 3 D220 Northstate-EAlexander 101421 3/31/15

FG1134 Distal Handle FG 1 D222 Northstate-SAllen 102139 10/31/15



FG1134 Distal Handle FG 1 D223 KNS-JPugliese 102783 4/30/16

FG1134 Distal Handle FG 1 D223 KNS-JPugliese 102866 5/31/16

FG1134 Distal Handle FG 1 D224 Northstate-TCoppedge 102139 10/31/15

FG1134 Distal Handle FG 4 D224 Northstate-TCoppedge 102914 6/30/16

FG1134 Distal Handle FG 1 D225 Advanced Medical-KMorin 102914 6/30/16




FG1134 Distal Handle FG 1 D227 True North-DBrown 102995 8/28/16



FG1134 Distal Handle FG 2 D229 Kevin Kearney 102573 1/31/16

FG1134 Distal Handle FG 1 D230 Touchstone-RWeaver 102995 8/28/16



FG1134 Distal Handle FG 1 D231 QB Medical-PParsons 102435 12/31/15

FG1134 Distal Handle FG 4 D231 QB Medical-PParsons 102573 1/31/16

FG1134 Distal Handle FG 1 D240 7 Spine Group-THenderson 101363 2/28/15

FG1134 Distal Handle FG 2 D241 Corvus Med-JeUnderwood 101894 8/31/15

FG1134 Distal Handle FG 2 D241 Corvus Med-JeUnderwood 102573 1/31/16



Page 19 or 54


FG1134 Distal Handle FG 1 D242 Elite Spine-BBooker 102995 8/28/16

FG1134 Distal Handle FG 2 D242 Elite Spine-BBooker 103050 8/28/16

FG1134 Distal Handle FG 1 D243 Corvus Medical-TKline 102783 4/30/16

FG1134 Distal Handle FG 5 D243 Corvus Medical-TKline 103050 8/28/16

FG1134 Distal Handle FG 1 D245 Jennifer Wyatt 102884 6/30/16

FG1134 Distal Handle FG 1 D245 Jennifer Wyatt 103050 8/28/16

FG1134 Distal Handle FG 1 D248 CLIP MEDICAL - DUBAI 102139 10/31/15

FG1134 Distal Handle FG 1 D248 CLIP MEDICAL - DUBAI 102573 1/31/16

FG1134 Distal Handle FG 1 D255 A2 MEDICAL 102573 1/31/16



FG1134 Distal Handle FG 1 D260 STIRLING SURGICAL - CURT 102914 6/30/16

FG1134 Distal Handle FG 3 D260 STIRLING SURGICAL - CURT 102995 8/28/16

FG1134 Distal Handle FG 1 D268 BLACK DIAMOND 102435 12/31/15



FG1134 Distal Handle FG 1 D270 Med Advise -DTighe 103050 8/28/16

FG1134 Distal Handle FG 2 D270 Med Advise -DTighe 103093 9/28/16

FG1134 Distal Handle FG 1 D271 KML Medical - KCook 102914 6/30/16

FG1134 Distal Handle FG 2 D271 KML Medical - KCook 103050 8/28/16

FG1134 Distal Handle FG 1 D274 CBR Medical-RDobson 101894 8/31/15

FG1134 Distal Handle FG 2 D274 CBR Medical-RDobson 102866 5/31/16

FG1134 Distal Handle FG 1 D277 Sand Med-B Ledford 102733 4/30/16

FG1134 Distal Handle FG 2 D277 Sand Med-B Ledford 102995 8/28/16

FG1134 Distal Handle FG 1 D280 Nicole Juber 102914 6/30/16



FG1134 Distal Handle FG 2 D281 Susan Rains 103050 8/28/16

FG1134 Distal Handle FG 3 D285 Touchstone-BDoyle 103050 8/28/16

FG1134 Distal Handle FG 1 D285 Touchstone-BDoyle 103093 9/28/16

FG1134 Distal Handle FG 2 D286 Tolan Mai 103050 8/28/16

FG1134 Distal Handle FG 2 D290 IoliteMedical-PGeiger 102914 6/30/16

FG1134 Distal Handle FG 2 D290 IoliteMedical-PGeiger 102995 8/28/16

FG1134 Distal Handle FG 1 D296 Denise Sheppard 102995 8/28/16

FG1134 Distal Handle FG 3 D296 Denise Sheppard 103050 8/28/16

FG1134 Distal Handle FG 4 D297 Synergy Surgical 103050 8/28/16

FG1134 Distal Handle FG 1 D297 Synergy Surgical 103093 9/28/16

FG1134 Distal Handle FG 4 D298 Emmerson Med. -THamilton 103050 8/28/16

FG1134 Distal Handle FG 1 D299 Innotek/Moore Med CZeise 102995 8/28/16



FG1134 Distal Handle FG 2 D300 Medical Innovation-RMaly 103050 8/28/16

FG1134 Distal Handle FG 3 D301 Elite Spine-DBalsamo 102733 4/30/16

FG1134 Distal Handle FG 1 D301 Elite Spine-DBalsamo 103050 8/28/16

FG1134 Distal Handle FG 1 D307 Synergy Surgical-SKlein 101704 7/31/15




FG1134 Distal Handle FG 2 D309 Central Valley -R. Green 103050 8/28/16

FG1134 Distal Handle FG 1 D310 Resurrection A. Gratsias 101806 8/31/15





Page 20 or 54


FG1134 Distal Handle FG 3 D311 Minivasive - Chris Rutt 103050 8/28/16

FG1134 Distal Handle FG 2 D315 PAL Medical - M. Balleux 102995 8/28/16

FG1134 Distal Handle FG 2 D316 Elite Spine CA - AGarcia 103050 8/28/16

FG1134 Distal Handle FG 3 D316 Elite Spine CA - AGarcia 103093 9/28/16

FG1134 Distal Handle FG 1 D317 Innotek Medical - TMoore 102884 6/30/16

FG1134 Distal Handle FG 1 D317 Innotek Medical - TMoore 103050 8/28/16

FG1134 Distal Handle FG 2 D318 Fidelis Surgical - Ligon 103050 8/28/16

FG1134 Distal Handle FG 1 D320 Dominic D'Abate 103050 8/28/16

FG1134 Distal Handle FG 3 D321 Spinal Restorative- Lacy 103050 8/28/16

FG1134 Distal Handle FG 1 D321 Spinal Restorative- Lacy 103093 9/28/16

FG1134 Distal Handle FG 2 D322 Innotek - M. Swanson 103050 8/28/16

FG1134 Distal Handle FG 1 D322 Innotek - M. Swanson 103093 9/28/16

FG1134 Distal Handle FG 4 D328 Bahler - J. McNamara 103050 8/28/16

FG1134 Distal Handle FG 1 iO-Loan1 iO-Loaner # 1 103093 9/28/16








FG1134 Distal Handle FG 2 iO-Loan8 iO-Loan8 102435 12/31/15

FG1134 Distal Handle FG 1 P103 Bob Cook 102914 6/30/16




FG1134 Distal Handle FG 1 S157 JOHN DIETERLY 102995 8/28/16

FG1134 Distal Handle FG 5 S157 JOHN DIETERLY 103050 8/28/16

FG1134 Distal Handle FG 2 S163 KATRYN FERNALD 102914 6/30/16

FG1134 Distal Handle FG 1 S169 MATT HART 102914 6/30/16



FG1134 Distal Handle FG 1 S175 STEVEN GREEN 102995 8/28/16

FG1134 Distal Handle FG 2 S175 STEVEN GREEN 103093 9/28/16

FG1134 Distal Handle FG 3 S176 SCOTT HEYMOSS 102914 6/30/16

FG1134 Distal Handle FG 1 S176 SCOTT HEYMOSS 102995 8/28/16

FG1134 Distal Handle FG 1 S180 Greg Pellatt 102995 8/28/16

FG1134 Distal Handle FG 2 S180 Greg Pellatt 103050 8/28/16

FG1134 Distal Handle FG 5 S185 MICHAEL DEFAZIO 103050 8/28/16

FG1134 Distal Handle FG 1 S186 KATIE MORONI 102914 6/30/16

FG1134 Distal Handle FG 1 S186 KATIE MORONI 102995 8/28/16

FG1134 Distal Handle FG 1 S192 ANDREW PINCKNEY 103050 8/28/16

FG1134 Distal Handle FG 6 S192 ANDREW PINCKNEY 103093 9/28/16

FG1134 Distal Handle FG 1 S193 APRIL SPILLANE 102914 6/30/16

FG1134 Distal Handle FG 2 S193 APRIL SPILLANE 102995 8/28/16

FG1134 Distal Handle FG 1 S204 Tanner Michael Shaw 102914 6/30/16



FG1135-01 MBS 5.5mm FG 1 180 SHIPPING TO RALEIGH 102046 9/30/15

FG1135-01 MBS 5.5mm FG 5 301 N. CAROLINA HOLD 100853 8/31/14





Page 21 or 54






FG1135-01 MBS 5.5mm FG 39 400 Sterile - SJ 103177

FG1135-01 MBS 5.5mm FG 1 501 N. CAROLINA FG 102308 11/30/15



FG1135-01 MBS 5.5mm FG 1 D101 KNS Medical Distribution 102768 4/30/16




FG1135-01 MBS 5.5mm FG 1 D102 City Surgical 101383 3/31/15



FG1135-01 MBS 5.5mm FG 1 D103 Bahler Medical 101697 7/31/15

FG1135-01 MBS 5.5mm FG 2 D105 Inline Spine 102896 6/30/16

FG1135-01 MBS 5.5mm FG 1 D107 Fusion Medical 102978 7/28/16

FG1135-01 MBS 5.5mm FG 2 D107 Fusion Medical 103034 8/28/16

FG1135-01 MBS 5.5mm FG 1 D111 Davey Medical 102641 2/29/16

FG1135-01 MBS 5.5mm FG 1 D116 Greg Stenzel 102308 11/30/15

FG1135-01 MBS 5.5mm FG 1 D116 Greg Stenzel 103071 9/28/16

FG1135-01 MBS 5.5mm FG 1 D117 Brannon Wyatt 101697 7/31/15

FG1135-01 MBS 5.5mm FG 1 D117 Brannon Wyatt 103101 6/28/16

FG1135-01 MBS 5.5mm FG 1 D117 Brannon Wyatt 103157

FG1135-01 MBS 5.5mm FG 1 D118 Amanda Turko 101302 1/31/15

FG1135-01 MBS 5.5mm FG 1 D118 Amanda Turko 103157

FG1135-01 MBS 5.5mm FG 1 D119 Align Alternatives 101302 1/31/15






FG1135-01 MBS 5.5mm FG 2 D119 Align Alternatives 103157

FG1135-01 MBS 5.5mm FG 1 D120 Choice Spine 102896 6/30/16

FG1135-01 MBS 5.5mm FG 1 D123 MetaGen 101383 3/31/15



FG1135-01 MBS 5.5mm FG 1 D125 Charles Pierce Martin 101536 5/31/15

FG1135-01 MBS 5.5mm FG 1 D125 Charles Pierce Martin 103034 8/28/16

FG1135-01 MBS 5.5mm FG 1 D125 Charles Pierce Martin 103157

FG1135-01 MBS 5.5mm FG 2 D126 Goalline Medical, LLC 103071 9/28/16

FG1135-01 MBS 5.5mm FG 1 D131 Duke Medical, LLC 101841 8/31/15

FG1135-01 MBS 5.5mm FG 1 D134 Advanced Medical SW 102308 11/30/15

FG1135-01 MBS 5.5mm FG 1 D134 Advanced Medical SW 103101 6/28/16

FG1135-01 MBS 5.5mm FG 1 D137 BIOlympic Medical 101536 5/31/15

FG1135-01 MBS 5.5mm FG 1 D137 BIOlympic Medical 101841 8/31/15

FG1135-01 MBS 5.5mm FG 1 D140 Long Medical Specialties 103034 8/28/16

FG1135-01 MBS 5.5mm FG 1 D144 Innovative Surgical LLC. 102194 10/31/15

FG1135-01 MBS 5.5mm FG 1 D144 Innovative Surgical LLC. 103157

FG1135-01 MBS 5.5mm FG 1 D155 Minivasive - B. Manning 101536 5/31/15

FG1135-01 MBS 5.5mm FG 1 D155 Minivasive - B. Manning 102806 5/31/16



Page 22 or 54


FG1135-01 MBS 5.5mm FG 2 D167 MetaGen-SBrown 103157

FG1135-01 MBS 5.5mm FG 2 D174 KRP Medical-KCorrado 102978 7/28/16

FG1135-01 MBS 5.5mm FG 1 D176 Ross Medical-RTate 102896 6/30/16

FG1135-01 MBS 5.5mm FG 1 D176 Ross Medical-RTate 102978 7/28/16

FG1135-01 MBS 5.5mm FG 1 D177 Carolina Surgi-PTracy 101697 7/31/15



FG1135-01 MBS 5.5mm FG 2 D181 OrthoMed-MSalinas 102536 1/31/16

FG1135-01 MBS 5.5mm FG 1 D181 OrthoMed-MSalinas 102806 5/31/16

FG1135-01 MBS 5.5mm FG 1 D187 Biotech Solutions-JNalli 102194 10/31/15

FG1135-01 MBS 5.5mm FG 1 D187 Biotech Solutions-JNalli 102536 1/31/16

FG1135-01 MBS 5.5mm FG 1 D188 INNOTEK-DTouhey 101178 12/31/14



FG1135-01 MBS 5.5mm FG 1 D188 INNOTEK-DTouhey 103157

FG1135-01 MBS 5.5mm FG 3 D191 Mesa Medical-SPutman 100961 9/30/14

FG1135-01 MBS 5.5mm FG 2 D194 Horse Creek Med-TOakes 103071 9/28/16

FG1135-01 MBS 5.5mm FG 2 D195 Med-Adv.-Faulkner/Benton 102978 7/28/16

FG1135-01 MBS 5.5mm FG 1 D195 Med-Adv.-Faulkner/Benton 103034 8/28/16

FG1135-01 MBS 5.5mm FG 2 D198 Axial Systems-JWing 102194 10/31/15




FG1135-01 MBS 5.5mm FG 1 D199 Innotek - K. Nevel 102194 10/31/15

FG1135-01 MBS 5.5mm FG 1 D199 Innotek - K. Nevel 102308 11/30/15

FG1135-01 MBS 5.5mm FG 2 D200 2K Spine -T Schultz 101383 3/31/15

FG1135-01 MBS 5.5mm FG 1 D203 AG Distribu-AGuidacan 103071 9/28/16

FG1135-01 MBS 5.5mm FG 1 D206 Patton Medical-APatton 102536 1/31/16



FG1135-01 MBS 5.5mm FG 1 D208 Team Harmony-SWilson 102768 4/30/16

FG1135-01 MBS 5.5mm FG 1 D210 Elite Spine-PHarmon 102194 10/31/15

FG1135-01 MBS 5.5mm FG 1 D210 Elite Spine-PHarmon 102308 11/30/15

FG1135-01 MBS 5.5mm FG 1 D212 Sand Medical-REstrada 101697 7/31/15



FG1135-01 MBS 5.5mm FG 2 D217 Freestone Med-JDoub 102194 10/31/15

FG1135-01 MBS 5.5mm FG 1 D217 Freestone Med-JDoub 102536 1/31/16

FG1135-01 MBS 5.5mm FG 2 D223 KNS-JPugliese 102978 7/28/16

FG1135-01 MBS 5.5mm FG 1 D223 KNS-JPugliese 103071 9/28/16

FG1135-01 MBS 5.5mm FG 1 D224 Northstate-TCoppedge 101109 11/30/14

FG1135-01 MBS 5.5mm FG 1 D225 Advanced Medical-KMorin 102896 6/30/16

FG1135-01 MBS 5.5mm FG 1 D227 True North-DBrown 102806 5/31/16

FG1135-01 MBS 5.5mm FG 1 D227 True North-DBrown 103034 8/28/16

FG1135-01 MBS 5.5mm FG 1 D229 Kevin Kearney 102536 1/31/16

FG1135-01 MBS 5.5mm FG 1 D230 Touchstone-RWeaver 101383 3/31/15



FG1135-01 MBS 5.5mm FG 1 D231 QB Medical-PParsons 102194 10/31/15

FG1135-01 MBS 5.5mm FG 5 D231 QB Medical-PParsons 102536 1/31/16

FG1135-01 MBS 5.5mm FG 3 D240 7 Spine Group-THenderson 101383 3/31/15

FG1135-01 MBS 5.5mm FG 3 D241 Corvus Med-JeUnderwood 101383 3/31/15



Page 23 or 54


FG1135-01 MBS 5.5mm FG 1 D242 Elite Spine-BBooker 102308 11/30/15



FG1135-01 MBS 5.5mm FG 1 D243 Corvus Medical-TKline 102308 11/30/15



FG1135-01 MBS 5.5mm FG 2 D245 Jennifer Wyatt 101383 3/31/15

FG1135-01 MBS 5.5mm FG 1 D245 Jennifer Wyatt 102536 1/31/16

FG1135-01 MBS 5.5mm FG 3 D248 CLIP MEDICAL - DUBAI 101841 8/31/15

FG1135-01 MBS 5.5mm FG 1 D252 SPINE NET - GERMANY 102641 2/29/16

FG1135-01 MBS 5.5mm FG 3 D255 A2 MEDICAL 103034 8/28/16

FG1135-01 MBS 5.5mm FG 1 D260 STIRLING SURGICAL - CURT 102806 5/31/16

FG1135-01 MBS 5.5mm FG 1 D260 STIRLING SURGICAL - CURT 102978 7/28/16

FG1135-01 MBS 5.5mm FG 1 D268 BLACK DIAMOND 101841 8/31/15

FG1135-01 MBS 5.5mm FG 1 D270 Med Advise -DTighe 102536 1/31/16

FG1135-01 MBS 5.5mm FG 2 D270 Med Advise -DTighe 103071 9/28/16

FG1135-01 MBS 5.5mm FG 1 D271 KML Medical - KCook 103071 9/28/16

FG1135-01 MBS 5.5mm FG 1 D271 KML Medical - KCook 103157

FG1135-01 MBS 5.5mm FG 1 D277 Sand Med-B Ledford 101841 8/31/15

FG1135-01 MBS 5.5mm FG 1 D277 Sand Med-B Ledford 103034 8/28/16

FG1135-01 MBS 5.5mm FG 1 D280 Nicole Juber 102806 5/31/16

FG1135-01 MBS 5.5mm FG 1 D280 Nicole Juber 103071 9/28/16

FG1135-01 MBS 5.5mm FG 1 D281 Susan Rains 101841 8/31/15



FG1135-01 MBS 5.5mm FG 1 D285 Touchstone-BDoyle 102194 10/31/15



FG1135-01 MBS 5.5mm FG 2 D286 Tolan Mai 102194 10/31/15

FG1135-01 MBS 5.5mm FG 1 D290 IoliteMedical-PGeiger 101841 8/31/15

FG1135-01 MBS 5.5mm FG 1 D290 IoliteMedical-PGeiger 102308 11/30/15

FG1135-01 MBS 5.5mm FG 2 D296 Denise Sheppard 102536 1/31/16

FG1135-01 MBS 5.5mm FG 2 D296 Denise Sheppard 103034 8/28/16

FG1135-01 MBS 5.5mm FG 1 D297 Synergy Surgical 103071 9/28/16

FG1135-01 MBS 5.5mm FG 2 D297 Synergy Surgical 103101 6/28/16

FG1135-01 MBS 5.5mm FG 1 D298 Emmerson Med. -THamilton 102768 4/30/16

FG1135-01 MBS 5.5mm FG 1 D298 Emmerson Med. -THamilton 103071 9/28/16

FG1135-01 MBS 5.5mm FG 1 D299 Innotek/Moore Med CZeise 102308 11/30/15

FG1135-01 MBS 5.5mm FG 2 D300 Medical Innovation-RMaly 103071 9/28/16

FG1135-01 MBS 5.5mm FG 2 D301 Elite Spine-DBalsamo 101257 1/31/15

FG1135-01 MBS 5.5mm FG 2 D307 Synergy Surgical-SKlein 102978 7/28/16

FG1135-01 MBS 5.5mm FG 3 D307 Synergy Surgical-SKlein 103101 6/28/16

FG1135-01 MBS 5.5mm FG 1 D309 Central Valley -R. Green 103071 9/28/16

FG1135-01 MBS 5.5mm FG 1 D310 Resurrection A. Gratsias 101178 12/31/14

FG1135-01 MBS 5.5mm FG 1 D310 Resurrection A. Gratsias 103100 1/28/16

FG1135-01 MBS 5.5mm FG 4 D310 Resurrection A. Gratsias 103157

FG1135-01 MBS 5.5mm FG 1 D311 Minivasive - Chris Rutt 102536 1/31/16

FG1135-01 MBS 5.5mm FG 1 D312 HEIDI THOMPSON -PER DIEM 102806 5/31/16

FG1135-01 MBS 5.5mm FG 2 D315 PAL Medical - M. Balleux 102978 7/28/16

FG1135-01 MBS 5.5mm FG 3 D316 Elite Spine CA - AGarcia 103100 1/28/16

FG1135-01 MBS 5.5mm FG 1 D316 Elite Spine CA - AGarcia 103101 6/28/16

FG1135-01 MBS 5.5mm FG 1 D317 Innotek Medical - TMoore 102978 7/28/16



Page 24 or 54


FG1135-01 MBS 5.5mm FG 1 D317 Innotek Medical - TMoore 103157

FG1135-01 MBS 5.5mm FG 2 D318 Fidelis Surgical - Ligon 103100 1/28/16

FG1135-01 MBS 5.5mm FG 2 D320 Dominic D'Abate 101841 8/31/15

FG1135-01 MBS 5.5mm FG 2 D321 Spinal Restorative- Lacy 103101 6/28/16

FG1135-01 MBS 5.5mm FG 3 D322 Innotek - M. Swanson 103071 9/28/16

FG1135-01 MBS 5.5mm FG 2 D324 Tyler Unzicker 102768 4/30/16

FG1135-01 MBS 5.5mm FG 4 D328 Bahler - J. McNamara 103157

FG1135-01 MBS 5.5mm FG 1 iO-Loan1 iO-Loaner # 1 102806 5/31/16






FG1135-01 MBS 5.5mm FG 1 iO-Loan8 iO-Loan8 102442 12/31/15

FG1135-01 MBS 5.5mm FG 1 iO-Loan8 iO-Loan8 102536 1/31/16

FG1135-01 MBS 5.5mm FG 1 P103 Bob Cook 102194 10/31/15

FG1135-01 MBS 5.5mm FG 1 P103 Bob Cook 102641 2/29/16

FG1135-01 MBS 5.5mm FG 3 S157 JOHN DIETERLY 102978 7/28/16



FG1135-01 MBS 5.5mm FG 2 S157 JOHN DIETERLY 103157

FG1135-01 MBS 5.5mm FG 1 S163 KATRYN FERNALD 101456 4/30/15

FG1135-01 MBS 5.5mm FG 1 S163 KATRYN FERNALD 102442 12/31/15

FG1135-01 MBS 5.5mm FG 2 S169 MATT HART 102308 11/30/15

FG1135-01 MBS 5.5mm FG 1 S169 MATT HART 103157

FG1135-01 MBS 5.5mm FG 1 S175 STEVEN GREEN 102896 6/30/16

FG1135-01 MBS 5.5mm FG 1 S175 STEVEN GREEN 103034 8/28/16

FG1135-01 MBS 5.5mm FG 2 S176 SCOTT HEYMOSS 102896 6/30/16

FG1135-01 MBS 5.5mm FG 2 S180 Greg Pellatt 103100 1/28/16

FG1135-01 MBS 5.5mm FG 3 S180 Greg Pellatt 103101 6/28/16

FG1135-01 MBS 5.5mm FG 2 S185 MICHAEL DEFAZIO 103071 9/28/16

FG1135-01 MBS 5.5mm FG 2 S186 KATIE MORONI 102896 6/30/16

FG1135-01 MBS 5.5mm FG 2 S186 KATIE MORONI 103101 6/28/16

FG1135-01 MBS 5.5mm FG 2 S192 ANDREW PINCKNEY 102768 4/30/16



FG1135-01 MBS 5.5mm FG 1 S193 APRIL SPILLANE 101302 1/31/15




FG1135-01 MBS 5.5mm FG 2 S204 Tanner Michael Shaw 103034 8/28/16

FG1135-01 MBS 5.5mm FG 1 S204 Tanner Michael Shaw 103071 9/28/16

FG1135-01 MBS 5.5mm FG 1 S207 PAT FORDE 101697 7/31/15

FG1135-03 MBS 7.5mm SC FG 1 301 N. CAROLINA HOLD 100803 7/31/14





FG1135-03 MBS 7.5mm SC FG 1 501 N. CAROLINA FG 101842 8/31/15






Page 25 or 54





FG1135-03 MBS 7.5mm SC FG 2 700 Demo Products - SJ 100962 9/30/14




FG1135-03 MBS 7.5mm SC FG 1 D101 KNS Medical Distribution 101983 9/30/15






FG1135-03 MBS 7.5mm SC FG 1 D102 City Surgical 101457 4/30/15






FG1135-03 MBS 7.5mm SC FG 3 D103 Bahler Medical 101344 2/28/15

FG1135-03 MBS 7.5mm SC FG 2 D103 Bahler Medical 101537 5/31/15

FG1135-03 MBS 7.5mm SC FG 4 D105 Inline Spine 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D107 Fusion Medical 101537 5/31/15

FG1135-03 MBS 7.5mm SC FG 3 D107 Fusion Medical 102942 7/28/16

FG1135-03 MBS 7.5mm SC FG 2 D111 Davey Medical 101698 7/31/15




FG1135-03 MBS 7.5mm SC FG 2 D114 Medifuse Surgical, LLC. 102942 7/28/16

FG1135-03 MBS 7.5mm SC FG 1 D114 Medifuse Surgical, LLC. 103072 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D116 Greg Stenzel 101457 4/30/15



FG1135-03 MBS 7.5mm SC FG 1 D117 Brannon Wyatt 102942 7/28/16

FG1135-03 MBS 7.5mm SC FG 3 D117 Brannon Wyatt 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D118 Amanda Turko 101457 4/30/15



FG1135-03 MBS 7.5mm SC FG 1 D119 Align Alternatives 102807 5/31/16





FG1135-03 MBS 7.5mm SC FG 2 D120 Choice Spine 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D123 MetaGen 102909 6/30/16



FG1135-03 MBS 7.5mm SC FG 4 D125 Charles Pierce Martin 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D126 Goalline Medical, LLC 103035 8/28/16



FG1135-03 MBS 7.5mm SC FG 1 D131 Duke Medical, LLC 101457 4/30/15



Page 26 or 54




FG1135-03 MBS 7.5mm SC FG 2 D134 Advanced Medical SW 102730 4/30/16



FG1135-03 MBS 7.5mm SC FG 4 D137 BIOlympic Medical 103072 9/28/16

FG1135-03 MBS 7.5mm SC FG 6 D137 BIOlympic Medical 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D140 Long Medical Specialties 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D144 Innovative Surgical LLC. 102309 11/30/15

FG1135-03 MBS 7.5mm SC FG 2 D144 Innovative Surgical LLC. 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 2 D155 Minivasive - B. Manning 101344 2/28/15




FG1135-03 MBS 7.5mm SC FG 1 D167 MetaGen-SBrown 101457 4/30/15

FG1135-03 MBS 7.5mm SC FG 2 D167 MetaGen-SBrown 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 2 D174 KRP Medical-KCorrado 103035 8/28/16

FG1135-03 MBS 7.5mm SC FG 2 D176 Ross Medical-RTate 101842 8/31/15



FG1135-03 MBS 7.5mm SC FG 1 D177 Carolina Surgi-PTracy 102909 6/30/16



FG1135-03 MBS 7.5mm SC FG 1 D181 OrthoMed-MSalinas 102642 2/29/16

FG1135-03 MBS 7.5mm SC FG 1 D181 OrthoMed-MSalinas 102730 4/30/16

FG1135-03 MBS 7.5mm SC FG 1 D187 Biotech Solutions-JNalli 101537 5/31/15




FG1135-03 MBS 7.5mm SC FG 1 D188 INNOTEK-DTouhey 101537 5/31/15




FG1135-03 MBS 7.5mm SC FG 4 D191 Mesa Medical-SPutman 100962 9/30/14

FG1135-03 MBS 7.5mm SC FG 1 D194 Horse Creek Med-TOakes 102642 2/29/16



FG1135-03 MBS 7.5mm SC FG 2 D195 Med-Adv.-Faulkner/Benton 102909 6/30/16

FG1135-03 MBS 7.5mm SC FG 5 D198 Axial Systems-JWing 102730 4/30/16

FG1135-03 MBS 7.5mm SC FG 1 D198 Axial Systems-JWing 102807 5/31/16

FG1135-03 MBS 7.5mm SC FG 1 D199 Innotek - K. Nevel 101258 1/31/15




FG1135-03 MBS 7.5mm SC FG 1 D200 2K Spine -T Schultz 102730 4/30/16

FG1135-03 MBS 7.5mm SC FG 3 D203 AG Distribu-AGuidacan 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 3 D206 Patton Medical-APatton 103072 9/28/16

FG1135-03 MBS 7.5mm SC FG 2 D208 Team Harmony-SWilson 103072 9/28/16

FG1135-03 MBS 7.5mm SC FG 2 D210 Elite Spine-PHarmon 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 2 D212 Sand Medical-REstrada 102909 6/30/16





Page 27 or 54


FG1135-03 MBS 7.5mm SC FG 1 D217 Freestone Med-JDoub 101698 7/31/15



FG1135-03 MBS 7.5mm SC FG 1 D220 Northstate-EAlexander 101537 5/31/15

FG1135-03 MBS 7.5mm SC FG 2 D220 Northstate-EAlexander 102942 7/28/16

FG1135-03 MBS 7.5mm SC FG 3 D222 Northstate-SAllen 101225 12/31/14

FG1135-03 MBS 7.5mm SC FG 1 D222 Northstate-SAllen 102642 2/29/16

FG1135-03 MBS 7.5mm SC FG 2 D223 KNS-JPugliese 101698 7/31/15




FG1135-03 MBS 7.5mm SC FG 4 D224 Northstate-TCoppedge 101384 3/31/15

FG1135-03 MBS 7.5mm SC FG 3 D224 Northstate-TCoppedge 101537 5/31/15

FG1135-03 MBS 7.5mm SC FG 1 D225 Advanced Medical-KMorin 102443 12/31/15




FG1135-03 MBS 7.5mm SC FG 1 D227 True North-DBrown 102942 7/28/16

FG1135-03 MBS 7.5mm SC FG 3 D227 True North-DBrown 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D229 Kevin Kearney 101303 1/31/15

FG1135-03 MBS 7.5mm SC FG 1 D229 Kevin Kearney 102309 11/30/15

FG1135-03 MBS 7.5mm SC FG 1 D230 Touchstone-RWeaver 101698 7/31/15



FG1135-03 MBS 7.5mm SC FG 1 D231 QB Medical-PParsons 101384 3/31/15





FG1135-03 MBS 7.5mm SC FG 1 D240 7 Spine Group-THenderson 101384 3/31/15

FG1135-03 MBS 7.5mm SC FG 1 D240 7 Spine Group-THenderson 101457 4/30/15

FG1135-03 MBS 7.5mm SC FG 1 D241 Corvus Med-JeUnderwood 101698 7/31/15



FG1135-03 MBS 7.5mm SC FG 2 D242 Elite Spine-BBooker 103035 8/28/16

FG1135-03 MBS 7.5mm SC FG 1 D242 Elite Spine-BBooker 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D243 Corvus Medical-TKline 102443 12/31/15




FG1135-03 MBS 7.5mm SC FG 2 D245 Jennifer Wyatt 102642 2/29/16

FG1135-03 MBS 7.5mm SC FG 1 D245 Jennifer Wyatt 102730 4/30/16

FG1135-03 MBS 7.5mm SC FG 2 D248 CLIP MEDICAL - DUBAI 102537 1/31/16

FG1135-03 MBS 7.5mm SC FG 1 D252 SPINE NET - GERMANY 102642 2/29/16

FG1135-03 MBS 7.5mm SC FG 1 D255 A2 MEDICAL 102195 10/31/15



FG1135-03 MBS 7.5mm SC FG 1 D260 STIRLING SURGICAL - CURT 102642 2/29/16



FG1135-03 MBS 7.5mm SC FG 1 D268 BLACK DIAMOND 101698 7/31/15




Page 28 or 54




FG1135-03 MBS 7.5mm SC FG 1 D270 Med Advise -DTighe 101537 5/31/15

FG1135-03 MBS 7.5mm SC FG 2 D270 Med Advise -DTighe 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D271 KML Medical - KCook 102537 1/31/16



FG1135-03 MBS 7.5mm SC FG 2 D274 CBR Medical-RDobson 101983 9/30/15

FG1135-03 MBS 7.5mm SC FG 2 D274 CBR Medical-RDobson 102807 5/31/16

FG1135-03 MBS 7.5mm SC FG 1 D275 Spinal Restorat- Lorenzo 102443 12/31/15

FG1135-03 MBS 7.5mm SC FG 1 D277 Sand Med-B Ledford 101258 1/31/15




FG1135-03 MBS 7.5mm SC FG 1 D280 Nicole Juber 102730 4/30/16

FG1135-03 MBS 7.5mm SC FG 1 D280 Nicole Juber 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D281 Susan Rains 102443 12/31/15

FG1135-03 MBS 7.5mm SC FG 3 D281 Susan Rains 103035 8/28/16

FG1135-03 MBS 7.5mm SC FG 1 D282 Weisz Surgical-PWeisz 101537 5/31/15



FG1135-03 MBS 7.5mm SC FG 1 D285 Touchstone-BDoyle 102942 7/28/16




FG1135-03 MBS 7.5mm SC FG 1 D286 Tolan Mai 102730 4/30/16



FG1135-03 MBS 7.5mm SC FG 1 D290 IoliteMedical-PGeiger 102730 4/30/16

FG1135-03 MBS 7.5mm SC FG 2 D290 IoliteMedical-PGeiger 103035 8/28/16

FG1135-03 MBS 7.5mm SC FG 2 D296 Denise Sheppard 102642 2/29/16



FG1135-03 MBS 7.5mm SC FG 1 D297 Synergy Surgical 102807 5/31/16




FG1135-03 MBS 7.5mm SC FG 1 D298 Emmerson Med. -THamilton 102942 7/28/16

FG1135-03 MBS 7.5mm SC FG 2 d298 Emmerson Med. -THamilton 103072 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D298 Emmerson Med. -THamilton 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D299 Innotek/Moore Med CZeise 102309 11/30/15

FG1135-03 MBS 7.5mm SC FG 2 D299 Innotek/Moore Med CZeise 102909 6/30/16

FG1135-03 MBS 7.5mm SC FG 2 D300 Medical Innovation-RMaly 103072 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D301 Elite Spine-DBalsamo 102807 5/31/16

FG1135-03 MBS 7.5mm SC FG 2 D301 Elite Spine-DBalsamo 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 3 D307 Synergy Surgical-SKlein 102730 4/30/16



FG1135-03 MBS 7.5mm SC FG 1 D310 Resurrection A. Gratsias 101842 8/31/15






Page 29 or 54


FG1135-03 MBS 7.5mm SC FG 1 D311 Minivasive - Chris Rutt 102807 5/31/16

FG1135-03 MBS 7.5mm SC FG 1 D311 Minivasive - Chris Rutt 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D312 HEIDI THOMPSON -PER DIEM 102909 6/30/16

FG1135-03 MBS 7.5mm SC FG 2 D315 PAL Medical - M. Balleux 103035 8/28/16

FG1135-03 MBS 7.5mm SC FG 1 D316 Elite Spine CA - AGarcia 102309 11/30/15



FG1135-03 MBS 7.5mm SC FG 1 D317 Innotek Medical - TMoore 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 2 D318 Fidelis Surgical - Ligon 103035 8/28/16

FG1135-03 MBS 7.5mm SC FG 1 D320 Dominic D'Abate 102909 6/30/16

FG1135-03 MBS 7.5mm SC FG 1 D320 Dominic D'Abate 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 3 D321 Spinal Restorative- Lacy 103035 8/28/16

FG1135-03 MBS 7.5mm SC FG 1 D321 Spinal Restorative- Lacy 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 D322 Innotek - M. Swanson 102942 7/28/16

FG1135-03 MBS 7.5mm SC FG 3 D322 Innotek - M. Swanson 103072 9/28/16

FG1135-03 MBS 7.5mm SC FG 2 D328 Bahler - J. McNamara 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 2 iO-Loan1 iO-Loaner # 1 103130 9/28/16









FG1135-03 MBS 7.5mm SC FG 2 iO-Loan8 iO-Loan8 102443 12/31/15

FG1135-03 MBS 7.5mm SC FG 1 P103 Bob Cook 102136 10/31/15



FG1135-03 MBS 7.5mm SC FG 1 S157 JOHN DIETERLY 103035 8/28/16

FG1135-03 MBS 7.5mm SC FG 5 S157 JOHN DIETERLY 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 S163 KATRYN FERNALD 102730 4/30/16

FG1135-03 MBS 7.5mm SC FG 2 S163 KATRYN FERNALD 102909 6/30/16

FG1135-03 MBS 7.5mm SC FG 2 S169 MATT HART 102909 6/30/16

FG1135-03 MBS 7.5mm SC FG 1 S169 MATT HART 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 3 S175 STEVEN GREEN 102942 7/28/16

FG1135-03 MBS 7.5mm SC FG 1 S175 STEVEN GREEN 103035 8/28/16

FG1135-03 MBS 7.5mm SC FG 2 S176 SCOTT HEYMOSS 102942 7/28/16

FG1135-03 MBS 7.5mm SC FG 2 S180 Greg Pellatt 103035 8/28/16

FG1135-03 MBS 7.5mm SC FG 1 S180 Greg Pellatt 103130 9/28/16

FG1135-03 MBS 7.5mm SC FG 1 S185 MICHAEL DEFAZIO 102443 12/31/15

FG1135-03 MBS 7.5mm SC FG 2 S185 MICHAEL DEFAZIO 103072 9/28/16

FG1135-03 MBS 7.5mm SC FG 4 S186 KATIE MORONI 103035 8/28/16

FG1135-03 MBS 7.5mm SC FG 1 S192 ANDREW PINCKNEY 101457 4/30/15





FG1135-03 MBS 7.5mm SC FG 2 S193 APRIL SPILLANE 101842 8/31/15






Page 30 or 54


FG1135-03 MBS 7.5mm SC FG 1 S204 Tanner Michael Shaw 102942 7/28/16

FG1135-03 MBS 7.5mm SC FG 1 S204 Tanner Michael Shaw 103035 8/28/16

FG1135-03 MBS 7.5mm SC FG 1 S207 PAT FORDE 101698 7/31/15

FG1135-04 MBS 10mm SC FG 48 180 SHIPPING TO RALEIGH 103131 9/28/16

FG1135-04 MBS 10mm SC FG 2 301 N. CAROLINA HOLD 100804 7/31/14



FG1135-04 MBS 10mm SC FG 75 400 Sterile - SJ 103179

FG1135-04 MBS 10mm SC FG 1 501 N. CAROLINA FG 101385 3/31/15










FG1135-04 MBS 10mm SC FG 24 501 N. CAROLINA FG 103158

FG1135-04 MBS 10mm SC FG 1 700 Demo Products - SJ 101030

FG1135-04 MBS 10mm SC FG 1 700 Demo Products - SJ 101111 11/30/14


FG1135-04 MBS 10mm SC FG 1 D101 KNS Medical Distribution 101385 3/31/15





FG1135-04 MBS 10mm SC FG 1 D102 City Surgical 101458 4/30/15




FG1135-04 MBS 10mm SC FG 1 D107 Fusion Medical 101984 9/30/15



FG1135-04 MBS 10mm SC FG 1 D111 Davey Medical 101111 11/30/14




FG1135-04 MBS 10mm SC FG 1 D114 Medifuse Surgical, LLC. 101538 5/31/15



FG1135-04 MBS 10mm SC FG 2 D116 Greg Stenzel 101458 4/30/15

FG1135-04 MBS 10mm SC FG 1 D116 Greg Stenzel 102137 10/31/15

FG1135-04 MBS 10mm SC FG 2 D117 Brannon Wyatt 103036 8/28/16


FG1135-04 MBS 10mm SC FG 2 D118 Amanda Turko 101458 4/30/15

FG1135-04 MBS 10mm SC FG 1 D119 Align Alternatives 101345 2/28/15








Page 31 or 54




FG1135-04 MBS 10mm SC FG 1 D120 Choice Spine 101385 3/31/15


FG1135-04 MBS 10mm SC FG 2 D123 MetaGen 103098 6/28/16

FG1135-04 MBS 10mm SC FG 1 D125 Charles Pierce Martin 102885 6/30/16




FG1135-04 MBS 10mm SC FG 1 D126 Goalline Medical, LLC 102885 6/30/16



FG1135-04 MBS 10mm SC FG 1 D131 Duke Medical, LLC 101304 1/31/15

FG1135-04 MBS 10mm SC FG 2 D134 Advanced Medical SW 101180 12/31/14


FG1135-04 MBS 10mm SC FG 2 D137 BIOlympic Medical 102808 5/31/16



FG1135-04 MBS 10mm SC FG 2 D144 Innovative Surgical LLC. 102943 7/28/16

FG1135-04 MBS 10mm SC FG 1 D155 Minivasive - B. Manning 102943 7/28/16


FG1135-04 MBS 10mm SC FG 1 D167 MetaGen-SBrown 101226 12/31/14







FG1135-04 MBS 10mm SC FG 2 D174 KRP Medical-KCorrado 102943 7/28/16

FG1135-04 MBS 10mm SC FG 1 D176 Ross Medical-RTate 101385 3/31/15



FG1135-04 MBS 10mm SC FG 1 D177 Carolina Surgi-PTracy 101385 3/31/15





FG1135-04 MBS 10mm SC FG 1 D181 OrthoMed-MSalinas 102885 6/30/16


FG1135-04 MBS 10mm SC FG 1 D187 Biotech Solutions-JNalli 102310 11/30/15



FG1135-04 MBS 10mm SC FG 1 D188 INNOTEK-DTouhey 102943 7/28/16



FG1135-04 MBS 10mm SC FG 4 D191 Mesa Medical-SPutman 101030 10/31/14

FG1135-04 MBS 10mm SC FG 1 D194 Horse Creek Med-TOakes 101843 8/31/15

FG1135-04 MBS 10mm SC FG 2 D195 Med-Adv.-Faulkner/Benton 102885 6/30/16

FG1135-04 MBS 10mm SC FG 2 D195 Med-Adv.-Faulkner/Benton 103073 9/28/16

FG1135-04 MBS 10mm SC FG 3 D198 Axial Systems-JWing 102943 7/28/16

FG1135-04 MBS 10mm SC FG 1 D199 Innotek - K. Nevel 102885 6/30/16

FG1135-04 MBS 10mm SC FG 1 D199 Innotek - K. Nevel 102943 7/28/16



Page 32 or 54


FG1135-04 MBS 10mm SC FG 1 D200 2K Spine -T Schultz 101385 3/31/15

FG1135-04 MBS 10mm SC FG 1 D203 AG Distribu-AGuidacan 102731 4/30/16

FG1135-04 MBS 10mm SC FG 2 D203 AG Distribu-AGuidacan 102885 6/30/16

FG1135-04 MBS 10mm SC FG 1 D206 Patton Medical-APatton 101345 2/28/15



FG1135-04 MBS 10mm SC FG 1 D208 Team Harmony-SWilson 102538 1/31/16




FG1135-04 MBS 10mm SC FG 2 D210 Elite Spine-PHarmon 103098 6/28/16

FG1135-04 MBS 10mm SC FG 1 D212 Sand Medical-REstrada 102196 10/31/15



FG1135-04 MBS 10mm SC FG 1 D217 Freestone Med-JDoub 102048 9/30/15



FG1135-04 MBS 10mm SC FG 2 D222 Northstate-SAllen 101226 12/31/14


FG1135-04 MBS 10mm SC FG 1 D223 KNS-JPugliese 101345 2/28/15




FG1135-04 MBS 10mm SC FG 1 D224 Northstate-TCoppedge 101304 1/31/15




FG1135-04 MBS 10mm SC FG 3 D225 Advanced Medical-KMorin 101345 2/28/15


FG1135-04 MBS 10mm SC FG 1 D227 True North-DBrown 102885 6/30/16




FG1135-04 MBS 10mm SC FG 2 D229 Kevin Kearney 101304 1/31/15


FG1135-04 MBS 10mm SC FG 1 D230 Touchstone-RWeaver 101699 7/31/15





FG1135-04 MBS 10mm SC FG 4 D231 QB Medical-PParsons 101180 12/31/14




FG1135-04 MBS 10mm SC FG 2 D240 7 Spine Group-THenderson 101458 4/30/15

FG1135-04 MBS 10mm SC FG 1 D241 Corvus Med-JeUnderwood 101385 3/31/15



FG1135-04 MBS 10mm SC FG 1 D242 Elite Spine-BBooker 102310 11/30/15






Page 33 or 54


FG1135-04 MBS 10mm SC FG 1 D243 Corvus Medical-TKline 101984 9/30/15



FG1135-04 MBS 10mm SC FG 2 D245 Jennifer Wyatt 103073 9/28/16

FG1135-04 MBS 10mm SC FG 2 D248 CLIP MEDICAL - DUBAI 101843 8/31/15

FG1135-04 MBS 10mm SC FG 2 D252 SPINE NET - GERMANY 102538 1/31/16

FG1135-04 MBS 10mm SC FG 3 D255 A2 MEDICAL 102943 7/28/16

FG1135-04 MBS 10mm SC FG 2 D260 STIRLING SURGICAL - CURT 102885 6/30/16


FG1135-04 MBS 10mm SC FG 1 D268 BLACK DIAMOND 101843 8/31/15




FG1135-04 MBS 10mm SC FG 2 D270 Med Advise -DTighe 102808 5/31/16


FG1135-04 MBS 10mm SC FG 2 D271 KML Medical - KCook 102196 10/31/15



FG1135-04 MBS 10mm SC FG 3 D274 CBR Medical-RDobson 101843 8/31/15

FG1135-04 MBS 10mm SC FG 4 D275 Spinal Restorat- Lorenzo 101843 8/31/15

FG1135-04 MBS 10mm SC FG 3 D277 Sand Med-B Ledford 101984 9/30/15

FG1135-04 MBS 10mm SC FG 3 D280 Nicole Juber 102137 10/31/15

FG1135-04 MBS 10mm SC FG 2 D281 Susan Rains 102137 10/31/15

FG1135-04 MBS 10mm SC FG 1 D282 Weisz Surgical-PWeisz 102196 10/31/15



FG1135-04 MBS 10mm SC FG 2 D285 Touchstone-BDoyle 102731 4/30/16



FG1135-04 MBS 10mm SC FG 1 D286 Tolan Mai 102808 5/31/16


FG1135-04 MBS 10mm SC FG 2 D290 IoliteMedical-PGeiger 102444 12/31/15

FG1135-04 MBS 10mm SC FG 1 D296 Denise Sheppard 102538 1/31/16



FG1135-04 MBS 10mm SC FG 1 D297 Synergy Surgical 102943 7/28/16


FG1135-04 MBS 10mm SC FG 1 D298 Emmerson Med. -THamilton 102943 7/28/16


FG1135-04 MBS 10mm SC FG 2 D299 Innotek/Moore Med CZeise 102731 4/30/16

FG1135-04 MBS 10mm SC FG 2 D300 Medical Innovation-RMaly 103036 8/28/16

FG1135-04 MBS 10mm SC FG 2 D301 Elite Spine-DBalsamo 102538 1/31/16

FG1135-04 MBS 10mm SC FG 1 D307 Synergy Surgical-SKlein 102048 9/30/15


FG1135-04 MBS 10mm SC FG 1 D310 Resurrection A. Gratsias 101226 12/31/14




FG1135-04 MBS 10mm SC FG 1 D311 Minivasive - Chris Rutt 102808 5/31/16



FG1135-04 MBS 10mm SC FG 2 D315 PAL Medical - M. Balleux 102943 7/28/16



Page 34 or 54


FG1135-04 MBS 10mm SC FG 1 D316 Elite Spine CA - AGarcia 102943 7/28/16


FG1135-04 MBS 10mm SC FG 2 D317 Innotek Medical - TMoore 102885 6/30/16

FG1135-04 MBS 10mm SC FG 2 D318 Fidelis Surgical - Ligon 103073 9/28/16

FG1135-04 MBS 10mm SC FG 1 D320 Dominic D'Abate 101699 7/31/15

FG1135-04 MBS 10mm SC FG 4 D321 Spinal Restorative- Lacy 103073 9/28/16

FG1135-04 MBS 10mm SC FG 1 D322 Innotek - M. Swanson 102943 7/28/16


FG1135-04 MBS 10mm SC FG 1 D324 Tyler Unzicker 103036 8/28/16

FG1135-04 MBS 10mm SC FG 1 iO-Loan1 iO-Loaner # 1 102538 1/31/16











FG1135-04 MBS 10mm SC FG 2 iO-Loan8 iO-Loan8 102444 12/31/15

FG1135-04 MBS 10mm SC FG 1 P103 Bob Cook 101385 3/31/15



FG1135-04 MBS 10mm SC FG 3 S157 JOHN DIETERLY 102943 7/28/16


FG1135-04 MBS 10mm SC FG 1 S163 KATRYN FERNALD 102137 10/31/15



FG1135-04 MBS 10mm SC FG 1 S169 MATT HART 102444 12/31/15



FG1135-04 MBS 10mm SC FG 2 S175 STEVEN GREEN 102943 7/28/16


FG1135-04 MBS 10mm SC FG 1 S176 SCOTT HEYMOSS 101699 7/31/15




FG1135-04 MBS 10mm SC FG 2 S180 Greg Pellatt 103036 8/28/16

FG1135-04 MBS 10mm SC FG 1 S185 MICHAEL DEFAZIO 102444 12/31/15



FG1135-04 MBS 10mm SC FG 1 S186 KATIE MORONI 102943 7/28/16

FG1135-04 MBS 10mm SC FG 2 S186 KATIE MORONI 103073 9/28/16

FG1135-04 MBS 10mm SC FG 1 S192 ANDREW PINCKNEY 101385 3/31/15





FG1135-04 MBS 10mm SC FG 1 S193 APRIL SPILLANE 101180 12/31/14





Page 35 or 54



FG1135-04 MBS 10mm SC FG 1 S204 Tanner Michael Shaw 102538 1/31/16





FG1135-04 MBS 10mm SC FG 1 S207 PAT FORDE 101345 2/28/15












FG1135-05 MBS 12mm SC FG 16 501 N. CAROLINA FG 103159












FG1135-05 MBS 12mm SC FG 1 D118 Amanda Turko 101346 2/28/15











FG1135-05 MBS 12mm SC FG 1 D155 Minivasive - B. Manning 103159


FG1135-05 MBS 12mm SC FG 1 D167 MetaGen-SBrown 103159

FG1135-05 MBS 12mm SC FG 1 D174 KRP Medical-KCorrado 102809 5/31/16







FG1135-05 MBS 12mm SC FG 1 D194 Horse Creek Med-TOakes 101094 11/30/14



Page 36 or 54







FG1135-05 MBS 12mm SC FG 2 D210 Elite Spine-PHarmon 103159




FG1135-05 MBS 12mm SC FG 1 D220 Northstate-EAlexander 101259 1/31/15










FG1135-05 MBS 12mm SC FG 1 D240 7 Spine Group-THenderson 101346 2/28/15





FG1135-05 MBS 12mm SC FG 1 D248 CLIP MEDICAL - DUBAI 102445 12/31/15

FG1135-05 MBS 12mm SC FG 1 D252 SPINE NET - GERMANY 102539 1/31/16

FG1135-05 MBS 12mm SC FG 2 D255 A2 MEDICAL 103094 3/28/16




FG1135-05 MBS 12mm SC FG 1 D281 Susan Rains 101259 1/31/15









FG1135-05 MBS 12mm SC FG 1 D299 Innotek/Moore Med CZeise 102311 11/30/15

FG1135-05 MBS 12mm SC FG 1 D300 Medical Innovation-RMaly 103094 3/28/16

FG1135-05 MBS 12mm SC FG 1 D301 Elite Spine-DBalsamo 102445 12/31/15

FG1135-05 MBS 12mm SC FG 1 D304 CREAMER MEDICAL -Denmark 102539 1/31/16








FG1135-05 MBS 12mm SC FG 1 D315 PAL Medical - M. Balleux 102809 5/31/16




Page 37 or 54


FG1135-05 MBS 12mm SC FG 1 D317 Innotek Medical - TMoore 102732 4/30/16

FG1135-05 MBS 12mm SC FG 1 D318 Fidelis Surgical - Ligon 103094 3/28/16

FG1135-05 MBS 12mm SC FG 1 D320 Dominic D'Abate 103095 6/28/16

FG1135-05 MBS 12mm SC FG 1 D321 Spinal Restorative- Lacy 101539 5/31/15


FG1135-05 MBS 12mm SC FG 1 D324 Tyler Unzicker 101700 7/31/15








FG1135-05 MBS 12mm SC FG 1 iO-Loan8 iO-Loan8 101700 7/31/15


















FG1378-01 iO-Wire FG 8 301 N. CAROLINA HOLD 100795 7/31/14



FG1378-01 iO-Wire FG 5 500 Finished Goods - iOF -SJ 102867

FG1378-01 iO-Wire FG 2 501 N. CAROLINA FG 102670 3/31/16

FG1378-01 iO-Wire FG 16 501 N. CAROLINA FG 103069 9/28/16

FG1378-01 iO-Wire FG 29 700 Demo Products - SJ 100760



FG1378-01 iO-Wire FG 1 700 Demo Products - SJ 102670 3/31/16

FG1378-01 iO-Wire FG 1 D101 KNS Medical Distribution 102670 3/31/16

FG1378-01 iO-Wire FG 1 D101 KNS Medical Distribution 103069 9/28/16

FG1378-01 iO-Wire FG 1 D102 City Surgical 101988 9/30/15




FG1378-01 iO-Wire FG 2 D105 Inline Spine 101988 9/30/15

FG1378-01 iO-Wire FG 3 D105 Inline Spine 102561 1/31/16

FG1378-01 iO-Wire FG 4 D107 Fusion Medical 102867 5/31/16

FG1378-01 iO-Wire FG 2 D111 Davey Medical 102867 5/31/16

FG1378-01 iO-Wire FG 4 D114 Medifuse Surgical, LLC. 102770 4/30/16



Page 38 or 54


FG1378-01 iO-Wire FG 3 D116 Greg Stenzel 102770 4/30/16

FG1378-01 iO-Wire FG 1 D117 Brannon Wyatt 102561 1/31/16




FG1378-01 iO-Wire FG 3 D118 Amanda Turko 102867 5/31/16

FG1378-01 iO-Wire FG 5 D118 Amanda Turko 103069 9/28/16

FG1378-01 iO-Wire FG 3 D119 Align Alternatives 102670 3/31/16



FG1378-01 iO-Wire FG 2 D120 Choice Spine 101407 3/31/15

FG1378-01 iO-Wire FG 11 D123 MetaGen 103069 9/28/16

FG1378-01 iO-Wire FG 2 D125 Charles Pierce Martin 102561 1/31/16

FG1378-01 iO-Wire FG 1 D125 Charles Pierce Martin 102867 5/31/16

FG1378-01 iO-Wire FG 1 D126 Goalline Medical, LLC 101307 1/31/15

FG1378-01 iO-Wire FG 1 D126 Goalline Medical, LLC 102770 4/30/16

FG1378-01 iO-Wire FG 1 D131 Duke Medical, LLC 101407 3/31/15

FG1378-01 iO-Wire FG 1 D131 Duke Medical, LLC 102436 12/31/15

FG1378-01 iO-Wire FG 1 D132 Axial Systems 101074 11/30/14

FG1378-01 iO-Wire FG 4 D134 Advanced Medical SW 102670 3/31/16

FG1378-01 iO-Wire FG 9 D137 BIOlympic Medical 102867 5/31/16

FG1378-01 iO-Wire FG 8 D137 BIOlympic Medical 103069 9/28/16

FG1378-01 iO-Wire FG 5 D144 Innovative Surgical LLC. 102867 5/31/16

FG1378-01 iO-Wire FG 4 D155 Minivasive - B. Manning 102770 4/30/16

FG1378-01 iO-Wire FG 2 D167 MetaGen-SBrown 103069 9/28/16

FG1378-01 iO-Wire FG 2 D174 KRP Medical-KCorrado 102867 5/31/16

FG1378-01 iO-Wire FG 2 D176 Ross Medical-RTate 103069 9/28/16

FG1378-01 iO-Wire FG 4 D177 Carolina Surgi-PTracy 102867 5/31/16

FG1378-01 iO-Wire FG 2 D181 OrthoMed-MSalinas 102561 1/31/16

FG1378-01 iO-Wire FG 1 D187 Biotech Solutions-JNalli 101407 3/31/15

FG1378-01 iO-Wire FG 5 D188 INNOTEK-DTouhey 102867 5/31/16

FG1378-01 iO-Wire FG 3 D191 Mesa Medical-SPutman 100795 7/31/14

FG1378-01 iO-Wire FG 3 D194 Horse Creek Med-TOakes 102670 3/31/16

FG1378-01 iO-Wire FG 1 D195 Med-Adv.-Faulkner/Benton 102770 4/30/16

FG1378-01 iO-Wire FG 2 D198 Axial Systems-JWing 102670 3/31/16

FG1378-01 iO-Wire FG 2 D198 Axial Systems-JWing 102867 5/31/16

FG1378-01 iO-Wire FG 2 D203 AG Distribu-AGuidacan 101493 4/30/15



FG1378-01 iO-Wire FG 4 D206 Patton Medical-APatton 102670 3/31/16

FG1378-01 iO-Wire FG 1 D208 Team Harmony-SWilson 102561 1/31/16

FG1378-01 iO-Wire FG 4 D208 Team Harmony-SWilson 102867 5/31/16

FG1378-01 iO-Wire FG 2 D210 Elite Spine-PHarmon 103069 9/28/16

FG1378-01 iO-Wire FG 1 D212 Sand Medical-REstrada 102770 4/30/16

FG1378-01 iO-Wire FG 1 D212 Sand Medical-REstrada 102867 5/31/16

FG1378-01 iO-Wire FG 2 D217 Freestone Med-JDoub 101988 9/30/15

FG1378-01 iO-Wire FG 1 D217 Freestone Med-JDoub 102770 4/30/16

FG1378-01 iO-Wire FG 3 D220 Northstate-EAlexander 101307 1/31/15

FG1378-01 iO-Wire FG 1 D222 Northstate-SAllen 101307 1/31/15

FG1378-01 iO-Wire FG 1 D222 Northstate-SAllen 102436 12/31/15

FG1378-01 iO-Wire FG 2 D223 KNS-JPugliese 102867 5/31/16

FG1378-01 iO-Wire FG 1 D223 KNS-JPugliese 103069 9/28/16



Page 39 or 54


FG1378-01 iO-Wire FG 2 D224 Northstate-TCoppedge 101407 3/31/15

FG1378-01 iO-Wire FG 2 D224 Northstate-TCoppedge 102867 5/31/16

FG1378-01 iO-Wire FG 1 D225 Advanced Medical-KMorin 102670 3/31/16

FG1378-01 iO-Wire FG 1 D227 True North-DBrown 102670 3/31/16



FG1378-01 iO-Wire FG 3 D229 Kevin Kearney 102561 1/31/16

FG1378-01 iO-Wire FG 1 D230 Touchstone-RWeaver 102436 12/31/15

FG1378-01 iO-Wire FG 2 D230 Touchstone-RWeaver 102561 1/31/16

FG1378-01 iO-Wire FG 4 D231 QB Medical-PParsons 101988 9/30/15

FG1378-01 iO-Wire FG 3 D231 QB Medical-PParsons 102561 1/31/16

FG1378-01 iO-Wire FG 1 D240 7 Spine Group-THenderson 101407 3/31/15

FG1378-01 iO-Wire FG 2 D241 Corvus Med-JeUnderwood 101988 9/30/15

FG1378-01 iO-Wire FG 5 D242 Elite Spine-BBooker 102867 5/31/16

FG1378-01 iO-Wire FG 1 D243 Corvus Medical-TKline 102436 12/31/15

FG1378-01 iO-Wire FG 3 D243 Corvus Medical-TKline 102867 5/31/16

FG1378-01 iO-Wire FG 1 D245 Jennifer Wyatt 101851 8/31/15

FG1378-01 iO-Wire FG 1 D248 CLIP MEDICAL - DUBAI 101988 9/30/15

FG1378-01 iO-Wire FG 1 D252 SPINE NET - GERMANY 102670 3/31/16

FG1378-01 iO-Wire FG 1 D255 A2 MEDICAL 102246 11/30/15

FG1378-01 iO-Wire FG 2 D255 A2 MEDICAL 102436 12/31/15

FG1378-01 iO-Wire FG 2 D260 STIRLING SURGICAL - CURT 101851 8/31/15

FG1378-01 iO-Wire FG 1 D268 BLACK DIAMOND 101183 12/31/14

FG1378-01 iO-Wire FG 1 D268 BLACK DIAMOND 102246 11/30/15

FG1378-01 iO-Wire FG 1 D270 Med Advise -DTighe 103069 9/28/16

FG1378-01 iO-Wire FG 1 D271 KML Medical - KCook 102246 11/30/15

FG1378-01 iO-Wire FG 1 D271 KML Medical - KCook 102561 1/31/16

FG1378-01 iO-Wire FG 2 D274 CBR Medical-RDobson 101851 8/31/15

FG1378-01 iO-Wire FG 1 D275 Spinal Restorat- Lorenzo 102246 11/30/15

FG1378-01 iO-Wire FG 1 D277 Sand Med-B Ledford 101988 9/30/15

FG1378-01 iO-Wire FG 1 D280 Nicole Juber 101307 1/31/15

FG1378-01 iO-Wire FG 2 D281 Susan Rains 102670 3/31/16

FG1378-01 iO-Wire FG 3 D281 Susan Rains 102770 4/30/16

FG1378-01 iO-Wire FG 4 D282 Weisz Surgical-PWeisz 102867 5/31/16

FG1378-01 iO-Wire FG 1 D285 Touchstone-BDoyle 102867 5/31/16

FG1378-01 iO-Wire FG 1 D285 Touchstone-BDoyle 103069 9/28/16

FG1378-01 iO-Wire FG 2 D286 Tolan Mai 102561 1/31/16



FG1378-01 iO-Wire FG 2 D290 IoliteMedical-PGeiger 101493 4/30/15

FG1378-01 iO-Wire FG 1 D290 IoliteMedical-PGeiger 102770 4/30/16

FG1378-01 iO-Wire FG 1 D296 Denise Sheppard 102561 1/31/16

FG1378-01 iO-Wire FG 3 D296 Denise Sheppard 102867 5/31/16

FG1378-01 iO-Wire FG 2 D297 Synergy Surgical 102770 4/30/16

FG1378-01 iO-Wire FG 2 D297 Synergy Surgical 102867 5/31/16

FG1378-01 iO-Wire FG 1 D298 Emmerson Med. -THamilton 102436 12/31/15

FG1378-01 iO-Wire FG 4 D299 Innotek/Moore Med CZeise 102770 4/30/16

FG1378-01 iO-Wire FG 1 D299 Innotek/Moore Med CZeise 103069 9/28/16

FG1378-01 iO-Wire FG 2 D300 Medical Innovation-RMaly 102770 4/30/16

FG1378-01 iO-Wire FG 2 D301 Elite Spine-DBalsamo 102436 12/31/15

FG1378-01 iO-Wire FG 5 D301 Elite Spine-DBalsamo 102670 3/31/16

FG1378-01 iO-Wire FG 4 D307 Synergy Surgical-SKlein 102436 12/31/15



Page 40 or 54


FG1378-01 iO-Wire FG 2 D309 Central Valley -R. Green 102867 5/31/16

FG1378-01 iO-Wire FG 1 D310 Resurrection A. Gratsias 101074 11/30/14




FG1378-01 iO-Wire FG 4 D311 Minivasive - Chris Rutt 102436 12/31/15

FG1378-01 iO-Wire FG 2 D315 PAL Medical - M. Balleux 102867 5/31/16

FG1378-01 iO-Wire FG 6 D316 Elite Spine CA - AGarcia 103069 9/28/16

FG1378-01 iO-Wire FG 1 D317 Innotek Medical - TMoore 102561 1/31/16

FG1378-01 iO-Wire FG 1 D317 Innotek Medical - TMoore 102867 5/31/16

FG1378-01 iO-Wire FG 2 D318 Fidelis Surgical - Ligon 103069 9/28/16

FG1378-01 iO-Wire FG 1 D320 Dominic D'Abate 101493 4/30/15

FG1378-01 iO-Wire FG 1 D320 Dominic D'Abate 102867 5/31/16

FG1378-01 iO-Wire FG 2 D321 Spinal Restorative- Lacy 103069 9/28/16

FG1378-01 iO-Wire FG 2 D322 Innotek - M. Swanson 101851 8/31/15

FG1378-01 iO-Wire FG 1 D322 Innotek - M. Swanson 102867 5/31/16

FG1378-01 iO-Wire FG 1 D324 Tyler Unzicker 102436 12/31/15

FG1378-01 iO-Wire FG 1 D324 Tyler Unzicker 102561 1/31/16

FG1378-01 iO-Wire FG 1 iO-Loan1 iO-Loaner # 1 102770 4/30/16









FG1378-01 iO-Wire FG 2 iO-Loan8 iO-Loan8 102561 1/31/16

FG1378-01 iO-Wire FG 1 P103 Bob Cook 102867 5/31/16

FG1378-01 iO-Wire FG 1 P103 Bob Cook 103069 9/28/16

FG1378-01 iO-Wire FG 1 S157 JOHN DIETERLY 101407 3/31/15

FG1378-01 iO-Wire FG 3 S157 JOHN DIETERLY 102867 5/31/16

FG1378-01 iO-Wire FG 1 S163 KATRYN FERNALD 102246 11/30/15

FG1378-01 iO-Wire FG 1 S163 KATRYN FERNALD 102670 3/31/16

FG1378-01 iO-Wire FG 4 S169 MATT HART 102867 5/31/16

FG1378-01 iO-Wire FG 1 S169 MATT HART 103069 9/28/16

FG1378-01 iO-Wire FG 1 S175 STEVEN GREEN 101407 3/31/15

FG1378-01 iO-Wire FG 1 S175 STEVEN GREEN 102436 12/31/15

FG1378-01 iO-Wire FG 5 S176 SCOTT HEYMOSS 102246 11/30/15

FG1378-01 iO-Wire FG 1 S180 Greg Pellatt 101851 8/31/15




FG1378-01 iO-Wire FG 3 S185 MICHAEL DEFAZIO 102770 4/30/16

FG1378-01 iO-Wire FG 1 S186 KATIE MORONI 103069 9/28/16

FG1378-01 iO-Wire FG 6 S192 ANDREW PINCKNEY 102867 5/31/16

FG1378-01 iO-Wire FG 5 S193 APRIL SPILLANE 102770 4/30/16

FG1378-01 iO-Wire FG 1 S204 Tanner Michael Shaw 101074 11/30/14




FG1378-01 iO-Wire FG 2 S207 PAT FORDE 101407 3/31/15



Page 41 or 54


FG1496-01 iO-Tome 10mm FG 6 301 N. CAROLINA HOLD 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 2 501 N. CAROLINA FG 102158 10/31/15





FG1496-01 iO-Tome 10mm FG 4 D101 KNS Medical Distribution 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D101 KNS Medical Distribution 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 1 D102 City Surgical 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D102 City Surgical 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 2 D103 Bahler Medical 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D114 Medifuse Surgical, LLC. 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D119 Align Alternatives 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 3 D125 Charles Pierce Martin 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D131 Duke Medical, LLC 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 1 D137 BIOlympic Medical 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D174 KRP Medical-KCorrado 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 2 D176 Ross Medical-RTate 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D176 Ross Medical-RTate 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 3 D188 INNOTEK-DTouhey 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 3 D188 INNOTEK-DTouhey 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 2 D203 AG Distribu-AGuidacan 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 1 D203 AG Distribu-AGuidacan 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 2 D224 Northstate-TCoppedge 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D241 Corvus Med-JeUnderwood 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D243 Corvus Medical-TKline 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D271 KML Medical - KCook 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D275 Spinal Restorat- Lorenzo 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D282 Weisz Surgical-PWeisz 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 1 D282 Weisz Surgical-PWeisz 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 2 D286 Tolan Mai 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 6 D290 IoliteMedical-PGeiger 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 2 D297 Synergy Surgical 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D298 Emmerson Med. -THamilton 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D307 Synergy Surgical-SKlein 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 3 D307 Synergy Surgical-SKlein 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 2 D309 Central Valley -R. Green 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 D310 Resurrection A. Gratsias 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 3 D316 Elite Spine CA - AGarcia 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 2 D318 Fidelis Surgical - Ligon 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 2 D322 Innotek - M. Swanson 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 5 S157 JOHN DIETERLY 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 S163 KATRYN FERNALD 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 3 S169 MATT HART 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 1 S169 MATT HART 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 4 S175 STEVEN GREEN 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 3 S176 SCOTT HEYMOSS 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 3 S180 Greg Pellatt 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 4 S185 MICHAEL DEFAZIO 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 1 S186 KATIE MORONI 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 1 S186 KATIE MORONI 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 3 S192 ANDREW PINCKNEY 102158 10/31/15



Page 42 or 54


FG1496-01 iO-Tome 10mm FG 1 S192 ANDREW PINCKNEY 102247 11/30/15

FG1496-01 iO-Tome 10mm FG 3 S193 APRIL SPILLANE 102158 10/31/15

FG1496-01 iO-Tome 10mm FG 2 S204 Tanner Michael Shaw 102158 10/31/15

FG1496-03 iO-Tome 7.5mm FG 5 301 N. CAROLINA HOLD 102562 1/31/16

FG1496-03 iO-Tome 7.5mm FG 2 501 N. CAROLINA FG 102159 10/31/15







FG1496-03 iO-Tome 7.5mm FG 1 D101 KNS Medical Distribution 102159 10/31/15



FG1496-03 iO-Tome 7.5mm FG 5 D102 City Surgical 102248 11/30/15

FG1496-03 iO-Tome 7.5mm FG 1 D103 Bahler Medical 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 2 D114 Medifuse Surgical, LLC. 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 1 D119 Align Alternatives 102159 10/31/15



FG1496-03 iO-Tome 7.5mm FG 2 D125 Charles Pierce Martin 102248 11/30/15

FG1496-03 iO-Tome 7.5mm FG 1 D131 Duke Medical, LLC 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 1 D137 BIOlympic Medical 102248 11/30/15

FG1496-03 iO-Tome 7.5mm FG 2 D174 KRP Medical-KCorrado 102625 2/29/16

FG1496-03 iO-Tome 7.5mm FG 1 D176 Ross Medical-RTate 102248 11/30/15

FG1496-03 iO-Tome 7.5mm FG 1 D176 Ross Medical-RTate 102562 1/31/16

FG1496-03 iO-Tome 7.5mm FG 3 D188 INNOTEK-DTouhey 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 4 D188 INNOTEK-DTouhey 102562 1/31/16

FG1496-03 iO-Tome 7.5mm FG 3 D203 AG Distribu-AGuidacan 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 1 D203 AG Distribu-AGuidacan 102625 2/29/16

FG1496-03 iO-Tome 7.5mm FG 1 D223 KNS-JPugliese 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 1 D224 Northstate-TCoppedge 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 1 D241 Corvus Med-JeUnderwood 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 1 D243 Corvus Medical-TKline 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 1 D243 Corvus Medical-TKline 102248 11/30/15

FG1496-03 iO-Tome 7.5mm FG 2 D271 KML Medical - KCook 102625 2/29/16

FG1496-03 iO-Tome 7.5mm FG 2 D275 Spinal Restorat- Lorenzo 102625 2/29/16

FG1496-03 iO-Tome 7.5mm FG 1 D282 Weisz Surgical-PWeisz 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 1 D286 Tolan Mai 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 2 D290 IoliteMedical-PGeiger 102248 11/30/15

FG1496-03 iO-Tome 7.5mm FG 5 D290 IoliteMedical-PGeiger 102625 2/29/16

FG1496-03 iO-Tome 7.5mm FG 2 D297 Synergy Surgical 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 2 D307 Synergy Surgical-SKlein 102159

FG1496-03 iO-Tome 7.5mm FG 3 D307 Synergy Surgical-SKlein 102248 11/30/15

FG1496-03 iO-Tome 7.5mm FG 1 D309 Central Valley -R. Green 102248 11/30/15

FG1496-03 iO-Tome 7.5mm FG 1 D309 Central Valley -R. Green 102625 2/29/16

FG1496-03 iO-Tome 7.5mm FG 2 D310 Resurrection A. Gratsias 102159

FG1496-03 iO-Tome 7.5mm FG 2 D316 Elite Spine CA - AGarcia 102636 2/29/16

FG1496-03 iO-Tome 7.5mm FG 2 D318 Fidelis Surgical - Ligon 102771 4/30/16

FG1496-03 iO-Tome 7.5mm FG 3 D322 Innotek - M. Swanson 102159

FG1496-03 iO-Tome 7.5mm FG 2 S157 JOHN DIETERLY 102159 10/31/15




Page 43 or 54



FG1496-03 iO-Tome 7.5mm FG 2 S163 KATRYN FERNALD 102562 1/31/16

FG1496-03 iO-Tome 7.5mm FG 1 S169 MATT HART 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 4 S175 STEVEN GREEN 102562 1/31/16

FG1496-03 iO-Tome 7.5mm FG 3 S176 SCOTT HEYMOSS 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 3 S180 Greg Pellatt 102636 2/29/16

FG1496-03 iO-Tome 7.5mm FG 5 S185 MICHAEL DEFAZIO 102248 11/30/15

FG1496-03 iO-Tome 7.5mm FG 3 S192 ANDREW PINCKNEY 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 1 S192 ANDREW PINCKNEY 102625 2/29/16

FG1496-03 iO-Tome 7.5mm FG 1 S193 APRIL SPILLANE 102248 11/30/15

FG1496-03 iO-Tome 7.5mm FG 1 S193 APRIL SPILLANE 102625 2/29/16

FG1496-03 iO-Tome 7.5mm FG 1 S204 Tanner Michael Shaw 102159 10/31/15

FG1496-03 iO-Tome 7.5mm FG 1 S204 Tanner Michael Shaw 102248 11/30/15

FG1577 iO-N Adapter FG 1 501 N. CAROLINA FG 100813






FG1577 iO-N Adapter FG 1 700 Demo Products - SJ 100323




FG1577 iO-N Adapter FG 1 D101 KNS Medical Distribution 101072

FG1577 iO-N Adapter FG 1 D117 Brannon Wyatt 102140

FG1577 iO-N Adapter FG 1 D117 Brannon Wyatt 102316

FG1577 iO-N Adapter FG 1 D119 Align Alternatives 101496

FG1577 iO-N Adapter FG 2 D134 Advanced Medical SW 100764

FG1577 iO-N Adapter FG 2 D155 Minivasive - B. Manning 101496

FG1577 iO-N Adapter FG 1 D167 MetaGen-SBrown 102140

FG1577 iO-N Adapter FG 1 D174 KRP Medical-KCorrado 102316

FG1577 iO-N Adapter FG 1 D200 2K Spine -T Schultz 101337

FG1577 iO-N Adapter FG 1 D210 Elite Spine-PHarmon 102140

FG1577 iO-N Adapter FG 1 D230 Touchstone-RWeaver 102316

FG1577 iO-N Adapter FG 2 D243 Corvus Medical-TKline 101072



FG1577 iO-N Adapter FG 2 D245 Jennifer Wyatt 100813

FG1577 iO-N Adapter FG 1 D255 A2 MEDICAL 102140

FG1577 iO-N Adapter FG 1 D260 STIRLING SURGICAL - CURT 101072

FG1577 iO-N Adapter FG 2 D262 JOINHANDS - HONG KONG 101337

FG1577 iO-N Adapter FG 1 D262 JOINHANDS - HONG KONG 101337

FG1577 iO-N Adapter FG 1 D271 KML Medical - KCook 102140

FG1577 iO-N Adapter FG 2 D285 Touchstone-BDoyle 102140

FG1577 iO-N Adapter FG 1 D285 Touchstone-BDoyle 102316

FG1577 iO-N Adapter FG 1 D286 Tolan Mai 102140

FG1577 iO-N Adapter FG 1 D290 IoliteMedical-PGeiger 100813

FG1577 iO-N Adapter FG 1 D291 BAARSurgical-JArthur 102316

FG1577 iO-N Adapter FG 1 D297 Synergy Surgical 100636

FG1577 iO-N Adapter FG 1 D298 Emmerson Med. -THamilton 102316

FG1577 iO-N Adapter FG 1 D299 Innotek/Moore Med CZeise 102140

FG1577 iO-N Adapter FG 1 D300 Medical Innovation-RMaly 100813



Page 44 or 54


FG1577 iO-N Adapter FG 1 D301 Elite Spine-DBalsamo 102316

FG1577 iO-N Adapter FG 1 D307 Synergy Surgical-SKlein 102316

FG1577 iO-N Adapter FG 2 D308 MEDVISION - MIDDLE EAST 102140

FG1577 iO-N Adapter FG 2 D310 Resurrection A. Gratsias 101496

FG1577 iO-N Adapter FG 1 D310 Resurrection A. Gratsias 102671

FG1577 iO-N Adapter FG 1 D315 PAL Medical - M. Balleux 102316

FG1577 iO-N Adapter FG 1 D316 Elite Spine CA - AGarcia 102671

FG1577 iO-N Adapter FG 1 D317 Innotek Medical - TMoore 101337

FG1577 iO-N Adapter FG 1 D318 Fidelis Surgical - Ligon 102671

FG1577 iO-N Adapter FG 1 D320 Dominic D'Abate 101496

FG1577 iO-N Adapter FG 1 D321 Spinal Restorative- Lacy 102671

FG1577 iO-N Adapter FG 1 D322 Innotek - M. Swanson 102671

FG1577 iO-N Adapter FG 1 D324 Tyler Unzicker 101496

FG1577 iO-N Adapter FG 1 iO-Loan1 iO-Loaner # 1 101496







FG1577 iO-N Adapter FG 1 iO-Loan8 iO-Loan8 102316

FG1577 iO-N Adapter FG 1 P103 Bob Cook 100813

FG1577 iO-N Adapter FG 1 S157 JOHN DIETERLY 101231



FG1577 iO-N Adapter FG 1 S163 KATRYN FERNALD 102140

FG1577 iO-N Adapter FG 2 S169 MATT HART 101337



FG1577 iO-N Adapter FG 1 S175 STEVEN GREEN 100323

FG1577 iO-N Adapter FG 1 S176 SCOTT HEYMOSS 101337

FG1577 iO-N Adapter FG 1 S180 Greg Pellatt 102671

FG1577 iO-N Adapter FG 1 S185 MICHAEL DEFAZIO 101337

FG1577 iO-N Adapter FG 1 S185 MICHAEL DEFAZIO 102316

FG1577 iO-N Adapter FG 1 S186 KATIE MORONI 101496

FG1577 iO-N Adapter FG 1 S200 CHUCK VESELITS 102140

FG1577 iO-N Adapter FG 1 S207 PAT FORDE 102316

FG1824-03 Contra Irrigation 119 180 SHIPPING TO RALEIGH 103150 9/28/16

FG1824-03 Contra Irrigation 2 301 N. CAROLINA HOLD 100794 7/31/14












FG1824-03 Contra Irrigation 69 400 Sterile - SJ 103172

FG1824-03 Contra Irrigation 1 501 N. CAROLINA FG 102694 3/31/16



Page 45 or 54




FG1824-03 Contra Irrigation 3 700 Demo Products - SJ 100601 4/30/14





FG1824-03 Contra Irrigation 5 D101 KNS Medical Distribution 102162 10/31/15

FG1824-03 Contra Irrigation 1 D101 KNS Medical Distribution 103065 9/28/16

FG1824-03 Contra Irrigation 1 D102 City Surgical 101133 11/30/14





FG1824-03 Contra Irrigation 2 D105 Inline Spine 101347 2/28/15

FG1824-03 Contra Irrigation 1 D107 Fusion Medical 102518 1/31/16

FG1824-03 Contra Irrigation 1 D107 Fusion Medical 102596 2/29/16

FG1824-03 Contra Irrigation 1 D111 Davey Medical 102694 3/31/16

FG1824-03 Contra Irrigation 1 D114 Medifuse Surgical, LLC. 102751 4/30/16

FG1824-03 Contra Irrigation 1 D116 Greg Stenzel 101471 4/30/15



FG1824-03 Contra Irrigation 5 D117 Brannon Wyatt 103065 9/28/16

FG1824-03 Contra Irrigation 1 D118 Amanda Turko 101347 2/28/15

FG1824-03 Contra Irrigation 2 D119 Align Alternatives 101471 4/30/15





FG1824-03 Contra Irrigation 1 D120 Choice Spine 103065 9/28/16

FG1824-03 Contra Irrigation 1 D120 Choice Spine 103150 9/28/16

FG1824-03 Contra Irrigation 1 D123 MetaGen 102417 12/31/15



FG1824-03 Contra Irrigation 1 D125 Charles Pierce Martin 102694 3/31/16

FG1824-03 Contra Irrigation 2 D134 Advanced Medical SW 101133 11/30/14



FG1824-03 Contra Irrigation 9 D137 BIOlympic Medical 102992 7/28/16

FG1824-03 Contra Irrigation 9 D137 BIOlympic Medical 103065 9/28/16

FG1824-03 Contra Irrigation 1 D155 Minivasive - B. Manning 102751 4/30/16

FG1824-03 Contra Irrigation 2 D167 MetaGen-SBrown 101288 1/31/15

FG1824-03 Contra Irrigation 2 D167 MetaGen-SBrown 103150 9/28/16

FG1824-03 Contra Irrigation 2 D174 KRP Medical-KCorrado 102915 7/31/16

FG1824-03 Contra Irrigation 1 D176 Ross Medical-RTate 101133 11/30/14




FG1824-03 Contra Irrigation 1 D177 Carolina Surgi-PTracy 102292 11/30/15



FG1824-03 Contra Irrigation 1 D187 Biotech Solutions-JNalli 102915 7/31/16



Page 46 or 54


FG1824-03 Contra Irrigation 1 D187 Biotech Solutions-JNalli 102992 7/28/16

FG1824-03 Contra Irrigation 1 D188 INNOTEK-DTouhey 103065 9/28/16

FG1824-03 Contra Irrigation 1 D188 INNOTEK-DTouhey 103150 9/28/16

FG1824-03 Contra Irrigation 2 D191 Mesa Medical-SPutman 100991 10/31/14

FG1824-03 Contra Irrigation 1 D194 Horse Creek Med-TOakes 102694 3/31/16

FG1824-03 Contra Irrigation 2 D195 Med-Adv.-Faulkner/Benton 101050 10/31/14

FG1824-03 Contra Irrigation 1 D198 Axial Systems-JWing 102751 4/30/16

FG1824-03 Contra Irrigation 7 D198 Axial Systems-JWing 102915 7/31/16

FG1824-03 Contra Irrigation 1 D206 Patton Medical-APatton 101347 2/28/15

FG1824-03 Contra Irrigation 1 D208 Team Harmony-SWilson 102915 7/31/16

FG1824-03 Contra Irrigation 1 D208 Team Harmony-SWilson 102992 7/28/16

FG1824-03 Contra Irrigation 2 D210 Elite Spine-PHarmon 103150 9/28/16

FG1824-03 Contra Irrigation 1 D212 Sand Medical-REstrada 101141 11/30/14

FG1824-03 Contra Irrigation 1 D212 Sand Medical-REstrada 102694 3/31/16

FG1824-03 Contra Irrigation 2 D217 Freestone Med-JDoub 101705 7/31/15

FG1824-03 Contra Irrigation 2 D220 Northstate-EAlexander 102810 5/31/16

FG1824-03 Contra Irrigation 1 D222 Northstate-SAllen 101288 1/31/15

FG1824-03 Contra Irrigation 1 D222 Northstate-SAllen 101845 8/31/15

FG1824-03 Contra Irrigation 2 D223 KNS-JPugliese 101288 1/31/15

FG1824-03 Contra Irrigation 2 D224 Northstate-TCoppedge 102810 5/31/16

FG1824-03 Contra Irrigation 2 D225 Advanced Medical-KMorin 102694 3/31/16




FG1824-03 Contra Irrigation 1 D227 True North-DBrown 102417 12/31/15



FG1824-03 Contra Irrigation 1 D229 Kevin Kearney 101288 1/31/15

FG1824-03 Contra Irrigation 1 D229 Kevin Kearney 102596 2/29/16

FG1824-03 Contra Irrigation 1 D230 Touchstone-RWeaver 101288 1/31/15



FG1824-03 Contra Irrigation 1 D231 QB Medical-PParsons 102162 10/31/15

FG1824-03 Contra Irrigation 2 D240 7 Spine Group-THenderson 101347 2/28/15

FG1824-03 Contra Irrigation 1 D241 Corvus Med-JeUnderwood 101471 4/30/15

FG1824-03 Contra Irrigation 2 D241 Corvus Med-JeUnderwood 101845 8/31/15

FG1824-03 Contra Irrigation 2 D242 Elite Spine-BBooker 102915 7/31/16

FG1824-03 Contra Irrigation 2 D242 Elite Spine-BBooker 103065 9/28/16

FG1824-03 Contra Irrigation 2 D243 Corvus Medical-TKline 102694 3/31/16

FG1824-03 Contra Irrigation 1 D245 Jennifer Wyatt 102810 5/31/16

FG1824-03 Contra Irrigation 1 D245 Jennifer Wyatt 103150 9/28/16

FG1824-03 Contra Irrigation 1 D248 CLIP MEDICAL - DUBAI 101845 8/31/15

FG1824-03 Contra Irrigation 2 D248 CLIP MEDICAL - DUBAI 102596 2/29/16

FG1824-03 Contra Irrigation 1 D252 SPINE NET - GERMANY 102694 3/31/16

FG1824-03 Contra Irrigation 2 D255 A2 MEDICAL 101845 8/31/15

FG1824-03 Contra Irrigation 1 D255 A2 MEDICAL 102751 4/30/16

FG1824-03 Contra Irrigation 2 D260 STIRLING SURGICAL - CURT 102810 5/31/16

FG1824-03 Contra Irrigation 2 D268 BLACK DIAMOND 101845 8/31/15

FG1824-03 Contra Irrigation 1 D270 Med Advise -DTighe 101845 8/31/15



FG1824-03 Contra Irrigation 2 D271 KML Medical - KCook 102292 11/30/15



Page 47 or 54


FG1824-03 Contra Irrigation 1 D274 CBR Medical-RDobson 101845 8/31/15

FG1824-03 Contra Irrigation 1 D274 CBR Medical-RDobson 102751 4/30/16

FG1824-03 Contra Irrigation 2 D275 Spinal Restorat- Lorenzo 101987 9/30/15

FG1824-03 Contra Irrigation 1 D277 Sand Med-B Ledford 102054 9/30/15

FG1824-03 Contra Irrigation 1 D277 Sand Med-B Ledford 102596 2/29/16

FG1824-03 Contra Irrigation 2 D280 Nicole Juber 102162 10/31/15

FG1824-03 Contra Irrigation 1 D281 Susan Rains 101987 9/30/15

FG1824-03 Contra Irrigation 1 D281 Susan Rains 102162 10/31/15

FG1824-03 Contra Irrigation 1 D282 Weisz Surgical-PWeisz 102915 7/31/16

FG1824-03 Contra Irrigation 1 D285 Touchstone-BDoyle 102054 9/30/15

FG1824-03 Contra Irrigation 1 D285 Touchstone-BDoyle 102915 7/31/16

FG1824-03 Contra Irrigation 1 D286 Tolan Mai 102417 12/31/15

FG1824-03 Contra Irrigation 1 D286 Tolan Mai 102694 3/31/16

FG1824-03 Contra Irrigation 1 D290 IoliteMedical-PGeiger 102751 4/30/16

FG1824-03 Contra Irrigation 1 D290 IoliteMedical-PGeiger 102810 5/31/16

FG1824-03 Contra Irrigation 1 D296 Denise Sheppard 102292 11/30/15



FG1824-03 Contra Irrigation 2 D297 Synergy Surgical 102751 4/30/16

FG1824-03 Contra Irrigation 1 D298 Emmerson Med. -THamilton 102751 4/30/16

FG1824-03 Contra Irrigation 1 D298 Emmerson Med. -THamilton 102992 7/28/16

FG1824-03 Contra Irrigation 1 D299 Innotek/Moore Med CZeise 102417 12/31/15

FG1824-03 Contra Irrigation 2 D299 Innotek/Moore Med CZeise 102694 3/31/16

FG1824-03 Contra Irrigation 2 D300 Medical Innovation-RMaly 102992 7/28/16

FG1824-03 Contra Irrigation 2 D301 Elite Spine-DBalsamo 102694 3/31/16

FG1824-03 Contra Irrigation 1 D301 Elite Spine-DBalsamo 103065 9/28/16

FG1824-03 Contra Irrigation 1 D304 CREAMER MEDICAL -Denmark 102694 3/31/16

FG1824-03 Contra Irrigation 1 D307 Synergy Surgical-SKlein 102292 11/30/15



FG1824-03 Contra Irrigation 1 D310 Resurrection A. Gratsias 102292 11/30/15



FG1824-03 Contra Irrigation 1 D311 Minivasive - Chris Rutt 102751 4/30/16

FG1824-03 Contra Irrigation 2 D315 PAL Medical - M. Balleux 102915 7/31/16

FG1824-03 Contra Irrigation 2 D316 Elite Spine CA - AGarcia 102992 7/28/16

FG1824-03 Contra Irrigation 2 D316 Elite Spine CA - AGarcia 103150 9/28/16

FG1824-03 Contra Irrigation 1 D317 Innotek Medical - TMoore 102810 5/31/16

FG1824-03 Contra Irrigation 2 D318 Fidelis Surgical - Ligon 102992 7/28/16

FG1824-03 Contra Irrigation 1 D320 Dominic D'Abate 101093 11/30/14

FG1824-03 Contra Irrigation 1 D320 Dominic D'Abate 101705 7/31/15

FG1824-03 Contra Irrigation 2 D321 Spinal Restorative- Lacy 102992 7/28/16

FG1824-03 Contra Irrigation 4 D322 Innotek - M. Swanson 103065 9/28/16

FG1824-03 Contra Irrigation 2 D324 Tyler Unzicker 102992 7/28/16

FG1824-03 Contra Irrigation 2 D328 Bahler - J. McNamara 103065 9/28/16

FG1824-03 Contra Irrigation 1 iO-Loan1 iO-Loaner # 1 103150 9/28/16









Page 48 or 54





FG1824-03 Contra Irrigation 2 iO-Loan8 iO-Loan8 102518 1/31/16

FG1824-03 Contra Irrigation 1 P103 Bob Cook 102596 2/29/16

FG1824-03 Contra Irrigation 1 P103 Bob Cook 103150 9/28/16

FG1824-03 Contra Irrigation 1 S157 JOHN DIETERLY 102162 10/31/15




FG1824-03 Contra Irrigation 1 S163 KATRYN FERNALD 102810 5/31/16

FG1824-03 Contra Irrigation 1 S169 MATT HART 102751 4/30/16




FG1824-03 Contra Irrigation 2 S175 STEVEN GREEN 102915 7/31/16

FG1824-03 Contra Irrigation 2 S175 STEVEN GREEN 103150 9/28/16

FG1824-03 Contra Irrigation 2 S176 SCOTT HEYMOSS 102292 11/30/15

FG1824-03 Contra Irrigation 2 S176 SCOTT HEYMOSS 102417 12/31/15

FG1824-03 Contra Irrigation 1 S180 Greg Pellatt 103065 9/28/16

FG1824-03 Contra Irrigation 2 S180 Greg Pellatt 103150 9/28/16

FG1824-03 Contra Irrigation 1 S185 MICHAEL DEFAZIO 102596 2/29/16

FG1824-03 Contra Irrigation 2 S185 MICHAEL DEFAZIO 103065 9/28/16

FG1824-03 Contra Irrigation 2 S186 KATIE MORONI 102751 4/30/16



FG1824-03 Contra Irrigation 1 S192 ANDREW PINCKNEY 102810 5/31/16



FG1824-03 Contra Irrigation 2 S193 APRIL SPILLANE 102162 10/31/15

FG1824-03 Contra Irrigation 2 S193 APRIL SPILLANE 102915 7/31/16

FG1824-03 Contra Irrigation 2 S204 Tanner Michael Shaw 102992 7/28/16

FG1824-03 Contra Irrigation 2 S204 Tanner Michael Shaw 103065 9/28/16

FG1824-03 Contra Irrigation 1 S207 PAT FORDE 101471 4/30/15

FG1824-03 Contra Irrigation 1 S207 PAT FORDE 101845 8/31/15

FG1824-04 Ipsi Irrigation 189 180 SHIPPING TO RALEIGH 103151 9/28/16

FG1824-04 Ipsi Irrigation 1 301 N. CAROLINA HOLD 100826 8/31/14









FG1824-04 Ipsi Irrigation 175 400 Sterile - SJ 103174

FG1824-04 Ipsi Irrigation 1 501 N. CAROLINA FG 102517 1/31/16








Page 49 or 54



FG1824-04 Ipsi Irrigation 1 700 Demo Products - SJ 100722 6/30/14

FG1824-04 Ipsi Irrigation 1 700 Demo Products - SJ 100758

FG1824-04 Ipsi Irrigation 1 700 Demo Products - SJ 100859 8/31/14

FG1824-04 Ipsi Irrigation 1 D101 KNS Medical Distribution 102916 7/31/16



FG1824-04 Ipsi Irrigation 1 D102 City Surgical 102534 1/31/16






FG1824-04 Ipsi Irrigation 1 D103 Bahler Medical 101267 1/31/15





FG1824-04 Ipsi Irrigation 7 D105 Inline Spine 103151 9/28/16

FG1824-04 Ipsi Irrigation 2 D107 Fusion Medical 102993 7/28/16

FG1824-04 Ipsi Irrigation 1 D111 Davey Medical 101051 10/31/14




FG1824-04 Ipsi Irrigation 1 D114 Medifuse Surgical, LLC. 102163 10/31/15

FG1824-04 Ipsi Irrigation 1 d114 Medifuse Surgical, LLC. 102349 11/30/15

FG1824-04 Ipsi Irrigation 1 D114 Medifuse Surgical, LLC. 102534 1/31/16

FG1824-04 Ipsi Irrigation 2 D116 Greg Stenzel 102163 10/31/15

FG1824-04 Ipsi Irrigation 1 D118 Amanda Turko 102534 1/31/16



FG1824-04 Ipsi Irrigation 3 D119 Align Alternatives 102916 7/31/16



FG1824-04 Ipsi Irrigation 1 D123 MetaGen 102993 7/28/16

FG1824-04 Ipsi Irrigation 3 D123 MetaGen 103151 9/28/16

FG1824-04 Ipsi Irrigation 1 D125 Charles Pierce Martin 101706 7/31/15



FG1824-04 Ipsi Irrigation 1 D126 Goalline Medical, LLC 101348 2/28/15




FG1824-04 Ipsi Irrigation 1 D131 Duke Medical, LLC 101433 4/30/15





FG1824-04 Ipsi Irrigation 1 D134 Advanced Medical SW 102993 7/28/16



FG1824-04 Ipsi Irrigation 1 D140 Long Medical Specialties 102163 10/31/15



Page 50 or 54




FG1824-04 Ipsi Irrigation 2 D144 Innovative Surgical LLC. 102349 11/30/15



FG1824-04 Ipsi Irrigation 1 D155 Minivasive - B. Manning 102811 5/31/16



FG1824-04 Ipsi Irrigation 1 D167 MetaGen-SBrown 101433 4/30/15



FG1824-04 Ipsi Irrigation 2 D174 KRP Medical-KCorrado 102993 7/28/16

FG1824-04 Ipsi Irrigation 1 D176 Ross Medical-RTate 102916 7/31/16



FG1824-04 Ipsi Irrigation 1 D177 Carolina Surgi-PTracy 102865 5/31/16

FG1824-04 Ipsi Irrigation 1 D177 Carolina Surgi-PTracy 102993 7/28/16

FG1824-04 Ipsi Irrigation 1 D181 OrthoMed-MSalinas 102865 5/31/16

FG1824-04 Ipsi Irrigation 1 D187 Biotech Solutions-JNalli 101113 11/30/14



FG1824-04 Ipsi Irrigation 1 D188 INNOTEK-DTouhey 102993 7/28/16



FG1824-04 Ipsi Irrigation 4 D191 Mesa Medical-SPutman 100992 10/31/14

FG1824-04 Ipsi Irrigation 1 D194 Horse Creek Med-TOakes 102865 5/31/16



FG1824-04 Ipsi Irrigation 2 D195 Med-Adv.-Faulkner/Benton 102916 7/31/16

FG1824-04 Ipsi Irrigation 1 D195 Med-Adv.-Faulkner/Benton 102993 7/28/16

FG1824-04 Ipsi Irrigation 2 D198 Axial Systems-JWing 101846 8/31/15

FG1824-04 Ipsi Irrigation 2 D198 Axial Systems-JWing 102534 1/31/16

FG1824-04 Ipsi Irrigation 1 D199 Innotek - K. Nevel 101951 9/30/15



FG1824-04 Ipsi Irrigation 1 D200 2K Spine -T Schultz 102695 3/31/16

FG1824-04 Ipsi Irrigation 2 D203 AG Distribu-AGuidacan 103066 9/28/16

FG1824-04 Ipsi Irrigation 1 D203 AG Distribu-AGuidacan 103151 9/28/16

FG1824-04 Ipsi Irrigation 8 D206 Patton Medical-APatton 103066 9/28/16

FG1824-04 Ipsi Irrigation 2 D208 Team Harmony-SWilson 102811 5/31/16

FG1824-04 Ipsi Irrigation 1 D208 Team Harmony-SWilson 103066 9/28/16

FG1824-04 Ipsi Irrigation 2 D210 Elite Spine-PHarmon 103151 9/28/16

FG1824-04 Ipsi Irrigation 1 D212 Sand Medical-REstrada 102349 11/30/15

FG1824-04 Ipsi Irrigation 2 D212 Sand Medical-REstrada 102695 3/31/16

FG1824-04 Ipsi Irrigation 1 D217 Freestone Med-JDoub 101515 5/31/15



FG1824-04 Ipsi Irrigation 4 D220 Northstate-EAlexander 101212 12/31/14

FG1824-04 Ipsi Irrigation 2 D222 Northstate-SAllen 102695 3/31/16

FG1824-04 Ipsi Irrigation 1 D223 KNS-JPugliese 101706 7/31/15

FG1824-04 Ipsi Irrigation 1 D224 Northstate-TCoppedge 101267 1/31/15




Page 51 or 54



FG1824-04 Ipsi Irrigation 2 d225 Advanced Medical-KMorin 102349 11/30/15

FG1824-04 Ipsi Irrigation 1 D225 Advanced Medical-KMorin 102916 7/31/16

FG1824-04 Ipsi Irrigation 2 D225 Advanced Medical-KMorin 102993 7/28/16

FG1824-04 Ipsi Irrigation 2 D227 True North-DBrown 102993 7/28/16

FG1824-04 Ipsi Irrigation 3 D229 Kevin Kearney 102534 1/31/16

FG1824-04 Ipsi Irrigation 1 D230 Touchstone-RWeaver 102163 10/31/15



FG1824-04 Ipsi Irrigation 1 D231 QB Medical-PParsons 102163 10/31/15

FG1824-04 Ipsi Irrigation 6 D231 QB Medical-PParsons 102534 1/31/16

FG1824-04 Ipsi Irrigation 1 D240 7 Spine Group-THenderson 101406 3/31/15

FG1824-04 Ipsi Irrigation 2 D241 Corvus Med-JeUnderwood 101951 9/30/15



FG1824-04 Ipsi Irrigation 1 D242 Elite Spine-BBooker 101433 4/30/15



FG1824-04 Ipsi Irrigation 2 D243 Corvus Medical-TKline 102163 10/31/15



FG1824-04 Ipsi Irrigation 1 D245 Jennifer Wyatt 102163 10/31/15

FG1824-04 Ipsi Irrigation 1 D245 Jennifer Wyatt 102811 5/31/16

FG1824-04 Ipsi Irrigation 2 D248 CLIP MEDICAL - DUBAI 101846 8/31/15

FG1824-04 Ipsi Irrigation 2 D252 SPINE NET - GERMANY 102695 3/31/16

FG1824-04 Ipsi Irrigation 1 D255 A2 MEDICAL 102293 11/30/15



FG1824-04 Ipsi Irrigation 1 D260 STIRLING SURGICAL - CURT 102865 5/31/16



FG1824-04 Ipsi Irrigation 3 D268 BLACK DIAMOND 103066 9/28/16

FG1824-04 Ipsi Irrigation 1 D270 Med Advise -DTighe 102865 5/31/16

FG1824-04 Ipsi Irrigation 2 D270 Med Advise -DTighe 103151 9/28/16

FG1824-04 Ipsi Irrigation 2 D271 KML Medical - KCook 103066 9/28/16

FG1824-04 Ipsi Irrigation 1 D271 KML Medical - KCook 103151 9/28/16

FG1824-04 Ipsi Irrigation 1 D274 CBR Medical-RDobson 102811 5/31/16

FG1824-04 Ipsi Irrigation 1 D277 Sand Med-B Ledford 102752 4/30/16

FG1824-04 Ipsi Irrigation 2 D277 Sand Med-B Ledford 102993 7/28/16

FG1824-04 Ipsi Irrigation 2 D280 Nicole Juber 102752 4/30/16



FG1824-04 Ipsi Irrigation 2 D281 Susan Rains 102993 7/28/16

FG1824-04 Ipsi Irrigation 1 D282 Weisz Surgical-PWeisz 102695 3/31/16

FG1824-04 Ipsi Irrigation 2 D285 Touchstone-BDoyle 103066 9/28/16

FG1824-04 Ipsi Irrigation 2 D285 Touchstone-BDoyle 103151 9/28/16

FG1824-04 Ipsi Irrigation 1 D286 Tolan Mai 102865 5/31/16

FG1824-04 Ipsi Irrigation 1 D286 Tolan Mai 103151 9/28/16

FG1824-04 Ipsi Irrigation 2 D290 IoliteMedical-PGeiger 101706 7/31/15

FG1824-04 Ipsi Irrigation 2 D290 IoliteMedical-PGeiger 102993 7/28/16

FG1824-04 Ipsi Irrigation 2 D296 Denise Sheppard 102916 7/31/16

FG1824-04 Ipsi Irrigation 2 D296 Denise Sheppard 102993 7/28/16



Page 52 or 54


FG1824-04 Ipsi Irrigation 1 D297 Synergy Surgical 102865 5/31/16



FG1824-04 Ipsi Irrigation 1 D298 Emmerson Med. -THamilton 102811 5/31/16

FG1824-04 Ipsi Irrigation 3 D298 Emmerson Med. -THamilton 103066 9/28/16

FG1824-04 Ipsi Irrigation 1 D299 Innotek/Moore Med CZeise 101406 3/31/15

FG1824-04 Ipsi Irrigation 1 D299 Innotek/Moore Med CZeise 102349 11/30/15

FG1824-04 Ipsi Irrigation 2 D300 Medical Innovation-RMaly 103066 9/28/16

FG1824-04 Ipsi Irrigation 2 D301 Elite Spine-DBalsamo 102695 3/31/16

FG1824-04 Ipsi Irrigation 1 D307 Synergy Surgical-SKlein 102752 4/30/16

FG1824-04 Ipsi Irrigation 1 D307 Synergy Surgical-SKlein 102993 7/28/16

FG1824-04 Ipsi Irrigation 2 D309 Central Valley -R. Green 103066 9/28/16

FG1824-04 Ipsi Irrigation 2 D310 Resurrection A. Gratsias 103151 9/28/16

FG1824-04 Ipsi Irrigation 1 D311 Minivasive - Chris Rutt 102916 7/31/16



FG1824-04 Ipsi Irrigation 2 D315 PAL Medical - M. Balleux 102993 7/28/16

FG1824-04 Ipsi Irrigation 1 D316 Elite Spine CA - AGarcia 103151 9/28/16

FG1824-04 Ipsi Irrigation 1 D317 Innotek Medical - TMoore 102865 5/31/16

FG1824-04 Ipsi Irrigation 1 D317 Innotek Medical - TMoore 102993 7/28/16

FG1824-04 Ipsi Irrigation 2 D318 Fidelis Surgical - Ligon 102993 7/28/16

FG1824-04 Ipsi Irrigation 1 D320 Dominic D'Abate 103151 9/28/16

FG1824-04 Ipsi Irrigation 3 D321 Spinal Restorative- Lacy 103066 9/28/16

FG1824-04 Ipsi Irrigation 1 D321 Spinal Restorative- Lacy 103151 9/28/16

FG1824-04 Ipsi Irrigation 3 D322 Innotek - M. Swanson 103066 9/28/16

FG1824-04 Ipsi Irrigation 4 D328 Bahler - J. McNamara 103151 9/28/16

FG1824-04 Ipsi Irrigation 1 iO-Loan1 iO-Loaner # 1 103066 9/28/16












FG1824-04 Ipsi Irrigation 2 iO-Loan8 iO-Loan8 102349 11/30/15

FG1824-04 Ipsi Irrigation 1 P103 Bob Cook 102916 7/31/16



FG1824-04 Ipsi Irrigation 1 S157 JOHN DIETERLY 102865 5/31/16




FG1824-04 Ipsi Irrigation 1 S163 KATRYN FERNALD 100992 10/31/14




FG1824-04 Ipsi Irrigation 3 S169 MATT HART 102865 5/31/16

FG1824-04 Ipsi Irrigation 3 S175 STEVEN GREEN 102993 7/28/16



Page 53 or 54


FG1824-04 Ipsi Irrigation 1 S176 SCOTT HEYMOSS 102865 5/31/16

FG1824-04 Ipsi Irrigation 3 S176 SCOTT HEYMOSS 102916 7/31/16

FG1824-04 Ipsi Irrigation 4 S180 Greg Pellatt 103066 9/28/16

FG1824-04 Ipsi Irrigation 1 S185 MICHAEL DEFAZIO 102163 10/31/15



FG1824-04 Ipsi Irrigation 3 S186 KATIE MORONI 102993 7/28/16

FG1824-04 Ipsi Irrigation 2 S186 KATIE MORONI 103151 9/28/16

FG1824-04 Ipsi Irrigation 2 S192 ANDREW PINCKNEY 101846 8/31/15




FG1824-04 Ipsi Irrigation 1 S193 APRIL SPILLANE 102865 5/31/16

FG1824-04 Ipsi Irrigation 2 S193 APRIL SPILLANE 102916 7/31/16

FG1824-04 Ipsi Irrigation 1 S204 Tanner Michael Shaw 102865 5/31/16

FG1824-04 Ipsi Irrigation 1 S204 Tanner Michael Shaw 103066 9/28/16

FG2235-03 Curette Dilator 10.5" FG 2 180 SHIPPING TO RALEIGH 101052

FG2235-03 Curette Dilator 10.5" FG 1 180 SHIPPING TO RALEIGH 101423

FG2235-03 Curette Dilator 10.5" FG 1 501 N. CAROLINA FG 101019




FG2235-03 Curette Dilator 10.5" FG 1 509 iO Curette Loaner - RDU 101018





FG2235-03 Curette Dilator 10.5" FG 1 700 Demo Products - SJ 102170

FG2235-03 Curette Dilator 10.5" FG 2 D119 Align Alternatives 102170

FG2235-03 Curette Dilator 10.5" FG 1 D126 Goalline Medical, LLC 102170

FG2235-03 Curette Dilator 10.5" FG 1 D137 BIOlympic Medical 101423

FG2235-03 Curette Dilator 10.5" FG 1 D177 Carolina Surgi-PTracy 101423

FG2235-03 Curette Dilator 10.5" FG 1 D188 INNOTEK-DTouhey 101018

FG2235-03 Curette Dilator 10.5" FG 1 D188 INNOTEK-DTouhey 102170

FG2235-03 Curette Dilator 10.5" FG 2 D195 Med-Adv.-Faulkner/Benton 101052

FG2235-03 Curette Dilator 10.5" FG 1 D222 Northstate-SAllen 101052

FG2235-03 Curette Dilator 10.5" FG 1 D224 Northstate-TCoppedge 101423

FG2235-03 Curette Dilator 10.5" FG 1 D227 True North-DBrown 102170

FG2235-03 Curette Dilator 10.5" FG 1 D242 Elite Spine-BBooker 101423

FG2235-03 Curette Dilator 10.5" FG 1 D260 STIRLING SURGICAL - CURT 101423

FG2235-03 Curette Dilator 10.5" FG 1 D275 Spinal Restorat- Lorenzo 102170

FG2235-03 Curette Dilator 10.5" FG 1 S157 JOHN DIETERLY 102170

FG2235-03 Curette Dilator 10.5" FG 2 S163 KATRYN FERNALD 102170

FG2235-03 Curette Dilator 10.5" FG 1 S176 SCOTT HEYMOSS 101423

FG2235-03 Curette Dilator 10.5" FG 1 S176 SCOTT HEYMOSS 1091008

FG2235-03 Curette Dilator 10.5" FG 1 S186 KATIE MORONI 101423

FG2235-03 Curette Dilator 10.5" FG 1 S198 PAUL DAWSON 102170

FG2235-03 Curette Dilator 10.5" FG 1 S204 Tanner Michael Shaw 101052

FG2846-01 iO-Tome Retention Band 52 501 N. CAROLINA FG 102672 3/31/16

FG2846-01 iO-Tome Retention Band 5 700 Demo Products - SJ 102306 5/31/14

FG2846-01 iO-Tome Retention Band 2 S185 MICHAEL DEFAZIO 102672 3/31/16

FG2846-01 iO-Tome Retention Band 1 S192 ANDREW PINCKNEY 102672 3/31/16



Page 54 or 54


FG2846-02 iO-Tome Retention Band 59 501 N. CAROLINA FG 102673 3/31/16

FG2846-02 iO-Tome Retention Band 3 700 Demo Products - SJ 102307 5/31/14

FG2846-02 iO-Tome Retention Band 1 S192 ANDREW PINCKNEY 102673 3/31/16


4.10-1 SL1 1342200v6 109188.00001

Schedule 4.10

Material Contracts

(i)

1. Kanban Supply Agreement dated December 2, 2012 by and between Wightman Engineering Services and Baxano, Inc.7

2. Kanban Supply Agreement dated February 24, 2012 by and between AIM Plastics and Baxano, Inc.

3. Kanban Supply Agreement dated November 14, 2011 by and between McCash and Baxano, Inc.

4. Kanban Supply Agreement dated March 1, 2013 by and between Bioconnect/RF Industries and Baxano, Inc.

5. Kanban Supply Agreement dated February 17, 2014 by and between Clean Cut Technology and Baxano, Inc.

6. Kanban Supply Agreement dated January 30, 2012 by and between Delta Pacific Products and Baxano, Inc.

7. Kanban Supply Agreement dated December 9, 2011 by and between Centerline Precision and Baxano, Inc.

8. Kanban Supply Agreement dated March 12, 2012 by and between Strand Products and Baxano, Inc.

7 The Seller is not offering to assume and assign any of the Kanban contracts.


4.10-2 SL1 1342200v6 109188.00001

9. Kanban Supply Agreement dated January 9, 2014 by and between Tech-Etch, Inc. and Baxano, Inc.

10. Kanban Supply Agreement dated December 2, 2013 by and between Mountain Manufacturing Technologies and Baxano, Inc.

11. Kanban Supply Agreement dated October 14, 2011 by and between Nitinol Devices and Components, Inc. and Baxano, Inc.

12. Master Agreement (Reference No. 22-5779) dated January 20, 2012 by and between Stryker Finance, a division of Stryker Sales Corporation, and TranS1, Inc.8

13. Supplier Agreement dated June 1, 2014 by and between Venta Medical, Inc. and Baxano Surgical, Inc.

14. Quality Agreement dated May 25, 2012 by and between Millstone Medical Outsourcing and TranS1, Inc.

15. Quality Agreement dated May 25, 2012 by and between Quality Tech Services, Inc. and TranS1, Inc.

16. Agreement dated December 23, 2008 by and between Millstone Medical Outsourcing and TranS1, Inc.

17. Requirements Agreement dated January 1, 2014 by and between QTS Packing Solutions and Baxano, Inc. 9

18. Service Contract dated February 2, 2006 by and between Quality Tech Services, Inc. and TranS1, Inc.10

(ii)

1. Schedules 4.12(b) and 4.12(c) are incorporated by reference.

(iii)

8 Not available for assumption and assignment 9 Not available for assumption and assignment. 10 Not available for assumption and assignment


4.10-3 SL1 1342200v6 109188.00001

1. Each of the distribution agreements identified in that certain Debtor Motion for Order under 11 U.S.C. 365 Authorizing Assumption of Distribution Agreements, as amended.11

(iv) 12

1. Agreement of Lease dated July 30, 2009 by and between Market Place Group LLC and the Seller.

2. Lease Agreement dated October 24, 2012, as amended, by and between Sun Life Assurance Company of Canada d/b/a Horizon IV and the Seller.

3. Lease Agreement dated September 30, 2009 by and between Montague Oaks Associates Phase I & II and the Seller.

4. Lease Agreement dated October 28, 2011 by and between Six Forks Capital, LLC and the Seller.

(v)

1. Paragraphs 2 and 3 of Schedule 4.12(b) are incorporated by reference.

2. Letter Agreement, dated November 12, 2014 by and between the Seller and Houlihan Lokey.

3. Letter Agreement, dated November 12, 2014 by and between the Seller and Tamarack Associates.

11 Subject to finalization of list of distributors in motion. 12 The Seller has moved to reject the leases with Market Place Group, LLC, Montague Oaks Associates Phase I & II

and Six Forks Capital, LLC and does not anticipate assuming and assigning any real estate leases.


4.12(a)-1 SL1 1342200v6 109188.00001

Schedule 4.12(a)


1. See Exhibit 4.12(a) attached hereto.


of

23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

(i)

Issu

ed U

nite

d St

ates

Pat

ents

Ow

ned

by C

ompa

ny

U.S

. Pat

ents

from

Tra

nS1

Inc.

Ref

eren

ce N

o.

Pate

nt N

o./

App

l. N

o.

Issu

e D

ate/

Fi

ling

Dat

eTi

tle

Expi

ratio

n D

ate

(w/ P

TA o

r Ter

m. D

iscl

aim

er)

1 AX

IAM

D.0

01A1

6,57

5,97

9 09

/640

,222

06

/10/

2003

08

/16/

2000

M

etho

d an

d ap

para

tus

for p

rovi

ding

pos

terio

r or a

nter

ior

trans

-sac

ral a

cces

s to

spi

nal v

erte

brae

01

/09/

2021

2 AX

IAM

D.0

02A2

6,55

8,38

6 09

/684

,820

05

/06/

2003

10

/10/

2000

Axia

l spi

nal i

mpl

ant a

nd m

etho

d an

d ap

para

tus

for

impl

antin

g an

axi

al s

pina

l im

plan

t with

in th

e ve

rtebr

ae o

f th

e sp

ine

05/1

6/20

21

3 AX

IAM

D.0

03A

6,74

0,09

0 09

/710

,369

05

/25/

2004

11

/10/

2000

M

etho

ds a

nd a

ppar

atus

for f

orm

ing

shap

ed a

xial

bor

es

thro

ugh

spin

al v

erte

brae

08

/26/

2021

4 AX

IAM

D.0

04A

6,79

0,21

0 09

/709

,105

09

/14/

2004

11

/10/

2000

M

etho

ds a

nd a

ppar

atus

for f

orm

ing

curv

ed a

xial

bor

es

thro

ugh

spin

al v

erte

brae

05

/01/

2021

5 AX

IAM

D.0

05A3

6,55

8,39

0 09

/782

,583

05

/06/

2003

02

/13/

2001

M

etho

ds a

nd a

ppar

atus

for p

erfo

rmin

g th

erap

eutic

pr

oced

ures

in th

e sp

ine

02/1

3/20

21

6 AX

IAM

D.0

05C

P2

6,89

9,71

6 10

/125

,771

05

/31/

2005

04

/18/

2002

M

etho

d an

d ap

para

tus

for s

pina

l aug

men

tatio

n 02

/13/

2021

7 AX

IAM

D.0

05C

P4

6,92

1,40

3 10

/309

,416

07

/26/

2005

12

/03/

2002

M

etho

d an

d ap

para

tus

for s

pina

l dis

tract

ion

and

fusi

on

02/1

3/20

21

8 AX

IAM

D.0

05C

P1

7,01

4,63

3 09

/848

,556

03

/21/

2006

05

/03/

2001

M

etho

ds o

f per

form

ing

proc

edur

es in

the

spin

e 02

/13/

2021

9 AX

IAM

D.0

01C

1 7,

087,

058

10/4

59,1

49

08/0

8/20

06

06/1

0/20

03

Met

hod

and

appa

ratu

s fo

r pro

vidi

ng p

oste

rior o

r ant

erio

r tra

ns-s

acra

l acc

ess

to s

pina

l ver

tebr

ae

01/0

9/20

21

1 The

Uni

ted

Stat

es p

aten

t mai

nten

ance

fee

for t

his p

aten

t was

due

on

Dec

embe

r 10,

201

4 bu

t was

not

pai

d by

the

Selle

r. 2 T

he U

nite

d St

ates

pat

ent m

aint

enan

ce fe

e fo

r thi

s pat

ent w

as d

ue o

n N

ovem

ber 6

, 201

4 bu

t was

not

pai

d by

the

Selle

r. 3 T

he U

nite

d St

ates

pat

ent m

aint

enan

ce fe

e fo

r thi

s pat

ent w

as d

ue o

n N

ovem

ber 6

, 201

4 bu

t was

not

pai

d by

the

Selle

r.

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 16

3 of

221

of

23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

Ref

eren

ce N

o.

Pate

nt N

o./

App

l. N

o.

Issu

e D

ate/

Fi

ling

Dat

eTi

tle

Expi

ratio

n D

ate

(w/ P

TA o

r Ter

m. D

iscl

aim

er)

10

AXIA

MD

.005

C1

7,30

9,33

8 10

/430

,841

12

/18/

2007

05

/06/

2003

M

etho

ds a

nd a

ppar

atus

for p

erfo

rmin

g th

erap

eutic

pr

oced

ures

in th

e sp

ine

02/1

3/20

21

11

AXIA

MD

.5C

P2C

1 7,

329,

259

10/9

90,7

05

02/1

2/20

08

11/1

7/20

04

Artic

ulat

ing

Spin

al Im

plan

t 12

/15/

2021

12

AXIA

MD

.025

A 7,

473,

256

10/9

71,7

65

01/0

9/20

09

10/2

2/20

04

Met

hod

and

appa

ratu

s fo

r spi

nal d

istra

ctio

n 02

/13/

2026

13

AXIA

MD

.024

A 7,

500,

977

10/9

72,0

77

03/1

0/20

09

10/2

2/20

04

Met

hod

and

appa

ratu

s fo

r man

ipul

atin

g m

ater

ial i

n th

e sp

ine

10/2

3/20

26

14

AXIA

MD

.015

A 7,

530,

993

10/9

71,7

79

05/1

2/20

09

10/2

2/20

04

Met

hod

of S

pina

l Fix

atio

n

02/1

3/20

21

15AX

IAM

D.5

CP1

C1

7,54

7,31

7 11

/386

,451

06

/16/

2009

03

/21/

2006

M

etho

ds o

f per

form

ing

proc

edur

es in

the

spin

e 02

/13/

2021

16AX

IAM

D.0

03C

1 7,

569,

056

10/8

53,4

76

08/0

4/20

09

05/2

5/20

04

Met

hods

and

app

arat

us fo

r for

min

g sh

aped

axi

al b

ores

th

roug

h sp

inal

ver

tebr

ae

08/2

6/20

21

17AX

IAM

D.0

29A

7,58

8,57

4 10

/971

,780

09

/15/

2009

10

/22/

2004

Ki

ts fo

r ena

blin

g ax

ial a

cces

s an

d pr

oced

ures

in th

e sp

ine

10/0

6/20

26

18AX

IAM

D.5

CP4

C1

7,60

8,07

7 11

/189

,943

10

/27/

1009

07

/26/

2005

M

etho

d an

d ap

para

tus

for s

pina

l dis

tract

ion

and

fusi

on

02/1

3/20

21

19

AXIA

MD

.001

C2

7,64

1,65

7 11

/462

,934

01

/05/

2010

08

/07/

2006

M

etho

d an

d ap

para

tus

for p

rovi

ding

pos

terio

r or a

nter

ior

trans

-sac

ral a

cces

s to

spi

nal v

erte

brae

09

/12/

2020

20AX

IAM

D.0

22A

7,74

0,63

3 10

/971

,781

06

/22/

2010

10

/22/

2004

G

uide

pin

for g

uidi

ng in

stru

men

tatio

n al

ong

a so

ft tis

sue

tract

to a

poi

nt o

n th

e sp

ine

6/26

/202

6

21AX

IAM

D.0

15D

V3

7,76

3,02

5 11

/940

,208

07

/27/

2010

11

/14/

2007

Sp

inal

fusi

on k

it fo

r gui

ding

inst

rum

enta

tion

thro

ugh

soft

tissu

e to

a p

oint

on

the

spin

e 10

/22/

2024

22

AXIA

MD

.5C

P2C

3 7,

727,

263

11/7

62,6

46

06/0

1/20

10

06/1

3/20

07

Artic

ulat

ing

Spin

al Im

plan

t 01

/9/2

021

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 16

4 of

221

of

23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

Ref

eren

ce N

o.

Pate

nt N

o./

App

l. N

o.

Issu

e D

ate/

Fi

ling

Dat

eTi

tle

Expi

ratio

n D

ate

(w/ P

TA o

r Ter

m. D

iscl

aim

er)

23AX

IAM

D.5

CP2

C2

7,74

4,59

9 11

/762

,669

06

/29/

2010

06

/13/

2007

Ar

ticul

atin

g Sp

inal

Impl

ant

02/1

3/20

21

24

AXIA

MD

.005

C1C

1 7,

794,

463

11/9

56,2

36

09/1

4/20

10

12/1

3/20

07

Met

hods

and

app

arat

us fo

r per

form

ing

ther

apeu

tic

proc

edur

es in

the

spin

e 08

/01/

2021

25AX

IAM

D.0

15D

V2

7,79

9,03

2 11

/940

,265

09

/21/

2010

11

/14/

2007

G

uide

pin

intro

duce

r for

gui

ding

inst

rum

enta

tion

thro

ugh

soft

tissu

e to

a p

oint

on

the

spin

e 11

/22/

2024

26AX

IAM

D.0

29D

V1

7,79

9,03

3 11

/942

,488

09

/21/

2010

11

/19/

2007

Ac

cess

kits

for e

nabl

ing

axia

l acc

ess

and

proc

edur

es in

th

e sp

ine

11/2

2/20

24

27AX

IAM

D.0

24C

1 7,

914,

535

12/3

67,3

97

03/2

9/20

11

02/0

6/20

09

Met

hod

and

appa

ratu

s fo

r man

ipul

atin

g m

ater

ial i

n th

e sp

ine

04/1

7/20

25

28AX

IAM

D.0

01C

3 8,

034,

055

12/4

73,9

99

10/1

1/20

11

05.2

8/20

09

Met

hod

And

Appa

ratu

s Fo

r Pro

vidi

ng A

cces

s To

A

Pres

acra

l Spa

ce

09/1

2/20

20

29

AXIA

MD

.023

A 8,

052,

613

10/9

71,7

31

11/0

8/20

11

10/2

2/20

04

Spin

al n

ucle

us e

xtra

ctio

n to

ol

11/2

9/20

27

30AX

IAM

D.0

05C

1C2

8,10

5,36

5 12

/856

,372

01

/31/

2012

08

/13/

2010

M

etho

ds A

nd A

ppar

atus

For

Per

form

ing

Ther

apeu

tic

Proc

edur

es In

The

Spi

ne

02/1

3/20

21

31

AXIA

MD

.5C

P4C

1C1

8,29

2,92

8 12

/561

,192

10

/23/

2012

09

/16/

2009

M

etho

d an

d ap

para

tus

for s

pina

l dis

tract

ion

and

fusi

on

02/1

4/20

21

32AX

IAM

D.0

24C

2 8,

308,

777

12/8

70,0

00

11/1

3/20

12

08/2

7/20

10

Met

hod

and

appa

ratu

s fo

r rem

ovab

le s

pina

l im

plan

t ex

tend

ing

betw

een

at le

ast t

wo

adja

cent

ver

tebr

al

bodi

es

05/2

6/20

25

33AX

IAM

D.0

05C

4 8,

317,

867

13/3

42,8

68

11/2

7/20

12

01/0

3/20

12

Met

hods

And

App

arat

us F

or P

erfo

rmin

g Th

erap

eutic

Pr

oced

ures

In T

he S

pine

02

/13/

2021

34

1003

-003

7,

491,

236

10/9

72,0

39

2/17

/200

9 D

ual A

ncho

r Pro

sthe

tic N

ucle

us A

ppar

atus

03

/06/

2022

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 16

5 of

221

of

23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

Ref

eren

ce N

o.

Pate

nt N

o./

App

l. N

o.

Issu

e D

ate/

Fi

ling

Dat

eTi

tle

Expi

ratio

n D

ate

(w/ P

TA o

r Ter

m. D

iscl

aim

er)

35

1003

-005

7,

547,

324

10/9

72,1

76

06/1

6/20

09

Spin

al M

obilit

y Pr

eser

vatio

n Ap

para

tus

Hav

ing

An

Expa

ndab

le M

embr

ane

03/0

6/20

22

36

T105

002U

SU

7,60

1,17

1

11/2

56,8

10

10/1

3/20

09

10/2

4/20

05

Spin

al M

otio

n Pr

eser

vatio

n As

sem

blie

s 10

/31/

2026

37

T107

001C

IP2

7,63

2,27

4

11/7

12,2

41

12/1

5/20

09

02/2

8/20

07

Thin

Cut

ter B

lade

s W

ith R

etai

ning

Film

For

Pre

parin

g In

terv

erte

bral

Dis

c S

pace

s 02

/28/

2027

3810

03-0

04

7,66

2,17

3

10/9

72,0

40

02/1

6/20

10

Spin

al M

obilit

y Pr

eser

vatio

n Ap

para

tus

07/1

6/20

26

39

T106

001U

SU

7,71

7,91

9

11/5

93,4

45

05/1

8/20

10

11/0

6/20

06

Appl

icat

ion

of T

hera

py A

ligne

d to

an

Inte

rnal

Tar

get

12/2

7/20

28

40

1003

-002

7,

717,

958

10/9

72,1

84

05/1

8/20

10

Pros

thet

ic N

ucle

us A

ppar

atus

08

/28/

2028

41

T105

001U

SU

7,77

6,04

2 11

/202

,655

08

/17/

2010

08

/13/

2005

M

etho

ds a

nd A

ppar

atus

for P

rovi

sion

of T

hera

py to

Ad

jace

nt M

otio

n Se

gmen

ts

12/1

6/20

28

42

T106

002U

SU

7,77

6,06

8 11

/586

,338

08

/17/

2010

10

/24/

2006

Sp

inal

Mot

ion

Pres

erva

tion

Asse

mbl

ies

01/1

4/20

25

43

1003

-004

Con

t. 1

7,90

5,90

5 11

/981

,413

03

/15/

2011

Sp

inal

Mob

ility

Pres

erva

tion

Appa

ratu

s 03

/19/

2021

44

1003

-004

Con

t. 2

7,90

5,90

8 11

/981

,331

03

/15/

2011

Sp

inal

Mob

ility

Pres

erva

tion

Met

hod

02/1

3/20

21

45

T105

003U

SU

7,

938,

836

11/2

59,6

14

05/1

0/20

11

10/2

6/20

05

Driv

er A

ssem

bly

for S

imul

tane

ous

Axi

al D

eliv

ery

of

Spi

nal I

mpl

ants

01

/22/

2029

46

T106

002U

SU2

8,03

8,68

0 11

/586

,486

10

/18/

2011

10

/24/

2006

D

river

s fo

r Ins

erts

to B

one

Anch

ors

07/0

6/20

28

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 16

6 of

221

of

23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

Ref

eren

ce N

o.

Pate

nt N

o./

App

l. N

o.

Issu

e D

ate/

Fi

ling

Dat

eTi

tle

Expi

ratio

n D

ate

(w/ P

TA o

r Ter

m. D

iscl

aim

er)

47

T108

001U

SU

8,08

8,14

7 12

/061

,556

01

/03/

2012

04

/02/

2008

M

ulti-

Mem

bran

e Pr

osth

etic

Nuc

leus

05

/17/

2029

48

T105

001D

V1

8,16

7,94

7 12

/821

,286

05

/01/

2012

06

/23/

2010

M

etho

ds fo

r Pus

h D

istra

ctio

n an

d fo

r Pro

visi

on o

f Th

erap

y to

Adj

acen

t Mot

ion

Segm

ents

05

/29/

2023

49

T108

001

DV1

8,

328,

846

12/6

48,7

58

12/1

1/20

12

12/2

9/20

09

Pros

thet

ic N

ucle

us w

ith a

Pre

form

ed M

embr

ane

11/2

9/20

27

50

T105

001C

1 8,

328,

847

12/8

51,7

13

12/1

1/20

12

08/0

6/20

10

Asse

mbl

ies

for P

rovi

sion

of T

hera

py to

Mot

ion

Segm

ents

05

/4/2

023

51

T105

001D

V2

8,52

3,91

8 13

/617

,030

09

/14/

2013

09

/14/

2012

Th

erap

y to

Adj

acen

t Mot

ion

Segm

ents

12

/03/

2022

89T1

0900

3US

U�8

,696

,672

�12

/692

,159

4/15

/201

4 1/

22/2

010

Abra

ding

Too

l for

Pre

parin

g In

terv

erte

bral

Dis

c Sp

aces

8/

19/2

032

90A

XIA

MD

.005

C5

8,70

9,08

7 13

/612

573�

4/29

/201

4 0

9/12

/201

2 M

etho

ds A

nd A

ppar

atus

For

Per

form

ing

Ther

apeu

tic

Pro

cedu

res

In T

he S

pine

91T1

0900

2US

U

8,74

7,47

2�12

/541

,785

6/10

/201

4 08

/14/

2009

Sp

inal

The

rapy

Dev

ice

with

Fix

ated

Dis

tract

ion

Dis

tanc

e8/

14/2

031

92T3

1200

1US

U

8,79

5,16

7

13/6

58,4

26 �

08/0

5/20

14

10/2

3/20

12

Spin

al T

hera

py L

ater

al A

ppro

ach

Acce

ss In

stru

men

ts a

nd

Impl

ants

�1

0/23

/203

2

U.S

. Pat

ents

from

Bax

ano,

Inc.

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 16

7 of

221

of

23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

��Fi

le�re

f.�#�

Title

�Ap

p.�N

o.�

App.

�Dat

ePa

tent

�No.

�Pa

tent

�Dat

eEs

p�Da

te�

52�

1037

6�70

0.20

1�DE

VICE

S�AN

D�M

ETHO

DS�

FOR�

SELE

CTIV

E�SU

RGIC

AL�

REM

OVA

L�O

F�TI

SSU

E�11

/250

,332

�10/

15/2

005

7,73

8,96

8�6/

15/2

010�

7/31

/202

7�

53�

1037

6�70

0.20

2�DE

VICE

S�AN

D�M

ETHO

DS�

FOR�

SELE

CTIV

E�SU

RGIC

AL�

REM

OVA

L�O

F�TI

SSU

E�11

/250

,369

�10/

15/2

005

7,55

5,34

3�6/

30/2

009�

3/5/

2027

�

54�

1037

6�70

0.20

4�DE

VICE

S�AN

D�M

ETHO

DS�F

OR�

TISS

UE�

ACCE

SS�

11/2

51,2

05�1

0/15

/200

57,

918,

849�

4/5/

2011

�10

/01/

2029

55�

1037

6�70

0.20

6�DE

VICE

S�AN

D�M

ETHO

DS�F

OR�

TISS

UE�

ACCE

SS�

11/2

51,1

86�1

0/15

/200

57,

963,

915�

6/21

/201

1�08

/16/

2029

56�

1037

6�70

0.20

7�DE

VICE

S�AN

D�M

ETHO

DS�F

OR�

TISS

UE�

MO

DIFI

CATI

ON

�11

/251

,165

�10/

15/2

005

7,55

3,30

7�6/

30/2

009�

02/2

5/20

27

57�

1037

6�70

0.20

8�DE

VICE

S�AN

D�M

ETHO

DS�F

OR�

TISS

UE�

MO

DIFI

CATI

ON

�11

/251

,204

�10/

15/2

005

7,74

0,63

1�6/

22/2

010�

02/2

3/20

29

58�

1037

6�70

0.20

9�DE

VICE

S�AN

D�M

ETHO

DS�F

OR�

TISS

UE�

MO

DIFI

CATI

ON

�11

/251

,199

�10/

15/2

005

8,19

2,43

5�6/

5/20

12�

01/2

8/20

27

59�

1037

6�70

0.30

7�DE

VICE

S�AN

D�M

ETHO

DS�F

OR�

TISS

UE�

MO

DIFI

CATI

ON

�12

/428

,369

�4/2

2/20

09�

8,22

1,39

7�7/

17/2

012�

11/2

3/20

26

60�

1037

6�70

0.31

0�DE

VICE

S�AN

D�M

ETHO

DS�F

OR�

TISS

UE�

MO

DIFI

CATI

ON

�13

/430

,500

�3/2

6/20

12�

8,57

9,90

2�11

/12/

2013

12/0

8/20

25

61�

1037

6�70

0.40

1�DE

VICE

S�AN

D�M

ETHO

DS�

FOR�

SELE

CTIV

E�SU

RGIC

AL�

REM

OVA

L�O

F�TI

SSU

E�12

/357

,289

�1/2

1/20

09�

7,73

8,96

9�6/

15/2

010�

10/1

5/20

25

62�

1037

6�70

0.40

2�SP

INAL

�ACC

ESS�

AND�

NEU

RAL�

LOCA

LIZA

TIO

N�

12/5

04,5

45�7

/16/

2009

�8,

419,

653�

4/16

/201

3�11

/06/

2026

63�

1037

6�70

0.50

1�M

ECHA

NIC

AL�

TISS

UE�

MO

DIFI

CATI

ON

�DE

VICE

S�AN

D�M

ETHO

DS�

11/4

05,8

48�4

/17/

2006

�8,

430,

881�

4/30

/201

3�06

/14/

2027

64�

1037

6�70

0.50

2�PO

WER

ED�T

ISSU

E�M

ODI

FICA

TIO

N�D

EVIC

ES�A

ND�

MET

HODS

�11

/406

,486

�4/1

7/20

06�

7,93

8,83

0�5/

10/2

011�

08/1

2/20

27

65�

1037

6�70

0.50

4�FL

EXIB

LE�T

ISSU

E�RA

SP�

11/4

29,3

77�5

/4/2

006�

8,04

8,08

0�11

/1/2

011�

12/2

9/20

27

66�

1037

6�70

0.50

5�SP

INAL

�ACC

ESS�

AND�

NEU

RAL�

LOCA

LIZA

TIO

N�

11/4

57,4

16�7

/13/

2006

�7,

578,

819�

8/25

/200

9�10

/15/

2025

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 16

8 of

221

of

23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

67�

1037

6�70

0.50

6�TI

SSU

E�RE

MO

VAL�

WIT

H�AT

�LE

AST�

PART

IALL

Y�FL

EXIB

LE�

DEVI

CES�

11/6

87,5

48�3

/16/

2007

�8,

062,

300�

11/2

2/20

1103

/24/

2028

68�

1037

6�70

0.50

7�FL

EXIB

LE�T

ISSU

E�RE

MO

VAL�

DEVI

CES�

AND�

MET

HODS

�11

/687

,558

�3/1

6/20

07�

8,06

2,29

8�11

/22/

2011

01/1

9/20

28

69�

1037

6�70

0.50

9�TI

SSU

E�M

ODI

FICA

TIO

N�D

EVIC

ES�

12/3

24,1

47�1

1/26

/200

88,

192,

436�

6/5/

2012

�12

/08/

2028

�

70�

1037

6�70

0.U

S1�

MET

HODS

�AN

D�AP

PARA

TUS�

FOR�

TISS

UE�

MO

DIFI

CATI

ON

�11

/375

,265

�3/1

3/20

06�

7,88

7,53

8�2/

15/2

011�

01/0

8/20

27

71�

1037

6�70

6.20

1�TI

SSU

E�AC

CESS

�GU

IDEW

IRE�

SYST

EM�A

ND�

MET

HOD�

11/4

68,2

47�8

/29/

2006

�7,

857,

813�

12/2

8/20

1005

/16/

2028

72�

1037

6�70

6.50

1�GU

IDEW

IRE�

EXCH

ANGE

�SY

STEM

S�TO

�TR

EAT�

SPIN

AL�

STEN

OSI

S�12

/127

,535

�5/2

7/20

08�

8,25

7,35

6�9/

4/20

12�

08/0

9/20

28

73�

1037

6�71

9.20

0�M

ETHO

D,�

SYST

EM,�

AND�

APPA

RATU

S�FO

R�N

EURA

L�LO

CALI

ZATI

ON

�12

/060

,229

�3/3

1/20

08�

7,95

9,57

7�6/

14/2

011�

06/2

7/20

28

74�

1037

6�71

9.40

0�M

ETHO

D,�

SYST

EM,�

AND�

APPA

RATU

S�FO

R�N

EURA

L�LO

CALI

ZATI

ON

�13

/090

,944

�4/2

0/20

11�

8,30

3,51

6�11

/6/2

012�

03/3

1/20

28

75�

1037

6�72

7.20

0�M

ULT

IPLE

�PA

THW

AYS�

FOR�

SPIN

AL�

NER

VE�

ROO

T�DE

COM

PRES

SIO

N�F

ROM

�A�S

ING

LE�A

CCES

S�PO

INT�

12/3

52,9

78�1

/13/

2009

�8,

092,

456�

1/10

/201

2�05

/08/

2026

76�

1037

6�72

7.30

0�M

ULT

IPLE

�PA

THW

AYS�

FOR�

SPIN

AL�

NER

VE�

ROO

T�DE

COM

PRES

SIO

N�F

ROM

�A�S

ING

LE�A

CCES

S�PO

INT�

13/3

12,2

72�1

2/6/

2011

�8,

366,

712�

2/5/

2013

�10

/15/

2025

77�

1037

6�73

0.20

0�SU

RGIC

AL�T

OO

LS�F

OR�

TREA

TMEN

T�O

F�SP

INAL

�STE

NO

SIS�

12/8

24,0

43�6

/25/

2010

�8,

394,

102�

3/12

/201

3�01

/30/

2031

78�

1037

6�73

1.20

0�TI

SSU

E�M

ODI

FICA

TIO

N�D

EVIC

ES�A

ND�

MET

HODS

�12

/773

,595

�5/4

/201

0�8,

409,

206�

4/2/

2013

�07

/01/

2029

79�

1037

6�73

1.50

0�TI

SSU

E�M

ODI

FICA

TIO

N�D

EVIC

ES�A

ND�

MET

HODS

�13

/338

,103

�12/

27/2

011

8,39

8,64

1�3/

19/2

013�

07/0

1/20

29

80�

1037

6�70

6.30

1�TI

SSU

E�AC

CESS

�GU

IDEW

IRE�

SYST

EM�A

ND�

MET

HOD�

12/9

17,2

53�1

1/1/

2010

�8,

551,

097�

10/8

/201

3�08

/29/

2026

81�

1037

6�70

6.50

2�AC

CESS

�AN

D�TI

SSU

E�M

ODI

FICA

TIO

N�

SYST

EMS�

AND�

MET

HODS

�13

/588

,969

�8/1

7/20

12�

8,56

8,41

6�10

/29/

2013

10/1

4/20

25

82�

1037

6�70

0.31

0�DE

VICE

S�AN

D�M

ETHO

DS�F

OR�

TISS

UE�

MO

DIFI

CATI

ON

�13

/430

,500

�3/2

6/20

12�

8,57

9,90

2�11

/12/

2013

12/8

/202

5�

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 16

9 of

221

of

23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

83�

1037

6�70

0.30

9�FL

EXIB

LE�T

ISSU

E�RE

MO

VAL�

DEVI

CES�

AND�

MET

HODS

�13

/267

,683

�10/

6/20

11�

8,58

5,70

4��

11/1

9/20

1305

/09/

2026

84�

1037

6�70

0.51

4�M

ETHO

DS,�S

YSTE

MS�

AND�

DEVI

CES�

FOR�

CARP

AL�T

UN

NEL

�RE

LEAS

E�13

/112

,886

�5/2

0/20

11�

8,61

7,16

312

/31/

2013

09/1

4/20

26

85�

1037

6�70

0.51

5�M

ETHO

DS,�S

YSTE

MS�

AND�

DEVI

CES�

FOR�

CARP

AL�T

UN

NEL

�RE

LEAS

E�13

/112

,918

�5/2

0/20

11�

8,61

3,74

512

/24/

2013

09/1

4/20

26

86�

1037

6�70

0.31

1�DE

VICE

S�AN

D�M

ETHO

DS�F

OR�

TISS

UE�

MO

DIFI

CATI

ON

�13

/484

,744

� 5/3

1/20

12�

8,64

7,34

602

/11/

2014

10/1

5/20

25

87�

1037

6�70

0.30

4�FL

EXIB

LE�T

ISSU

E�RA

SP�

13/2

43,0

95�9

/23/

2011

�8,

652,

138�

2/18

/201

4�10

/15/

2025

88�

1037

6�70

0.40

3�TI

SSU

E�M

ODI

FICA

TIO

N�D

EVIC

ES�

13/2

32,8

82�9

/14/

2011

�8,

662,

228�

�3/

4/20

14�

12/0

7/20

27

93�

1037

6�72

9.50

0�FL

EXIB

LE�N

EURA

L�LO

CALI

ZATI

ON

�DEV

ICES

�AN

D�M

ETHO

DS�

13/3

40,3

63�1

2/29

/201

18,

801,

626�

8/12

/201

4��

94�

1037

6�70

6.40

1�TI

SSU

E�AC

CESS

�GU

IDEW

IRE�

SYST

EM�A

ND�

MET

HOD�

14/0

23,8

93�9

/11/

2013

��8

,845

,637

�9/

30/2

014�

�

95�

1037

6�72

5.30

0�TI

SSU

E�M

ODI

FICA

TIO

N�D

EVIC

ES�

13/0

07,3

81�1

/14/

2011

��8

.845

,639

�9/

30/2

014�

�

U.S

. Pat

ents

Allo

wed

– is

sue

fee

paid

/ is

sue

pend

ing

�

T312

001U

C1�

�

IMPL

ANTS

�FO

R�SP

INAL

�THE

RAPY�

14/1

52,8

8301

/10/

2014

��

�

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 17

0 of

221

of

23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

14/0

33,8

00

US

2014

-002

5117

A1

not

ice

of a

llow

ance

(ii)

U.S

. Pen

ding

Pat

ent A

pplic

atio

ns U.S

. Pen

ding

Pat

ent A

pplic

atio

ns fr

om T

ranS

1 In

c.

Ref

eren

ce N

o.

Title

Pu

b/Se

rial N

o.

Dat

eSt

atus

T109

002D

V1

Ther

apy�

Devi

ce�W

ith�F

ixat

ed�

Dist

ract

ion�

Dist

ance

2014

0236

244�

14/2

60,6

0308

/21/

2014

04

/24/

2014

pe

ndin

g

AXIA

MD

.115

ASp

inal

�Impl

ants

�And

�Im

plan

tatio

n�Sy

stem

�N

ot�y

et�p

ublis

hed�

03/1

0/20

14

Pend

ing

AX

IAM

D.1

15A

1Sp

inal

�Impl

ants

�And

�Im

plan

tatio

n�Sy

stem

�N

ot�y

et�p

ublis

hed�

03/1

3/20

14

Pend

ing

T114

002U

SU

M

ulti�

Thre

aded

�Ped

icle

�Scr

ew�

Syst

em�

Not

�yet

�pub

lishe

d�03

/13/

2014

Pe

ndin

g

U.S

. Pen

ding

Pat

ent A

pplic

atio

ns c

urre

ntly

bei

ng m

aint

aine

d fr

om B

axan

o, In

c.

File

�Ref

.�no.

�Ti

tle�

App.

�No.

�Ap

p.�D

ate�

Pub.

�No.

�Pu

b.�D

ate�

Stat

us�

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 17

1 of

221

o

f 23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

1037

6-70

0.40

4

�

FLEX

IBLE

�TIS

SUE�

RASP

��

14/1

80,2

21�

02/1

3/20

14�

2014

0163

562�

6/12

/201

4�pend

ing�

1037

6�70

0.31

4�FL

EXIB

LE�T

ISSU

E�RE

MO

VAL�

DEVI

CES�

AND�

MET

HODS

��

14/0

82,0

52�

11/1

5/20

13�

2014

0074

097�

3/13

/201

4�pend

ing�

1037

6�72

4.30

1�SY

STEM

S�AN

D�M

ETHO

DS�F

OR�

PERF

ORM

ING�

SPIN

AL�

FUSI

ON

�13

/783

,135

�3/

1/20

13�

�201

3017

8904

��7

/11/

2013

�Pe

ndin

g��

�

(iii)

U.S

. Pen

ding

Pro

visi

onal

Pat

ent A

pplic

atio

ns

U.S

. Pen

ding

Pro

visi

onal

Pat

ent A

pplic

atio

ns fr

om T

ranS

1

Ref

eren

ce N

o.Ti

tlePu

b/Se

rial N

o.D

ate

Stat

us

1406

11 L

LG-2

2 Pe

dicl

e Sc

rew

and

Rod

Im

plan

tatio

n Sy

stem

(in

situ

mea

sure

men

t)

61/9

97,8

46

6-11

-201

4 Pe

ndin

g�co

nver

sion�

Add

ition

al P

aten

ts:4

US

2011

-006

0314

A1

- D

EV

ICE

S A

ND

ME

TH

OD

S FO

R T

RE

AT

ING

TIS

SUE

US

2011

-016

0731

A1

- DE

VIC

ES

AN

D M

ET

HO

DS

FOR

TIS

SUE

AC

CE

SS

US

2011

-006

0314

A1

- D

EV

ICE

S A

ND

ME

TH

OD

S FO

R T

RE

AT

ING

TIS

SUE

4 The

Sel

ler h

as n

ot p

aid

the

asso

ciat

ed re

gist

ratio

n an

d/or

mai

nten

ance

fees

for a

ny o

f the

pat

ents

list

ed b

elow

, nor

has

it, s

ince

Aug

ust 2

014,

oth

erw

ise

enfo

rced

an

y su

ch p

aten

ts.

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 17

2 of

221

o

f 23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

US

2012

-019

1003

A1

- FL

EX

IBL

E N

EU

RA

L L

OC

AL

IZA

TIO

N D

EV

ICE

S A

ND

ME

TH

OD

S

U

S 20

13-0

1508

55 A

1 -

MU

LT

IPL

E P

AT

HW

AY

S FO

R S

PIN

AL

NE

RV

E R

OO

T D

EC

OM

PRE

SSIO

N F

RO

M A

SIN

GL

E

AC

CE

SS P

OIN

T

US

2013

-015

0856

A1_

TIS

SUE

MO

DIF

ICA

TIO

N D

EV

ICE

S A

ND

ME

TH

OD

S

U

S 20

13-0

3108

37 A

1 - P

OW

ER

ED

TIS

SUE

MO

DIF

ICA

TIO

N D

EV

ICE

S A

ND

ME

TH

OD

S

US

2014

-018

0293

A1

- TIS

SUE

MO

DIF

ICA

TIO

N D

EV

ICE

S

US

2014

-010

7709

A1

- AC

CE

SS A

ND

TIS

SUE

MO

DIF

ICA

TIO

N S

YST

EM

S A

ND

ME

TH

OD

S

WO

200

8/02

7926

- T

ISSU

E A

CC

ESS

GU

IDE

WIR

E S

YST

EM

AN

D M

ET

HO

D

JP20

1050

2305

(A)

EP2

0567

10 (A

2)

CA

2661

869

(A1)

A

U20

0728

9243

(A1)

A

U20

0728

9243

(B2)

WO

200

7/10

6740

- M

ET

HO

DS

AN

D A

PPA

RA

TU

S FO

R T

ISSU

E M

OD

IFIC

AT

ION

WO

200

6/04

4727

- D

EV

ICE

S A

ND

ME

TH

OD

S FO

R T

ISSU

E R

EM

OV

AL

JP

2012

1793

71 (A

) J

P560

7100

(B2)

JP

2008

5166

94 (A

) J

P524

3034

(B2)

E

P179

9129

(A2)

E

P179

9129

(A4)

C

A25

8390

6 (A

1)

CA

2583

906

(C)

AU

2005

2955

89 (A

1)

AU

2005

2955

89 (B

2)

WO

201

0/00

9093

- T

ISSU

E M

OD

IFIC

AT

ION

DE

VIC

ES

MX

2011

0005

10 (A

) E

P232

8489

(A2)

E

P232

8489

(A4)

C

A27

3073

2 (A

1)

AU

2009

2710

47 (A

1)

AU

2009

2710

47

(iv

) Is

sued

For

eign

Pat

ents

and

Pat

ent A

pplic

atio

ns O

wne

d by

Com

pany

Issu

ed F

orei

gn P

aten

ts fr

om T

ranS

1 In

c. –

cas

es in

ital

ics w

ill n

ot h

ave

annu

ities

pai

d / b

e m

aint

aine

d m

ovin

g fo

rwar

d

File

No.

Ti

tle

Pate

nt N

o. /

App

. No.

Is

sue

Dat

e/

Filin

g D

ate

Stat

us

AXIA

MD

.005

VEP

Appa

ratu

s fo

r per

form

ing

EP 1

2572

17

01/0

9/20

08

GR

ANTE

D.

Valid

ated

: Uni

ted

King

dom

, Fra

nce,

Ger

man

y, It

aly,

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 17

3 of

221

o

f 23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

File

No.

Ti

tle

Pate

nt N

o. /

App

. No.

Is

sue

Dat

e/

Filin

g D

ate

Stat

us

ther

apeu

tic p

roce

dure

s in

th

e sp

ine

0191

0681

.4

02/1

4/20

01

Spai

n, T

urke

y, a

nd A

ustri

a.

AXIA

MD

.005

PEP

Met

hod

and

appa

ratu

s fo

r sp

inal

dis

tract

ion

and

fusi

on

EP 1

5783

15 B

1

0379

0235

.0

06/1

8/20

08

12/0

2/20

03

GR

ANTE

D.

Valid

ated

in U

nite

d Ki

ngdo

m, F

ranc

e, G

erm

any,

Ital

y,

Spai

n, T

urke

y, a

nd A

ustri

a.

AXIA

MD

.002

VEP

Axia

l spi

nal i

mpl

ant a

nd

appa

ratu

s fo

r im

plan

ting

an

axia

l spi

nal i

mpl

ant w

ithin

th

e ve

rtebr

ae o

f the

spi

ne

EP 1

2655

41 B

1 01

9106

14.5

11

/26/

2008

02

/14/

2001

G

RAN

TED

. Va

lidat

ed in

Uni

ted

King

dom

, Fra

nce,

Ger

man

y, It

aly,

AXIA

MD

.003

VJP

Appa

ratu

s fo

r for

min

g sh

aped

axi

al b

ores

thro

ugh

spin

al v

erte

brae

JP 4

2923

60

2001

-559

362

04/1

7/20

09

02/1

4/20

01

GR

ANTE

D

AXIA

MD

.006

VJP

Appa

ratu

s fo

r per

form

ing

a di

scec

tom

y th

roug

h a

trans

-sac

ral a

xial

bor

e w

ithin

the

verte

brae

of t

he

spin

e

JP 4

3408

34

2001

-559

364

07/1

7/20

09

02/1

4/20

01

GR

ANTE

D

AXIA

MD

.004

VJP

Appa

ratu

s fo

r for

min

g cu

rved

axi

al b

ores

thro

ugh

spin

al v

erte

brae

JP 4

3522

04

2001

-559

333

08/0

7/20

09

02/1

4/20

01

Gra

nted

.

AXIA

MD

.001

VEP

Appa

ratu

s fo

r pro

vidi

ng

post

erio

r or a

nter

ior a

cces

s to

spi

nal v

erte

brae

EP 1

2572

12

0190

9230

.3

09/0

2/20

09

02/1

4/20

01

Valid

ated

in D

E FR

GB

IT T

R.

AXIA

MD

.005

VJP

Appa

ratu

s fo

r per

form

ing

ther

apeu

tic p

roce

dure

s in

th

e sp

ine

JP 4

7030

84

2001

-559

335

03/1

8/20

11

02/1

4/20

01

Gra

nted

AXIA

MD

.001

VJP

Appa

ratu

s fo

r pro

vidi

ng

post

erio

r or a

nter

ior a

cces

s JP

472

6377

4/

22/2

011

Gra

nted

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 17

4 of

221

o

f 23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

File

No.

Ti

tle

Pate

nt N

o. /

App

. No.

Is

sue

Dat

e/

Filin

g D

ate

Stat

us

to s

pina

l ver

tebr

ae

2001

-559

363

2003

-531

648

02/1

4/20

01

10/2

8/20

03

AXIA

MD

.001

VREP

Ap

para

tus

for p

rovi

ding

po

ster

ior o

r ant

erio

r acc

ess

to s

pina

l ver

tebr

ae

EP 2

2236

63

0916

2645

.7

4/18

/201

2 02

/14/

2001

G

rant

ed V

alid

ated

in G

B, F

R, D

E,

AXIA

MD

.015

VEP

Tool

s An

d To

ol K

its F

or

Perfo

rmin

g M

inim

ally

In

vasi

ve P

roce

dure

s O

n Th

e Sp

ine

EP 1

6918

48

0479

6283

.2

08/2

2/20

12

10/2

2/20

04

Gra

nted

– V

alid

ated

in G

B, F

R, D

E

T105

001A

U

Ther

apy

Prov

isio

n to

Ad

jace

nt M

otio

n Se

gmen

ts

AU 2

0052

7259

6

08/1

5/20

05

02/0

3/20

11

Expi

res

8/15

/202

5

T105

001E

P Th

erap

y Pr

ovis

ion

to

Adja

cent

Mot

ion

Segm

ents

EP

178

6341

05

7851

15.6

08/1

5/20

05

1214

/201

1 G

rant

ed –

Val

idat

ed in

GB,

FR

, DE,

AT,

NE

T105

001J

P Th

erap

y Pr

ovis

ion

to

Adja

cent

Mot

ion

Segm

ents

JP

499

3500

20

07-5

2585

2 is

sued

05

/18/

2012

G

rant

ed; E

xpire

s 8/

15/2

025

Fore

ign

Pend

ing

Pate

nt A

pplic

atio

ns c

urre

ntly

bei

ng m

aint

aine

d fr

om T

ranS

1 In

c.

File

No.

Ti

tle

Doc

umen

t No.

Fi

ling

Dat

e / p

ub. d

ate

Stat

us

T109

002E

P S

pina

l The

rapy

Dev

ice

with

Fix

ated

Dis

tract

ion

Dis

tanc

e

10 8

08 6

80.2

. EP

246

4317

08

/11/

2010

6/

20/ 2

012

Pend

ing

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 17

5 of

221

o

f 23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

File

No.

Ti

tle

Doc

umen

t No.

Fi

ling

Dat

e / p

ub. d

ate

Stat

us

T312

001E

PO

Spi

nal T

hera

py L

ater

al

App

roac

h A

cces

s In

stru

men

ts

1284

9798

.9Ef

fect

ive

filin

g�Da

te�

Nov

embe

r�9,

�201

2.

Pend

ing

T312

001C

NS

pina

l The

rapy

Lat

eral

A

ppro

ach

Acc

ess

Inst

rum

ents

pend

ing

5/15

/201

4 Pe

ndin

g

AX

IAM

D.1

15W

OSp

inal

�Impl

ants

�And

�Im

plan

tatio

n�Sy

stem

�N

ot�y

et�p

ublis

hed�

03/1

0/20

14

Pend

ing

Fore

ign

Issu

ed P

aten

ts c

urre

ntly

bei

ng m

aint

aine

d fr

om B

axan

o, In

c.

File

�Ref

.�no.

�Ti

tle�

App.

�No.

�Ap

p.�D

ate�

Nat

.�Dat

e�Pa

tent

�No.

�Pa

tent

�Da

te�

1037

6�70

0.DE

5�TI

SSU

E�RE

MO

VAL�

DEVI

CES�

AND�

MET

HODS

�10

0750

66.0

�12

/7/2

007�

��EP

�224

1274

�2/

1/20

12�

1037

6�70

0.FR

5�TI

SSU

E�RE

MO

VAL�

DEVI

CES�

AND�

MET

HODS

�10

0750

66.0

�12

/7/2

007�

��22

4127

4�2/

1/20

12�

1037

6�70

0.G

B5�

TISS

UE�

REM

OVA

L�DE

VICE

S�AN

D�M

ETHO

DS�

1007

5066

.0�

12/7

/200

7��

2241

274�

2/1/

2012

�

1037

6�70

0.IT

5�TI

SSU

E�RE

MO

VAL�

DEVI

CES�

AND�

MET

HODS

�10

0750

66.0

�12

/7/2

007�

��22

4127

4�2/

1/20

12�

(i)

Fede

ral T

rade

mar

ks o

wne

d by

Com

pany

Fede

ral T

rade

mar

ks c

urre

ntly

bei

ng m

aint

aine

d fr

om T

ranS

1 In

c.

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 17

6 of

221

3D

A AX

12/3

1/20

14 S

L1 1

34

MA

RK

AXIA

L R

OD

AV

AN

CE

AXIA

LIF

AXIA

LIF

2L

XIA

LIF

360º

RE

VE

AL

VE

O

1692

v5 1

0918

8.00

00

KM

OB

FIL

(AXI

AM

020T

097T

019T

042T

044T

094T

082T 01LE

NO

. M

D*)

T T T T T T T 85

Pa

APP

. NO

./ A

PP.

DA

TE

78/4

85,7

13

09

/17/

04

85/8

24,7

99

01/1

6/13

78/4

85,7

08

09

/17/

04

78/9

52,8

10

08

/15/

06

77/0

79,4

09

01

/09/

07

85/7

81,1

71

11/1

6/12

5/48

6931

12/

05/1 ag

e15

of 2

3

REG

. NO

./ R

EG.

DA

TE

3980

124

06/2

1/11

30

7292

0

03/2

8/06

3677

966

09/0

1/09

3803

524

06/1

5/10

4569

051

�7/1

5/20

14

1 42

4343

8 11

/13/

12

RE

GIS

TER

ED Ren

R

EG

ISTE

R

RE

GIS

TER

E

Re

RE

GIS

TER

E

Ren

RE

GIS

TER

E

Re

ST

D;

Sec

tion

8 D

e 06ne

wal

due

bet

we Al

ED;

Ren

ewal

du

ED; S

ectio

n 8

De 09

enew

al d

ue b

etw

e

ED; S

ectio

n 8

Dec 06

new

al d

ue b

etw

e

RE

GI

Cla

ED; S

ectio

n 8

De 11

enew

al d

ue b

etw

eTATU

S

ecla

ratio

n du

e be

t/2

1/17

een

06/2

1/20

- 0

6

low

ed

ue b

etw

een

03/2

8

clar

atio

n du

e be

tw/0

1/15

ee

n 09

/01/

18 -

09

clar

atio

n du

e be

tw/1

5/16

een

06/1

5/19

- 0

6

STER

ED

ass

10

ecla

ratio

n du

e be

t/1

3/18

ee

n 11

/13/

21- 1

1/twee

n 06

/21/

16 –

6/21

/21

8/15

- 0

3/28

/16

wee

n 09

/01/

14 -

9/01

/19

wee

n 06

/15/

15 –

6/15

/20

twee

n 11

/13/

17-

/13/

22

–

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 17

7 of

221

BA

X

Che

T 12/3

1/20

14 S

L1 1

34

MA

RK

XA

NO

with

C

hevr

on

evro

n (d

esig

n)

TRA

JEC

T

1692

v5 1

0918

8.00

00

KM

OB

FIL

(AXI

AM

151T

152T

161T

01LE N

O.

MD

*)

T T T

Pa

APP

. NO

./ A

PP.

DA

TE

86/0

4777

508

/26/

2013

86/0

4783

508

/26/

2013

86/2

4845

8.

04/1

0/20

14

age

16 o

f 23

REG

. NO

./ R

EG.

DA

TE

4,56

2,76

97/

8/20

14

4,56

2,77

17/

8/20

14

ST Reg

Reg

ALLTA

TUS

gist

ered

gist

ered

LOW

ED

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 17

8 of

221

o

f 23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

Fede

ral T

rade

mar

ks c

urre

ntly

bei

ng m

aint

aine

d fr

om B

axan

o, In

c.

MA

RK

A

PP. N

O.

FIL

ING

D

AT

E

RE

G. N

O.

RE

G. D

AT

E

CL

ASS

C

LA

SS:

GO

OD

S/SE

RV

ICE

S ST

AT

US

BA

XA

NO

78

/867

,271

21

-Apr

-200

6 37

5942

2 09

-Mar

-201

0 10

10: S

urgi

cal a

nd m

edic

al d

evic

es, m

achi

nes,

inst

rum

ents

, app

arat

us a

nd sy

stem

s, na

mel

y,

min

imal

ly in

vasi

ve su

rgic

al in

stru

men

ts fo

r re

mov

ing

tissu

e

RE

GIS

TER

ED

BA

XA

NO

78

/867

,272

21

-Apr

-200

6 38

0123

5 08

-Jun

-201

0 44

44

: Pr

ovid

ing

med

ical

info

rmat

ion

RE

GIS

TER

ED

IOFL

EX

77/8

17,7

65

01-S

ept-2

009

3894

968

21-D

ec-2

010

10

10:

Surg

ical

and

med

ical

dev

ices

and

in

stru

men

ts, n

amel

y, su

rgic

al in

stru

men

ts fo

r ac

cess

ing,

loca

lizin

g an

d m

odify

ing

tissu

e;

Surg

ical

and

med

ical

syst

ems,

com

pris

ed o

f a se

t of

min

imal

ly in

vasi

ve su

rgic

al in

stru

men

ts u

sed

in se

quen

ce fo

r acc

essi

ng, l

ocal

izin

g an

d m

odify

ing

tissu

e

RE

GIS

TER

ED

IOFL

EX

77/8

17,7

82

01-S

ept-2

009

3887

573

07-D

ec-2

010

44

44:

Med

ical

serv

ices

R

EG

IST

ERE

D

iO-F

lex

77/8

17,7

91

01-S

ept-2

009

3894

969

21-D

ec-2

010

10

10:

Surg

ical

and

med

ical

dev

ices

and

in

stru

men

ts, n

amel

y, su

rgic

al in

stru

men

ts fo

r ac

cess

ing,

loca

lizin

g an

d m

odify

ing

tissu

e;

Surg

ical

and

med

ical

syst

ems,

com

pris

ed o

f a se

t of

min

imal

ly in

vasi

ve su

rgic

al in

stru

men

ts u

sed

in se

quen

ce fo

r acc

essi

ng, l

ocal

izin

g an

d m

odify

ing

tissu

e

RE

GIS

TER

ED

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 17

9 of

221

o

f 23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

MA

RK

A

PP. N

O.

FIL

ING

D

AT

E

RE

G. N

O.

RE

G. D

AT

E

CL

ASS

C

LA

SS:

GO

OD

S/SE

RV

ICE

S ST

AT

US

iO-F

lex

77/8

17,7

94

01-S

ept-2

009

3887

574

07-D

ec-2

010

44

44:

Med

ical

serv

ices

R

EG

IST

ERE

D

77/8

17,8

29

01-S

ept-2

009

3894

970

21-D

ec-2

010

10

10:

Surg

ical

and

med

ical

dev

ices

and

in

stru

men

ts, n

amel

y, su

rgic

al in

stru

men

ts fo

r ac

cess

ing,

loca

lizin

g an

d m

odify

ing

tissu

e;

Surg

ical

and

med

ical

syst

ems,

com

pris

ed o

f a se

t of

min

imal

ly in

vasi

ve su

rgic

al in

stru

men

ts u

sed

in se

quen

ce fo

r acc

essi

ng, l

ocal

izin

g an

d m

odify

ing

tissu

e

RE

GIS

TER

ED

77/8

17,8

33

01-S

ept-2

009

3894

971

21-D

ec-2

010

44

44:

Med

ical

serv

ices

R

EG

IST

ERE

D

MIC

RO

BLA

DE

SHA

VER

A

XIA

MD

.138

T 77

/817

,695

01

-Sep

t-200

9 39

2128

6 15

-Feb

-201

1 10

10

: Su

rgic

al a

nd m

edic

al d

evic

es a

nd

inst

rum

ents

, nam

ely,

surg

ical

inst

rum

ents

for

acce

ssin

g an

d m

odify

ing

soft

tissu

e an

d bo

ne

RE

GIS

TER

ED

MIC

RO

BLA

DE

SHA

VER

77

/817

,698

01

-Sep

t-200

9 39

2651

4 01

-Mar

-201

1 44

44

: M

edic

al se

rvic

es

RE

GIS

TER

ED

NEU

RO

CH

ECK

A

XIA

MD

.139

T 77

/817

,683

01

-Sep

t-200

9 3,

958,

689

10-M

ay-

2011

10

10:

Surg

ical

and

med

ical

dev

ices

and

in

stru

men

ts, n

amel

y, su

rgic

al in

stru

men

ts fo

r ac

cess

ing

and

loca

lizin

g tis

sue

RE

GIS

TER

ED

NEU

RO

CH

ECK

77

/817

,687

01

-Sep

t-200

9 40

7454

7 20

-Dec

-201

1 44

44

: Pr

ovid

ing

med

ical

info

rmat

ion

conc

erni

ng

the

use

of su

rgic

al d

evic

es a

nd in

stru

men

ts

RE

GIS

TER

ED

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 18

0 of

221

T ( 5 e 12/3

1/20

14 S

L1 1

34MA

IO-T

Trad

emar

ks5 �

8565

4590

�42

8 585

5719

95�

4326

7781

7743

�38

8777

8177

42�

3958

7781

7733

�38

9477

8177

27�

3958

7781

7720

�38

8777

8177

15�

3958

7781

7707

�38

8777

8177

02�

3958

(ii)

Fore

ign

5 The

Sel

ler

has

noen

forc

ed a

ny su

ch t 16

92v5

109

188.

0000

AR

K

TOM

E

�59

02�IO

�FLE

XIBI

LI69

80�IO

�CO

NN

EC75

72�IN

SIDE

�OU

T86

93�IN

SIDE

�OU

T49

67�S

URG

ERY�

FR86

92�S

URG

ERY�

FR75

71�D

ISCO

VER�

T86

91�D

ISCO

VER�

T75

70�P

RECI

SIO

N�D

8690

�PRE

CISI

ON

�D

Trad

emar

ks

ot p

aid

the

asso

cia

trade

mar

ks.

01

APP

. NO

. FI

LIN

G

DA

TE

85/0

82,8

46

12-J

ul-2

010

ITY� T� T.

�THE

�INTU

ITIV

E�D

T.�T

HE�IN

TUIT

IVE�

DRO

M�T

HE�IN

SIDE

�RO

M�T

HE�IN

SIDE

�TH

E�U

PSID

E�O

F�TH

THE�

UPS

IDE�

OF�

THDE

COM

PRES

SIO

NDE

COM

PRES

SIO

N

Fore

ign

Trad

e

ated

reg

istra

tion

an

Pa

RE

G. N

O.

RE

G. D

AT

E

4415

146

10/0

8/20

13

DIRE

CTIO

N�

DIRE

CTIO

N�

OU

T�O

UT�

HE�IN

SIDE

�OU

T�HE

�INSI

DE�O

UT�

N�F

ROM

�THE

�INSI

N�F

ROM

�THE

�INSI

emar

ks c

urre

nt

nd/o

r m

aint

enan

ce

age

19 o

f 23

CL

ASS

10 &

41

10: S

inst

rac

ce

41: E

sem

itra

in

DE�O

UT�

DE�O

UT�

tly b

eing

mai

nt

fees

for

any

of

the

CL

ASS

: G

O

Surg

ical

and

med

icru

men

ts, n

amel

y, s

essi

ng a

nd m

odify

in

Educ

atio

n, n

amel

yin

ars,

conf

eren

ces

ning

serv

ices

all

in

tain

ed fr

om T

r

e tra

dem

arks

list

edOO

DS/

SER

VIC

ES

cal d

evic

es a

nd

surg

ical

inst

rum

ent

ng so

ft tis

sue

and

b

y, p

rovi

ding

cla

sses

and

wor

ksho

ps a

nth

e m

edic

al fi

eld.

ranS

1 In

c.

d be

low

, nor

has

itS ts fo

r bo

ne.

s, nd

RE

GI S

t, si

nce

Aug

ust 2

0

STA

TU

S

STER

ED

14, o

ther

wise

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 18

1 of

221

o

f 23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

MA

RK

C

OU

NTR

Y K

MO

B F

ILE

NO

. A

PP. N

O./

APP

. D

ATE

R

EG. N

O./

REG

. DA

TE

STA

TUS

AX

IALI

F C

anad

a 01

9WC

A 14

1098

3

09/1

6/08

TM

A80

3911

08

/09/

11

RE

GIS

TER

ED R

enew

al D

ue 0

8/09

/26

AX

IALI

F C

hina

01

9WC

N

1012

8355

10

/31/

11

1012

8355

12

/21/

12

RE

GIS

TER

ED

AX

IALI

F E

urop

ean

Com

mun

ity

019W

EU

43

3946

1

03/1

5/05

43

3946

1

04

/18/

06

RE

GIS

TER

ED; R

enew

al D

ue 0

3/15

/15

AX

IALI

F 2L

E

urop

ean

Com

mun

ity

042W

EU

00

5648

639

01/2

9/07

00

5648

639

02/0

4/08

R

EG

ISTE

RED

; Ren

ewal

Due

01/

29/1

7

AX

IALI

F 36

0º

Eur

opea

n C

omm

unity

04

4WE

U

6053

731

06

/29/

07

6053

731

05/3

0/08

R

EG

ISTE

RED

; Ren

ewal

Due

06/

29/1

7

TRA

NS

1 C

hina

01

2WC

N

1012

8354

10

/31/

11

P

EN

DIN

G; D

ecis

ion

expe

cted

Sep

tem

ber 2

014.

TRA

NS

1 E

urop

ean

Com

mun

ity

012W

EU

33

0362

5

08/0

6/03

33

0362

5

03

/24/

05

RE

GIS

TER

ED; R

enew

al D

ue 0

8/06

/13

VE

O

Chi

na

082W

CN

10

8810

74

05/0

8/12

RE

GIS

TER

ED re

new

al d

ue S

ept 6

, 202

3

(Chi

nese

tra

nslit

erat

ion

of

VEO

)

Chi

na

083W

CN

10

8810

73

05/0

8/12

RE

GIS

TER

ED re

new

al d

ue S

ept 6

, 202

3

VE

O

Eur

opea

n C

omm

unity

08

2WE

U

1083

7268

04

/25/

12

1083

7268

01

/09/

13

RE

GIS

TER

ED; R

enew

al D

ue 0

4/25

/22

Fore

ign

Trad

emar

ks fr

om B

axan

o, In

c.

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 18

2 of

221

o

f 23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

MA

RK

TE

RR

ITO

RY

APP

. NO

.

FILI

NG

D

ATE

REG

. NO

.

REG

. DA

TE

CLA

SSES

C

LASS

: G

OO

DS/

SER

VIC

ES

STA

TUS

BAXA

NO

Eu

rope

an

Com

mun

ity

5311

865

13-S

ept-2

006

5311

865

16-A

ug-2

007

10 &

44

10:

Surg

ical

and

med

ical

dev

ices

, m

achi

nes,

ins

trum

ents

, ap

para

tus

and

syst

ems,

and

44: M

edic

al s

ervi

ces.

REG

ISTE

RED

iO-F

lex

Euro

pean

C

omm

unity

89

1905

2

01-M

ar-2

010

8919

052

13-O

ct-2

010

10 &

44

10:

Surg

ical

and

med

ical

dev

ices

an

d in

stru

men

ts,

nam

ely,

sur

gica

l in

stru

men

ts

for

acce

ssin

g,

loca

lizin

g an

d m

odify

ing

tissu

e;

Surg

ical

an

d m

edic

al

syst

ems,

co

mpr

ised

of

a se

t of

min

imal

ly

inva

sive

sur

gica

l ins

trum

ents

use

d in

se

quen

ce

for

acce

ssin

g,

loca

lizin

g an

d m

odify

ing

tissu

e

44: M

edic

al s

ervi

ces.

REG

ISTE

RED

IO-T

OM

E Eu

rope

an

Uni

on

9647

389

10-Ja

n-20

11

9647

389

16-Ju

n-20

11

10, 4

1, 4

4 10

: Su

rgic

al a

nd m

edic

al d

evic

es,

mac

hine

s, i

nstr

umen

ts,

appa

ratu

s an

d sy

stem

s; s

urgi

cal a

nd m

edic

al

devi

ces

and

inst

rum

ents

, na

mel

y,

surg

ical

ins

trum

ents

for

acc

essi

ng

and

mod

ifyin

g so

ft tis

sue

and

bone

.

41:

Educ

atio

n;

Prov

idin

g of

tr

aini

ng;

educ

atio

n an

d tr

aini

ng

serv

ices

in th

e m

edic

al fi

eld.

44:

Med

ical

Se

rvic

es;

prov

idin

g m

edic

al in

form

atio

n.

REG

ISTE

RED

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 18

3 of

221

o

f 23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

Dis

tribu

tion

Agr

eem

ent b

etw

een

Ber

kele

y A

dvan

ced

Bio

mat

eria

ls, I

nc. (

“Ber

kele

y”) a

nd T

ranS

1 In

c., d

ated

Janu

ary

19, 2

010

(lice

nse

to u

se B

erke

ley’

s bra

nd, t

rade

mar

ks, a

nd d

istri

bute

Ber

kele

y’s w

ritte

n m

arke

ting

mat

eria

ls a

nd d

ocum

enta

tion

sole

ly in

con

nect

ion

with

the

Dis

tribu

tion

Agr

eem

ent).

Excl

usiv

e Li

cens

e A

gree

men

t bet

wee

n M

itche

ll A

. Har

denb

rook

, M.D

., M

H B

rook

, Inc

., an

d Tr

anS1

, Inc

., da

ted

Janu

ary

24, 2

011

(exc

lusi

ve li

cens

e to

pat

ents

and

kno

w-h

ow, i

nclu

ding

any

impr

ovem

ents

, rel

atin

g to

the

follo

win

g pa

tent

and

pat

ent a

pplic

atio

n:Su

rgic

al R

etra

ctor

Sys

tem

(U.S

. 8,5

68,3

06 i

ssue

d 10

/29/

2013

)an

d Su

rgic

al R

etra

ctor

Sys

tem

(PC

T/U

S201

0/00

1014

). S

ee E

xhib

it 10

.20

to C

ompa

ny’s

For

m 1

0-K

file

d w

ith th

e SE

C o

n M

arch

7, 2

013

for d

etai

ls.

The

Com

pany

lice

nses

the

follo

win

g pa

tent

s pur

suan

t to

licen

se a

gree

men

ts m

ater

ial t

o th

e C

ompa

ny’s

bus

ines

s:

Ref

eren

ce N

o.

Pate

nt N

o./

App

l. N

o.

Issu

e D

ate/

Fi

ling

Dat

eTi

tle

1AX

IAM

D.0

37L

Mid

dlet

on

6,74

6,45

1 09

/872

,042

06

/08/

2004

06

/01/

2001

Ti

ssue

Cav

itatio

n D

evic

e an

d M

etho

d

2AX

IAM

D.0

87L

Jack

son

7,96

7,85

0 12

/290

,244

06

/28/

2011

10

/29/

2008

Po

lyax

ial B

one

Anch

or w

ith H

elic

al C

aptu

re C

onne

ctio

n, In

sert

and

Dua

l Loc

king

Ass

embl

y

6,72

6,68

9 10

/236

,123

04

/27/

2004

09

/06/

2002

H

elic

al In

terlo

ckin

g M

atin

g G

uide

and

Adv

ance

men

t Stru

ctur

e

8,27

3,10

9

10/8

31,9

19

09/2

5/20

12

04/2

6/20

04

Hel

ical

Wou

nd M

echa

nica

lly In

terlo

ckin

g M

atin

g G

uide

and

Adv

ance

men

t Stru

ctur

e

5,59

1,16

5 24

4.43

5 01

/07/

2997

10

/15/

1993

Ap

para

tus

and

Met

hod

for S

pina

l Fix

atio

n an

d C

orre

ctio

n of

Def

orm

ities

6,26

1,28

8 09

/500

.297

07

/17/

2001

02

/08/

2000

Im

plan

t Sta

biliz

atio

n an

d Lo

ckin

g Sy

stem

5,72

0,75

1 75

7,48

3 02

/24/

1998

11

/27/

1996

To

ols

for U

se in

Sea

ting

Spin

al R

ods

in O

pen

Ende

d Im

plan

ts

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 18

4 of

221

o

f 23

12/

31/2

014

SL1

1341

692v

5 10

9188

.000

01

Ref

eren

ce N

o.

Pate

nt N

o./

App

l. N

o.

Issu

e D

ate/

Fi

ling

Dat

eTi

tle

7,16

0,30

0 10

/789

,149

01

/09/

2007

02

/27/

2004

O

rthop

edic

Impl

ant R

od R

educ

tion

Tool

Set

and

Met

hod

8,15

2,81

0 10

/996

,289

04

/10/

2012

11

/23/

2004

Sp

inal

Fix

atio

n To

ol S

et a

nd M

etho

d

8,16

2,94

8 12

/220

,185

04

/24/

2012

07

/22/

2008

O

rthop

edic

Impl

ant R

od R

educ

tion

Tool

Set

and

Met

hod

7,47

0,27

9 10

/789

,134

12

/30/

2008

02

/27/

2004

O

rthop

edic

Impl

ant R

od R

educ

tion

Tool

Set

and

Met

hod

8,10

0,91

5 12

/584

,413

01

/24/

2012

09

/04/

2009

O

rthop

edic

Impl

ant R

od R

educ

tion

Tool

Set

and

Met

hod

8,29

2,89

2 12

/454

,152

10

/23/

2012

05

/13/

2009

O

rthop

edic

Impl

ant R

od R

educ

tion

Tool

Set

and

Met

hod

3H

arde

nbro

ok

T311

01U

SU

8,56

8,30

6is

sued

10/2

9/20

13Su

rgic

al R

etra

ctor

Sys

tem

T3

1100

1UC

1

8,80

1,60

8

14/0

35,915

8-12

-201

4

9/24

/201

3

Two-

Sta

ge S

pina

l Acc

ess

Cha

nnel

with

Pso

as D

ocki

ng

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 18

5 of

221

Exhibit 4.12(a) SL1 1342200v6 109188.00001

Exhibit 4.12(a)


See attached.


4.12(b)-1 SL1 1342200v6 109188.00001

Schedule 4.12(b)

In-Bound Licenses

1. The Seller licenses the following software pursuant to standard end-user license agreements:13

� QAD Enterprise Applications � Sales Force � Adaptive Planning � Concur� ADP � Office 365 � AST

2. Exclusive License Agreement dated January 24, 2011 by and among Dr. Mitchell A. Hardenbrook, MH Brook, Inc., and the Seller.

3. Option Agreement dated August 11, 2014 by and between IKYN Surgical, LLC and the Seller, pursuant to which IKYN has granted to the Seller an exclusive option for a worldwide, exclusive license to the patent rights associated with U.S. Patent Provisional Application #61/942,737.14

4. The Seller has entered into several license agreements, pursuant to which a third party assigns, conveys, grants a license or right of use to, or sells to the Seller the intellectual property described therein:

a. Agreement for Tranforaminal Lumbar Interbody Fusion System Product Design and Development Consulting Services dated February 19, 2014 with Dr. Lawrence Cohen;

b. Agreement for Tranforaminal Lumbar Interbody Fusion System Product Design and Development Consulting Services dated January 30, 2014 with Dr. Richard Ozuna;

13 ADP, Office 365 and AST contract not available for assumption and assignment. Sales Force agreement for assumption and assignment only to if Acquired Assets include substantially all assets of Seller.

14 Counterparty has taken position that agreement was terminated prepetition.


4.12(b)-2 SL1 1342200v6 109188.00001

c. Agreement for Tranforaminal Lumbar Interbody Fusion System Product Design and Development Consulting Services dated December 16, 2013 with Dr. Jed Vanichkachorn;

d. Agreement for Lateral System Instrumentation Product Design and Development Consulting dated December 22, 2011 with Dr. Gary Fleischer;15

e. Agreement for Pedicle Screw System Product Design and Development Consulting Services dated June 13, 2012 with Dr. Sameer Mathur;

f. Agreement for Lordosis/Presacral Cage Product Design and Development Consulting Services dated October 8, 2013 with Dr. Gary Fleischer;

g. Agreement for Tranforaminal Lumbar Interbody Fusion System Product Design and Development Consulting Services dated January 1, 2014 with Anders Cohen, DO;

h. Agreement for Lateral System Instrumentation Product Design and Development Consulting dated December 22, 2011 with Dr. Tung Nguyen;16

i. Agreement for Lordosis/Presacral Cage Product Design and Development Consulting Services dated September 27, 2013 with Dr. Larry Khoo;

j. Agreement for Pedicle Screw System Product Design and Development Consulting Services dated June 13, 2012 with Dr. Nael Shanti;

k. Agreement for Lordosis/Presacral Cage Product Design and Development Consulting Services dated May 12, 2014 with Future Solutions II, LLC (Dr. James Billys);

l. Development and License Agreement (Polyaxial Screw/MIS/LIS/Helical Flange/BOT) dated January 1, 2013 with Dr. Roger P. Jackson and SMS Trust;

m. Agreement for Lateral System Instrumentation Product Design and Development Consulting dated December 8, 2011 with Dr. Neel Anand;

n. Agreement for Single Cutting Wire System Product Design and Development Consulting Services dated July 24, 2013 with Dr. William D. Smith; and

o. Agreement for Tranforaminal Lumbar Interbody Fusion System Product Design and Development Consulting Services dated December 16, 2013 with Dr. Daniel Park.

5. See also Exhibit 4.12(a) for additional licenses granted to the Seller.

15 Counterparty has taken position that agreement was terminated prepetition. 16 Counterparty has taken position that agreement was terminated prepetition.


4.12(c)-1 SL1 1342200v6 109188.00001

Schedule 4.12(c)

Out-Bound Licenses

None, other than rights of use granted to vendors, suppliers, consultants or independent contractors under or pursuant to any of the Material Contracts.


4.12(d)-1 SL1 1342200v6 109188.00001

Schedule 4.12(d)

Infringements

1. In October 2013, Paradigm BioDevices alleged that the Seller’s ICBGH infringes on the claimant’s U.S. Patent RE 40,796 (the reissue of U.S. Patent 5,954,671). The Seller responded in a letter from its counsel disputing the allegation. Since December 2013, the Seller has not received any further correspondences concerning the patent infringement claim.

2. In September 2012, an individual inventor alleged that the Seller’s ICBGH infringes on the claimant’s U.S. Patent 6,007,496. The Seller responded twice in a letter from its counsel disputing the allegation. Since the last correspondence in November 2012, the Seller has not received any further correspondences concerning the patent infringement claim.

3. On October 8, 2013, Mölnlycke Healthcare AB (“Mölnlycke”) filed a 90 Day Request for Extension of Time to Oppose Seller’s application for the mark AVANCE. Seller’s trademark counsel contacted Mölnlycke to discuss Mölnlycke’s concerns with Seller’s proposed use and registration of the AVANCE mark, and this matter was resolved between the parties permitting Seller to utilize the AVANCE mark for its pedicle screw system.


4.13(a)-1 SL1 1342200v6 109188.00001

Schedule 4.13(a)

Compliance with Law

1. The Seller is subject to periodic routine inspection by the FDA and other applicable Governmental Bodies.

In the last five years, there have been three (3) FDA inspections at the Seller’s facilities, the results of which have been previously provided to the Purchaser.

2. On January 24, 2012, the Seller received notice that a putative class action lawsuit had been filed in the U.S. District Court for the Eastern District of North Carolina, on behalf of all persons who purchased the Seller’s securities between February 21, 2008 and October 17, 2011. The complaint alleged violations of the Exchange Act based upon purported omissions and/or false and misleading statements concerning the Seller’s financial statements and reimbursement practices. The complaint sought damages sustained by the putative class, pre- and post-judgment interest, and attorneys’ fees and other costs. On September 7, 2012, the Seller filed a motion to dismiss the complaint for failure to meet the heightened pleading requirements of the Private Securities Litigation Reform Act of 1995, among other grounds. On September 19, 2013, the Seller’s motion was granted and the complaint was dismissed with prejudice. On October 17, 2013, the plaintiff filed a motion to alter or amend the order dismissing the complaint with prejudice.

3. On June 28, 2013, the Seller entered into a Settlement Agreement and Corporate Integrity Agreement (CIA) with various U.S. Governmental Bodies. Under the terms of this settlement agreement, the Seller has agreed to pay an aggregate of $6.0 million (plus accrued interest) in installments from July 2013 through July 2015 in settlement of certain government investigatory matters related to its compliance with federal healthcare fraud and false claims statutes. In addition, the Seller has agreed under the CIA, among other things, to maintain a compliance program designed to promote compliance with various federal health care and FDA requirements. Pursuant to the CIA, the Seller is required to notify the applicable Governmental Body in writing, among other things, of (i) any ongoing government investigation or legal proceeding involving an allegation that the Seller has committed a crime or have engaged in fraudulent activities; (ii) any other matter that a reasonable person would consider a probable violation of applicable criminal, civil, or administrative laws related to compliance with federal healthcare programs or FDA requirements; and (iii) any change in location, sale, closing, purchase, or establishment of a new business unit or location related to items or services that may be reimbursed by federal health care programs. The Seller is also subject to periodic reporting and certification


4.13(a)-2 SL1 1342200v6 109188.00001

requirements attesting that the provisions of the CIA are being implemented and followed, as well as certain document and record retention mandates.

4. The Seller did not files its 2014 Third Quarter Financial Statements with the SEC and has notified that SEC that it will no longer be making the filings that are required in order for it to remain as a publically traded company in good standing. The Seller makes no representation regarding its status as a publically traded company or the status of its equity.


4.13(b)-1 SL1 1342200v6 109188.00001

Schedule 4.13(b)

Governmental Authorizations

See Exhibit 4.13(b) for a listing of the CE Marks, 510(k) Clearances, and 510(k) Filings relating to the Products.


M

aste

r Reg

ulat

ory

Regi

stra

tions

Tab

le

Sept

embe

r 30,

201

4

US

Prod

uct

510k

#

Cla

ss

Prod

uct C

ode

Axi

aLI

F Pl

us

K100

210

II of

III

KWQ

V

EO

K123

997

II of

III

MA

X Fa

cet S

crew

s K0

7351

5 II

of II

I M

RW

Ma

nua

l Sur

gica

l Ins

trum

ents

Ex

emp

t I o

f III

LXH

Pr

esa

cra

l Acc

ess K

it Ex

emp

t I o

f III

LXH

IC

BGH

Ex

emp

t I o

f III

HW

K Te

mp

late

(VEO

Tria

ls, D

ilato

r Tria

ls)

Exem

pt

I of I

II H

WT

Axi

aLI

F 2L

K0

7364

3 II

of II

I KW

Q

iO-F

lex

K100

958,

K06

3231

II

HA

E N

euro

chec

k K0

9272

9, K

0817

42

II ET

N

Ca

thet

er

K102

594

II BS

O

CA

NA

DA

Prod

uct

Regi

stra

tion

#

Cla

ss

Regi

stra

tion

Hol

der

Fi

rst I

ssue

Tim

elin

e fo

r a

pp

rova

l

Regi

stra

tion

Ag

ent

Exp

iry

Freq

uenc

y fo

r ren

ewa

l N

otes

Axi

aLI

F 87

152

3 of

4

Baxa

no

Surg

ical

9/

13/2

011

9-12

m

onth

s Ba

xano

Su

rgic

al

N/A

a

nnua

l M

ust c

onfir

m

ann

ually

bef

ore

11/1

tha

t the

re

are

no

cha

nges

a

nd p

ay

fee

to

sell

Late

ral

8802

0 3

of 4

iO-F

lex

8806

0 3

of 4

Ba

xano

Su

rgic

al

1/13

/201

2

Baxa

no

Surg

ical

ann

ual

EU

Prod

uct

Regi

stra

tion

#

Cla

ss

Regi

stra

tion

Hol

der

Fi

rst I

ssue

Tim

elin

e fo

r a

pp

rova

l

Not

ified

Bod

y Ex

piry

Fr

eque

ncy

for r

enew

al

Not

es

Axi

aLI

F 41

3149

65

IIb o

f III

Baxa

no

Surg

ical

3/

17/2

005

6-12

m

onth

s In

terte

k 3/

9/20

15

(EC

Cer

t)

5 ye

ars

N

B re

certi

fica

tion

ever

y 3

year

s; UK

re

quire

s no

tific

atio

n of

C

lass

I p

rodu

cts

by M

edPa

ss

Face

t Scr

ews

4131

4965

IIb

of I

II 3/

17/2

005

3/9/

2015

(E

C C

ert)

La

tera

l 41

3149

65

IIb o

f III

3/17

/200

5 3/

9/20

15

(EC

Cer

t)

iO-F

lex

4131

4965

IIb

Tr

ansf

erre

d fr

om B

Si

3/

9/20

15

(EC

Cer

t)

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 19

4 of

221

M

aste

r Reg

ulat

ory

Regi

stra

tions

Tab

le

Sept

embe

r 30,

201

4

CHI

NA

Pr

oduc

t Re

gist

ratio

n #

C

lass

Re

gist

ratio

n Ho

lder

Fi

rst I

ssue

Tim

elin

e fo

r a

pp

rova

l

Regi

stra

tion

Ag

ent

Exp

iry

Freq

uenc

y fo

r ren

ewa

l N

otes

IMPL

AN

TS

Spin

al F

ixa

tion

Syst

em (A

xiaL

IF 1

L Le

gacy

)

(I) 2

0113

4625

09

III o

f III

Tra

nS1

8/10

/11

1-2

yea

rs

NA

MSA

(fo

rmer

ly u

sed

Ko

enig

)

8/9/

2015

4

yea

rs

Lega

l age

nt:

Koen

ig,

cha

ngin

g to

N

AM

SA

Spin

al F

ixa

tion

Syst

em (A

xiaL

IF 2

L Le

gacy

)

(I) 2

0113

4625

10

NA

MSA

(fo

rmer

ly u

sed

Ko

enig

)

8/9/

2015

A

fter S

ales

a

gent

: Ji

ad

e Su

nshi

ne

Face

t Scr

ew

Syst

em

(I) 2

0113

4625

11

NA

MSA

(fo

rmer

ly u

sed

Ko

enig

)

8/9/

2015

INST

RUM

ENTS

Su

rgic

al

Inst

rum

enta

tion

(Reu

sabl

es)

(I) 2

0091

1028

58

I,

pot

entia

lly

bec

omin

g II

Tra

nS1

12/1

0/09

1

yea

r N

AM

SA

(form

erly

use

d

Koen

ig)

12/9

/201

3 4

yea

rs

Pend

ing

rene

wa

l

Spin

al F

ixa

tion

Syst

em S

ingl

e-Us

e In

stru

men

ts

Pend

ing

III o

f III

Pend

ing

1-2

yea

rs

NA

MSA

(fo

rmer

ly u

sed

Ko

enig

)

Pend

ing

INDI

A

Prod

uct

Regi

stra

tion

#

Cla

ss

Regi

stra

tion

Hol

der

Fi

rst I

ssue

Tim

elin

e fo

r a

pp

rova

l

Regi

stra

tion

Ag

ent

Exp

iry

Freq

uenc

y fo

r ren

ewa

l N

otes

Axi

aLI

F Sy

stem

Fo

rm 4

1: M

D-

686

N/A

; is a

“N

otifi

ed

Med

ica

l D

evic

e”

Tra

nS1

2/10

/10

6-9

mon

ths

MN

Sol

utio

ns

4/15

/201

5 3

yea

rs

Cha

nges

: N

otifi

catio

n w

ithin

30

da

ys

Form

10:

Cur

e Su

rgic

al,

licen

se

# M

D-6

86-1

037

Axi

aLI

F 2L

Sys

tem

Re

new

al m

ust

be 3

mon

ths

befo

re e

xpiry

Tr

anS1

Fac

et

Scre

ws (

Axi

aLIF

36

0)

C

ase

14-1

2545

-CS

S

Doc

191

F

iled

12/3

1/14

P

age

195

of 2

21

M

aste

r Reg

ulat

ory

Regi

stra

tions

Tab

le

Sept

embe

r 30,

201

4

ISRA

EL

Prod

uct

Regi

stra

tion

#

Cla

ss

Regi

stra

tion

Hold

er

Firs

t Iss

ue

Timel

ine

for

ap

pro

val

Regi

stra

tion

Ag

ent

Exp

iry

Freq

uenc

y fo

r ren

ewa

l N

otes

Axi

aLI

F 56

8001

4 N

/A

Tra

nS1

6/12

/07

4-6

wee

ks

Med

ica

l Te

chno

logi

cal

Co.

5

yea

rs

Reco

gnize

CE

Ma

rk/F

DA

cl

eara

nce

Axi

aLI

F 2L

A

xia

LIF

360

VEO

56

8040

9 4/

17/1

2 S. K

ORE

A

Prod

uct

Regi

stra

tion

#

Cla

ss

Regi

stra

tion

Hold

er

Firs

t Iss

ue

Timel

ine

for

ap

pro

val

Regi

stra

tion

Ag

ent

Exp

iry

Freq

uenc

y fo

r ren

ewa

l N

otes

Axi

aLI

F re

usab

le

kit

Susin

10-

110

I of I

V

Tra

nS1

1/29

/10

9-12

m

onth

s Sy

nex

1/20

13

KGM

P: 3

ye

ars

Le

t La

pse

Axi

aLI

F TR

1-22

08

Susin

10-

109

I 1/

15/1

0 1/

2013

A

xia

LIF

2L

inst

rum

ents

Su

sin 1

0-20

0 I

1/29

/10

1/20

13

TR1-

2200

, TR1

-22

01, T

R1-2

202,

TR

1-20

07

Susin

10-

455

II 5/

12/1

0 5/

2013

TR1-

2210

, TR1

-22

11

Susin

10-

202

II 1/

29/1

0 1/

2013

Axi

aLI

F 36

0 Im

pla

nts

Suhe

o 09

-122

1 III

11

/25/

09

11/2

012

Axi

aLI

F 2L

Im

pla

nts

Suhe

o 09

-122

2 III

11

/25/

09

11/2

012

Axi

aLI

F Im

pla

nts

Suhe

o 09

-122

3 III

11

/25/

09

11/2

012

Axi

aLI

F Si

ngle

Use

In

stru

men

ts

Suhe

o 10

-020

1

1/29

/10

1/20

13

SERB

IA/C

ROA

TIA

Prod

uct

Regi

stra

tion

#

Cla

ss

Regi

stra

tion

Hold

er

Firs

t Iss

ue

Timel

ine

for

ap

pro

val

Regi

stra

tion

Ag

ent

Exp

iry

Freq

uenc

y fo

r ren

ewa

l N

otes

Axi

aLI

F 04

-180

5/10

IIb

of I

II H

erm

es

Syst

em (U

nior

Bi

onic

)

12/1

3/10

4-

6 m

onth

s Un

ior B

ioni

c 6/

7/20

15 (9

0 d

ays a

fter

EC C

ert

exp

iry)

Whe

n w

e re

ceiv

e ne

w

EC C

ert

Reco

gnize

C

E M

ark

A

xia

LIF

Plus

IIb

of I

II Fa

cet S

crew

s IIb

of I

II

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 19

6 of

221

M

aste

r Reg

ulat

ory

Regi

stra

tions

Tab

le

Sept

embe

r 30,

201

4

MEX

ICO

Pr

oduc

t Re

gist

ratio

n #

C

lass

Re

gist

ratio

n Ho

lder

Fi

rst I

ssue

Tim

elin

e fo

r a

pp

rova

l

Regi

stra

tion

Ag

ent

Exp

iry

Freq

uenc

y fo

r ren

ewa

l N

otes

Axi

aLI

F Pl

us-

Imp

lant

s 22

91C

2013

SS

A

II of

III

Tra

nS1

9-6-

13

3-6

mon

ths

Biom

edic

al

9-6-

18

5 ye

ars

Axi

aLI

F Pl

us-

Inst

rum

ents

19

39E2

013

SSA

II

of II

I 8-

7-13

8-

7-18

VEO

-Imp

lant

s 13

91C

2013

SS

A

II of

III

6-7-

13

6-7-

18

VEO

Inst

rum

ents

00

14E2

014

SSA

I o

f III

1-10

-14

1-10

-19

iO-F

lex

Not

Sta

rted

C

OLO

MBI

A

Prod

uct

Regi

stra

tion

#

Cla

ss

Regi

stra

tion

Hold

er

Firs

t Iss

ue

Timel

ine

for

ap

pro

val

Regi

stra

tion

Ag

ent

Exp

iry

Freq

uenc

y fo

r ren

ewa

l N

otes

Axi

aLI

F, A

xia

LIF

Plus

, Axi

aLI

F 2L

, V

EO

2013

0623

29

IIb o

f III

Tra

nS1

9/6/

2013

6-

8 m

onth

s D

isorth

o 9/

20/2

023

10 y

ears

Axi

aLI

F 36

0 Pe

ndin

g Iib

of I

II Pe

ndin

g Pe

ndin

g RU

SSIA

Pr

oduc

t Re

gist

ratio

n #

C

lass

Re

gist

ratio

n Ho

lder

Fi

rst I

ssue

Tim

elin

e fo

r a

pp

rova

l

Regi

stra

tion

Ag

ent

Exp

iry

Freq

uenc

y fo

r ren

ewa

l N

otes

Axi

aLI

F Pl

us

Pend

ing

Iib o

f III

? Pe

ndin

g 1

yea

r G

CP-

Gro

up

Ltd

. Pe

ndin

g N

o ex

pira

tion

DoC

is v

alid

for 1

or

3 y

ears

d

epen

din

g on

ty

pe

of

regi

stra

tion

VEO

Pe

ndin

g Iib

of I

II Pe

ndin

g Pe

ndin

g

JAPA

N

Prod

uct

Regi

stra

tion

#

Cla

ss

Regi

stra

tion

Hold

er

Firs

t Iss

ue

Timel

ine

for

ap

pro

val

Regi

stra

tion

Ag

ent

Exp

iry

Freq

uenc

y fo

r ren

ewa

l N

otes

Axi

aLI

F Pl

us

Pend

ing

? of

IV

? Pe

ndin

g 1-

2 ye

ars

Su

gica

l Spi

ne,

Inc.

Pe

ndin

g N

o ex

pira

tion

SLO

VAKI

A

Prod

uct

Regi

stra

tion

#

Cla

ss

Regi

stra

tion

Firs

t Iss

ue

Timel

ine

Regi

stra

tion

Exp

iry

Freq

uenc

y N

otes

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 19

7 of

221

M

aste

r Reg

ulat

ory

Regi

stra

tions

Tab

le

Sept

embe

r 30,

201

4

Hold

er

for

ap

pro

val

Ag

ent

for r

enew

al

Axi

aLI

F A

ppro

ved

Iib

of I

II H

erm

es

Syst

em (U

nior

Bi

onic

)

1/15

/14

See

note

s Un

ior B

ioni

c V

alid

un

der

te

rms o

f EC

Cer

t

N/A

- s

ubm

issio

n of

a

n a

pp

licat

ion

from

1.

4. to

30.

6.20

13

- pub

lica

tion

of

the

first

inst

anc

e d

ecisi

on

15.1

0.20

13

- pub

lica

tion

of

the

seco

nd in

sta

nce

dec

ision

15

.11.

2013

- fin

al c

ateg

orize

d

list o

f med

ica

l d

evic

es fr

om

1.1.

2014

Axi

aLI

F Pl

us

Ap

pro

ved

Iib

of I

II 1/

15/1

4 A

xia

LIF

360

Ap

pro

ved

Iib

of I

II 1/

15/1

4

KUW

AIT

All

Prod

ucts

Pe

ndin

g

BR

AZI

L A

xia

LIF

1L+

Pend

ing

Axi

aLI

F 2L

+ Pe

ndin

g

V

ectre

Pe

ndin

g

V

EO

Pend

ing

CHI

LE

DUBA

I A

xia

LIF

Plus

A

ppro

ved

A

xia

LIF

Ap

pro

ved

V

EO

Ap

pro

ved

iO

-Fle

x A

pp

rove

d

NET

HERL

AN

DS

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 19

8 of

221

M

aste

r Reg

ulat

ory

Regi

stra

tions

Tab

le

Sept

embe

r 30,

201

4

MA

LAYS

IA

PORT

UGA

L

SA

UDI A

RABI

A

SLO

VEN

IA

CZE

CH

REPU

BLIC

A

xiaL

IF

A

xiaL

IF P

lus

36

0

Vect

re

SPA

IN

Axi

aLI

F 20

07

TU

RKEY

Pr

oduc

t Na

me

and

Re

gist

ratio

n Lis

tings

C

lass

Re

gist

ratio

n Ho

lder

Fi

rst I

ssue

Tim

elin

e fo

r a

pp

rova

l

Regi

stra

tion

Ag

ent

Exp

iry

Freq

uenc

y fo

r ren

ewa

l N

otes

See

Da

taba

se L

istin

gs

IIb

Med

ikon

N

/A

2 w

eeks

M

edik

on

3/9/

2015

(E

C C

ert)

5

yea

rs

TITUB

B D

ata

ba

se

Regi

stra

tion

ITALY

Pr

oduc

t Nam

e &

Reg

istra

tion

#

Cla

ss

Regi

stra

tion

Hol

der

Fi

rst I

ssue

Tim

elin

e fo

r a

pp

rova

l

Regi

stra

tion

Ag

ent

Exp

iry

Freq

uenc

y fo

r ren

ewa

l N

otes

See

belo

w fo

r Da

taba

se li

stin

gs

IIb

Tra

nS1

N/A

5-

7 d

ays

A

MS

Gro

up /

M

edPa

ss

Va

lid

und

er

term

s of

EC C

ert

N/A

N

SIS

Dat

aba

se

regi

stra

tion

exce

pt C

lass

I

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 19

9 of

221

M

aste

r Reg

ulat

ory

Regi

stra

tions

Tab

le

Sept

embe

r 30,

201

4

Italia

n Re

perto

ry D

atab

ase

Listin

gs

Axi

aLIF

(Leg

acy

and

2L)

Axi

aLIF

Plu

s VE

O

Ca

talo

g #

Re

perto

ry L

istin

g #

C

ata

log

#

Repe

rtory

List

ing

#

Ca

talo

g #

Re

perto

ry L

istin

g #

C

ata

log

#

Repe

rtory

List

ing

#

TR1-

2202

11

7589

/R

TR1-

2329

12

5540

/R

TR1-

1104

38

5050

/R

TR1-

1107

58

7010

/R

TR1-

2203

23

0897

/R

TR1-

2330

12

5550

/R

TR1-

2212

38

7126

/R

TR1-

1105

58

6994

/R

TR1-

2207

38

5078

/R

TR1-

2331

12

6930

/R

TR1-

2213

38

7124

/R

TR1-

1109

58

7013

/R

TR1-

2208

11

7595

/R

TR1-

2332

12

6932

/R

TR1-

2222

75

8789

/R

TR1-

1110

58

7008

/R

TR1-

2210

23

0900

TR

1-23

33

1269

34/R

TR

1-22

20

5253

91/R

TR

1-11

06

5870

09/R

TR

1-22

11

TR

1-23

34

1269

42/R

TR

1-22

17

5047

96/R

A

xial

IF 3

60

TR1-

1101

14

1429

/R

TR1-

2335

12

6944

/R

TR1-

2218

50

6768

/R

TR1-

1102

+ (3

60)

1414

49/R

TR

1-11

02

1413

98/R

TR

1-23

36

1269

48/R

TR

1-22

19

5086

07/R

TR

1-27

00

1151

17/R

TR

1-22

00

1152

50/R

TR

1-23

37

1269

50/R

TR

1-22

21

TR

1-27

01

2308

99

TR1-

2201

11

7582

/R

TR1-

2338

12

6953

/R

TR1-

2357

38

5121

/R

TR1-

2800

10

0156

/R

TR1-

2300

98

832/

R TR

1-23

39

1269

55/R

TR

1-23

58

3851

22/R

TR

1-28

01

1150

90/R

TR

1-23

01

1149

82/R

TR

1-23

40

1269

58/R

TR

1-23

59

3851

24/R

TR

1-28

02

1150

92/R

TR

1-23

02

1149

85/R

TR

1-23

41

1269

62/R

TR

1-23

60

3851

25/R

TR

1-28

03

1150

94/R

TR

1-23

03

1149

85/R

TR

1-23

42

1269

69/R

TR

1-23

61

3851

26/R

TR

1-28

08

1150

96/R

TR

1-23

04

1149

96/R

TR

1-23

43

1269

74/R

TR

1-23

62

3851

28/R

TR

1-28

09

1150

98/R

TR

1-23

05

1149

97/R

TR

1-23

44

1269

76/R

TR

1-23

63

3851

30/R

TR

1-28

10

1151

00/R

TR

1-23

06

1149

98/R

TR

1-23

46

1393

05/R

TR

1-23

64

3851

31/R

TR

1-28

11

1151

01/R

TR

1-23

07

1150

00/R

TR

1-23

45

1269

79/R

TR

1-23

65

3851

32/R

TR

1-28

24

1151

03/R

TR

1-23

08

1150

01/R

TR

1-23

47

1269

83/R

TR

1-23

66

3851

35/R

TR

1-28

25

1151

04/R

TR

1-23

09

1150

03/R

TR

1-23

48

1269

87/R

TR

1-23

67

3851

37/R

TR

1-28

26

1151

06/R

TR

1-23

10

1150

04/R

TR

1-23

49

1150

60/R

TR

1-23

68

3851

38/R

TR

1-28

27

1151

08/R

TR

1-23

11

1150

05/R

TR

1-23

50

1150

63/R

TR

1-23

72

3851

17/R

TR

1-28

28

3991

00/R

TR

1-23

12

9982

8/R

TR1-

2351

11

5067

/R

TR1-

2373

38

5115

/R

TR1-

2829

39

9101

/R

TR1-

2313

11

5041

/R

TR1-

2374

38

5118

/R

TR1-

2830

39

9102

/R

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 20

0 of

221

M

aste

r Reg

ulat

ory

Regi

stra

tions

Tab

le

Sept

embe

r 30,

201

4

TR1-

2314

11

5042

/R

TR1-

2375

38

5117

/R

TR1-

2831

39

9103

/R

TR1-

2315

11

5050

/R

TR1-

2376

45

7888

/R

Vect

re

TR1-

2316

11

5052

/R

TR1-

2377

46

2524

/R

TR1-

1700

28

8793

/R

TR1-

2317

11

5054

/R

TR1-

2378

46

2537

/R

TR1-

1701

28

8794

/R

TR1-

2318

11

5057

/R

TR1-

2379

46

2538

/R

TR1-

2702

28

8786

/R

TR1-

2319

11

5059

/R

TR1-

2380

46

2538

/R

TR1-

2703

28

8792

/R

TR1-

2320

11

5007

/R

TR1-

2381

46

2540

/R

TR1-

2704

TR1-

2320

11

5007

/R

TR1-

2382

46

2525

/R

TR1-

2832

28

8771

/R

TR1-

2321

11

5008

/R

TR1-

2383

46

2526

/R

TR1-

2833

28

8772

/R

TR1-

2322

11

5010

/R

TR1-

2384

TR1-

2834

28

8775

/R

TR1-

2323

11

5011

/R

TR1-

2385

TR1-

2835

28

8776

/R

TR1-

2324

11

5012

/R

TR1-

2386

TR1-

2836

28

8778

/R

TR1-

2325

11

5014

/R

TR1-

2387

TR1-

2837

28

8779

/R

TR1-

2326

11

5016

/R

TR1-

2388

TR1-

2838

28

8781

/R

TR1-

2327

11

5017

/R

TR1-

2389

TR1-

2839

28

8782

/R

TR1-

2328

11

2866

/R

TR1-

2390

TR1-

2391

TR1-

2392

TR1-

2393

iO-F

lex

TR1-

2394

TR1-

2395

TR1-

2396

TR1-

2397

TR1-

2398

TR1-

2399

TR1-

2310

0

TR1-

2310

1

TR1-

2310

2

TR1-

2310

3

TR1-

2310

4

TR1-

2310

5

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 20

1 of

221

M

aste

r Reg

ulat

ory

Regi

stra

tions

Tab

le

Sept

embe

r 30,

201

4

Turk

ey TI

TUBB

Dat

abas

e Lis

tings

A

xiaL

IF (L

egac

y an

d 2L

) A

xiaL

IF P

lus

VEO

C

ata

log

#

Listin

g #

C

ata

log

#

Listin

g #

C

ata

log

#

Listin

g #

C

ata

log

#

Listin

g #

TR

1-22

02

0245

0057

0156

52

TR1-

2329

08

9009

1001

549

TR1-

1104

N

/A

TR1-

1107

TR1-

2203

TR1-

2330

08

9009

1001

556

TR1-

2212

08

9009

1001

389

TR1-

1105

TR1-

2207

08

9009

1001

518

TR1-

2331

08

9009

1001

563

TR1-

2213

08

9009

1001

396

TR1-

1109

TR1-

2208

TR1-

2332

08

9009

1001

570

TR1-

2222

TR1-

1110

TR1-

2210

TR1-

2333

08

9009

1001

587

TR1-

2220

TR1-

1106

TR1-

2211

TR1-

2334

08

9009

1001

594

TR1-

2217

Axi

alIF

360

TR

1-11

01

TR

1-23

35

0890

0910

0160

0 TR

1-22

18

TR

1-27

00

0245

0057

0003

68

TR1-

1102

TR1-

2336

08

9009

1001

617

TR1-

2219

TR1-

2701

TR1-

2200

08

9009

1001

013

TR1-

2337

08

9009

1001

624

TR1-

2221

TR1-

2800

08

9009

1001

228

TR1-

2201

08

9009

1001

488

TR1-

2338

08

9009

1001

631

TR1-

2357

08

9009

1001

525

TR1-

2801

08

9009

1001

235

TR1-

2300

08

9009

1001

020

TR1-

2339

08

9009

1001

648

TR1-

2358

08

9009

1001

839

TR1-

2802

08

9009

1001

242

TR1-

2301

08

9009

1001

037

TR1-

2340

08

9009

1001

655

TR1-

2359

08

9009

1001

846

TR1-

2803

08

9009

1001

259

TR1-

2302

08

9009

1001

044

TR1-

2341

08

9009

1001

662

TR1-

2360

08

9009

1001

853

TR1-

2808

08

9009

1001

266

TR1-

2303

08

9009

1001

051

TR1-

2342

08

9009

1001

679

TR1-

2361

08

9009

1001

860

TR1-

2809

08

9009

1001

273

TR1-

2304

08

9009

1001

068

TR1-

2343

08

9009

1001

686

TR1-

2362

08

9009

1001

877

TR1-

2810

08

9009

1001

280

TR1-

2305

08

9009

1001

075

TR1-

2344

08

9009

1001

693

TR1-

2363

08

9009

1001

884

TR1-

2811

08

9009

1001

297

TR1-

2306

08

9009

1001

082

TR1-

2345

08

9009

1001

709

TR1-

2364

08

9009

1001

891

TR1-

2824

08

9009

1001

303

TR1-

2307

08

9009

1001

099

TR1-

2346

08

9009

1001

501

TR1-

2365

08

9009

1001

907

TR1-

2825

08

9009

1001

310

TR1-

2308

08

9009

1001

105

TR1-

2347

08

9009

1001

716

TR1-

2366

08

9009

1001

914

TR1-

2826

08

9009

1001

327

TR1-

2309

08

9009

1001

112

TR1-

2348

08

9009

1001

723

TR1-

2367

08

9009

1001

921

TR1-

2827

08

9009

1001

334

TR1-

2310

08

9009

1001

129

TR1-

2349

08

9009

1001

761

TR1-

2368

08

9009

1001

938

TR1-

2828

08

9009

1001

341

TR1-

2311

08

9009

1001

136

TR1-

2350

08

9009

1001

785

TR1-

2372

08

9009

1001

945

TR1-

2829

08

9009

1001

358

TR1-

2312

08

9009

1001

396

TR1-

2351

08

9009

1001

792

TR1-

2373

08

9009

1001

952

TR1-

2830

08

9009

1001

365

TR1-

2313

08

9009

1001

396

TR1-

2374

08

9009

1001

969

TR1-

2831

08

9009

1001

372

TR1-

2314

08

9009

1001

402

TR1-

2375

08

9009

1001

976

Vect

re

TR1-

2315

08

9009

1001

419

TR1-

2376

08

1486

4010

014

TR1-

1700

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 20

2 of

221

M

aste

r Reg

ulat

ory

Regi

stra

tions

Tab

le

Sept

embe

r 30,

201

4

TR1-

2316

08

9009

1001

426

TR1-

2377

08

1486

4010

015

TR1-

1701

TR1-

2317

08

9009

1001

433

TR1-

2378

08

1486

4010

016

TR1-

2702

TR1-

2318

08

9009

1001

440

TR1-

2379

08

1486

4010

017

TR1-

2703

TR1-

2319

08

9009

1001

457

TR1-

2380

08

1486

4010

018

TR1-

2704

TR1-

2320

08

9009

1001

143

TR1-

2381

08

1486

4010

019

TR1-

2832

00

8148

6401

0019

TR

1-23

21

0890

0910

0115

0

TR

1-23

82

0814

8640

1002

3 TR

1-28

33

0081

4864

0100

26

TR1-

2322

08

9009

1001

167

TR1-

2383

08

1486

4010

024

TR1-

2834

00

8148

6401

0033

TR

1-23

23

0890

0910

0117

4

TR

1-23

84

TR

1-28

35

0081

4864

0100

40

TR1-

2324

08

9009

1001

181

TR1-

2385

TR1-

2836

00

8148

6401

0057

TR

1-23

25

0890

0910

0119

8

TR

1-23

86

TR

1-28

37

0081

4864

0100

64

TR1-

2326

08

9009

1001

204

TR1-

2387

TR1-

2838

00

8148

6401

0071

TR

1-23

27

0890

0910

0121

1

TR

1-23

88

TR

1-28

39

0081

4864

0100

88

TR1-

2328

08

9009

1001

143

TR1-

2389

iO-F

lex/

iO-T

ome

TR1-

2390

iO-W

ire

0081

4864

0105

45

TR1-

2391

iO-C

P45

0081

4864

0105

52

TR1-

2392

iO-IP

00

8148

6401

0569

TR

1-23

93

iO

-IP-T

R 00

8148

6401

0576

TR

1-23

94

iO

-NC

W

0081

4864

0105

83

TR1-

2395

iO-D

H

0081

4864

0105

90

TR1-

2396

iO-M

BS5.

5 00

8148

6401

0606

TR

1-23

97

iO

-MBS

7.5s

c 00

8148

6401

0613

TR

1-23

98

iO

-MBS

10sc

00

8148

6401

0620

TR

1-23

99

iO

-MBS

12sc

00

8148

6401

0637

TR

1-23

100

iO

-Tom

e7.5

00

8148

6401

0644

TR

1-23

101

iO

-Tom

e10

0081

4864

0106

51

TR1-

2310

2

iO-IC

00

8148

6401

0668

TR

1-23

103

iO

-CC

00

8148

6401

0675

TR

1-23

104

TR

1-23

105

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 20

3 of

221

Exhibit 4.13(b) SL1 1342200v6 109188.00001

Exhibit 4.13(b)

CE Marks, 510(k) Clearances, and all 510(k) Filings relating to the Products

See attached.


4.13(c)-1 SL1 1342200v6 109188.00001

Schedule 4.13(c)

Other Governmental Authorizations

None, other than those set forth on Exhibit 4.13(b) and those that are not material to the Business or the Acquired Assets either individually or in the aggregate.


4.17

-1 S

L1 1

3422

00v6

109

188.

0000

1

Sche

dule

4.1

7

Em

ploy

ee M

atte

rs

17 C

ompe

nsat

ion

info

rmat

ion

to b

e re

dact

ed fr

om th

e ve

rsio

n of

the

sche

dule

s file

d of

reco

rd in

the

BR

pro

ceed

ing.

Nam

eT

itle

2014

Com

pens

atio

n (S

alar

y, B

onus

, Oth

er

Com

pens

atio

n)17

Ken

Rea

liC

hief

Exe

cutiv

e O

ffic

erSt

eve

Ain

swor

thV

ice

Pres

iden

t of R

&D

and

Bus

ines

s Dev

elop

men

tC

athe

rine

Mah

erC

omm

erci

al O

pera

tions

Rep

rese

ntat

ive

Laur

a H

owar

dC

omm

erci

al O

pera

tions

Rep

rese

ntat

ive

Am

elia

Sm

ithC

omm

erci

al O

pera

tions

Rep

rese

ntat

ive

Mar

tina

Hrn

cir

Seni

or Q

ualit

y A

ssur

ance

Man

ager

Gre

g W

elsh

Vic

e Pr

esid

ent,

Ope

ratio

nsC

harli

e To

rres

Seni

or B

uyer

Pla

nner

Tom

a B

arke

rSe

nior

Sta

ff A

ccou

ntan

tB

aile

y R

obbi

nsA

ssis

tant

Con

trolle

rG

retc

hen

McR

eyno

lds

Acc

ount

s Rec

eiva

ble

Spec

ialis

tJu

stin

Den

ning

App

licat

ion

Supp

ort S

peci

alis

tG

reg

Pella

ttN

atio

nal S

ales

Dire

ctor

Pat C

aylo

rR

SDSt

eve

Gre

enR

SDK

atry

n Fe

rnal

dR

SDJo

hn D

iete

rlyR

SDR

ober

t Coo

kSe

nior

Man

ager

, iO

Pro

duct

s and

Stra

tegi

c M

arke

ting

Cas

e 14

-125

45-C

SS

D

oc 1

91

File

d 12

/31/

14

Pag

e 21

9 of

221

5.7-1 SL1 1342200v6 109188.00001

Schedule 4.20

Insurance

AON Financing Agreement-Quote 100000775221.002 – International PFA

POLICY NUMBER

Prefix Number

Full Name of Insurance Company and Address of

Branch Reporting Office and Full Name and Address of

General Agent

TYPE OF INSURANCE

TERM IN MONTHS

POLICY EFFECTIVE

DATE

MM/DD/YYYY

POLICY PREMIUM

WS11002931 Insurance Company of the State of Pennsylvania FRLB 12 10/01/2014 6,015.00

AON Financing Agreement-Quote 199949.1 – Omnibus PFA

POLICY NUMBER

Prefix Number

Full Name of Insurance Company and Address of Branch Reporting Office

and Full Name and Address of General Agent

TYPE OF INSURANCE

TERM IN MONTHS

POLICY EFFECTIVE

DATE

MM/DD/YYYY

POLICY PREMIUM

LPK5001316Q17 Berkley National Insurance Company, PO Box 152180, Irving, TX 75015-2180

PACKAGE 12 10/16/2014 Premium: $68,477.00 Taxes: $0.00 Fees: $0.00

016945634

National Union Fire Ins Co Pittsburgh, PA/AIG (NY), 175 Water St, FL 18, New York, NY 10038

FIDUCIARY 12 10/16/2014 Premium: $4,925.00 Taxes: $0.00 Fees: $0.00

82310-1404

Federal Insurance Company/Chubb (New York NY), 55 Water Street, New York, NY 10041

EMPLOYMENT PRACTICES LIABILITY

12 10/16/2014 Premium: $30, 881.00 Taxes: $0.00 Fees: $0.00

LWC500132014 Berkley National Insurance Company, PO Box 152180, Irving, TX 75015-2180

WORKERS COMPENSATION -

VOLUNTARY 12 10/16/2014

Premium: 36.236.00 Taxes: $1,172.00 Fees: $0.00

016945633

National Union Fire Ins Co Pittsburgh, PA/AIG (NY), 175 Water St, FL 18, New York, NY 10038

CRIME 12 10/16/2014 Premium: $4,996.00 Taxes: $0.00 Fees: $0.00

GL-108744 Gemini Insurance Company, 1250 E Diehl Rd, Suite 200, Naperville, IL 60563

PRODUCT LIABILITY 12 10/16/2014

Premium: $186,002.00 Taxes: $9,300.10 Fees: $0.00

00064455-0

James River Insurance Company, AmWins Insurance Brokerage of California – San Francisco, One Bush Street, San Francisco, CA 94104


Premium: $130,000.00 Taxes: $6,500.00 Fees: $110.00

LSR-XS-00035-14 Lloyds of London, One Lime Street, London, EC3M 7HA ENGLAND


Premium: $85,000.00 Taxes 4,250.50 Fees: $0.00

The Seller’s D &O Liability Policy is not financed

National Union Fire Ins Co of Pittsburgh

014682707

Baxano Surgical, Inc.

Oct 16, 2013 - Oct 16, 2015

Oct 16, 2014 Endorsement – Directors & Officers-Primary

229,944.00


5.7-1 SL1 1342200v6 109188.00001

XL Specialty Insurance Co

ELU13173913


Oct 16, 2013 - Oct 16, 2015

Oct 16, 2014 Endorsement – Directors & Officers-Excess

55,000.00

Berkley Insurance Company

11228604


Oct 16, 2013 - Oct 16, 2015

Oct 16, 2014 Endorsement – Directors & Officers-Excess

80,500.00
